

EUROPEAN
CURRICULUM
VITAE
FORMAT



PERSONAL INFORMATION

Name **MARCO MATUCCI CERINIC**

SCOPUS CITATIONS 50.052

HI SCOPUS 101

H5 SCOPUS 136

D.INDEX 108 (47,383 citations, 1119 publications)

1883 PUBLICATIONS IN THE WEB OF SCIENCE

WEB OF SCIENCE RESEARCHER IDAAO-2769-2020

ORCID: 0000-0002-9324-3161 <https://orcid.org/0000-0002-9324-3161>

CAREER

- Dates (from – to) **2022-2025**
 - Name Italian College of Rheumatology Professors
 - Type of business or sector Rheumatology
 - Occupation or position held President

- Dates (from – to) **2021-present**
 - Name and address of employer IRCCS- Hospital San Raffaele, Milan, Italy
 - Type of business or sector University Vita-Salute San Raffaele, Milan, Italy
 - Occupation or position held Director, Inflammation, Fibrosis and Ageing Initiative (INFLAGE)

- Dates (from – to) **2020-2022**

- Name and address of employer
 - Type of business or sector
 - Occupation or position held
- Dates (from – to)
- Name and address of employer
 - Type of business or sector
 - Occupation or position held
- Dates (from – to)
- Name and address of employer
 - Type of business or sector
 - Occupation or position held
- Dates (from – to)
- Name and address of employer
 - Type of business or sector
 - Occupation or position held
- Dates (from – to)
- Name and address of employer
 - Type of business or sector
 - Occupation or position held
- Dates (from – to)
- Name and address of employer
 - Type of business or sector
 - Occupation or position held
- Dates (from – to)
- Name and address of employer
 - Type of business or sector
 - Occupation or position held
- Dates (from – to)
- Name and address of employer
 - Type of business or sector
 - Occupation or position held
- Dates (from – to)
- Name and address of employer
 - Type of business or sector
 - Occupation or position held
- Dates (from – to)
- Name and address of employer
 - Type of business or sector
 - Occupation or position held

Therapeutic Committee COVID-19
Tuscan Government
Member

2020-2022

Careggi University Hospital, Florence, Italy
Research Committee COVID-19
Coordinator

2016– 2023

European IRB Committee of the Tuscan Region
Central Tuscan Region
President

2003 – 2020

Careggi University Hospital, Florence, Italy
Division of Rheumatology
Director

2000 – 2003

Careggi University Hospital, Florence, Italy
Division of Internal Medicine
Director

1996 – 2000

Institute of Medicine IV, University of Florence, Italy
Outpatient clinic and Day Hospital
Director

1990– 1996

Azienda Sanitaria di Pontassieve e Firenze, Italy
Consultant in rheumatology
Medical specialist in rheumatology, outpatient branch

1989 – 1990

Medical University of South Carolina, Charleston, USA
Systemic sclerosis
Visiting scientist

1986-1989

Hospital Pitigliano, Pitigliano, Italy
Emergency night shift
Emergency Consultant

1984-1985

Universite Paris La Sorbonne V, France
Interne en Rhumatologie – Hospital Mondor

- Occupation or position held Ancien Interne des Hospitiaux de Paris
- Dates (from – to) **1982-1989**
- Name and address of employer Institute of Medicine IV, University of Florence, Italy
 - Type of business or sector Clinical Pathology I – Director Prof. M. Cagnoni
 - Occupation or position held Medical Internship
- Dates (from – to) **1980-1981**
- Name and address of employer Santa Maria Nuova Hospital, Florence, Italy
 - Type of business or sector Division of Respiratory Pathophysiology at the Division of Lung Diseases
 - Occupation or position held Post-graduate practical training – Proffs. Brettoni e Nozzoli
- Dates (from – to) **1977-1981**
- Name and address of employer Clinica Medica I, Florence, Italy
 - Type of business or sector Division of Rheumatology, Prof. G. A. Morandi
 - Occupation or position held Student Internship

TEACHING

- Dates (from – to) **2023- present**
- Name and address of employer University Vita Salute San Raffaele, Italy
 - Type of business or sector Faculty of Medicine
 - Occupation or position held Professor of Rheumatology
- Dates (from – to) **2000-2023**
- Name and address of employer University of Florence, Italy
 - Type of business or sector Faculty of Medicine and Surgery
 - Occupation or position held Professor of Medicine and Rheumatology
- Dates (from – to) **1996-2000**
- Name and address of employer University of Florence, Italy
 - Type of business or sector Faculty of Medicine and Surgery
 - Occupation or position held Associate Professor of Clinical Physiopathology
- Dates (from – to) **1992 – 1996**
- Name and address of employer University of Cagliari, Italy
 - Type of business or sector Faculty of Medicine and Surgery
 - Occupation or position held Associate Professor of Clinical Physiopathology
- Dates (from – to) **1983 -1992**
- Name and address of employer University of Florence, Italy
 - Type of business or sector Faculty of Medicine and Surgery
 - Occupation or position held Coordinator of the theoretical and practical exercises for the student of the Clinical Pathology and Medicine Course

EDUCATION AND TRAINING

- Dates (from – to) **1984-1987**

- Name and type of organization providing education and training University of Siena, Italy
- Principal subjects/occupational
 - Title of qualification awarded PhD Experimental Rheumatology
- Dates (from – to) **1980-1984**
- Name and type of organization providing education and training University of Genova, Italy
- Principal subjects/occupational
 - Title of qualification awarded Fellowship in Rheumatology
Post – graduated degree specialisation – 50/50
- Dates (from – to) **1974-1980**
- Name and type of organization providing education and training University of Florence, Faculty of Medicine and Surgery
- Title of qualification awarded Degree in Medicine and Surgery – 110 and praise
- Dates (from – to) **1974**
- Name and type of organization providing education and training Liceo Classico Le Querce, Florence, Italy
- Title of qualification awarded High School Degree

PERSONAL SKILLS AND COMPETENCES

MOTHER TONGUES

ITALIAN & SERBO-CROATIAN

OTHER LANGUAGES

ENGLISH & FRENCH

- Reading skills EXCELLENT
- Writing skills EXCELLENT
- Verbal skills EXCELLENT

SPANISH

- Reading skills GOOD
- Writing skills SUFFICIENT
- Verbal skills GOOD

MACEDONIAN, BOSNIAN & BULGARIAN

- Reading skills SUFFICIENT
- Writing skills SUFFICIENT
- Verbal skills GOOD

SOCIAL SKILLS AND COMPETENCES

-President of the College of Rheumatology Professors (2022 – present) -
-SIR President (2012-2014) - Italian Society of Rheumatology
-EULAR Scientific Committee (2001-2011) where the activity was devoted to the scientific organization of the EULAR annual Congress.

-Secretary General of European League Against Rheumatism (2003- 2007) where the activity was devoted to:

1. Focus on Introducing Eastern, Middle East and Asian Countries in the EULAR Framework;
2. Raise at the European Level New patient associations, in particular those devoted to systemic sclerosis;

-ILAR, Executive Secretary (1999-2001) Activities characterized by organization of the Committees and coordination on leagues

ORGANISATIONAL SKILLS AND COMPETENCES

-Founder & Chairman of the Italian World Scleroderma Foundation (2023 - present)

-Founder & Chairman of the World Scleroderma Foundation (2013- present)

-Founder & Chairman of EUSTAR (2004-2010) www.eustar.org

Has Organized:

1. The structure of Eustar, gathering more than 150 centers worldwide. All the continents are now part of the network,
2. The database with more than 25.000 patients (medsoline).
3. The education on systemic sclerosis with international courses, summer courses and course on line.

CONGRESS AND COURSES ORGANIZED

- **Vth international symposium on interstitial lung diseases in rheumatic diseases January 2025**
- **ILD-SSc WSF/Serbian and Rumunian Societies of Rheumatology e-Masterclass – December 2024**
- **ILD-CTD WSF/Greek Society of Rheumatology e-Masterclass – April 2024**
- **8th world Congress on Systemic Sclerosis- March 2024**
- **ILD-CTD WSF/APLAR e-Masterclass – November 2024**
- **4th International Symposium on ILD in Rheumatic Diseases – February 2024**
- **3rd International Symposium on ILD in Rheumatic Diseases – February 2023**
- **7th World e-Congress on Systemic Sclerosis – e-Congress 2022**
- **2nd International Symposium on ILD in RD – February 2022**
- **ILD-SSc WSF/Chinese e-Masterclass – December 2021**
- **ILD-SSc WSF/Brazilian e-Masterclass – May 2021**
- **1st International Symposium on ILD in Rheumatic Diseases – February 2021**
- **ILD-SSc WSF/German e-Masterclass – December 2020**
- **ILD-SSc WSF/JP e-Masterclass – November 2020**
- **6th World e-Congress on Systemic Sclerosis , e-Congress 2020**
- **ILD-SSc WSF Masterclass – Florence, Italy_ September 2019**
- **ILD-SSc WSF Masterclass – Bucharest, Romania _ July 2019**
- **World Scleroderma Day “ The heart involvement in Scleroderma” – Rome, Italy _ June 2019**
- **New Insights in Rheumatoid Arthritis on the cutting edge of real life course- Florence, Italy _ April 2019**
- **Skin Score Course - Guangzhou, Cina_ April 2019**
- **5th World Congress on Systemic Sclerosis, Bordeaux, France, 2018**
- **12th EULAR Online Course on Rheumatic Diseases (2 year course), 2017 - 2019**
- **7th EULAR On-line Course on Systemic Sclerosis, 2017-2018**
- **Master on Principles and methods on complementary and assisted therapies in hospital with animals, University of Florence, Italy 2017**

- **4th World Congress on Systemic Sclerosis**, Lisboa, Portugal, 2016
- **WSF Masterclasses on Digital Ulcers in Systemic Sclerosis**, Bucharest & Split 2015, Tel Aviv 2016
- **Digital Ulcers in SSc WSF Masterclass** - Split, Croatia _ September 2015
- **Triangular summerschool rheumatology** – September 2015
- **3rd World Congress on Systemic Sclerosis**, Rome, Italy, 2014
- **5th EULAR/EUSTAR course on the assessment of systemic sclerosis patient**, Cluj-Napoca, Romania, 2013
- **2nd World Congress on Systemic Sclerosis**, Madrid, Spain, 2012
- **4th EULAR/EUSTAR course on the assessment of systemic sclerosis patient**, Belgrade, Serbia, 2011
- **PAH in SSc Summerschool** – Florence, Italy June 2011
- **1st World Congress on Systemic Sclerosis**, Florence, Italy, 2010
- **La sclerosi sistemica e le sue complicanze: la gestione pratica del paziente sclerodermico**, Abano Terme, Italy, 2009
- **3rd EULAR/EUSTAR course on the assessment of systemic sclerosis patient**, Paris, France, 2009
- **Fight pain and Inflammation: questions and answers**, Florence, Italy, 2008
- **5th International Conference on sex hormones, pregnancy and the rheumatic diseases**, Florence, Italy, 2007
- **27th European Workshop on Rheumatology Research**, Florence, Italy, 2007
- **2nd EULAR/EUSTAR course on the assessment of systemic sclerosis patient**, Bad Nauheim, Germany, 2007
- **National Course of Nurses: Biological therapy**, Florence, Italy, 2006
- **1st EULAR/EUSTAR course on the assessment of systemic sclerosis patient**, Budapest, Hungary, 2005.
- **Podology master**, University of Florence, Italy 2005-2011
- **Rehabilitative Rheumatology master**, University of Florence, Italy 2005-2011
- **Consensus Conference: the assessment of the patient with systemic sclerosis. Definition of a preliminary core set of variables for clinical trials.** Portonovo di Ancona, Italy, 2002
- **International Conference on Systemic Sclerosis: pathogenesis, clinical features and treatment**, Montecatini, Italy, 1998
- **Pain, rheumatic diseases and quality of life**, Florence, Italy, 1997
- **I^o International Workshop on hypertrophic osteoarthropathy**, Florence, Italy, 1992
- **International Congress on connective tissue disease in pediatric age**, Florence, Italy, 1991
- **Latin Congress of Rheumatology**, Florence, Italy, 1982

COOPERATION WORKS

National Institutions:

- University of Florence
- University of Bari
- University of Ancona
- University of Rome la Sapienza
- Catholic University of the Sacred Heart, Rome
- University of Milan,
- University of Naples Federico II
- The Institute of Cell Biology and Neurobiology (IBCN) of the National Research Council (CNR),
- Clinical Labour Foundation, Montescano,

International Institutions:

- University of Split, School of Medicine, Croatia

- Belaurusian Gomel State Medical University, Belarus
- Belarusian State Medical University, Belarus
- University of Belgrade, Serbia .
- Belarusian State Pedagogical University,
- Ludwig Boltzmann Institut fur Rheumatologie of Vienna, Austria
- University of Vienna, Austria
- Medical University of South Carolina, Charleston, USA
- Medical College of Ohio, USA
- University of Connecticut, USA
- University of Boston, USA
- University of Michigan at Ann Arbor, USA
- University of Pennsilnavia, Philadelphia, USA
- University McMaster, Canada,
- University of Helsinki, Finland
- Hopital Cochin, Paris
- University of Zagabria, Croatia
- University of Belgrade, Serbia
- University of Shantou, Medical Hospital, China

EDITORIAL ACTIVITIES

- Founder & Editor in Chief of *Journal of scleroderma and related diseases*.
- Associate Editor *Arthritis Research & Therapy* 2015-2025
- Associate Editor of *Clinical Experimental Rheumatology* 1995-2022
- Co-Editor of *Rheumatology* 2013-2015
- Associate Editor of *Rheumatology* 2007-2013
- Co-Assistant-Editor-in-Chief and Associate Editor of *Rheumatology and Immunology Research* 2021-present

Editorial Board of the following journals:

- *Annals of the Rheumatic Diseases*
- *Rheumatology*
- *Journal of Rheumatology*
- *Clinical Rheumatology*
- *Scandinavian Journal of Rheumatology*
- *Current Rheumatology Review*
- *European Journal Rheumatology*
- *Reumatismo*
- *Journal of Rumunian Rheumatology*
- *Pulmonary Circulation*
- *Rheumaology and Immunology Research*
- *Rheumatology of Kazakhstan*
- *Mediterranean Journal of Rheumatology*
- *Journal of IMIDs*
- *Annals of Rheumatology and autoimmunity*
- *Advances in Rheumatology*
- *American Journal Medicine*
- *American Academy of Dermatology.*
- *Arthritis & Rheumatology.*
- *Association pour la lutte a la sclerodermie, France.*
- *Clinical & Experimental Rheumatology.*
- *Cinica Chimica Acta.*
- *Circulation.*
- *Drugs.*
- *Journal of Rheumatology.*

REFeree FOR INTERNATIONAL AND NATIONAL JOURNALS

- International Journal of Dermatology.
- Journal of the European Academy of Dermatology & Venereology.
- Journal of the American Academy of Dermatology.
- Giornale Italiano di Geriatria e Gerontologia.
- Lancet.
- Lancet Rheumatology
- New England Journal of Medicine.
- Clinical Experimental Immunology.
- Nature Rheumatology Clinical Practice.
- Reumatismo.
- Scandinavian Journal of Rheumatology.
- Scleroderma Association, UK.
- Scleroderma Foundation.
- Wellcome Trust, UK.

Affiliation to Societies

- Fellow of the Royal College of Physicians.
- Honorary Fellow of the Italian Society of Rheumatology.
- Fellow of the American College of Rheumatology.
- Honorary Fellow of the British Society for Rheumatology.
- Honorary member of Polish Society of Internal Medicine
- Honorary member of the Slovak Association of Rheumatology
- Honorary member of the Association of Rheumatologists of Russia

National Offices:

- Italian Society for Rheumatology, President 2012-2014 & Past President 2014-2016
- Executive Committee of the Italian Society for Rheumatology, 2007-2012
- Italian Society for Rheumatology, Vicepresident 2007-2010
- GISEA, Vicepresident 2004-2007
- ANVUR- committee for the definition of ANS criteria 2011-2012

International Offices:

- Osteoarthritis International Foundation, Member of the board, 2016-present
- World Scleroderma Foundation, Chairman, 2014- present
- World Scleroderma Association, Chairman, 2010-2014
- American College of Rheumatology: abstract committee- Scleroderma 2002-2006, 2008-2014
- International Board, Skleroderma Netzwerke, Germany
- EUSTAR (EULAR Scleroderma Trial and Research group): Chairman 2003-2007 & 2007-2010
- European League Against Rheumatism (EULAR): General Secretary 2003-2007
- European League Against Rheumatism (EULAR) chairman abstract committee 2002-2003
- European League Against Rheumatism (EULAR): Scientific Committee 2001-2011
- International League Against Rheumatology (ILAR): Executive Secretary 2001-2003
- Scleroderma Clinical Trial Consortium (SCTC): Vicepresident 2001-2003 & 2003-2005
- Rumenian Society for Rheumatology- International Board 2004-present
- Japanese Rheumatism Association: International Advisory Committee 2001-2003
- American College of Rheumatology: International Advisory Committee 1999-

International Consulting Activities:

- Association pour la lutte a la sclerodermie, France.
- Wellcome Trust, UK.
- German Ministry of Health.
- Croatian Ministry of Health.
- France- Agence Nationale de la Recherche, Institut des Maladies Rares.
- Spanish Ministry of Health.
- Scleroderma Association, UK.
- Rumunian National Agency for Research.

**ADDITIONAL
INFORMATIONS****Studies**

- **Principal Investigator:** *"Studio osservazionale per valutazione della safety a lungo termine sul Baricitinib (JAJA)" (2023)*
- **Principal Investigator:** *"Randomized, multicenter, placebo-controlled, fase III double-blind study with open-label estensione to investigate the efficacy and safety of IgPro20 (sc Ig Hizentra) in adults with IIM" (2023)*
- **Principal Investigator:** *"Studio di sicurezza post-autorizzazione (PASAS): studio osservazionale di coorte su pazienti affetti da PAH trattati per la prima volta con Uptravi (Selexipag) o un'altra terapia specifica per PAH nella pratica clinica" (2023)*
- **Principal Investigator:** *"A Multicenter, Open-label Extension Trial to Evaluate the Efficacy, Safety, and Tolerability of HZN-825 in Patients with Diffuse Cutaneous Systemic Sclerosis" (2023)*
- **Principal Investigator:** *"A Double Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of PRA023 in Subjects with Systemic Sclerosis Associated with Interstitial Lung Disease (SSc-ILD)" (2023)*
- **Principal Investigator:** *"A Phase III, Randomized, Double-Blind, Single-Dose, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of Study Drug in Subjects with Active Psoriatic Arthritis I" (2023)*
- **Principal Investigator:** *"A Phase 1b/2 Open-Label, Multiple-Ascending Dose Study Followed by a Randomized, Double-Blind, Placebo controlled Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamic Effects, and Efficacy of ACE-1334 Plus Standard of Care in Participants with Systemic Sclerosis with and Without Interstitial Lung Disease" (2023)*
- **Principal Investigator:** *"A phase 2a/2b, randomized, double-blinded, placebo-controlled, parallel-group study to evaluate the efficacy, safety, tolerability, pharmacodynamics, pharmacokinetics and immunogenicity of Efgartigimod PH20 SC in patients with active Idiopathic Inflammatory Myopathy (IIM)" (2023)*
- **Principal Investigator:** *"A Double Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of PRA023 in Subjects with Systemic Sclerosis Associated with Interstitial Lung Disease (SSc-ILD)" (2023)*
- **Principal Investigator:** *"A phase II, randomized, placebo-controlled, double-blind, parallel group, efficacy and safety study of at least 48 weeks of oral BI685509 treatment in adults with early progressive diffuse cutaneous SSc" (2023)*
- **Principal Investigator:** *"A Phase 2/3, randomized, double-blind, placebo-controlled, parallel-group treatment study to evaluate the efficacy and safety of belimumab administered subcutaneously in adult participants with interstitial lung disease associated with diffuse cutaneous systemic sclerosis (dcSSc-ILD) (2023)*
- **Principal Investigator:** *"A Multicenter, Open-label Extension Trial to Evaluate the Efficacy, Safety, and Tolerability of HZN-825 in Patients with Diffuse Cutaneous Systemic Sclerosis" (2023)*
- **Principal Investigator:** *"A Phase 2, randomized, double-blind, placebo-*

controlled, efficacy and safety study of daxdilimab subcutaneous injection in adult participants with inadequately controlled dermatomyositis or anti-synthetase inflammatory myositis.” (2023)

- **Principal Investigator:** “A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of PF 06823859 in participants with Active Idiopathic Inflammatory Myopathies (including participants with Active Dermatomyositis, Juvenile Dermatomyositis, and with Polymyositis) who have or have had an inadequate response or are intolerant to at least one commonly used therapy” (2023)
- **Principal Investigator:** “A randomized, placebo controlled, double-blind, reapeat-dose, multicenter trial, to evaluate the efficacy, safety, tolerability and pharmacokinetics of HZN-825 in patientes with dcSSC. (2022)
- **Principal Investigator:** “Prospective observational cohort study on LES”. Bayer contribution (2018).
- **Principal Investigator:** “Prospective observational cohort study on LES”. Quintiles contribution (2018).
- **Principal Investigator:** “A prospective, multinational observational study aimed at evaluating the efficacy, use of health benefits and costs in patients treated with Baricitinib.” Inc.Research Italia contribution (2018).
- **Principal Investigator:** “A phase 3, randomized, double blind clinical trial to evaluate the efficacy and safety of Abatacept sc with standard treatment compared to standard treatment alone in improving disease activity in adults with active IIM”. ICON Clinical Research Lim. contribution (2018).
- **Principal Investigator:** “Phase 3 random, double-blind trial of Abatacept SC for improvement in adults of idiopathic inflammatory myopathy (MII) ”. ICON Clinical Research Lim. contribution (2018).
- **Principal Investigator:** “Thermal therapy for the rehabilitation of patients with systemic sclerosis and spondylarthritis ”. FORST contribution (2018).
- **Principal Investigator:** “Research Project in the field of Clinical Rheumatology”. FIRA contribution (2018).
- **Principal Investigator:** “Multicenter, randomized, double-blind, placebo-controlled, phase 3 study to evaluate the efficacy and safety of dcSSC Lenabasum”. Corbus contribution (2018).
- **Principal Investigator:** “Development Research in the immunological field”. CLS Behring contribution (2018).
- **Principal Investigator:** “A multicenter observational study to evaluate the real life effectiveness of Benepali following transition from Enbrel in patients with RA and axSPA”. Chilter Int. contribution (2018).
- **Principal Investigator:** “Early diagnosis of rheumatic diseases: realization of a fast track for a "real time referral" of the patient”. Bristol-Myers Squibb contribution (2018).
- **Principal Investigator:** “Post-authorization safety study (PASAS): observational cohort study on patients with PAH treated for the first time with Uptravi (Selexipag) or another specific therapy for PAH in clinical practice”. Actelion Pharmaceuticals contribution (2018).
- **Principal Investigator:** “Screening and diagnosis of pulmonary hypertension in connective diseases”. Actelion Pharmaceuticals contribution (2018).
- **Principal Investigator:** “Randomized, double-blind, placebo-controlled, 24-week, proof of concept study to evaluate the efficacy and safety of SAR156597 in patients with widespread SSC”. Sanofi contribution (2017).
- **Principal Investigator:** “Phase 3 randomized, double-blind, multi-dose, placebo-controlled trial to evaluate the safety and long-term efficacy of fasinumab in patients with osteoarthritis of the knee or hip”. Regeneron contribution (2017).
- **Principal Investigator:** “Prospective, mulcentre, double-blind interventional study to compare the maintenance of efficacy of tocilizumab in reumathoid

arthritis patients with or without glucocorticoids discontinuations". Roche contribution (2017).

- **Principal Investigator:** "Prospective observational cohort study on systemic lupus erythematosus (LES) (SPOCS)". Quintiles contribution (2017).
- **Principal Investigator:** "A multicenter, randomized double-blind, placebo-controlled trial with secukinumab to evaluate efficacy, safety and tolerability for up to two years in patients with non-radiographic active axial spondyloarthritis". Novartis contribution (2017).
- **Principal Investigator:** "A prospective observational study to evaluate the efficacy of golimumab in patients with RA, PsA or axSpA". Msd-Go-Beyond Italy (2017).
- **Principal Investigator:** "Contribution for the creation of a corporate and territorial rheumatological care network". MSD contribution (2017).
- **Principal Investigator:** "Assessment of Stelara (Ustekinumab) and Tumor Necrosis Factor Alpha Inhibitor Therapies with Psoriatic Arthritis in standard health-care practice; a prospective, observational cohort". Janssen Contribution (2017).
- **Principal Investigator:** "In search for the parenchymal and vascular features in SSc-ILD: how to address the challenge of quantitative analysis of CT images and correlation with clinical and instrumental data". GILS contribution (2017).
- **Principal Investigator:** "Pre-adipocytes as inducers of angiogenesis and remodeling of the extracellular matrix in patients affected by Systemic Sclerosis". FIRA contribution (2017).
- **Principal Investigator:** "A 2-fold, randomized, double-blind, placebo-controlled phase 2 study to evaluate the safety and efficacy of LY3337641 in adults with rheumatoid arthritis. Studio RAjuvenate." Eli Lilly contribution (2017).
- **Principal Investigator:** "Multicenter, randomized, double-blind, placebo-controlled study of RO7123520 for rheumatoid arthritis and inadequate response to TNF alpha inhibitors". Roche contribution (2017).
- **Principal Investigator:** "Contribution to research on inflammatory and degenerative joint diseases". Bruno Farmaceutici contribution (2017).
- **Principal Investigator:** "Phase 3 Multicentric Study, Randomized, In Double Blind, Controlled Towards Placebo On The Analgesic Efficacy And The Security Of The Subcutaneous Administration. Inventiva Health (2016).
- **Principal Investigator:** "Use of intravenous prostanoids in the treatment of scleroderma vasculopathy". GILS contribution (2016).
- **Principal Investigator:** BMS-Phase II study "Randomized, multicenter, double-blind, multi-dose, placebo-controlled, adaptive design to evaluate efficacy and safety / pharmacokinetics". Bristol-Myers Squibb contribution (2016).
- **Principal Investigator:** "Randomized suspension study to compare Etanercept in monotherapy and methotrexate". AMGEN contribution (2016).
- **Principal Investigator:** "Project to carry out an information / awareness campaign against osteoporosis in rheumatic patients". AMGEN contribution (2016).
- **Principal Investigator:** "Early treatment of Exercise-induced pulmonary hypertension in systemic sclerosis", funded by the Ministry of Health. (Bando Saluto 2011-2012).
- **Principal Investigator:** "Systemic sclerosis patients Evaluated by Chest Ultrasound: Redefining the diagnostic approach to lung involvement (SECURE)", funded by the Program for Regional Research in Health Matters 2009. Regional Health System.
- **Principal Investigator:** "Sputum induced in Systemic Sclerosis (SSc) proposal of a new tool to evaluate pulmonary interstitial disease in the SSC and comparison with bronchoalveolar lavage (BAL)". Italiana Ministry for Research (PRIN 2005, duration 24 months; co-funded by MIUR - Ministry of Education University and

Research).

- **Principal Investigator:** *Neuropeptides in bronchoalveolar lavage (BAL) of patients with Systemic Sclerosis (SSc)*. PRIN 2002, duration 24 months; co-funded by MIUR - Ministry of Education University and Research).
- **Principal Investigator:** "Neurophysiological, morphological and molecular study of the peripheral nervous system in Systemic Sclerosis (SSc duration 24 months; co-funded by MIUR - Ministry of Education University and Research).
- **Principal Investigator:** *Effects of Raloxifene in vitro on chemotaxis and on u-PA dependent proliferation in human synoviocytes* ", funded by Ely Lilly (2000-2001), duration 24 months.

Clinical Trials

- **ASPIRE:** "A randomized, trial of anti-TNF alfa chimeric monoclonal antibody (Infliximab) in combination with Methotrexate alone for the treatment of patients with early rheumatoid arthritis"
- **Rapids-1**(Protocollo AC-052-401): "An exploratory, double-blind, randomized, placebo-controlled study on the prevention of ischemic digital ulcers secondary to systemic sclerosis"
- **IL-1ra 20000258:** "A multicentre, open label study to describe the HAQ (Health Assessment Questionnaire) disability in subject with active Rheumatoid Arthritis given daily subcutaneous injection of Anakinra (r-metHuIL-1ra)"
- **IL-1ra 2002 0125:** "Anakinra Simple Ject: "Studio in aperto, randomizzato, crossover, per verificare mediante un questionario di auto-valutazione, , l'accettabilità e la funzionalità nell'uso del dispositivo Simple-Ject rispetto all'uso di siringhe pre-riempite per la somministrazione di Anakinra in soggetti con Artrite REumatoide".
- **Re-Act -M02-497:** "An Open-Label, Multi-Center Study to Assess the Safety and Efficacy of the Fully Human Anti-TNF- α Monoclonal Antibody Adalimumab (D2E7) when added to inadequate standard Anti-Rheumatic therapy in patients with active Rheumatoid Arthritis"
- **Rapids 2** (AC-052-331): "A randomized double-blind, placebo-controlled, multicenter study to assess the effect of Bosentan on Healing and prevention of ischemic digital ulcers in patients with Systemic Sclerosis"
- **Build 1**(AC-052-332): "A double-blind, randomized, placebo-controlled, multicenter study to assess the efficacy, safety and tolerability of Bosentan in patients with interstitial lung disease associated with Systemic Sclerosis"
- **Build 2** (AC-052-332 open label): "Bosentan use in interstitial lung disease, long term study in patient with interstitial lung disease associated with Systemic Sclerosis who completed the protocol AC-052-330/Build 2"
- **RA-1:** "A phase II, multicenter, randomized, double-blind, « sham » pheresis-controlled, study of extracorporeal photoimmune therapy with uvadex ® for patients who have an inadequate response to disease-modifying antirheumatic drugs and biological agents"
- **Re-Alise** (M03-634): "A five year, post-marketing observational study to follow-up patients with rheumatoid arthritis formerly treated in study M02-497 (ReAct) and subsequently prescribed HUMIRA"
- **Heal-RA** (ITAL-04-004): "Health Economics of Adalimumab in Rheumatoid Arthritis"
- **REFLEC Study:** "Rheumatological evaluation of facts leading to excellent treatment. Symptomatic outcome measures in musculoskeletal disorders revisited"
- **COX 189:** "Studio internazionale, multicentrico, randomizzato, in doppio cieco, a gruppi paralleli, della durata di 52 settimane, per comparare la permanenza al trattamento, la sicurezza, la tollerabilità e l'efficacia del Lumiracoxib 100 mg 1 volta al giorno, Lumiracoxib 100 mg 2 volte al giorno e Celecoxib 200mg 1 volta

al giorno in pazienti con osteoartrite primaria del ginocchio, dell'anca delle mani o del rachide"

- **CRx-139**: "A phase II multi center, randomized, blinded study of 14 weeks duration comparing the effects of CRx-139 plus DMARD therapy to that of steroids plus DMARD therapy using ACR-20 in subject with active rheumatoid arthritis partially responsive to the DMARD"
- **RIVIERA**: "Aspettativa di sicurezza per le terapie anti TNF-alpha, intravenose e sottocute, in pazienti affetti da artrite reumatoide"
- **DART**: "Anti TNF drug utilization and dosing patterns assessment: a retrospective chart review study of subject created for rheumatoid arthritis"
- **SOJIA** (IFT2357 DSC/05/2357/19): "Studio di fase II, open label, internazionale, multicentrico, per valutare la sicurezza e l'efficacia di ITF2357 per via orale in pazienti con artrite idiopatica sistemica ad esordio giovanile"
- **LITHE** (WA 17823): "Studio fase III, doppio cieco, gruppi paralleli, controllato verso placebo a 3 gruppi in pazienti con Artrite Reumatoide moderata –severa in fase attiva in risposta inadeguata a MTX"
- **RHAPSODY** (M05-760): "Revisione della sicurezza e dell'efficacia di Adalimumab in pazienti affetti da Spondilite anchilosante- Studio open-label per valutare la risposta di Adalimumab in pazienti che hanno fallito altre terapie con anti-TNF-alpha"
- **SAVE**: "Very early steroid therapy in Arthritis- prospective, controlled clinical trial for evaluating the effect of 120 mg Depo-metilprednisolone in comparison to placebo in early inflammatory joint disease" .
- **WA17047**: "Studio multicentrico randomizzato, controllato, di fase II, in doppio cieco e a gruppi paralleli, per valutare l'efficacia e la sicurezza di rituximab in associazione con MTX rispetto al MTX da solo, in pazienti con artrite reumatoide attiva naive al MTX"
- **RESULTS**: "Studio osservazionale internazionale multicentrico della sicurezza a lungo termine di Infliximab (Remicade)"
- **PACE** (0881A-101750): "Studio osservazionale per la valutare i costi del trattamento dell'ArtritePsoriasica refrattaria alle terapie convenzionali"
- **LEADER** (LEFLU_R_01143): "Valutazione del tasso di risposta precoce in termini di efficacia di leflunomide in funzione del regime terapeutico in pazienti affetti da artrite reumatoide in fase precoce non precedentemente trattati con DMARDs"
- **STI571** (Gleevec-AIFA): "Amulti-centre, open-label, Proof of Concept (PoC) study to evaluate the efficacy and tolerability of STI571 for the treatment of pulmonary fibrosis in patients with systemic sclerosis"
- **ARG098-CL-001**: "Dose-escalation study of a single intra-articular administration of ARG098 to the target knee in patients with rheumatoid arthritis"
- **Studio CURE**: "Studio prospettico sul trattamento intensivo della AR precoce con Adalimumab: induzione di remissione e mantenimento"
- **A3921035**: "Studio multicentrico, di fase 2B, randomizzato, placebo controllato conun comparatore attivo, per confrontare 5 dosi di regime diverso di terapia con CP-690.550 e Adalimumab verso placebo, somministrato per 6mesi in pazienti con artrite reumatoide in fase attiva".
- **A3921029**: "Studio di follow-up di post trattamento per valutare la sicurezza e lo stato funzionale a lungo termine di soggetti con artrite reumatoide precedentemente trattati con CP-69.550".
- **A3921024**: "Studio a lungo termine, con follw-up in aperto del CP- 69550, un inibitore moderatamente selettivo dell janino kinasi 3, nel trattamento dell'artrite reumatoide"
- **Registro DUO**: "Registro sulle ulcere digitali associate a sclerodermia"
- **REMARK**: "Epidemiology, correlation and predictive value of disease activity and biomarkers in RA patients initiated on IFX in clinical practice"

- **FP-009-IT:** "Adherence to PTH treatments in Italy. A non-interventional cohort study collecting safety information and examining reasons and predictor for adherence to PTH treatments in usual clinical setting"
- **ISSO (B3D-IT-B014):** "Studio osservazionale in pazienti con osteoporosi severa trattati con terapia convenzionale, per valutare l'outcome delle fratture vertebrali, la compliance al trattamento, la lombalgia e la qualità di vita"
- **GAG urinari:** "Studio per la ricerca di GAG urinary per la diagnosi della mucopolisaccaridosi"
- **CTI571E2205:** "A multi-centre, open-label, Proof of Concept (PoC) study to evaluate the efficacy and tolerability of CTI571 for the treatment of skin fibrosis in patients with systemic sclerosis"
- **VOLT (AMB110094):** "Studio osservazionale per la valutazione di Ambrisentan nel trattamento dell'ipertensione arteriosa polmonare secondo pratica clinica in pazienti affetti da Sclerosi Sistemica"
- **QUEST-RA:** "Studio multicentrico internazionale. Lo scopo è quello di definire lo standard terapeutico in rapporto con lo status di attività della malattia. Ogni centro dovrebbe inserire 100 pazienti AR consecutivi".
- **WORK-ABILITY:** "Studio atto a valutare il recupero della workability fra i pazienti in terapia con anti-TNF alpha"
- **ISD003-P144-08:** "Studio di fase II, multicentrico, randomizzato, in doppio cieco, placebo controllato, per valutare efficacia e sicurezza del P144 per somministrazione topica per la fibrosi cutanea in pazienti affetti da Sclerosi Sistemica"
- **ISD003-P144-08 OLE:** "Studio di estensione in open label (OLE) per il trattamento locale della fibrosi cutanea con P144 in pazienti affetti da Sclerosi Sistemica"
- **RAPSODIA:** "La qualità di vita e i bisogni dei pazienti con Artrite Reumatoide, Artrite Psoriasica e Spondilite Anchilosante"
- **BKOS-02 – MEN 16132:** "Trattamento intra-articolare con MEN 16132 in pazienti con osteoartrosi sintomatica del ginocchio: studio randomizzato, multicentrico, in doppio cieco, placebo-controllato, a 5 gruppi paralleli, dose-finding"
- **ACTION (IM101-151):** "Esperienza a lungo termine con abatacept nella pratica clinica"
- **PRESERVE:** "A Randomized, Double-Blind Study Comparing the Safety and Efficacy of Once-Weekly Administration of Etanercept 50 mg, Etanercept 25 mg, and Placebo in Combination With Methotrexate in Subjects With Moderately Active Rheumatoid Arthritis Who Have Achieved an Adequate Response With Etanercept 50 mg Once Weekly and Methotrexate"
- **SWITCH-RA (MA22401):** "Studio osservazionale multicentrico globale nell'artrite reumatoide per pazienti non responder o intolleranti ad un singolo anti TNF"
- **TRUST (ML 25728):** "Pazienti con artrite reumatoide in trattamento con Tocilizumab nella reale pratica clinica: benefici clinici e profilo di sicurezza"
- **ACT11575:** "Studio randomizzato, in doppio cieco, a gruppi paralleli, placebo e calibratore controllo attivo per valutare i benefici clinici di SAR153191 sottocute con MTX in pazienti con artrite reumatoide attiva che hanno fallito un precedente anti TNF"
- **RA-TL011-101:** "Studio di fase Ib per la valutazione della sicurezza, dei profili di farmacocinetica e farmacodinamica di un singolo ciclo di trattamento con TL011 per infusione, in soggetti affetti da artrite reumatoide attiva severa"
- **GOSAVE (CNT0148ART3002):** "Studio di fase 3b multicentrico per valutare l'efficacia del passaggio a golimumab sottocutaneo ed endovenoso in pazienti con artrite reumatoide che presentano un controllo inadeguato della malattia malgrado il trattamento con etanercept (ENBREL®) o con adalimumab"
- **AS001:** "Phase 3, multicenter, randomized, double blind, placebo controlled study to evaluate efficacy and safety of certolizumab pegol in subjects with axial"

spondyloarthritis (axial SpA)”

- **CAIN457F2309**: “A randomized, double-blind, placebo- and active-controlled study of secukinumab to demonstrate the efficacy at 24 weeks and to assess the safety, tolerability and long term efficacy up to 1 year in patients with active rheumatoid arthritis who have an inadequate response to anti-TNF α agents”
- **DUAL**: “Prospective, randomized, placebo-controlled, double-blind, multicenter, parallel, group study to assess the efficacy, safety and tolerability of macitentan in patients with ischemic digital ulcers associated with systemic sclerosis”
- **SPEED**: “Studio multicentrico in aperto, per valutare la predittività della risposta precoce a Certolizumab Pegol (con MTX) confermata a 52 settimane in soggetti con AR di grado moderato severo”
- **IM133-004**: “Studio multicentrico, dose ranging, placebo controllato, doppio cieco per valutare safety ed efficacy di BMS-945429 sc in APs”
- **ENTRACT (WA25204)**: “A clinical outcomes study to evaluate the effects of IL 6 receptor blockade with TOCI in comparison with ETA on the rate of cardiovascular events in patients with moderate RA”
- **MA 25522**: “A multicenter, randomized, double-blind, parallel-group study of the reduction of signs and symptoms during treatment with tocilizumab (TCZ) versus adalimumab (ADA) in combination with methotrexate (MTX) in patients with moderate to severe active rheumatoid arthritis and an inadequate efficacy response to treatment with only one tumor necrosis factor (TNF) inhibitor”
- **EFC10832 (TARGET)**: “A randomized, double-blind, parallel, placebo-controlled study assessing the efficacy and safety of sarilumab added to non-biologic DMARD therapy in patients with rheumatoid arthritis who are inadequate responders to or intolerant of TNF- α antagonists”
- **CAIN457F2309E1**: “A four year extension study to evaluate the long term efficacy, safety and tolerability of secukinumab in patients with active rheumatoid arthritis”
- **EFC11574 (COMPARE)**: “A randomised controlled study of sarilumab and methotrexate vs etanercept and mtx in patients with rheumatoid arthritis and an inadequate response to 4 months of treatment with adalimumab and mtx”
- **SFY13370 (ASCERTAIN)**: “A randomized, double-blind, double-dummy study assessing the safety and tolerability of sarilumab and tocilizumab in patients with rheumatoid arthritis who are inadequate responders to or intolerant of TNF antagonists”
- **ML28336 (UMBRELLA ACT-UP)**: “Studio su PCR e BMI: valutazione nella pratica clinica del tasso di remissione clinica e della correlazione tra PCR e BMI in pazienti trattati con Tocilizumab”
- **ML28552 (ARMONIA)**: “Studio osservazionale multicentrico sull'uso dei farmaci biologici in monoterapia o in combinazione con DMARDs in pazienti con artrite reumatoide nella pratica clinica italiana”
- **IM133-004**: “A phase 2b, randomized, double-blind, placebo-controlled, dose ranging, multicenter study to evaluate the efficacy and safety of BMS-945429 subcutaneous injection in adults with active psoriatic arthritis”
- **14V-MC-JADZ**: “A randomized, double-blind, active-controlled, phase 3 study to evaluate the efficacy and safety of Baricitinib (LY3009104) in patients with moderately to severely active rheumatoid arthritis who have had limited or no treatment with DMARDs”
- **14V-MC-JADW**: “A randomized, double-blind, active-controlled, phase 3 study to evaluate the efficacy and safety of Baricitinib (LY3009104) in patients with moderately to severely active rheumatoid arthritis who have had limited or no treatment with anti-TNF α ”
- **NN8226-3612**: “A randomised, double-blind, placebo-controlled, multiple dose, phase 2b, 24 week trial followed by an open label extension of NNC0109-0012, an anti-IL-20 biologic, in patients with active rheumatoid arthritis who are

- inadequate responders to anti-TNFalfa biologics”
- **NN8226-3613**: “A randomised, double-blind, placebo-controlled, multiple dose, phase 2b, 24 week trial followed by an open label extension of NNC0109-0012, an anti-IL-20 biologic, in patients with active rheumatoid arthritis who are inadequate responders to methotrexate”
 - **LTS11210**: “A multicenter, uncontrolled extension study evaluating efficacy and safety of SAR153191 on top of DMARDs in patients with active rheumatoid arthritis”
 - **PSSc-001**: “An open-label, randomized, phase 2 study of the safety and tolerability of pirfenidone when administered to patients with Systemic Sclerosis-related Interstitial Lung Disease (LOTUSS)”
 - **IM101-332**: “A phase III randomized, placebo-controlled study to evaluate the efficacy and safety of abatacept subcutaneous injection in adults with active psoriatic arthritis”
 - **14V-MC-JADY**: “Studio multicentrico di fase III teso a valutare la sicurezza e l'efficacia a lungo termine di baricitinib nei pazienti affetti da artrite reumatoide”
 - **BKOS-04 (ALBATROSS-3)**: “Studio in doppio cieco, randomizzato, controllato con placebo, a 4 bracci paralleli, di ricerca della dose, per valutare l'efficacia, sicurezza, tollerabilità e farmacocinetica di una singola iniezione intra-articolare di fasitibant in pazienti con osteoartrite sintomatica del ginocchio”
 - **CNT0136ARA3004**: “A multicenter, parallel group study of long-term safety and efficacy of CNT0136 (sirukumab) for rheumatoid arthritis in subjects completing treatment in CNT0136ARA3002 e CNT0136ARA3003”
 - **ML28699 (TOZURA)**: “Studio nazionale, in aperto, a singolo braccio, di fase IIIb, per valutare l'efficacia di tocilizumab sottocute, somministrato una volta a settimana in monoterapia o in combinazione con methotrexato e/o con altri DMARD in pazienti con artrite reumatoide (TOZURA)”
 - **12EU/C106**: “A multicenter, comparative, randomised, double-blind, double-dummy clinical trial on the efficacy and safety of Condrosulf versus Celebrex and versus placebo in the treatment of knee osteoarthritis”
 - **IM133-066**: “A phase 2b, randomised, multi-center, double-blind, dose-ranging, placebo controlled study to evaluate the efficacy and safety of clazakizumab compared to placebo in subject with moderate to severe active RA who have experienced an inadequate response to TNF-inhibitors”
 - **CARA**: “Preferenze dei pazienti, medici, infermieri e farmacisti verso gli attributi dei farmaci biologici utilizzati nel trattamento delle malattie reumatiche in Italia”
 - **ASCORE**: “Studio osservazionale prospettivo, non interventistico, internazionale e multicentrico dal titolo “Esperienza a lungo termine con Abatacept sottocute nella pratica clinica: studio ASCORE”
 - **RISE (16277)**: “A randomized, double-blind, placebo-controlled phase II study to investigate the efficacy and safety of Riociguat in patients with cutaneous Systemic Sclerosis (dcSSc)”
 - **PREDICT (MK8259)**: “Achieving minimal disease activity and predictors of clinical response in patients with psoriatic arthritis treated with golimumab in clinical practice: A multicenter observational study”
 - **SEMIRA(MA29585)**: “Prospective, multicentre, double-blind interventional study to compare the maintenance of efficacy of tocilizumab in rheumatoid arthritis patients with or without glucocorticoids discontinuation”
 - **FOCUSSED(WA29767)**: “A phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy and safety of tocilizumab versus placebo in patients with systemic sclerosis”
 - **Study #220973 (Prot. 201755)**: “A Phase IIb, double-blind, placebo-controlled, dose-adaptive, study of efficacy and safety of GSK3196165 in combination with methotrexate therapy, in subjects with active moderate-severe rheumatoid arthritis despite treatment with methotrexate”

- **IVA337 SSC POC:** "Studio clinico proof of concept multicentrico, randomizzato, in doppio cieco, controllato verso placebo di IVA337 nel trattamento della sclerosi sistemica cutanea diffusa"
- **Psa 222323:** "Assessment of Stelara (Ustekinumab) and Tumor Necrosis Factor Alpha Inhibitor Therapies with Psoriatic Arthritis in standard health-care practice; a prospective, observational cohort"
- **As002:** "Studio non interventistico per valutare l'efficacia di Certolizumab Pegol nella pratica clinica in pazienti con SPA"
- **I8K-MC-JPDA:** "Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study to Evaluate the Efficacy and Safety of LY3337641 in Adult Subjects with Moderate to Severe Rheumatoid Arthritis"
- **GO-Beyond:** "A prospective observational study to assess real world effectiveness of Golimumab in active RA, PsA, SPA and failure of first tIF alpha"
- **BP29261:** "A double-blind, active-controlled, randomized, parallel-group, three part global multicaster study to evaluate the safety and efficacy of treatment with RO7123520 as adjunctive therapy in RA"
- **ACT14604:** "Studio randomizzato, doppio cieco, placebo controllato, 24 settimane, proof of concept per valutare efficacia e sicurezza del SAR156597 in pazienti con SSc diffusa"
- **IM006-016:** "Phase 2, Randomized, Multi-Center, Double-Blind, Dose-Ranging, Placebo-Controlled, Adaptive Design Study to Evaluate the Efficacy and Safety of BMS-986142 in Subjects with Moderate to Severe Rheumatoid Arthritis with an Inadequate Response to Methotrexate or TNF Inhibitors"
- **BENEFIT:** "Studio multicentrico, osservazionale per valutare l'efficacia nella pratica clinica di Benepali dopo transizione da Enbrel in pazienti affetti da Artrite reumatoide e Spondiloartrite assiale"
- **20110186:** "A randomized withdrawal Double-blind study of etanercept monotherapy compared to MTX monotherapy for maintenance of remission in subject with RA"
- **IM101611:** "Sperimentazione clinica di fase 3, randomizzata in doppio cieco per valutare efficacia e sicurezza di Abatacept sc con il trattamento standard, rispetto al trattamento standard da solo, nel migliorare l'attività di malattia in pazienti affetti da miopatia infiammatoria idiopatica (MII) attiva"
- **SPOCS:** "Studio di coorte osservazionale prospettico sul lupus eritematoso sistemico (LES) (SPOCS) Coorte prospettica osservazionale di pazienti affetti da LES da moderato a grave volta a caratterizzare l'attività della malattia trasversale e longitudinale, i modelli di trattamento e l'efficacia, gli esiti e le comorbidità, l'utilizzo delle risorse sanitarie e l'impatto del LES sulla qualità della vita in base allo stato dell'espressione dell'interferone di tipo
- Studio multicentrico randomizzato in doppio cieco placebo controllato di fase 3 per valutare efficacia e sicurezza di Lenabasum di dcSSC: **CORBUS**
- Registro italiano delle gravidanze nelle malattie reumatiche. **P-RHEUMIT**
- Ricerca delle caratteristiche parenchimali e vascolari dell'interstiziopatia sclerodermica: correlazioni tra parametri di analisi quantitative di tomografia computerizzata e dati clinici e strumentali **SCLERO IRR**
- "Definizione dei livelli di severità di malattia in corso di fibromialgia. Progetto multicentrico Nazinale".
- "A phase IIa randomized double-blind, placebo controlled, multicenter study to evaluate the efficacy, safety and tolerability of orally administered GLPG1690 for 24 weeks in SSC: **GLPG1690-CL20**
- "Registro italiano delle gravidanze nelle malattie reumatiche"
- "Studio osservazionale prospettico, multinazionale, volto a valutare l'efficacia, l'uso di risorse sanitarie ed i costi in paziente trattati con Baricitinib"

SCIENTIFIC PUBLICATION
LIST
(ONLY A PART OF THE
PUBLICATION IS LISTED)

2025

1. De Luca G, De Santis M, Batani V, Tonutti A, Campochiaro C, Palmisano A, Vignale D, Motta F, Monti L, Francone M, Selmi C, **Matucci-Cerinic M**, Esposito A, Dagna L. Immunosuppressive therapy to treat newly diagnosed primary heart involvement in patients with systemic sclerosis: An Italian cardiac magnetic resonance based study *Semin Arthritis Rheum.* 2025;71:152622
2. Tonutti A, Motta F, De Angelis R, Cipolletta E, Ferri C, Bajocchi G, Bellando-Randone S, Bruni C, Orlandi M, Zanframundo G, Foti R, Cuomo G, Ariani A, Rosato E, Lepri G, Girelli F, Zanatta E, Bosello SL, Cavazzana I, Ingegnoli F, Cacciapaglia F, Murdaca G, Abignano G, Pettiti G, Rossa AD, Caminiti M, Iuliano AM, Ciano G, Beretta L, Bagnato G, Lubrano E, De Andres I, Idolazzi L, Saracco M, Agnes C, Campochiaro C, Fornaro M, Lumetti F, Spinella A, Magnani L, De Luca G, Codullo V, Visalli E, Iandoli C, Gigante A, Pellegrino G, Pigatto E, Lazzaroni MG, De Lorenzis E, Mennillo G, Di Battista M, Pagano-Mariano G, Furini F, Vultaggio L, Parisi S, Peroni CL, Bianchi G, Fusaro E, Sebastiani GD, Govoni M, D'Angelo S, Cozzi F, Franceschini F, Guiducci S, Dagna L, Doria A, Giuggioli D, Riccieri V, Salvarani C, Iannone F, **Matucci-Cerinic M**, Selmi C, De Santis M; SPRING-SIR (Systemic Sclerosis PRogression INvestiGation group of the Italian Society for Rheumatology). First-line diagnostic tests to intercept primary heart involvement in systemic sclerosis: Clinical associations from the SPRING-SIR registry. *Eur J Clin Invest.* 2025 Jul 4:e70094.
3. Bandini G, Bellando Randone S, Manetti M, Dagna L, **Matucci Cerinic M**, Moggi Pignone A. Endotheliopathy in systemic sclerosis: from endothelium-dependent vasodilation to the dysfunction of the vascular reserve, is the paradise lost? *Arthritis Res Ther.* 2025 May 17;27(1):107.
4. Batani V, Palmisano A, Campochiaro C, Vignale D, Bruno E, Peretto G, Sala S, Dagna L, Esposito A, **Matucci-Cerinic M**, De Luca G. The complex diagnosis of primary heart involvement in systemic sclerosis: red flags to drive the choice of cardiac magnetic resonance. *Rheumatology (Oxford).* 2025 May 12:keaf234
5. Campochiaro C, Suliman YA, Giuggioli D, Moinzadeh P, Alunno A, Schoones JW, Baron M, Chung L, Ross L, Maltez N, Alcacer-Pitarch B, El-Aoufy K, Allanore Y, Del Galdo F, Denton CP, Distler O, Frech T, Furst DE, Khanna D, Krieg T, Kuwana M, **Matucci-Cerinic M**,

- Pope J, Hughes M.J Recommendations for the local management of digital ulcers in systemic sclerosis: A report from the World Scleroderma Foundation (WSF) 'Ad hoc committee'. J Scleroderma Relat Disord. 2025 May 15:23971983251339821
6. Orlandi M, Giuggioli D, Ferri C, De Angelis R, Riccieri V, Cacciapaglia F, Bosello SL, Codullo V, Bajocchi G, Dagna L, Campochiaro C, De Luca G, Zanframundo G, Foti R, Cuomo G, Ariani A, Rosato E, Girelli F, Zanatta E, Cavazzana I, Ingegnoli F, De Santis M, Murdaca G, Abignano G, Petitti G, Della Rossa A, Caminiti M, Iuliano AM, Ciano G, Beretta L, Bagnato G, Lubrano E, De Andres I, Giollo A, Saracco M, Agnes C, Cipolletta E, Lumetti F, Spinella A, Magnani L, Visalli E, Iandoli C, Gigante A, Pellegrino G, Pigatto E, Lazzaroni MG, Franceschini F, Generali E, Mennillo G, Barsotti S, Pagano Mariano G, Furini F, Vultaggio L, Parisi S, Peroni CL, Bianchi G, Fusaro E, Sebastiani GD, Govoni M, D'Angelo S, Cozzi F, Doria A, Salvarani C, Iannone F, Guiducci S, Bellando-Randone S, **Matucci-Cerinic M**, Bruni C. Menopause in systemic sclerosis: the impact on clinical presentation in a multicenter cross-sectional analysis from the National Registry of the Italian Society for Rheumatology (SPRING-SIR). Ther Adv Musculoskelet Dis. 2025 Jul 14;17:1759720X251354898.
 7. Orlandi M, De Luca G, Ferri C, Spinella A, Lumetti F, Costantini RC, De Angelis R, Riccieri V, Bosello SL, Cacciapaglia F, Codullo V, Bajocchi G, Campochiaro C, Zanframundo G, Foti R, Cuomo G, Ariani A, Rosato E, Girelli F, Zanatta E, Cavazzana I, Ingegnoli F, De Santis M, Murdaca G, Abignano G, Giorgio P, Della Rossa A, Caminiti M, Iuliano AM, Ciano G, Beretta L, Bagnato G, Lubrano E, De Andres I, Giollo A, Saracco M, Agnes C, Cipolletta E, Magnani L, Visalli E, Iandoli C, Gigante A, Pellegrino G, Pigatto E, Lazzaroni MG, Franceschini F, Generali E, Mennillo G, Barsotti S, Mariano GP, Furini F, Vultaggio L, Parisi S, Peroni CL, Bianchi G, Fusaro E, Sebastiani GD, Govoni M, D'Angelo S, Cozzi F, Guiducci S, Doria A, Salvarani C, Iannone F, Dagna L, **Matucci-Cerinic M**, Bellando-Randone S, Giuggioli D; SPRING-SIR (Systemic Sclerosis PRogression INvestiGation group of the Italian Society of Rheumatology) coworkers. Prevalence and clinical relevance of digital ulcers in systemic sclerosis patients from the real-life: the experience of the SPRING Registry of the Italian Society for Rheumatology. Clin Rheumatol. 2025 Jul;44(7):2849-2860
 8. Batani V, Palmisano A, Campochiaro C, Vignale D, Bruno E, Peretto G, Sala S, Dagna L, Esposito A, **Matucci-Cerinic M**, De Luca G. The complex diagnosis of primary heart involvement in systemic sclerosis: red flags to drive the choice of cardiac magnetic resonance. Rheumatology (Oxford). 2025 May 12:keaf234
 9. Matucci-Cerinic P, Akpabio A, Hughes M, Schoones JW, McMahan ZH, Vecchiato M, Martino A, Petri R, Terrosu G, **Matucci-Cerinic M**, Alunno A. The role of surgery in esophageal involvement in systemic sclerosis: A systematic literature review. Semin Arthritis Rheum. 2025 Jul 25;74:152791
 10. Bonomi F, Bandini G, Guiducci S, **Matucci-Cerinic M**, Bellando-Randone S. Unveiling the hidden trajectories of gastrointestinal disease in systemic sclerosis. Rheumatology (Oxford). 2025 May 1;64(5):2343-2344
 11. Bonomi F, Bandini G, Peretti S, **Matucci-Cerinic M**, Bellando-Randone S. Redefining GI involvement in scleroderma: beyond fibrosis toward functional neuroimmunity and anti-M3R

- antibodies. *Rheumatology (Oxford)*. 2025 Jul 7:keaf359.
12. Bruni C, Tofani L, Fretheim H, Liem SIE, Velauthapillai A, Bjørkekjær H, Barua I, Galetti I, Garaiman A, Becker MO, Hoffmann-Vold AM, de Vries-Bouwstra J, Vonk MC, Distler JHW, **Matucci-Cerinic M**, Distler O. A screening tool to detect interstitial lung disease in systemic sclerosis: the ILD-RISC Score. *Rheumatology (Oxford)*. 2025 Aug 14:keaf445
 13. Thaçi D, Gerdes S, Schulze-Koops H, Allanore Y, Kavanaugh A, Both C, Gattu S, Hachaichi S, **Matucci-Cerinic M**. Patient-Reported Outcome Measures in Patients with Rheumatoid Arthritis, Psoriasis, or Psoriatic Arthritis Treated with GP2015, an Etanercept Biosimilar: Results from Two Phase III Studies (EGALITY and EQUIRA). *Drugs R D*. 2025 Jun;25(2):107-11
 14. Markovic M, Campochiaro C, Glisic B, Petronijevic M, Ristic G, Stanojevic I, Vojvodic D, Viapiana N, **Matucci-Cerinic M**, Dagna L. Association of circulating levels of anti-CarP antibodies with disease activity, disability and radiological damage in rheumatoid arthritis patients: an open-label, observational study. *Sci Rep*. 2025 May 26;15(1):18325
 15. Abraham DJ, Black CM, Denton CP, Distler JHW, Domsic R, Feghali-Bostwick C, Gourh P, Hinchcliff M, Kolling F 4th, Kuwana M, Lafyatis R, Landegren U, Mahoney JM, Martin J, **Matucci-Cerinic M**, McMahan ZH, Mora AL, Mouthon L, Rabinovitch M, Rojas M, Rubin K, Trojanowska M, Varga J, Whitfield ML, Gabrielli A, Krieg T An international perspective on the future of systemic sclerosis research. *Nat Rev Rheumatol*. 2025 Mar;21(3):174-187
 16. Ramirez GA, Calabrese C, Secci M, Moroni L, Gallina GD, Benanti G, Bozzolo EP, **Matucci-Cerinic M**, Dagna L Infection-Associated Flares in Systemic Lupus Erythematosus. *Pathogens*. 2024 Oct 26;13(11):934
 17. Sobanski V, de Vries-Bouwstra J, Hoffmann-Vold AM, Huscher D, Alves M, **Matucci-Cerinic M**, Riemekasten G, Li M, Czirják L, Kowal-Bielecka O, Allanore Y, Schoof N, Distler O. Lung function and skin fibrosis changes as predictors of survival in SSc-associated interstitial lung disease: a EUSTAR study. *Rheumatology (Oxford)*. 2025 Jun 3:keaf264
 18. Zhang W, Cai S, Zheng S, Hu S, Zheng K, Lin J, Chen M, Du G, **Matucci-Cerinic M**, Furst DE, Wang Y. Vasculopathy, embolism, xerostomia, arthritis, and stomachache. *Ann Rheum Dis*. 2025 Jun 26:S0003-4967
 19. Fiumara M, Molteni R, Scorpio G, Tomelleri A, Bergonzi GM, Ferrari S, **Matucci-Cerinic M**, Cenci S, Dagna L, Ciceri F, Diral E, Campochiaro C. Clonal hematopoiesis meets an autoinflammatory disease: the new paradigm of VEXAS syndrome. *Expert Rev Hematol*. 2025 Jul;18(7):509-519
 20. Moroni L, Veronica B, Gallina GD, Benanti G, Cilona M, Cariddi A, Lanzillotta M, Danè G, Tanzini U, **Matucci-Cerinic M**, Dagna L. Step-down treatment with mepolizumab for eosinophilic granulomatosis with polyangiitis: a real-life single-centre study *Rheumatology (Oxford)*. 2025 Apr 12:keaf201
 21. Di Donato S, Pauling JD, Ramjug S, Allanore Y, Jude EB, Truchetet ME, Airò P, Ananieva L, Balanescu A, Boleto G, Cantatore FP, Carreira PE, de Souza Müller C, Kuwana M, Moroncini GL, DiBattista M, Mouthon L, Vonk MC, Zanatta E, **Matucci-Cerinic M**, Del Galdo F, Hughes

- M, EUSTAR collaborators Temporal trends in vascular medication use in 8,079 patients with systemic sclerosis: insights to inform future trials and therapeutic strategies from the EUSTAR cohort Rheumatology, keaf290, <https://doi.org/10.1093/rheumatology/keaf290>
22. Boleto G, Campochiaro C, Distler O, Balanescu A, Launay D, Bergmann D, Airò P, Oksel F, Gheorghiu AM, Anic B, Mouthon L, Yavuz S, Cristina-Mihaela Tanaseanu, **Marco Matucci-Cerinic M**, Allanore Y: Interstitial lung disease in anti-U1RNP systemic sclerosis patients: A European Scleroderma Trials and Research analysis J Scleroderma Related Disord Mar 19, 2025 Mar 19:23971983251324827
 23. Dubas V, Buch MH, Seferovic P, **Matucci-Cerinic M**, Bruni C: International expert agreement on World Scleroderma Foundation/Heart Failure Association consensus-based definition and guidance on screening, diagnosis, and follow-up assessment of systemic sclerosis-associated primary heart involvement J Scleroderma Related Disord Mar 19, 2025
 24. Campanaro G, Bandini G, Alunno A, Di Donato S, Alcacer-Pitarch B, Galetti I, Ruaro B, Bellando Randone S, Moggi Pignone A, **Matucci-Cerinic M**, McMahan ZH, Hughes M Clinicians' perspectives concerning treatment initiation and escalation strategies for digital ulcers in patients with systemic sclerosis J Scleroderma Relat Disord Apr 30, 2025
 25. Colic J, Pruner I, Damjanov N, Antovic J, Sefik Bukilica M, Matucci Cerinic M, Antovic A: Circulating extracellular vesicles as predictive biomarkers of progressive interstitial lung disease in systemic sclerosis—a prospective cohort study Frontiers Med 2025; 12: <https://doi.org/10.3389/fmed.2025.1594201>
 26. Talarico R, Marinello D, Palla I, Cannizzo S, Galetti I, Farrington S, Aguilera S, Andersen J, Ceccatelli E, Cornet A, Cutillas G, Esteves M, Frank C, Leite C, Niehaus G, Perez Gomez E, Polfliet K, Sandulescu S, Schriemer R, Barsotti S, Bellando-Randone S, Beretta L, Bernardino V, Boleto G, Bombardieri S, Burmester G, Cavazzana I, Codullo V, Cutolo M, Dalm V, Damian L, Della Rossa A, Doria A, Farhat MM, Eurico Fonseca J, Hachulla E, Houssiau F, Lazzaroni MG, Limper M, Lorenzoni V, Montecucco CM, Mosca M, Mouthon L, Müller-Ladner U, Pha M, Ponte C, Spierings J, Sulli A, Taulaigo A, Ticiati S, Tincani A, Toplak N, Trieste L, van Hagen PM, van Laar J, Vanthuyne M, Barbara Vigone, de Vries-Bouwstra JK, Zen M, Turchetti G, Smith V, **Matucci Cerinic M**: Improving organisation to improve care: ERN ReCONNET organisational reference model for systemic sclerosis patients' care pathway J Scleroderma Related Disord Mar 19, 2025
 27. Molteni R, Fiumara M, Campochiaro C, Alfieri R, Pacini G, Licari E, Tomelleri A, Diral E, Varesi A, Weber A, Quaranta P, Albano L, Gaddoni C, Basso-Ricci L, Stefanoni D, Alessandrini L, Degl'Innocenti S, Sanvito F, Bergonzi GM, Annoni A, Panigada M, Cantoni E, Canarutto D, Xie SZ, D'Alessandro A, Di Micco R, Aiuti A, Ciceri F, De Luca G, Dagna L, **Matucci-Cerinic M**, Merelli I, Cenci S, Scala S, Cavalli G, Naldini L, Ferrari S. Mechanisms of hematopoietic clonal dominance in VEXAS syndrome Nat Med. 2025 Apr 7. doi: 10.1038/s41591-025-03623-9
 28. Scaletti C, Pratesi S, Bellando Randone S, Di Pietro L, Campochiaro C, Annunziato F, **Matucci Cerinic M**. The B-cells paradigm in systemic sclerosis: an update on pathophysiology and B-cell-targeted

therapies.

Clin Exp Immunol. 2025;219(1):uxae098

29. Cacciapaglia F, De Angelis R, Ferri C, Bajocchi G, Bellando-Randone S, Bruni C, Orlandi M, Fornaro M, Cipolletta E, Zanframundo G, Foti R, Cuomo G, Ariani A, Rosato E, Lepri G, Girelli F, Zanatta E, Bosello SL, Cavazzana I, Ingegnoli F, De Santis M, Murdaca G, Abignano G, Giorgio P, Della Rossa A, Caminiti M, Iuliano A, Ciano G, Beretta L, Bagnato G, Lubrano E, De Andres I, Giollo A, Saracco M, Agnes C, Campochiaro C, Lumetti F, Spinella A, Magnani L, De Luca G, Codullo V, Visalli E, Iandoli C, Gigante A, Pellegrino G, Cozzi F, Lazzaroni MG, Generali E, Mennillo G, Barsotti S, Pagano-Mariano G, Furini F, Vultaggio L, Parisi S, Peroni CL, Bianchi G, Fusaro E, Sebastiani GD, Govoni M, D'Angelo S, Pigatto E, Franceschini F, Guiducci S, Dagna L, Doria A, Giuggioli D, Riccieri V, Salvarani C, **Matucci-Cerinic M**, Iannone F; Systemic Sclerosis Progression Investigation Group of the Italian Society for Rheumatology (SPRING-SIR) Pulmonary Arterial Hypertension Incidence in Patients With Systemic Sclerosis Treated With Bosentan for Digital Ulcers: Evidence From the SPRING-SIR Registry. J Rheumatol. 2025 Feb 1;jrheum.2024-0750. doi: 10.3899/jrheum.2024-0750
30. Denton CP, Kowal-Bielecka O, Proudman SM, Olesińska M, Worm M, Del Papa N, **Matucci-Cerinic M**, Radewonuk J, Jochems J, Panaite A, Shebl A, Krupa A, Allanore Y, Hofmann JH, Gasior MJ A Phase 2 randomised trial of safety and pharmacokinetics of IgPro20 and IgPro10 in patients with diffuse cutaneous systemic sclerosis.Rheumatology (Oxford). 2025 :keaf066. doi: 10.1093/rheumatology/keaf066.
31. Del Galdo F, Lescoat A, Conaghan PG, Bertoldo E, Čolić J, Santiago T, Suliman YA, **Matucci-Cerinic M**, Gabrielli A, Distler O, Hoffmann-Vold AM, Castellvi I, Balbir-Gurman A, Vonk M, Ananyeva L, Rednic S, Tarasova A, Ostojic P, Boyadzhieva V, El Aoufy K, Farrington S, Galetti I, Denton CP, Kowal-Bielecka O, Mueller-Ladner U, Allanore Y. EULAR recommendations for the treatment of systemic sclerosis: 2023 update. Ann Rheum Dis. 2025;84(1):29-40
32. Colalillo A, Pellicano C, Ananyeva LP, Hachulla E, Cuomo G, Györfi AH, Czirájk L, de Vries-Bouwstra J, Mouthon L, Poormoghim H, Del Galdo F, Hunzelmann N, Spierings J, Kuwana M, Rosato E; and the EUSTAR Collaborators. Tricuspid Annular Plane Systolic Excursion/Systolic Pulmonary Artery Pressure Ratio and Cardiorenal Syndrome Type 2 in the Systemic Sclerosis EUSTAR Cohort .Arthritis Care Res (Hoboken). 2025;77(2):257-265
33. Chen S, Fan Y, Wu Q, Zhang G, Wang Y, Li W, Yang S, **Matucci-Cerinic M**, Furst DE. Integrative Transcriptomic Analysis of Peripheral Blood Monocytes in Systemic Sclerosis and Shared Pathogenic Pathways in Autoimmune Diseases.Arch Med Res. 2025;56(1):103072.
34. Jenssen Bjørkekjær H, Bruni C, Broch K, Brunborg K, Carreira PE, Airò P, Simeon-Aznar CP, Truchetet ME, Giollo A, Balbir-Gurman A, Martin M, Denton CP, Gabrielli A, Del Galdo F, Vonk MC, Fretheim H, Bitter H, Midtvedt O, Andreassen A, Høie S, Tanaka Y, Riemekasten G, Muller-Ladner U, **Matucci-Cerinic Marco**, Castellvi I, Siegert E, Hachulla E, Molberg O, Distler O, Hoffmann-Vold AM, on behalf of the EUSTAR Collaborators# A comparative analysis of risk stratification tools in SSc-associated

- pulmonary arterial hypertension: a EUSTAR analysis *Rheumatology* 2025;64; 1-14
35. Spierings J, Bandini G, Allanore Y, Del Papa N, Denton CP, Distler O, Furst DE, Greco R, Khanna D, Kuwana M, **Matucci-Cerinic M**, Nikpour M, van Rhenen A, M van Laar J, Hughes M: Management of disease progression after autologous hematopoietic stem cell transplantation in systemic sclerosis: Results from an international questionnaire-based study *Semin Arthritis Rheum* 2025; 71: 15263
 36. Romanazzo S, Ceccatelli S, Mansueto G, Sera F, Guiducci S, **Matucci Cerinic M**, Cosci F Well Being Therapy in systemic sclerosis outpatients: a randomized controlled trial *Rheumatology* 2025; **64**: 66
 37. De Luca G, De Lorenzis E, Campochiaro C, Cacciapaglia F, Del Papa N, Zanatta E, Airò P, Lazzaroni MG, Giuggioli D, De Santis M, Alonzi G, Stano S, Binda M, Moccaldi B, Tonutti A, Cavalli S, Batani V, Natalello G, Iannone F, D'Agostino MA, Dagna L, **Matucci-Cerinic M**, Bosello SL. Rituximab retention rate in systemic sclerosis: a long term real-life multicentre study. *Rheumatology (Oxford)*. 2025;64:1284-1291.
 38. Farina N, De Luca G, Peretto G, Bartoli A, Esposito A, **Matucci-Cerinic M**, Dagna L, Campochiaro C. Cardiac Sarcoidosis: Clinical Insights, Diagnosis, and Management Strategies. *Rev Cardiovasc Med*. 2025;26(2):26605.
 39. Mongin D, **Matucci-Cerinic M**, Walker UA, Distler O, Becvar R, Siegert E, Ananyeva LP, Smith V, Alegre-Sancho JJ, Yavuz S, Limonta M, Riemekasten G, Rezus E, Vonk M, Truchetet ME, Del Galdo F, Courvoisier DS, Iudici M; EUSTAR Collaborators. Oral Glucocorticoids for Skin Fibrosis in Early Diffuse Systemic Sclerosis: A Target Trial Emulation Study From the EUSTAR Database. *Arthritis Care Res (Hoboken)*. 2025;77:649-65
 40. Chen S, Fan Y, Wu Q, Zhang G, Wang Y, Li W, Yang S, **Matucci-Cerinic M**, Furst DE. Integrative Transcriptomic Analysis of Peripheral Blood Monocytes in Systemic Sclerosis and Shared Pathogenic Pathways in Autoimmune Diseases. *Arch Med Res*. 2025;56:103072
 41. De Lorenzis E, Natalello G, Pellegrino G, Verardi L, Batani V, Lepri G, Stano S, Armentano G, De Pinto M, Motta F, Di Donato S, Kakkar V, Fiore S, Bisconti I, Campochiaro C, Cometi L, Tonutti A, Spinella A, Truglia S, Cavalli S, De Santis M, Giuggioli D, Del Papa N, Guiducci S, Cacciapaglia F, De Luca G, Iannone F, Ricceri V, **Matucci Cerinic M**, D'Agostino MA, Del Galdo F, Bosello SL Long-term retention rate, adverse event temporal patterns and rescue treatment strategies of mycophenolate mofetil in systemic sclerosis: insights from real-life. *Rheumatology (Oxford)*. 2025;64(4):1966-1974
 42. Bandini G, Alunno A, Alcacer-Pitarch B, Ruaro B, Galetti I, El-Aoufy K, Pinheiro F, Campanaro G, Jade J, Di Donato S, Muir L, Moggi Pignone A, Bellando Randone S, Del Galdo F, McMahan ZH, **Matucci-Cerinic M**, Hughes M. Patients' unmet needs and treatment preferences concerning digital ulcers in systemic sclerosis. *Rheumatology (Oxford)*. 2025;64:1277-1283.
 43. Bandini G, Monami M, Ciuti G, Mercatelli P, Lo Cricchio A, De Santis MC, Bonomi F, Bellando Randone S, Campochiaro C, El Aoufy K, Ruaro B, Giuggioli D, Hughes M, McMahan ZH, Benfaremo D, Moroncini G, Maconi G, Accogli E, Dagna L, **Matucci Cerinic M**, Moggi Pignone A. Doppler ultrasound, a noninvasive tool for the study of mesenteric arterial flow in systemic sclerosis: a cross-

sectional study of a patient cohort with review and meta-analysis of the literature. *Intern Emerg Med*. 2025;20:381-394

44. Bellando-Randone S, Wilhalme H, Bruni C, Czirkjak L, Distler O, Allanore Y, Cuomo G, Denton C, Del Galdo F, Gheorghiu AM, Riccieri V, Walker U, Truchetet ME, Vonk MC, Foeldvari I, **Matucci-Cerinic M**, Furst DE; and the EUSTAR collaborators. The effect of hydroxychloroquine on activities of daily living and hand function in systemic sclerosis: results from an analysis of the EUSTAR cohort. *Arthritis Res Ther*. 2025;27:66.
45. Zhang W, Huang G, Zheng S, Lin J, Hu S, Zhuang J, Zhou Z, Du G, Zheng K, Chen S, Zhang Q, Mikish A, Hoffmann-Vold AM, Kuwana M, **Matucci-Cerinic M**, Furst DE, Wang Y. Risk prediction modelling in idiopathic inflammatory myositis-associated interstitial lung disease based on seven factors including serum KL-6 and lung ultrasound B-lines. *Clin Exp Rheumatol*. 2025 ;43:260-268.
46. Bandini G, Campochiaro C, Ciuti G, Baccellieri D, Ardita V, Bellando Randone S, El Aoufy K, Giuggioli D, Orlandi M, Dagna L, Chiesa R, **Matucci Cerinic M**, Moggi Pignone A. Doppler ultrasound unveils splanchnic arteries ischemia allowing early successful revascularization in symptomatic systemic sclerosis patients. *Eur J Intern Med*. 2025:S0953-6205(25)00105-0

2024

47. De Luca G, **Matucci-Cerinic M**, Mavrogeni SI Diagnosis and management of primary heart involvement in systemic sclerosis. *Curr Opin Rheumatol*. 2024;36:76-9
48. Khanna D, Kramer F, Höfler J, Ghadessi M, Sandner P, Allanore Y, Denton CP, Kuwana M, **Matucci-Cerinic M**, Pope JE, Atsumi T, Bečvář R, Czirkjak L, De Langhe E, Hachulla E, Ishii T, Ishikawa O, Johnson SR, Riccieri V, Schiopu E, Silver RM, Smith V, Stagnaro C, Steen V, Stevens W, Szűcs G, Truchetet ME, Wosnitzer M, Distler O. Biomarker analysis from the phase 2b randomized placebo-controlled trial of riociguat in early diffuse cutaneous systemic sclerosis. *Rheumatology (Oxford)*. 2024;63(11):3124-3134
49. Loganathan A, Zanframundo G, Yoshida A, Faghihi-Kashani S, Bauer Ventura I, Dourado E, Bozan F, Sambataro G, Yamano Y, Bae SS, Lim D, Ceribelli A, Isailovic N, Selmi C, Fertig N, Bravi E, Kaneko Y, Saraiva AP, Jovani V, Bachiller-Corral J, Cifrian J, Mera-Varela A, Moghadam-Kia S, Wolff V, Campagne J, Meyer A, Giannini M, Triantafyllidis K, Knitza J, Gupta L, Molad Y, Iannone F, Cavazzana I, Piga M, De Luca G, Tansley S, Bozzalla-Cassione E, Bonella F, Corte TJ, Doyle TJ, Fiorentino D, Gonzalez-Gay MA, Hudson M, Kuwana M, Lundberg IE, Mammen AL, McHugh NJ, Miller FW, Montecucco C, Oddis CV, Rojas-Serrano J, Schmidt J, Scirè CA, Selva-O'Callaghan A, Werth VP, Alpini C, Bozzini S, Cavagna L, Aggarwal R; CLASS Project. Agreement between local and central anti-synthetase antibodies detection: results from the Classification Criteria of Anti-Synthetase Syndrome project biobank. *Clin Exp Rheumatol*. 2024 Feb;42(2):277-287
50. Chen S, Fan Y, Wu Q, Zhang G, Wang Y, Li W, Yang S, **Matucci-Cerinic M**, Furst DE. Integrative Transcriptomic Analysis of Peripheral Blood Monocytes in Systemic Sclerosis and Shared Pathogenic Pathways in Autoimmune Diseases. *Arch Med Res*. 2025;56(1):103072

51. Ramirez GA, Calabrese C, Secci M, Moroni L, Gallina GD, Benanti G, Bozzolo EP, **Matucci-Cerinic M**, Dagna L. Infection-Associated Flares in Systemic Lupus Erythematosus. *Pathogens*. 2024;13(11):934
52. Bellando-Randone S, Russo E, Di Gloria L, Lepri G, Baldi S, Fioretto BS, Romano E, Ghezzi G, Bertorello S, El Aoufy K, Rosa I, Pallecchi M, Bruni C, Cei F, Nannini G, Niccolai E, Orlandi M, Bandini G, Guiducci S, Bartolucci GL, Ramazzotti M, Manetti M, **Matucci-Cerinic M**, Amedei A. Gut microbiota in very early systemic sclerosis: the first case-control taxonomic and functional characterisation highlighting an altered butyric acid profile. *RMD Open*. 2024;10:e004647.
53. Mongin D, **Matucci-Cerinic M**, Walker UA, Distler O, Becvar R, Siegert E, Ananyeva LP, Smith V, Alegre-Sancho JJ, Yavuz S, Limonta M, Riemekasten G, Rezus E, Vonk M, Truchetet ME, Del Galdo F, Courvoisier DS, Iudici M; EUSTAR collaborators. Oral glucocorticoids for skin fibrosis in early diffuse systemic sclerosis: a target trial emulation study from the European Scleroderma Trials and Research group database. *Arthritis Care Res (Hoboken)*. 2024 Nov 14. doi: 10.1002/acr.25469. Online ahead of print.PMID: 39542851
54. Dobrota R, Garaiman A, Fligelstone K, Tyrrell Kennedy A, Roennow A, Allanore Y, Carreira PE, Czirják L, Denton C, Hesselstrand R, Sandqvist G, Kowal-Bielecka O, Bruni C, **Matucci-Cerinic M**, Mihai C, Gherghe AM, Mueller-Ladner U, Kvien T, Heiberg T, Distler O, Becker MO. Performance of the EULAR Systemic sclerosis Impact of Disease (ScleroID) questionnaire as a patient-reported outcome measure for patients with diffuse systemic sclerosis. *RMD Open*. 2024;10(4):e004653.
55. Orlandi M, Bellando-Randone S, De Angelis R, Ferri C, Giuggioli D, Cacciapaglia F, Magnani L, Cuomo G, Gigante A, Codullo V, Campochiaro C, Ariani A, Foti R, Guiducci S, **Matucci-Cerinic M**, Bruni C. et SPRING-SIR (Systemic Sclerosis PROgression INvestiGation group of the Italian Society of Rheumatology) coworkers. Towards a comprehensive approach to the management and prognosis of systemic sclerosis's patients: The role of comorbidities in the SPRING-SIR registry.*Eur J Intern Med*. 2024 ;130:130
56. Damiani A, Orlandi M, Bruni C, Bandini G, Lepri G, Scaletti C, Ravaglia C, Frassanito F, Guiducci S, Moggi-Pignone A, **Matucci-Cerinic M**, Poletti V, Tofani L, Colby TV, Randone SB, Tomassetti S. The role of lung biopsy for diagnosis and prognosis of interstitial lung disease in systemic sclerosis: a systematic literature review. *Respir Res*. 2024;25(1):138
57. Colic J, Campochiaro C, **Matucci-Cerinic M** Extracellular vesicles and interstitial lung disease in systemic sclerosis: State of the art!.*Rheumatol Immunol Res*. 2024 Oct 21;5(3):136-140.
58. Avanoglu Guler A, De Luca G, Dagna L, **Matucci-Cerinic M**, Campochiaro C Unraveling the Pathogenesis of Calcinosis in Systemic Sclerosis: A Molecular and Clinical Insight.*Int J Mol Sci*. 2024 Oct 19;25(20):11257
59. Tomassetti S, Ciani L, Luzzi V, Gori L, Trigiani M, Giuntoli L, Lavorini F, Poletti V, Ravaglia C, Torrego A, Maldonado F, Lentz R, Annunziato F, Maggi L, Rossolini GM, Pollini S, Para O, Ciurleo G, Casini A, Rasero L, Bartoloni A, Spinicci M, Munavvar M, Gasparini S, Comin C, **Matucci-Cerinic M**, Peired A, Henket M, Ernst B, Louis R, Corhay JL, Nardi C, Guiot J Utility of bronchoalveolar lavage for COVID-19: a perspective from the Dragon consortium. *Front Med*

(Lausanne). 2024 ;11:1259570

60. Farina N, Tomelleri A, Boffini N, Cariddi A, Calvisi S, Viapiana N, E Baldissera, **Matucci-Cerinic M**, Dagna L Retention rates of different Janus kinase inhibitors in rheumatoid arthritis: experience from a large monocentric cohort Scand J Rheumatol 2024; 53: 428-32
61. Campochiaro C, Hoffmann-Vold AM, Avouac J, Henes J, de Vries-Bouwstra J, Smith V, Siegert E, Airò P, Oksel F, Pellerito R, Vanthuyne M, Pozzi MR, Inanc M, Sibia J, Gabrielli A, Distler O, Allanore Y; EUSTAR Collaborators. Sex influence on outcomes of patients with systemic sclerosis-associated interstitial lung disease: a EUSTAR database analysis. *Rheumatology (Oxford)*. 2023 Jul 5;62(7):2483-2491
62. Lescoat A, Huscher D, Schoof N, Airò P, de Vries-Bouwstra J, Riemekasten G, Hachulla E, Doria A, Rosato E, Hunzelmann N, Montecucco C, Gabrielli A, Hoffmann-Vold AM, Distler O, Ben Shimol J, Cutolo M, Allanore Y; EUSTAR collaborators. Systemic sclerosis-associated interstitial lung disease in the EUSTAR database: analysis by region. *Rheumatology (Oxford)*. 2023 Jun 1;62(6):2178-2188
63. De Lorenzis E, Natalello G, Pellegrino G, Verardi L, Batani V, Lepri G, Stano S, Armentano G, De Pinto M, Motta F, Di Donato S, Kakkar V, Fiore S, Bisconti I, Campochiaro C, Cometi L, Tonutti A, Spinella A, Truglia S, Cavalli S, De Santis M, Giuggioli D, Del Papa N, Guiducci S, Cacciapaglia F, De Luca G, Iannone F, Ricceri V, **Matucci Cerinic M**, D'Agostino MA, Del Galdo F, Bosello SL. Long-term retention rate, adverse event temporal patterns and rescue treatment strategies of mycophenolate mofetil in systemic sclerosis: insights from real-life. *Rheumatology (Oxford)*. 2024 Sep 30:keae532. doi: 10.1093/rheumatology/keae532. Online ahead of print.
64. Campochiaro C, Allanore Y, Braun-Moscovici Y, **Matucci-Cerinic M**, Balbir Gurman A: Is cyclophosphamide still the gold standard in early severe rapidly progressive systemic sclerosis? *Autoimmun Rev*. 2024;23(1):10343
65. Bandini G, Alunno A, Alcacer-Pitarch B, Ruaro B, Galetti I, El-Aoufy K, Pinheiro F, Campanaro G, Jade J, Di Donato S, Muir L, Moggi Pignone A, Bellando Randone S, Del Galdo F, McMahan ZH, **Matucci-Cerinic M**, Hughes M. Patients' unmet needs and treatment preferences concerning digital ulcers in systemic sclerosis. *Rheumatology (Oxford)*. 2024 Mar 2:keae130. doi: 10.1093/rheumatology/keae130. Online ahead of print.
66. D'Angelo S, Tirri E, Giardino AM, De Rosa T, **Matucci-Cerinic M**, Dagna L, Santo L, Ciccia F, Frediani B, Govoni M, Pallavicini FB, Grembiale RD, Sedie AD, Mulè R, Cantatore FP, Foti R, Gremese E, Conigliaro P, Salaffi F, Viapiana O, Cauli A, Giacomelli R, Arcarese L, Guggino G, Russo R, Puenpatom A, Capocotta D, Nacci F, Anelli MG, Picerno V, Binetti C, Iannone F; GO-BEYOND Italy Study Investigators. Real-world effectiveness and persistence of golimumab as second-line anti-TNF α drug in rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis patients in Italy: GO-BEYOND, a 12-month prospective observational study *Int J Rheum Dis*. 2024;27(3):e15091. doi: 10.1111/1756-185X.15091.
67. Bruni C, Tofani L, Garaiman A, Jordan S, Mihai CM, Dobrota R, Elhai M, Becker MO, Hoffmann-Vold AM, Frauenfelder T, **Matucci-Cerinic M**, Distler O. Histogram-Based Densitometry Index to Assess the Severity of Interstitial Lung Disease in Systemic Sclerosis in Standard and Low-Dose Computed Tomography *J Rheumatol*.

- 2024;1;51(3):270-276. doi: 10.3899/jrheum.2023-0415.
68. Campochiaro C, **Matucci-Cerinic M**. Interstitial lung disease in limited cutaneous systemic sclerosis patients: never let your guard down *Rheumatology (Oxford)*. 2024;63(3):589-590.
 69. Romanazzo S, Ceccatelli S, Mansueto G, Sera F, Guiducci S, **Matucci Cerinic M**, Cosci F. Well-Being Therapy in systemic sclerosis outpatients: a randomized controlled trial. *Rheumatology (Oxford)*. 2024 Feb 17;keae114. doi: 10.1093/rheumatology/keae114. Online ahead of print.
 70. Riccieri V, Pellegrino G, Cipolletta E, Giuggioli D, Bajocchi G, Bellando-Randone S, Dagna L, Zanframundo G, Foti R, Cacciapaglia F, Cuomo G, Ariani A, Rosato E, Lepri G, Girelli F, Zanatta E, Bosello SL, Cavazzana I, Ingegnoli F, De Santis M, Murdaca G, Abignano G, Romeo N, Della Rossa A, Caminiti M, Iuliano A, Ciano G, Beretta L, Bagnato G, Lubrano E, De Andres I, Giollo A, Saracco M, Agnes C, Lumetti F, Spinella A, Magnani L, Campochiaro C, De Luca G, Codullo V, Visalli E, Di Vico C, Gigante A, Saccon F, Grazia Lazzaroni M, Franceschini F, Generali E, Mennillo G, Barsotti S, Pagano Mariano G, Calabrese F, Furini F, Vultaggio L, Parisi S, Peroni CL, Bianchi G, Conti F, Cozzi F, D'Angelo S, Doria A, Fusaro E, Govoni M, Guiducci S, Iannone F, Salvarani C, Sebastiani GD, Ferri C, **Matucci-Cerinic M**, De Angelis R. Practice pattern for the use of intravenous iloprost for the treatment of peripheral vasculopathy in systemic sclerosis: A case-control study from the Italian national multicenter "SPRING" (Systemic Sclerosis Progression InvestiGation) Registry. *J Scleroderma Relat Disord*. 2024;9(1):38-49.
 71. Tomelleri A, Benanti G, Cariddi A, Calvisi SL, Baldissera E, Boffini N, **Matucci-Cerinic M**, Dagna L The impact of 2023 EMA recommendations on patients treated with JAK inhibitors: real-life experience from a prospective monocentric cohort. *Rheumatology (Oxford)*. 2024 Feb 1;63(2):e39-e42. doi: 10.1093/rheumatology/kead395
 72. Mavrogeni SI, Fotis L, **Matucci-Cerinic M**. Cardiovascular involvement in autoimmune diseases, volume II. *Front Cardiovasc Med*. 2024 Jan 31;11:1352268. doi: 10.3389/fcvm.2024.1352268. eCollection 2024
 73. Lepri G, Bruni C, Tofani L, Moggi-Pignone A, Orlandi M, Tomassetti S, Hughes M, Del Galdo F, Irace R, Distler O, Riccieri V, Allanore Y, Gheorghiu AM, Siegert E, De Vries-Bouwstra J, Hachulla E, Tikly M, Damjanov N, Spertini F, Mouthon L, Hoffmann-Vold AM, Gabrielli A, Guiducci S, **Matucci-Cerinic M**, Furst D, Bellando-Randone S, Eustar Collaborators The Performance of Pulmonary Function Tests in Predicting Systemic Sclerosis-Interstitial Lung Disease in the European Scleroderma Trial and Research Database. *Diagnostics (Basel)*. 2024 ;14(3):295. doi: 10.3390/diagnostics14030295
 74. De Luca G, Campochiaro C, Palmisano A, Bruno E, Vignale D, Peretto G, Sala S, Ferlito A, Cilona MB, Esposito A, **Matucci-Cerinic M**, Dagna L. Myocarditis in anti-synthetase syndrome: clinical features and diagnostic modalities. *Rheumatology (Oxford)*. 2024;63(7):1902-1910. doi: 10.1093/rheumatology/kead541.
 75. Avanoglu-Guler A, Campochiaro C, De Luca G, Hughes M, Tufan A, Green L, Del Galdo F, **Matucci-Cerinic M**, Dagna L Calcinosis in systemic sclerosis: An update on pathogenesis, related complications, and management: A heavy burden still waiting to be lifted off patients' hands. *Semin Arthritis Rheum*. 2024;66:152431.
 76. Ciaffi J, Liem SIE, Cannegieter S, Ahmed S, Hoekstra EM, Wiland P,

- Atsumi T, Szücs G, Balbir Gurman A, Czirják L, Zanatta E, Koetter I, Henes JC, **Matucci-Cerinic M**, Airò P, Ursini F, Huizinga TWJ, De Vries-Bouwstra J, Collaborators E. Untangling the relationship between smoking and systemic sclerosis: an analysis of the EUSTAR cohort. *RMD Open*. 2024 May 20;10(2):e004101. doi: 10.1136/rmdopen-2024-004101.
77. De Luca G, De Lorenzis E, Campochiaro C, Cacciapaglia F, Del Papa N, Zanatta E, Airò P, Lazzaroni MG, Giuggioli D, De Santis M, Alonzi G, Stano S, Binda M, Moccaldi B, Tonutti A, Cavalli S, Batani V, Natalello G, Iannone F, D'Agostino MA, Dagna L, **Matucci-Cerinic M**, Bosello SL Rituximab retention rate in systemic sclerosis: a long term real-life multicenter study. *Rheumatology (Oxford)*. 2024 May 15;keae280. doi: 10.1093/rheumatology/keae280. Online ahead of print.
 78. Campochiaro C, Farina N, De Luca G, Batani V, Trignani G, Vignale D, Palmisano A, **Matucci-Cerinic M**, Dagna L. Effectiveness and safety of mycophenolate mofetil and rituximab combination therapy for immune idiopathic myopathies *Arthritis Res Ther*. 2024 Apr 3;26(1):79. doi: 10.1186/s13075-024-03310-z.
 79. Lescoat A, Khanna D, Kuwana M, Allanore Y, **Matucci-Cerinic M**. Pre-scleroderma and new opportunities for preventive medicine - *Lancet Rheumatol*. 2024 ;6(4):e201.
 80. **Matucci-Cerinic M**, Ciccica F, Foti R, Giunta A, Loconsole F, Prignano F, Scrivo R, Girolomoni G. Adalimumab in the management of psoriasis and psoriatic arthritis: Results from a Delphi investigation. *Rheumatol Immunol Res*. 2024 Mar 31;5(1):49-56.
 81. Khanna D, Kramer F, Höfler J, Ghadessi M, Sandner P, Allanore Y, Denton CP, Kuwana M, **Matucci-Cerinic M**, Pope JE, Atsumi T, Bečvář R, Czirják L, De Langhe E, Hachulla E, Ishii T, Ishikawa O, Johnson SR, Riccieri V, Schiopu E, Silver RM, Smith V, Stagnaro C, Steen V, Stevens W, Szücs G, Truchetet ME, Wosnitzer M, Distler O. Biomarker analysis from the phase 2b randomized placebo-controlled trial of riociguat in early diffuse cutaneous systemic sclerosis. *Rheumatology (Oxford)*. 2024 Mar 9;keae150. doi: 10.1093/rheumatology/keae150.
 82. El Aoufy K, Melis MR, Iovino P, Bambi S, Lorini C, Bonaccorsi G, Galetti I, Garbagnati C, Canziani P, Tonolo S, Mitola M, Guiducci S, Furst DE, **Matucci-Cerinic M**, Rasero L, Bellando-Randone S. The Rising Challenge of Poor Health Literacy of Patients with Systemic Sclerosis: Preliminary Data Identify Important Unmet Needs in an Italian Cohort. *Nurs Rep*. 2024 Mar 5;14(1):556-565.
 83. Farina N, Tomelleri A, Boffini N, Cariddi A, Calvisi S, Baldissera E, **Matucci-Cerinic M**, Dagna L. Secukinumab is not associated with cancer recurrence or progression in patients with spondyloarthritis and history of neoplastic disease *Rheumatol Int*. 2024;44:2431-2434
 84. Zhang W, Huang G, Zheng S, Lin J, Hu S, Zhuang J, Zhou Z, Du G, Zheng K, Chen S, Zhang Q, Mikish A, Hoffmann-Vold AM, Kuwana M, **Matucci-Cerinic M**, Furst DE, Wang Y. Risk prediction modelling in idiopathic inflammatory myositis-associated interstitial lung disease based on seven factors including serum KL-6 and lung ultrasound B-lines *Clin Exp Rheumatol*. 2024 Oct 2. doi: 10.55563/clinexprheumatol/ylf0oe. Online ahead of print.
 85. De Lorenzis E, Natalello G, Pellegrino G, Verardi L, Batani V, Lepri G, Stano S, Armentano G, De Pinto M, Motta F, Di Donato S, Kakkar V, Fiore S, Bisconti I, Campochiaro C, Cometi L, Tonutti A, Spinella A, Truglia S, Cavalli S, De Santis M, Giuggioli D, Del Papa N,

- Guiducci S, Cacciapaglia F, De Luca G, Iannone F, Ricceri V, **Matucci Cerinic M**, D'Agostino MA, Del Galdo F, Bosello SL. Long-term retention rate, adverse event temporal patterns and rescue treatment strategies of mycophenolate mofetil in systemic sclerosis: insights from real-life..Rheumatology (Oxford). 2024 Sep 30;keae532. doi: 10.1093/rheumatology/keae532.
86. Wang Y, Chen S, Zheng S, Zhou Z, Zhang W, Du G, Mikish A, Ruaro B, Bruni C, Hoffmann-Vold AM, Gargani L, **Matucci-Cerinic M**, Furst DE. A versatile role for lung ultrasound in systemic autoimmune rheumatic diseases related pulmonary involvement: a narrative review Arthritis Res Ther. 2024 Sep 18;26(1):164. doi: 10.1186/s13075-024-03399-2.
 87. El Aoufy K, Melis MR, Magi CE, Bellando-Randone S, Tamburini M, Bandini G, Moggi-Pignone A, **Matucci-Cerinic M**, Bambi S, Rasero L. Evidence for telemedicine heterogeneity in rheumatic and musculoskeletal diseases care: a scoping review. Clin Rheumatol. 2024 Sep;43(9):2721-2763.
 88. Chen S, Fan Y, Wu Q, Zhang G, Wang Y, Li W, Yang S, **Matucci-Cerinic M**, Furst DE. Integrative Transcriptomic Analysis of Peripheral Blood Monocytes in Systemic Sclerosis and Shared Pathogenic Pathways in Autoimmune Diseases. Arch Med Res. 2024 Aug 28;56(1):103072.
 89. Orlandi M, Bellando-Randone S, De Angelis R, Ferri C, Giuggioli D, Cacciapaglia F, Magnani L, Cuomo G, Gigante A, Codullo V, Campochiaro C, Ariani A, Foti R, Guiducci S, **Matucci-Cerinic M**, Bruni C; SPRING-SIR (Systemic Sclerosis PROgression INvestiGation group of the Italian Society of Rheumatology) coworkers. Towards a comprehensive approach to the management and prognosis of systemic sclerosis's patients: The role of comorbidities in the SPRING-SIR registry. Eur J Intern Med. 2024 Aug 14:S0953-6205
 90. Coccia C, Bonomi F, Lo Cricchio A, Russo E, Peretti S, Bandini G, Lepri G, Bartoli F, Moggi-Pignone A, Guiducci S, Del Galdo F, Furst DE, **Matucci Cerinic M**, Bellando-Randone S. The Potential Role of Butyrate in the Pathogenesis and Treatment of Autoimmune Rheumatic Diseases. Biomedicines. 2024 Aug 5;12(8):1760.
 91. Bandini G, Alunno A, Oliveira Pinheiro F, Campochiaro C, Galetti I, Matucci Cerinic P, Ruaro B, Moggi Pignone A, Bellando Randone S, Dagna L, **Matucci Cerinic M**, McMahan ZH, Hughes M A multi-national survey to identify clinicians' perspectives concerning Proton Pump inhibitors in patients with systemic sclerosis. Semin Arthritis Rheum. 2024 Aug;67:152419.
 92. Del Galdo F, Lescoat A, Conaghan PG, Bertoldo E, Čolić J, Santiago T, Suliman YA, **Matucci-Cerinic M**, Gabrielli A, Distler O, Hoffmann-Vold AM, Castellví I, Balbir-Gurman A, Vonk M, Ananyeva L, Rednic S, Tarasova A, Ostojic P, Boyadzhieva V, El Aoufy K, Farrington S, Galetti I, Denton CP, Kowal-Bielecka O, Mueller-Ladner U, Allanore Y.EULAR recommendations for the treatment of systemic sclerosis: 2023 update Ann Rheum Dis 2024 Oct 11:ard-2024-226430.
 93. Lepri G, Bruni C, Tofani L, Moggi-Pignone A, Orlandi M, Tomassetti S, Hughes M, Del Galdo F, Irace R, Distler O, Ricceri V, Allanore Y, Gheorghiu AM, Siegert E, De Vries-Bouwstra J, Hachulla E, Tikly M, Damjanov N, Spertini F, Mouthon L, Hoffmann-Vold AM, Gabrielli A, Guiducci S, **Matucci-Cerinic M**, Furst D, Bellando-Randone S, Eustar Collaborators. The Performance of Pulmonary Function Tests in Predicting Systemic Sclerosis-Interstitial Lung Disease in the

European Scleroderma Trial and Research Database. *Diagnostics* (Basel). 2024;14(3):295

94. Riccieri V, Pellegrino G, Cipolletta E, Giuggioli D, Bajocchi G, Bellando-Randone S, Dagna L, Zanframundo G, Foti R, Cacciapaglia F, Cuomo G, Ariani A, Rosato E, Lepri G, Girelli F, Zanatta E, Bosello SL, Cavazzana I, Ingegnoli F, De Santis M, Murdaca G, Abignano G, Romeo N, Della Rossa A, Caminiti M, Iuliano A, Ciano G, Beretta L, Bagnato G, Lubrano E, De Andres I, Giollo A, Saracco M, Agnes C, Lumetti F, Spinella A, Magnani L, Campochiaro C, De Luca G, Codullo V, Visalli E, Di Vico C, Gigante A, Saccon F, Grazia Lazzaroni M, Franceschini F, Generali E, Mennillo G, Barsotti S, Pagano Mariano G, Calabrese F, Furini F, Vultaggio L, Parisi S, Peroni CL, Bianchi G, Conti F, Cozzi F, D'Angelo S, Doria A, Fusaro E, Govoni M, Guiducci S, Iannone F, Salvarani C, Sebastiani GD, Ferri C, **Matucci-Cerinic M**, De Angelis R. Practice pattern for the use of intravenous iloprost for the treatment of peripheral vasculopathy in systemic sclerosis: A case-control study from the Italian national multicenter "SPRING" (Systemic Sclerosis Progression InvestiGation) Registry. *J Scleroderma Relat Disord*. 2024;9(1):38-49
95. D'Angelo S, Tirri E, Giardino AM, De Rosa T, **Matucci-Cerinic M**, Dagna L, Santo L, Ciccia F, Frediani B, Govoni M, Pallavicini FB, Grembiale RD, Sedie AD, Mulè R, Cantatore FP, Foti R, Gremese E, Conigliaro P, Salaffi F, Viapiana O, Cauli A, Giacomelli R, Arcarese L, Guggino G, Russo R, Puenpatom A, Capocotta D, Nacci F, Anelli MG, Picerno V, Binetti C, Iannone F; GO-BEYOND Italy Study Investigators Real-world effectiveness and persistence of golimumab as second-line anti-TNF α drug in rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis patients in Italy: GO-BEYOND, a 12-month prospective observational study. *Int J Rheum Dis*. 2024;27(3):e15091
96. Campochiaro C, Farina N, De Luca G, Batani V, Trignani G, Vignale D, Palmisano A, **Matucci-Cerinic M**, Dagna L Effectiveness and safety of mycophenolate mofetil and rituximab combination therapy for immune idiopathic myopathies. *Arthritis Res Ther*. 2024;26(1):79.
97. Russo E, Bellando-Randone S, Carboni D, Fioretto BS, Romano E, Baldi S, El Aoufy K, Ramazzotti M, Rosa I, Lepri G, Di Gloria L, Pallacchi M, Bruni C, Melchiorre D, Guiducci S, Manetti M, Bartolucci GL, **Matucci-Cerinic M**, Amedei A. The differential crosstalk of the skin-gut microbiome axis as a new emerging actor in systemic sclerosis *Rheumatology* (Oxford). 2024;63(1):226-234.
98. Avanoğlu-Güler A, Campochiaro C, De Luca G, Hughes M, Tufan A, Green L, Del Galdo F, **Matucci-Cerinic M**, Dagna L. Calcinosis in systemic sclerosis: An update on pathogenesis, related complications, and management: A heavy burden still waiting to be lifted off patients' hands. *Semin Arthritis Rheum*. 2024 ;66:152431.
99. Khanna D, Kramer F, Höfler J, Ghadessi M, Sandner P, Allanore Y, Denton CP, Kuwana M, **Matucci-Cerinic M**, Pope JE, Atsumi T, Bečvář R, Czirják L, De Langhe E, Hachulla E, Ishii T, Ishikawa O, Johnson SR, Riccieri V, Schiopu E, Silver RM, Smith V, Stagnaro C, Steen V, Stevens W, Szűcs G, Truchetet ME, Wosnitza M, Distler O. Biomarker analysis from the phase 2b randomized placebo-controlled trial of riociguat in early diffuse cutaneous systemic sclerosis. *Rheumatology* (Oxford). 2024;keae150
100. Loganathan A, Zanframundo G, Yoshida A, Faghihi-Kashani S, Bauer Ventura I, Dourado E, Bozan F, Sambataro G, Yamano Y, Bae SS, Lim D, Ceribelli A, Isailovic N, Selmi C, Fertig N, Bravi E, Kaneko

- Y, Saraiva AP, Jovani V, Bachiller-Corral J, Cifrian J, Mera-Varela A, Moghadam-Kia S, Wolff V, Campagne J, Meyer A, Giannini M, Triantafyllis K, Knitza J, Gupta L, Molad Y, Iannone F, Cavazzana I, Piga M, De Luca G, Tansley S, Bozzalla-Cassione E, Bonella F, Corte TJ, Doyle TJ, Fiorentino D, Gonzalez-Gay MA, Hudson M, Kuwana M, Lundberg IE, Mammen AL, McHugh NJ, Miller FW, Montecucco C, Oddis CV, Rojas-Serrano J, Schmidt J, Scirè CA, Selva-O'Callaghan A, Werth VP, Alpini C, Bozzini S, Cavagna L, Aggarwal R; CLASS Project. Agreement between local and central anti-synthetase antibodies detection: results from the Classification Criteria of Anti-Synthetase Syndrome project biobank. *Clin Exp Rheumatol*. 2024;42:277-287
101. **Matucci-Cerinic M**, Ciccio F, Foti R, Giunta A, Loconsole F, Prignano F, Scrivo R, Girolomoni G Adalimumab in the management of psoriasis and psoriatic arthritis: Results from a Delphi investigation. *Rheumatol Immunol Res*. 2024;5(1):49-56.
 102. Mavrogeni SI, Fotis L, **Matucci-Cerinic M**. Cardiovascular involvement in autoimmune diseases, volume I *Front Cardiovasc Med*. 2024;11:1352268
 103. Bruni C, Tofani L, Garaiman A, Jordan S, Mihai CM, Dobrota R, **Elhai M**, Becker MO, Hoffmann-Vold AM, Frauenfelder T, **Matucci-Cerinic M**, Distler O. Histogram-Based Densitometry Index to Assess the Severity of Interstitial Lung Disease in Systemic Sclerosis in Standard and Low-Dose Computed Tomography. *J Rheumatol*. 2024;51:270-6. doi: 10.3899/jrheum.2023-0415
 104. Russo E, Bellando-Randone S, Carboni D, Fioretto BS, Romano E, Baldi S, El Aoufy K, Ramazzotti M, Rosa I, Lepri G, Di Gloria L, Pallecchi M, Bruni C, Melchiorre D, Guiducci S, Manetti M, Bartolucci GL, **Matucci-Cerinic M**, Amedei A The differential crosstalk of the skin-gut microbiome axis as a new emerging actor in systemic sclerosis. *Rheumatology (Oxford)*. 2024;63:226-34
 105. Natalello G, Bosello SL, Campochiaro C, Abignano G, De Santis M, Ferlito A, Karadağ DT, Padula AA, Cavalli G, D'Agostino MA, Selmi C, **Matucci-Cerinic M**, Dagna L, De Luca G Adherence to the Mediterranean Diet in Italian Patients With Systemic Sclerosis: An Epidemiologic Survey. *ACR Open Rheumatol*. 2024 ;6:14-20.
 106. Tomelleri A, Benanti G, Cariddi A, Calvisi SL, Baldissera E, Boffini N, **Matucci-Cerinic M**, Dagna L The impact of 2023 EMA recommendations on patients treated with JAK inhibitors: real-life experience from a prospective monocentric cohort. *Rheumatology (Oxford)*. 2024;63:e39-e42
 107. Landini N, Orlandi M, Calistri L, Nardi C, Ciet P, Bellando-Randone S, Guiducci S, Benkert T, Panebianco V, Morana G, **Matucci-Cerinic M**, Colagrande S Advanced and traditional chest MRI sequence for the clinical assessment of systemic sclerosis related interstitial lung disease, compared to CT: disease extent analysis and correlations with pulmonary function tests. *Eur J Radiol*. 2024 ;170:111239.

2023

108. Russo E, Bellando-Randone S, Carboni D , Fioretto BS, Romano E, Baldi S, El Aoufy K, Ramazzotti M, Rosa I , Lepri G , Di Gloria L, Pallecchi M, Bruni C, Melchiorre D, Guiducci S, Manetti M, Bartolucci GL, **Matucci-Cerinic M** , Amedei A. The differential crosstalk of the skin-gut microbiome axis as a new emerging actor in systemic sclerosis. *Rheumatology (Oxford)* 2023 May

doi:10.1093/rheumatology/kead208.

109. Lescoat A, Huang S, Carreira PE, Siegert E, de Vries-Bouwstra J, Distler JHW, Smith V, Del Galdo F, Anic B, Damjanov N, Rednic S, Ribi C, Bancel DF, Hoffmann-Vold AM, Gabrielli A, Distler O, Khanna D, Allanore Y; EUSTAR collaborators. Cutaneous Manifestations, Clinical Characteristics, and Prognosis of Patients with Systemic Sclerosis Sine Scleroderma: Data From the International EUSTAR Database. *JAMA Dermatol.* 2023;159(8):837-847
110. De Luca G, Campochiaro C, G Peretto, E Bernardo, **M Matucci Cerinic M**, Dagna L Cardiac involvement, a threatening very early manifestation of systemic sclerosis: evidence from VEDOSS patients *Clin Exp Rheumatol* 2023;41;1723-4
111. Campochiaro C, Hoffmann-Vold AM, Avouac J, Henes J, de Vries-Bouwstra J, Smith V, Siegert E, Airò P, Oksel F, Pellerito R, Vanthuyne M, Pozzi MR, Inanc M, Sibilia J, Gabrielli A, Distler O, Allanore Y; EUSTAR Collaborators. Sex influence on outcomes of patients with systemic sclerosis-associated interstitial lung disease: a EUSTAR database analysis. *Rheumatology (Oxford).* 2023;62(7):2483-2491
112. Tomassetti S, Ravaglia C, Puglisi S, Wells AU, Ryu JH, Bosi M, Dubini A, Piciucchi S, Girelli F, Parronchi P, Lavorini F, Rosi E, Luzzi V, **Matucci Cerinic M**, Poletti V. Clinical implications of interstitial pneumonia with autoimmune features diagnostic criteria in idiopathic pulmonary fibrosis: A case control study. *Front Med (Lausanne).* 2023 Feb 16;10:1087485.
113. Iudici M, Mongin D, Siegert E, Carreira PE, Distler J, Henes J, Zanatta E, Hachulla E, De Luca G, de Souza Müller C, Santiago T, Tandaipan JL, Valdetaro Bianchi B, De Santis M, Hoffmann-Vold AM, Gabrielli A, Distler O, Courvoisier DS; EUSTAR collaborators. Glucocorticoids prescribing practices in systemic sclerosis: an analysis of the EUSTAR database. *Rheumatology (Oxford).* 2023;62(4):1559-1567.
114. Lescoat A, Huscher D, Schoof N, Airò P, de Vries-Bouwstra J, Riemekasten G, Hachulla E, Doria A, Rosato E, Hunzelmann N, Montecucco C, Gabrielli A, Hoffmann-Vold AM, Distler O, Ben Shimol J, Cutolo M, Allanore Y; EUSTAR collaborators Systemic sclerosis-associated interstitial lung disease in the EUSTAR database: analysis by region. Systemic sclerosis-associated interstitial lung disease in the EUSTAR database: analysis by region. *Rheumatology (Oxford).* 2023;62(6):2178-2188
115. Migliore A, Maheu E, Saccone L, de Campos GC, Alekseeva L, Chevalier X, Conrozier T, Crimaldi S, Diracoglu D, Herrero-Beaumont G, Iolascon G, Ionescu R, Jerosch J, Láins J, Makri S, Martusevich N, **Matucci Cerinic M**, Pavelka K, J Petrella R, Tarantino U, R Bannuru R. What We Should Expect from an Innovative Intra-Articular Hyaluronic Acid Product: Expert Opinion Based on a Comprehensive Review of the Literature. *J Clin Med.* 2023 Nov 30;12(23):7422
116. Tani C, Cardelli C, Depascale R, Gamba A, Iaccarino L, Doria A, Bandeira M, Dinis SP, Romão VC, Gotelli E, Paolino S, Cutolo M, Di Giosaffatte N, Ferraris A, Grammatico P, Cavagna L, Codullo V, Montecucco C, Longo V, Beretta L, Cavazzana I, Fredi M, Peretti S, Guiducci S, **Matucci-Cerinic M**, Bombardieri S, Burmester GR, Fonseca JE, Frank C, Galetti I, Hachulla E, Müller-Ladner U, Schneider M, Smith V, Tamirou F, Van Laar JM, Vieira A, D'Urzo R, Cannizzo S, Gaglioti A, Marinello D, Talarico R, Mosca M. Long-

- term outcomes of COVID-19 vaccination in patients with rare and complex connective tissue diseases: The ERN-ReCONNET VACCINATE study. *J Transl Autoimmun.* 2023 Nov 28;7:100221.
117. Tomelleri A, Benanti G, Cariddi A, Calvisi SL, Baldissera E, Boffini N, **Matucci-Cerinic M**, Dagna L. The impact of 2023 EMA recommendations on patients treated with JAK inhibitors: real-life experience from a prospective monocentric cohort. *Rheumatology (Oxford).* 2024 Feb 1;63(2):e39-e42.
 118. Campochiaro C, Allanore Y, Braun-Moscovici Y, **Matucci-Cerinic M**, Balbir-Gurman A. Is cyclophosphamide still the gold standard in early severe rapidly progressive systemic sclerosis? *Autoimmun Rev.* 2023 Sep 9;103439. doi: 10.1016/j.autrev.2023.103439.
 119. Campochiaro C, Farina N, De Luca G, Trignani G, Tomelleri A, **Matucci-Cerinic M**, Dagna L. Anakinra for the Treatment of Antisynthetase Syndrome: A Monocentric Case Series and a Systematic Literature Review. *J Rheumatol.* 2023 ;50(1):151-153.
 120. Campochiaro C, Suliman YA, Hughes M, Schoones JW, Giuggioli D, Moinsadeh P, Baron M, Chung L, Ross L, Maltez N, Allanore Y, Denton CP, Distler O, Frech T, Furst DE, Khanna D, Krieg T, Kuwana M, **Matucci-Cerinic M**, Pope J, Alunno A. Non-surgical local treatments of digital ulcers in systemic sclerosis: a systematic literature review. *Semin Arthritis Rheum.* 2023;63:152267.
 121. Campochiaro C, De Luca G, Lazzaroni MG, Armentaro G, Spinella A, Vigone B, Ruaro B, Stanziola A, Benfaremo D, De Lorenzis E, Moccaldi B, Bosello SL, Cuomo G, Beretta L, Zanatta E, Giuggioli D, Del Papa N, Airo P, Confalonieri M, Moroncini G, Dagna L, **Matucci-Cerinic M**. Real-life efficacy and safety of nintedanib in systemic sclerosis-interstitial lung disease: data from an Italian multicentre study. *RMD Open.* 2023;9(1):e002850.
 122. Colic J, Campochiaro C, Hughes M, **Matucci Cerinic M**, Dagna L. Investigational drugs for the treatment of scleroderma: what's new?. *Expert Opin Investig Drugs.* 2023 Jul-Dec;32(7):601-614
 123. Ferri C, Raimondo V, Giuggioli D, Gragnani L, Lorini S, Dagna L, Bosello SL, Foti R, Ricciari V, Guiducci S, Cuomo G, Tavoni A, De Angelis R, Cacciapaglia F, Zanatta E, Cozzi F, Murdaca G, Cavazzana I, Romeo N, Codullo V, Pellegrini R, Varcasia G, De Santis M, Selmi C, Abignano G, Caminiti M, L'Andolina M, Olivo D, Lubrano E, Spinella A, Lumetti F, De Luca G, Ruscitti P, Urraro T, Visentini M, Bellando-Randone S, Visalli E, Testa D, Sciascia G, Masini F, Pellegrino G, Saccon F, Balestri E, Elia G, Ferrari SM, Tonutti A, Dall'Ara F, Pagano Mariano G, Pettiti G, Zanframundo G, Brittelli R, Aiello V, Dal Bosco Y, Foti R, Di Cola I, Scorpiniti D, Fusaro E, Ferrari T, Gigliotti P, Campochiaro C, Francioso F, Iandoli C, Caira V, Zignego AL, D'Angelo S, Franceschini F, **Matucci-Cerinic M**, Giacomelli R, Doria A, Santini SA, Fallahi P, Iannone F, Antonelli A; COVID-19 & ASD Italian Study Group. Impact of COVID-19 and vaccination campaign on 1,755 systemic sclerosis patients during first three years of pandemic. Possible risks for individuals with impaired immunoreactivity to vaccine, ongoing immunomodulating treatments, and disease-related lung involvement during the next pandemic phase *J Transl Autoimmun.* 2023 Oct 9;7:100212
 124. De Angelis R, Ferri C, Giuggioli D, Bajocchi G, Dagna L, Bellando-Randone S, Zanframundo G, Foti R, Cacciapaglia F, Cuomo G, Ariani A, Rosato E, Lepri G, Girelli F, Ricciari V, Zanatta E, Bosello SL, Cavazzana I, Ingegnoli F, De Santis M, Murdaca G, Abignano G, Romeo N, Della Rossa A, Caminiti M, Iuliano AM, Ciano G, Beretta

- L, Bagnato G, Lubrano E, De Andres I, Giollo A, Saracco M, Agnes C, Cipolletta E, Lumetti F, Spinella A, Magnani L, Campochiaro C, De Luca G, Codullo V, Visalli E, Di Vico C, Gigante A, Pellagrino G, Pigatto E, Lazzaroni MG, Franceschini F, Generali E, Mennillo G, Barsotti S, Mariano GP, Furini F, Vultaggio L, Parisi S, Peroni CL, Rozza D, Zanetti A, Carrara G, Landolfi G, Scirè CA, Bianchi G, Fusaro E, Sebastiani GD, Govoni M, D'Angelo S, Cozzi F, Guiducci S, Doria A, Salvarani C, Iannone F, **Matucci-Cerinic M**; SPRING-SIR (Systemic Sclerosis PRogression INvestiGation group of the Italian Society of Rheumatology). Systemic sclerosis sine scleroderma: clinical and serological features and relationship with other cutaneous subsets in a large series of patients from the national registry 'SPRING' of the Italian Society for Rheumatology. Systemic sclerosis sine scleroderma: clinical and serological features and relationship with other cutaneous subsets in a large series of patients from the national registry 'SPRING' of the Italian Society for Rheumatology. *RMD Open*. 2023 Mar;9(1):e002890.
125. Frech, TM, Poole, JL, Murtaugh, M, **Matucci-Cerinic, M**. Expanding the Treatment Team: What Is the Role for Occupational Therapy, Physical Therapy, Wound Care, and Nutritional Support in Systemic Sclerosis?. *Rheum Dis Clin North Am*. 2023. doi: 10.1016/j.rdc.2023.01.009.
 126. Andreucci, E, Fioretto, BS, Rosa, I, **Matucci-Cerinic, M**, Biagioni, A, Romano, E et al.. Extracellular Lactic Acidosis of the Tumor Microenvironment Drives Adipocyte-to-Myofibroblast Transition Fueling the Generation of Cancer-Associated Fibroblasts. *Cells*. 2023; doi: 10.3390/cells12060939.
 127. Melis, MR, El Aoufy, K, Bambi, S, Bruni, C, Guiducci, S, Bellando-Randone, S, **M Matucci-Cerinic, L**. Rasero, Correction to: Nursing interventions for patients with rheumatic and musculoskeletal diseases on biological therapies: a systematic literature review. *Clin Rheumatol*. 2023 doi: 10.1007/s10067-023-06580-1.
 128. De Angelis, R, Ferri, C, Giuggioli, D, Bajocchi, G, Dagna, L, Bellando-Randone, S, G Zanframundo, R. Foti, F Cacciapaglia, G Cuomo, A Ariani, E Rosato, G Lepri, F Girelli, V Riccieri, E Zanatta, S L Bosello, I Cavazzana, F Ingegnoli, M De Santis, G Murdaca, G Abignano, N Romeo, A Della Rossa, M Caminiti, AM Iuliano, G Ciano, L Beretta, G Bagnato, E Lubrano I De Andres, A Giollo, M Saracco, C Agnes, E Cipolletta, F Lumetti, A Spinella, L Magnani, C Campochiaro, G De Luca, V Codullo, E Visalli, C Di Vico, A Gigante, G Pellagrino, E Pigatto, MG Lazzaroni, F Franceschini, E Generali, G Mennillo, S Barsotti, GP Mariano, F Furini, L Vultaggio, S Parisi, CL Peroni, D Rozza, A Zanetti, G Carrara, G Landolfi, CA Scirè, G Bianchi, E Fusaro, GD Sebastiani, M Govoni, S D'Angelo, F Cozzi, S Guiducci, A Doria, C Salvarani, F Iannone, **M Matucci-Cerinic** Systemic sclerosis sine scleroderma: clinical and serological features and relationship with other cutaneous subsets in a large series of patients from the national registry 'SPRING' of the Italian Society for Rheumatology. *RMD Open*. 2023 doi: 10.1136/rmdopen-2022-002890.
 129. Zhang, W, Huang, G, Zheng, K, Lin, J, Hu, S, Zheng, S, J Lin, S Hu, S Zheng, G Du, G Zhang, C Bruni, **M Matucci-Cerinic**, DE Furst, Y Wang Application of logistic regression and machine learning methods for idiopathic inflammatory myopathies malignancy prediction. *Clin Exp Rheumatol*. 2023. doi: 10.55563/clinexprheumatol/8ievtq.
 130. Migliore A, Alekseeva L, Avasthi SR, Bannuru RR, Chevalier X,

- Conrozier T, S Crimaldi, GC de Campos, D Diracoglu, G Gigliucci, G Herrero-Beaumont, G Iolascon, R Ionescu, J Jerosch, J Lains, E Maheu, S Makri, N Martusevich, **M Matucci-Cerinic**, K Pavelka, RJ Petrella, R Raman, Tarantino U Early Osteoarthritis Questionnaire (EOAQ): a tool to assess knee osteoarthritis at initial stage. *Ther Adv Musculoskelet Dis*. 2023. doi: 10.1177/1759720X221131604
131. Fioretto, BS, Rosa, I, **Matucci-Cerinic, M**, Romano, E, Manetti, M. Current Trends in Vascular Biomarkers for Systemic Sclerosis: A Narrative Review. *Int J Mol Sci*. 2023; doi: 10.3390/ijms24044097.
 132. Cantoni, E, Merelli, I, Stefanoni, D, Tomelleri, A, Campochiaro, C, Giordano, V, M Panigada, EM Baldissera, L Merlo Pich, V Natoli, A Ziogas, J Domínguez-Andrés, G De Luca, D Mazza, S Zambrano, D Gnani, M Ferrarini, E Ferrero, A Agresti, B Vergani, BE Leone, S Cenci, A Ravelli, **M Matucci-Cerinic**, et al. Myelomonocytic cells in giant cell arteritis activate trained immunity programs sustaining inflammation and cytokine production. *Rheumatology (Oxford)*. 2023 doi: 10.1093/rheumatology/kead061.
 133. Khanna, D, Denton, CP, Furst, DE, Mayes, MD, **Matucci-Cerinic, M**, Smith, V et al. A 24-Week, Phase IIa, Randomized, Double-blind, Placebo-controlled Study of Ziritaxestat in Early Diffuse Cutaneous Systemic Sclerosis (NOVESA). *Arthritis Rheumatol*. 2023 doi: 10.1002/art.42477.
 134. Tomelleri, A, Campochiaro, C, Farina, N, Mariotti, L, Baldissera, E, Grayson, PC, **M Matucci-Cerinic**, L Dagna Effectiveness of a two-year tapered course of tocilizumab in patients with giant cell arteritis: A single-centre prospective study. *Semin Arthritis Rheum*. 2023: doi: 10.1016/j.semarthrit.2023.152174.
 135. El Aoufy, K, Pezzutto, A, Pollina, A, Rasero, L, Bambi, S, Bellando-Randone, S Guiducci, S Maddali-Bongi, **M Matucci Cerinic** Systemic Sclerosis Patients Experiencing Mindfulness-Based Stress Reduction Program: The Beneficial Effect on Their Psychological Status and Quality of Life. *Int J Environ Res Public Health*. 2023 doi: 10.3390/ijerph20032512.
 136. Meloni, A, Gargani, L, Bruni, C, Cavallaro, C, Gobbo, M, D'Agostino, A, G D'Angelo, N Martini, F Grigioni, G Sinagra, R De Caterina, E Quaia, S Mavrogeni, F Cademartiri, **M Matucci-Cerinic**, A Pepe Additional value of T1 and T2 mapping techniques for early detection of myocardial involvement in scleroderma. *Int J Cardiol*. 2023. doi: 10.1016/j.ijcard.2023.01.066.
 137. Gremese, E, Ciccica, F, Selmi, C, Cuomo, G, Foti, R, **Matucci-Cerinic, M** et al. Persistence, effectiveness and safety of ustekinumab compared to TNF inhibitors in psoriatic arthritis within the Italian PsABio cohort. *Clin Exp Rheumatol*. 2023;. doi: 10.55563/clinexprheumatol/j33pjt.
 138. Alten, R, Burmester, GR, **Matucci-Cerinic, M**, Salmon, JH, Lopez-Romero, P, Fakhouri, W et al. The RA-BE-REAL Multinational, Prospective, Observational Study in Patients with Rheumatoid Arthritis Receiving Baricitinib, Targeted Synthetic, or Biologic Disease-Modifying Therapies: a 6-Month Interim Analysis. *Rheumatol Ther*. 2023. doi: 10.1007/s40744-022-00500-6.
 139. Garaiman, A, Steigmiller, K, Gebhard, C, Mihai, C, Dobrota, R, Bruni, C, **M Matucci-Cerinic** et al. Use of platelet inhibitors for digital ulcers related to systemic sclerosis: EUSTAR study on derivation and validation of the DU-VASC model. *Rheumatology (Oxford)*. 2023 doi: 10.1093/rheumatology/keac405.
 140. Romano E, Rosa I, Fioretto BS, **Matucci-Cerinic M**, Manetti M.

- Circulating Neurovascular Guidance Molecules and Their Relationship with Peripheral Microvascular Impairment in Systemic Sclerosis. *Life* (Basel). 2022 Jul 14;12(7):1056
141. Romano, E, Rosa, I, Fioretto, BS, Giuggioli, D, Manetti, **M, Matucci-Cerinic, M** et al.. Soluble guanylate cyclase stimulation fosters angiogenesis and blunts myofibroblast-like features of systemic sclerosis endothelial cells. *Rheumatology* (Oxford). 2023 doi: 10.1093/rheumatology/keac433.
 142. Mavrogeni, S, Pepe, A, Gargani, L, Bruni, C, Quaia, E, Kitas, GD, PP Sfikakis, **M Matucci-Cerinic** Cardiac inflammation and fibrosis patterns in systemic sclerosis, evaluated by magnetic resonance imaging: An update. *Semin Arthritis Rheum*. 2023 doi: 10.1016/j.semarthrit.2022.152126.
 143. Damiani, A, Bartoli, F, Pacini, G, Carboni, D, Bellando Randone, S, Fiori, G, **M Matucci-Cerinic, S Guiducci** Persistence of remission after lengthening of golimumab in inflammatory joint diseases. *Clin Exp Rheumatol*. 2023; doi: 10.55563/clinexprheumatol/k76z51.
 144. Lepri G, Orlandi M, Bellando-Randone S, **Matucci-Cerinic M, Guiducci S**. The COVID-19 pandemic highlights the need for a psychological support in systemic sclerosis patients. *Clin Exp Rheumatol*. 2023 Aug;41(8):1575-1577.
 145. Alten R, Burmester GR, **Matucci-Cerinic M**, Salmon JH, Lopez-Romero P, Fakhouri W, de la Torre I, Zaremba-Pechmann L, Holzkämper T, Fautrel B The RA-BE-REAL Multinational, Prospective, Observational Study in Patients with Rheumatoid Arthritis Receiving Baricitinib, Targeted Synthetic, or Biologic Disease-Modifying Therapies: a 6-Month Interim Analysis. *Rheumatol Ther*. 2023 Feb;10(1):73-93.
 146. Matteson EL, **Matucci-Cerinic M**, Kreuter M, Burmester GR, Dieudé P, Emery P, Allanore Y, Pope J, Khanna D. Patient-level factors predictive of interstitial lung disease in rheumatoid arthritis: a systematic review. *RMD Open*. 2023 Jul;9(3):e003059.
 147. Bruni C, Buch MH, Djokovic A, De Luca G, Dumitru RB, Giollo A, Galetti I, Steelandt A, Bratis K, Suliman YA, Milinkovic I, Baritussio A, Hasan G, Xintarakou A, Isomura Y, Markousis-Mavrogenis G, Mavrogeni S, Gargani L, Caforio AL, Tschöpe C, Ristic A, Plein S, Behr E, Allanore Y, Kuwana M, Denton CP, Furst DE, Khanna D, Krieg T, Marcolongo R, Pepe A, Distler O, Sfikakis P, Seferovic P, **Matucci-Cerinic M**. Consensus on the assessment of systemic sclerosis-associated primary heart involvement: World Scleroderma Foundation/Heart Failure Association guidance on screening, diagnosis, and follow-up assessment. *J Scleroderma Relat Disord*. 2023 Oct;8(3):169-182.
 148. Gargani L, Pugliese NR, De Biase N, Mazzola M, Agoston G, Arcopinto M, Argiento P, Armstrong WF, Bandera F, Cademartiri F, Carbone A, Castaldo R, Citro R, Cocchia R, Codullo V, D'Alto M, D'Andrea A, Douschan P, Fabiani I, Ferrara F, Franzese M, Frumento P, Ghio S, Grünig E, Guazzi M, Kasprzak JD, Kolias T, Kovacs G, La Gerche A, Limogelli G, Marra AM, **Matucci-Cerinic M**, Mauro C, Moreo A, Pratali L, Ranieri B, Rega S, Rudski L, Saggat R, Salzano A, Serra W, Stanziola AA, Vannan MA, Voilliot D, Vriz O, Wierzbowska-Drabik K, Cittadini A, Naeije R, Bossone E; RIGHT Heart International NETwork (RIGHT-NET) Investigators. Exercise Stress Echocardiography of the Right Ventricle and Pulmonary Circulation. *J Am Coll Cardiol*. 2023 Nov 21;82(21):1973-1985
 149. Ross L, Maltez N, Hughes M, Schoones JW, Baron M, Chung L,

- Giuggioli D, Moinzadeh P, Suliman YA, Campochiaro C, Allanore Y, Denton CP, Distler O, Frech T, Furst DE, Khanna D, Krieg T, Kuwana M, **Matucci-Cerinic M**, Pope J, Alunno A. Systemic pharmacological treatment of digital ulcers in systemic sclerosis: a systematic literature review. *Rheumatology (Oxford)*. 2023 Dec 1;62(12):3785-3800
150. Guler S, Sarbu AC, Stalder O, Allanore Y, Bernardino V, Distler J, Gabrielli A, Hoffmann-Vold AM, **Matucci-Cerinic M**, Müller-Ladner U, Ortiz-Santamaria V, Rednic S, Riccieri V, Smith V, Ullman S, Walker UA, Geiser TK, Distler O, Maurer B, Kollert F. Phenotyping by persistent inflammation in systemic sclerosis associated interstitial lung disease: a EUSTAR database analysis. *Thorax*. 2023 Dec;78(12):1188-1196
151. Lescoat A, Huang S, Carreira PE, Siegert E, de Vries-Bouwstra J, Distler JHW, Smith V, Del Galdo F, Anic B, Damjanov N, Rednic S, Ribi C, Bancel DF, Hoffmann-Vold AM, Gabrielli A, Distler O, Khanna D, Allanore Y; EUSTAR collaborators. Cutaneous Manifestations, Clinical Characteristics, and Prognosis of Patients With Systemic Sclerosis Sine Scleroderma: Data From the International EUSTAR Database *JAMA Dermatol*. 2023 Aug 1;159(8):837-847
152. Spiera R, Kuwana M, Khanna D, Hummers L, Frech TM, Stevens W, **Matucci-Cerinic M**, Kafaja S, Distler O, Jun JB, Levy Y, Leszczyński P, Gordon J, Steen V, Lee EB, Jankowski T, Litinsky I, Chung L, Hsu V, Mayes M, Sandorfi N, Simms RW, Finzel S, de Vries-Bouwstra J, Constantine S, Dgetluck N, Dinh Q, Bloom BJ, Furst DE, White B, Denton CP; RESOLVE-1 Study Group. Efficacy and Safety of Lenabasum, a Cannabinoid Type 2 Receptor Agonist, in a Phase 3 Randomized Trial in Diffuse Cutaneous Systemic Sclerosis. *Arthritis Rheumatol*. 2023 Sep;75(9):1608-1618.
153. Petelytska L, Bonomi F, Cannistrà C, Fiorentini E, Peretti S, Torracchi S, Bernardini P, Coccia C, De Luca R, Economou A, Levani J, **Matucci-Cerinic M**, Distler O, Bruni C. Heterogeneity of determining disease severity, clinical course and outcomes in systemic sclerosis-associated interstitial lung disease: a systematic literature review. *RMD Open*. 2023 Nov;9(4):e003426
154. Colalillo A, Pellicano C, Ananyeva LP, Hachulla E, Cuomo G, Györfi AH, Czirájk L, de Vries-Bouwstra J, Mouthon L, Poormoghim H, Del Galdo F, Hunzelmann N, Spierings J, Kuwana M, Rosato E; and the EUSTAR Collaborators. Tricuspid Annular Plane Systolic Excursion/Systolic Pulmonary Artery Pressure Ratio and Cardiorenal Syndrome Type 2 in the Systemic Sclerosis EUSTAR Cohort. *Arthritis Care Res (Hoboken)*. 2023 Jul 17. doi: 10.1002/acr.25196
155. Garaiman A, Steigmiller K, Gebhard C, Mihai C, Dobrota R, Bruni C, **Matucci-Cerinic M**, Henes J, de Vries-Bouwstra J, Smith V, Doria A, Allanore Y, Dagna L, Anic B, Montecucco C, Kowal-Bielecka O, Martin M, Tanaka Y, Hoffmann-Vold AM, Held U, Distler O, Becker MO; EUSTAR Collaborators. Use of platelet inhibitors for digital ulcers related to systemic sclerosis: EUSTAR study on derivation and validation of the DU-VASC model. *Rheumatology (Oxford)*. 2023 Feb 6;62(SI):SI91-SI100.
156. Fioretto BS, Rosa I, **Matucci-Cerinic M**, Romano E, Manetti M. *Int J Mol Sci*. 2023 Feb 17;24(4):4097.
157. Marongiu F, Ruberto MF, Marongiu S, **Matucci Cerinic M**, Barcellona D. A journey to vasculopathy in systemic sclerosis: focus on haemostasis and thrombosis. *Clin Exp Med*. 2023 Dec;23(8):4057-4064

158. Suliman YA, Campochiaro C, Hughes M, Schoones JW, Giuggioli D, Moinzadeh P, Baron M, Chung L, Ross L, Maltez N, Allanore Y, Denton CP, Distler O, Frech T, Furst DE, Khanna D, Krieg T, Kuwana M, **Matucci-Cerinic M**, Pope J, Alunno A. Surgical management of digital ulcers in systemic sclerosis: A systematic literature review. *Semin Arthritis Rheum*. 2023 Dec;63:152266.
159. Lepri G, Hughes M, Allanore Y, Denton CP, Furst DE, Wang Y, Santiago T, Galetti I, Del Galdo F, Khanna D, **Matucci-Cerinic M**. The role of skin ultrasound in systemic sclerosis: looking below the surface to understand disease evolution. *Lancet Rheumatol*. 2023 Jul;5(7):e422-e425
160. Lescoat A, Bellando-Randone S, Campochiaro C, Del Galdo F, Denton CP, Farrington S, Galetti I, Khanna D, Kuwana M, Truchetet ME, Allanore Y, **Matucci-Cerinic M**. Beyond very early systemic sclerosis: deciphering pre-scleroderma and its trajectories to open new avenues for preventive medicine. *Lancet Rheumatol*. 2023 Nov;5(11):e683-e694
161. Frech TM, Poole JL, Murtaugh M, **Matucci-Cerinic M**. Expanding the Treatment Team: What Is the Role for Occupational Therapy, Physical Therapy, Wound Care, and Nutritional Support in Systemic Sclerosis? *Rheum Dis Clin North Am*. 2023 May;49(2):377-387.
162. De Luca G, Campochiaro C, Palmisano A, Bruno E, Vignale D, Peretto G, Sala S, Ferlito A, Cilona MB, Esposito A, **Matucci-Cerinic M**, Dagna L. Myocarditis in anti-synthetase syndrome: clinical features and diagnostic modalities. *Rheumatology (Oxford)*. 2023 Oct 5:kead541
163. Distler O, Allanore Y, Denton CP, Kuwana M, **Matucci-Cerinic M**, Pope JE, Atsumi T, Bečvář R, Czirják L, Hachulla E, Ishii T, Ishikawa O, Johnson SR, De Langhe E, Stagnaro C, Ricciari V, Schiopu E, Silver RM, Smith V, Steen V, Stevens W, Szűcs G, Truchetet ME, Wosnitza M, Laapas K, Kramer F, Khanna D. Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): open-label, long-term extension of a phase 2b, randomised, placebo-controlled trial. *Lancet Rheumatol*. 2023;5(11):e660-e669

2022

164. Peretti, S, Torracchi, S, Russo, E, Bonomi, F, Fiorentini, E, Aoufy, KE, C Bruni, G Lepri, M Orlandi, MS Chimenti, S Guiducci, A Amedei, **M Matucci-Cerinic**, S Bellando Randone The Yin-Yang Pharmacomicrobiomics on *Treatment Response in Inflammatory Arthritides: A Narrative Review*. *Genes (Basel)*. 2022 doi: 10.3390/genes14010089.
165. De Luca G, Palmisano A, Campochiaro C, Vignale D, Cavalli G, Bruno E, Sartorelli S, Ferlito A, Peretto G, Sala S, **Matucci-Cerinic M**, Dagna L, Esposito A. Cardiac magnetic resonance in systemic sclerosis myocarditis: the value of T2 mapping to detect myocardial inflammation. *Rheumatology (Oxford)*. 2022 Nov 2;61(11):4409-4419
166. De Luca G, **Matucci-Cerinic M**, Dagna L Improvements of vascular outcomes in systemic sclerosis: halfway through, but still far to go. *Rheumatology (Oxford)*. 2022 Jul 6;61(7):2714-2716
167. Ruaro B, **Matucci Cerinic M**, Salton F, Baratella E, Confalonieri M, Hughes M. Pulmonary fibrosis: One manifestation, various diseases. *Front Pharmacol*. 2022 Oct 17;13:1027332.
168. Wang, Y, Xie, X, Zheng, S, Du, G, Chen, S, Zhang, W, J Zhuang, J Lin, S Hu, K Zheng, A Mikish, Z Xu, G Zhang, L Gargani, C Bruni ,

- A-M Hoffmann-Vold, **M Matucci-Cerinic**, DE Furst *Serum B-cell activating factor and lung ultrasound B-lines in connective tissue disease related interstitial lung disease*. Front Med (Lausanne). 2022; doi: 10.3389/fmed.2022.1066111.
169. Orlandi, M, Meliante, LA, Damiani, A, Tofani, L, Bruni, C, Guiducci, S, **M Matucci-Cerinic**, S Bellando-Randone, S Tomassetti *The Role of Bronchoalveolar Lavage in Systemic Sclerosis Interstitial Lung Disease: A Systematic Literature Review*. Pharmaceuticals (Basel). 2022; doi: 10.3390/ph15121584.
170. Fiorentini, E, Bonomi, F, Peretti, S, Orlandi, M, Lepri, G, **Matucci Cerinic, M** et al.. *Potential Role of JAK Inhibitors in the Treatment of Systemic Sclerosis-Associated Interstitial Lung Disease: A Narrative Review from Pathogenesis to Real-Life Data*. Life (Basel). 2022; doi: 10.3390/life12122101.
171. Luciano, N, Fusaro, E, Ditto, MC, Ianniello, A, Bellis, E, Bruni, C, O Viapiana, E, Gremese, A, Migliore, E, Romoli, L, Conforti, M, Govoni, **M Matucci-Cerinic**, C Selmi *Effectiveness of SB4 Transition from Originator Etanercept in Rheumatoid Arthritis and Axial Spondyloarthritis: A Subgroup Analysis from the BENEFIT Study*. Rheumatol Immunol Res. 2022. doi: 10.2478/rir-2022-0005.
172. Mormile, I, Mormile, M, Rossi, FW, Williams, M, Valente, T, Candia, C, F Granata, R, Rega, M, Orlandi, **M Matucci-Cerinic**, A Molino, A de Paulis *Radiological patterns and pulmonary function values of lung involvement in primary Sjögren's syndrome: A pilot analysis*. Front Med (Lausanne). 2022. doi: 10.3389/fmed.2022.998028.
173. Romano, E, Rosa, I, Fioretto, BS, **Matucci-Cerinic, M**, Manetti, M. *Increased Circulating Soluble Junctional Adhesion Molecules in Systemic Sclerosis: Association with Peripheral Microvascular Impairment*. Life (Basel). 2022; doi: 10.3390/life12111790.
174. Romano E, I Rosa, B Saveria Fioretto, D Giuggioli, M Manetti, **M Matucci-Cerinic**. *Soluble guanylate cyclase stimulation fosters angiogenesis and blunts myofibroblast-like features of systemic sclerosis endothelial cells*. Rheumatology (Oxford) 2022 Jul. doi: 10.1093/rheumatology/keac433.
175. Romano E, Rosa I, Fioretto BS, Kosalka-Wegiel J, Sticchi E, Bellando-Randone S, Manetti M, **Matucci-Cerinic M**. *A candidate gene study reveals association between a variant of the SRP55 splicing factor gene and systemic sclerosis*. Clin Exp Rheumatol. 2022 Oct;40(10):1921-1925.
176. Hughes, M, Umair, HM, Sandler, RD, Alunno, A, **Matucci-Cerinic, M**. *Harnessing the therapeutic potential therapeutic efficacy of α -1 adrenergic blockers for Raynaud's phenomenon and digital ischaemia secondary to central nervous system stimulants used for attention deficit hyperactivity disorder*. Semin Arthritis Rheum. 2022. doi: 10.1016/j.semarthrit.2022.152114.
177. Bandeira, M, Di Cianni, F, Marinello, D, Arnaud, L, Cannizzo, S, Carta, C, Alain Cornet, Sara M Barril, Inita Bulina, Alessandro Ferraris, João Fonseca, Andrea Gaglioti, Marteen Limper, Valentina Lorenzoni, Judith Majnik, **M Matucci-Cerinic**, I Palla, S Rednic, M Schneider, V Smith, A Sulli, K Søndergaard, S Ticciati, A Tincani, G Turchetti, R Talarico, M Cutolo, M Mosca, D Taruscio *An overlook on the current registries for rare and complex connective tissue diseases and the future scenario of TogetHERN ReCONNET*. Front Med (Lausanne). 2022; doi: 10.3389/fmed.2022.889997.
178. Talarico, R, Aguilera, S, Alexander, T, Amoura, Z, Antunes, AM, Arnaud, L, T Avcin, L Beretta, S Bombardieri, GR Burmester, S

- Cannizzo, L Cavagna, B Chaigne, A Cornet, N Costedoat-Chalumeau, A Doria, A Ferraris, R Fischer-Betz, JE Fonseca, C Frank, A Gaglioti, I Galetti, J Grunert, V Guimarães, E Hachulla, F Houssiau, L Iaccarino, T Krieg, M Limper, F Malfait, X Mariette, D Marinello, T Martin, L Matthews, **M Matucci-Cerinic** et al.. *The impact of COVID-19 on rare and complex connective tissue diseases: the experience of ERN ReCONNECT*. Nat Rev Rheumatol. 2022. doi: 10.1038/s41584-022-00862-9.
179. Stamenkovic, B, Stojanovic, S, Zivkovic, V, Djordjevic, D, Bojanovic, M, Stankovic, A, N Rancic, N Damjanov, **M Matucci Cerinic** *Low-Frequency Magnetic Resonance Imaging Identifies Hand Joint Subclinical Inflammation in Systemic Sclerosis*. Diagnostics (Basel). 2022. doi: 10.3390/diagnostics12092165.
180. Lepri, G, Catalano, M, Bellando-Randone, S, Pillozzi, S, Giommoni, E, Giorgione, R, C Botteri, **M Matucci-Cerinic**, L Antonuzzo, S Guiducci *Systemic Sclerosis Association with Malignancy*. Clin Rev Allergy Immunol. 2022. doi: 10.1007/s12016-022-08930-4.
181. Bellando-Randone, S, Del Galdo, F, **Matucci-Cerinic, M**. Insights into molecular and clinical characteristics of very early systemic sclerosis. Curr Opin Rheumatol. 2022. doi: 10.1097/BOR.0000000000000903.
182. Campochiaro, C, Lazzaroni, MG, Bruni, C, Zanatta, E, De Luca, G, **Matucci-Cerinic, M** et al.. *Open questions on the management of targeted therapies for the treatment of systemic sclerosis-interstitial lung disease: results of a EUSTAR survey based on a systemic literature review*. Ther Adv Musculoskelet Dis. 2022 doi: 10.1177/1759720X221116408.
183. Taylor, PC, Matucci Cerinic, M, Alten, R, Avouac, J, Westhovens, R. *Managing inadequate response to initial anti-TNF therapy in rheumatoid arthritis: optimising treatment outcomes*. Ther Adv Musculoskelet Dis. 2022. doi: 10.1177/1759720X221114101.
184. Ferri, C, De Angelis, R, Giuggioli, D, Bajocchi, G, Dagna, L, Zanframundo, G, R Foti, F Cacciapaglia, G Cuomo, A Ariani, E Rosato, S Guiducci, F Girelli, V Riccieri, E Zanatta, S Bosello, I Cavazzana, F Ingegnoli, M De Santis, G Murdaca, G Abignano, N Romeo, A Della Rossa, M Caminiti, A Iuliano, G Ciano, L Beretta, G Bagnato, E Lubrano, I De Andres, A Giollo, M Saracco, C Agnes, F Lumetti, A Spinella, L Magnani, C Campochiaro, G De Luca, V Codullo, E Visalli, F Masini, A Gigante, S Bellando-Randone, G Pellegrino, E Pigatto, MG Lazzaroni, F Franceschini, E Generali, G Mennillo, S Barsotti, G Pagano Mariano, F Calabrese, F Furini, L Vultaggio, S Parisi, C L Peroni, D Rozza, A Zanetti, G Carrara, G Landolfi, C Alberto Scirè, G Bianchi, E Fusaro, G D Sebastiani, M Govoni, S D'Angelo, F Cozzi, A Doria, F Iannone, C Salvarani, **M Matucci-Cerinic** *Geographical heterogeneity of clinical and serological phenotypes of systemic sclerosis observed at tertiary referral centres. The experience of the Italian SIR-SPRING registry and review of the world literature*. Autoimmun Rev. 2022. doi: 10.1016/j.autrev.2022.103159.
185. Bonomi, F, Peretti, S, Lepri, G, Venerito, V, Russo, E, Bruni, C, F Iannone, S Tangaro, A Amedei, S Guiducci, **M Matucci Cerinic**, S Bellando Randone. *The Use and Utility of Machine Learning in Achieving Precision Medicine in Systemic Sclerosis: A Narrative Review*. J Pers Med. 2022 doi: 10.3390/jpm12081198.
186. Hoffmann-Vold, AM, Distler, O, Bruni, C, Denton, CP, de Vries-Bouwstra, J, **Matucci Cerinic, M** et al.. *Systemic sclerosis in the time*

- of COVID-19. Lancet Rheumatol. 2022. doi: 10.1016/S2665-9913(22)00130-8
187. Bruni, C, Mattolini, L, Tofani, L, Gargani, L, Landini, N, Roma, N, G Lepri, M Orlandi, S Guiducci, S Bellando-Randone, C Romei, Y Wang, **M Matucci-Cerinic** Lung Ultrasound B-Lines in the Evaluation of the Extent of Interstitial Lung Disease in Systemic Sclerosis. Diagnostics (Basel). 2022 doi: 10.3390/diagnostics12071696.
 188. Santiago, T, Santos, EJF, Ruaro, B, Lepri, G, Green, L, Wildt, M, S Watanabe, A Lescoat, R Hesselstrand, F Del Galdo, JD Pauling, L Jean Reeve, MA D'Agostino, **M Matucci-Cerinic**, A Iagnocco, JA Pereira da Silva Recommendations for the execution and reporting of skin ultrasound in systemic sclerosis: an international collaboration under the WSF skin ultrasound group. RMD Open. 2022 doi: 10.1136/rmdopen-2022-002371.
 189. Bandini, G, Accogli, E, Cometi, L, Matucci-Cerinic, M, Moggi Pignone, A. Ultrasound assessment of splanchnic circulation in Systemic Sclerosis: a non-invasive approach for the study of bowel vasculopathy? Eur J Intern Med. 2022. doi: 10.1016/j.ejim.2022.06.024
 190. Stamenkovic B, Stojanovic S, Zivkovic V, Djordjevic D, Bojanovic M; Stankovic A, Rancic N, DamjanovN, **Matucci Cerinic M** Low-Frequency Magnetic Resonance Imaging Identifies Hand Joint Subclinical Inflammation in Systemic Sclerosis Diagnostics 2022 **doi.org/10.3390/diagnostics12092165**
 191. Zhang W, G Huang, J Lin, Q Lin, K Zheng, S Hu, S Zheng, G Du , **M Matucci-Cerinic** , D E Furst, Yi Wang. *Predictive model of risk and severity of enteritis in systemic lupus erythematosus*. Lupus. 2022 Sep. doi: 10.1177/09612033221110743.
 192. Bruni C, Occhipinti M, Pienn M, Camiciottoli G, Bartolucci M, Bosello SL, Payer C, Bálint Z, Larici AR, Tottoli A, Tofani L, De Lorenzis E, Lepri G, Bellando-Randone S, Spinella A, Giuggioli D, Masini F, Cuomo G, Lavorini F, Colagrande S, Olschewski H, **Matucci-Cerinic M**. Lung vascular changes as biomarkers of severity in systemic sclerosis-associated interstitial lung disease. Rheumatology (Oxford). 2022 Jun 16;keac311. doi: 10.1093/rheumatology/keac311.
 193. Hughes M, Allanore Y, Baron M, Del Galdo F, Denton CP, Frech T, Furst DE, Galetti I, Dagna L, Herrick AL, Kuwana M, Matucci-Cerinic P, McMaha ZHn, Murray CD, Proudman S , **Matucci-Cerinic M** *Proton pump inhibitors in systemic sclerosis: a reappraisal to optimise treatment of gastro-oesophageal reflux disease* Lancet Rheumatology Published online July 25, 2022 [https://doi.org/10.1016/S2665-9913\(22\)00183-7](https://doi.org/10.1016/S2665-9913(22)00183-7)
 194. Campochiaro C, N Farina, A Tomelleri, R Ferrara, S Viola, C Lazzari, G De Luca, D Raggi, A Bulotta , **M Matucci-Cerinic**, A Necchi , M Garassino, V Gregorc, L Dagna. *Autoantibody positivity predicts severity of rheumatic immune-related adverse events to immune-checkpoint inhibitors*. Eur J Intern Med. 2022 Sep. doi: 10.1016/j.ejim.2022.07.005.
 195. Bandini G, E Accogli, L Cometi, **M Matucci-Cerinic**, A Moggi Pignone. *Ultrasound assessment of splanchnic circulation in Systemic Sclerosis: a non-invasive approach for the study of bowel vasculopathy?* Eur J Intern Med. 2022 Sep. doi: 10.1016/j.ejim.2022.06.024.
 196. Mavrogeni S, A Pepe, R Nijveldt, N Ntusi, L M Sierra-Galan, K Bratis, J Wei, M Mukherjee, G Markousis-Mavrogenis , L Gargani, L

- E Sade, N Ajmone-Marsan, P Seferovic, E Donal, M Nurmohamed, **M Matucci Cerinic**, P Sfrikakis, G Kitas, J Schwitter, J A C Lima, Dana Dawson, Marc Dweck, Kristina H Haugaa, Niall Keenan, James Moon, Ivan Stankovic, Erwan Donal, Bernard Cosyns. *Cardiovascular magnetic resonance in autoimmune rheumatic diseases: a clinical consensus document by the European Association of Cardiovascular Imaging*. Eur Heart J Cardiovasc Imaging 2022 Aug. doi: 10.1093/ehjci/jeac134.
197. Landini N, Orlandi M, Occhipinti M, Nardi C, Tofani L, Bellando-Randone S, Ciet P, Wielopolski P, Benkert T, Bruni C, Bertolo S, Moggi-Pignone A, **Matucci-Cerinic M**, Morana G, Colagrande S. *Ultrashort Echo-Time Magnetic Resonance Imaging Sequence in the Assessment of Systemic Sclerosis-Interstitial Lung Disease*. J Thorac Imaging. 2022 Feb 4. doi: 10.1097/RTI.0000000000000637
198. Taylor PC, **M Matucci Cerinic**, R Alten, J Avouac, R Westhovens. *Managing inadequate response to initial anti-TNF therapy in rheumatoid arthritis: optimising treatment outcomes*. Ther Adv Musculoskelet Dis 2022 Aug doi: 10.1177/1759720X221114101.
199. Ruaro, R Pozzan, P Confalonieri, S Tavano, M Hughes, **M Matucci Cerinic**, E Baratella, E Zanatta, S Lerda, P Geri, M Confalonieri, F Salton. *Gastroesophageal Reflux Disease in Idiopathic Pulmonary Fibrosis: Viewer or Actor? To Treat or Not to Treat*. Pharmaceuticals (Basel) 2022 Aug 22 doi: 10.3390/ph15081033.
200. S Mavrogeni, L Fotis, P V. Voulgari, A I Venetsanopoulou, **M Matucci-Cerinic**. *Cardiovascular involvement in autoimmune diseases*. Front Cardiovasc Med. 2022 Jul. doi: 10.3389/fcvm.2022.982559.
201. Hoffmann-Vold A-M, O Distler, C Bruni, CP Denton, J de Vries-Bouwstra, **M Matucci Cerinic**, M C Vonk, A Gabrielli. *Systemic sclerosis in the time of COVID-19*. Lancet Rheumatol 2022 Aug. doi: 10.1016/S2665-9913(22)00130-8.
202. Santiago T, E J Ferreira Santos, B Ruaro, G Lepri, L Green, M Wild, S Watanabe, A Lescoat, R Hesselstrand, F Del Galdo, J D Pauling, L Jean Reeve, MA D'Agostino, **M Matucci-Cerinic**, A Iagnocco, JA Pereira da Silva. *Recommendations for the execution and reporting of skin ultrasound in systemic sclerosis: an international collaboration under the WSF skin ultrasound group*. RMD Open 2022 Jul. doi: 10.1136/rmdopen-2022-002371
203. Bruni C, L Mattolini, L Tofani, L Gargani, N Landini, N Roma, G Lepri, M Orlandi, S Guiducci, S Bellando-Randone, C Romei, Y Wang, **M Matucci-Cerinic**. *Lung Ultrasound B-Lines in the Evaluation of the Extent of Interstitial Lung Disease in Systemic Sclerosis*. Diagnostics (Basel) 2022 Jul. doi: 10.3390/diagnostics12071696.
204. Kreuter M, A-M Hoffmann-Vold, **M Matucci-Cerinic**, L Ann Saketko, K B Highland, H Wilson, M Alves, E Erhardt, N Schoof, T M Maher. *Impact of lung function and baseline clinical characteristics on patient-reported outcome measures in systemic sclerosis-associated interstitial lung disease*. Rheumatology (Oxford) 2022 May doi: 10.1093/rheumatology/keac325.
205. Maglie R, Baffa ME, Montefusco F, Pipitò C, Senatore S, Capassoni M, Maio V, **Matucci Cerinic M**, Antiga E, Guiducci S. *Bullous Pemphigoid Associated With Morphea and Lichen Sclerosus: Coincidental Diseases or Pathogenetic Association?* Front. Immunol., 03 May 2022 | <https://doi.org/10.3389/fimmu.2022.887279>
206. Becker M.O. Dobrota R; Garaiman A; Debelak R., Fligelstone K.;

- Kennedy A.T.; Roennow A.; Allanore Y.; Carreira P.E., Czirkjak L, Denton, C.P.; Hesselstrand R.; Sandqvist G.;Kowal-Bielecka O., Bruni C. **Matucci-Cerinic M.**; Mihai C.; Gheorghiu A.M.;Mueller-Ladner U.; Sexton J.; Kvien T.K.; Heiberg T.; Distler O. *Development and validation of a patient-reported outcome measure for systemic sclerosis: the EULAR Systemic Sclerosis Impact of Disease (ScleroID) questionnaire.* Ann Rheum Dis. doi: 10.1136/annrheumdis-2021-220702
- 207.Wang Y; Xie X.;Zhang C.;Su M.; Gao S.; Wang J.; Lu C; Lin Q; Lin J; **Matucci-Cerinic M.**; Furst D.E.; Zhang G. *Rheumatoid arthritis, systemic lupus erythematosus and primary Sjogren's syndrome shared megakaryocyte expansion in peripheral blood.* Mar 2022 Ann Rheum Dis .doi: 10.1136/annrheumdis-2021-220066
- 208.Talarico R, Aguilera S, Alexander T, Amoura Z, Andersen J, Arnaud L, Avcin T, Marsal Barril S, Beretta L, Bombardieri S, Bortoluzzi A, Bouillot C, Bulina I, Burmester GR, Cannizzo S, Cavagna L, Chaigne B, Cornet A, Corti P, Costedoat-Chalumeau N, Dāvidsone Z, Doria A, Fenech C, Ferraris A, Fischer-Betz R, Fonseca JE, Frank C, Gaglioti A, Galetti I, Guimarães V, Hachulla E, Holmner M, Houssiau F, Iaccarino L, Jacobsen S, Limper M, Malfait F, Mariette X, Marinello D, Martin T, Matthews L, **Matucci-Cerinic M.**, Meyer A, Milas-Ahić J, Moinzadeh P, Montecucco C, Mouthon L, Müller-Ladner U, Nagy G, Patarata E, Pilecky M, Pruunsild C, Rednic S, Romão VC, Schneider M, Scirè CA, Smith V, Sulli A, Tamirou F, Tani C, Taruscio D, Taulaigo AV, Tincani A, Ticciati S, Turchetti G, van Hagen PM, van Laar JM, Viera A, de Vries-Bouwstra JK, Zschocke J, Cutolo M, Mosca M. *The added value of a European Reference Network on rare and complex connective tissue and musculoskeletal diseases: insights after the first 5 years of the ERN ReCONNET.* Clin Exp Rheumatol. 2022 Mar 29. doi: 10.55563/clinexprheumatol/d2qz38.
- 209.Baldini C, Arnaud L, Avčin T, Beretta L, Bellocchi C, Bouillot C, Burmester GR, Cavagna L, Cutolo M, de Vries-Bouwstra J, Doria A, Ferro F, Fonseca JE, Fonzetti S, Fulvio G, Galetti I, Gottenberg JE, Hachulla E, Krieg T, La Rocca G, Martin T, **Matucci-Cerinic M.**, Moinzadeh P, Montecucco C, Mosca M, Mouthon L, Müller-Ladner U, Rednic S, Smith V, Talarico R, van Laar JM, Vieira A, Romão VC, Mariette X. *Sjögren's syndrome and other rare and complex connective tissue diseases: an intriguing liaison.* Clin Exp Rheumatol. 2022 Mar 21. doi: 10.55563/clinexprheumatol/3y0hq.
- 210.Bruni C, M.H Buch, D. E Furst, G. De Luca, A. Djokovic, R.B. Dumitru, A. Giollo, M.Polovina, A. Steelandt, K. Bratis, Y.A. Suliman, I. Milinkovic, A. Baritussio,G.Hasan, A. Xintarakou, Y. Isomura, G. Markousis-Mavrogenis, L.Tofani, S.Mavrogeni,L.Gargani, A.Lp Caforio, C.Tschöpe, A.Ristic, K. Klingel, S.Plein, E.R Behr, Y. Allanore, M. Kuwana, C.P Denton, D. Khanna,T.Krieg,R.Marcolongi,I.Galetti,E.Zanatta,F.Tona,P.Seferovic, **Marco Matucci-Cerinic.** *Primary systemic sclerosis heart involvement: A systematic literature review and preliminary data-driven, consensus-based WSF/HFA definition.* J Scleroderma Relat Disord 2022 Feb doi: 10.1177/23971983211053246.
- 211.De Luca G, **Matucci-Cerinic M.**, Dagna L. *Improvements of vascular outcomes in systemic sclerosis: halfway through, but still far to go.* Rheumatology (Oxford). Jan. doi: 10.1093/rheumatology/keac056
- 212.Luciano N, Fusaro E, Ditto MC, Ianniello A, Bellis E, Bruni C, Viapiana O, Gremese E, Migliore E, Romoli E, Conforti L, Govoni

- M, **Matucci-Cerinic M**, Selmi C *Effectiveness of SB4 transition from originator etanercept in rheumatoid arthritis and axial spondyloarthritis: A subgroup analysis from the BENEFIT study* Rheumatol Immunol Res 2022;3: 31-5
213. R De Angelis, D Giuggioli, G Bajocchi, L Dagna, G Zanframundo, R Foti, F Cacciapaglia, G Cuomo, A Ariani, E Rosato, S Guiducci, F Girelli, V Riccieri, E Zanatta, S Bosello, I Cavazzana, F Ingegnoli, M De Santis, G Murdaca, G Abignano, N Romeo, A Della Rossa, M Caminiti, A Iuliano, G Ciano, L Beretta, G Bagnato, E Lubrano, I De Andres, A Giollo, M Saracco, C Agnes, F Lumetti, A Spinella, L Magnani, C Campochiaro, G De Luca, V Codullo, E Visalli, F Masini, A Gigante, S Bellando-Randone, G Pellegrino, E Pigatto, F Dall'Ara, M Grazia Lazzaroni, E Generali, G Mennillo, S Barsotti, G Pagano Mariano, F Calabrese, F Furini, L Vultaggio, S Parisi, C Lisa Peron, A M Risa, D Rozza, A Zanetti, G Carrara, G Landolfi, C A Scirè, G Bianchi, EFusaro, G D Sebastiani, M Govoni, S D'Angelo, F Cozzi, A Doria, F Iannone, C Salvarani, **M Matucci-Cerinic**, C Ferri, Systemic sclerosis PROgression INvestiGation group (SPRING). *Sex-related Differences in Systemic Sclerosis: A Multicenter Cross-sectional Study From the National Registry of the Italian Society for Rheumatology*. J Rheumatol 2022 Feb. doi: 10.3899/jrheum.210794
214. Orlandi M, Vannuccini S, El Aoufy K, Melis MR, Lepri G, Sambataro G, Bellando-Randone S, Guiducci S, **Matucci Cerinic M**, Petraglia F. *Menstruation-Related Disorders-Dysmenorrhea and Heavy Bleeding-as Significant Epiphenomena in Women With Rheumatic Diseases* Front Pharmacol. 2022 Feb.
215. Cavagna L, Meloni F, Meyer A, Sambataro G, Belliato M, De Langhe E, Cavazzana I, Pipitone N, Triantafyllas K, Mosca M, Barsotti S, Zampogna G, Biglia A, Emmi G, De Visser M, Van Der Kooi A, Parronchi P, Hirschi S, da Silva JAP, Scirè CA, Furini F, Giannini M, Martinez Gonzalez O, Damian L, Piette Y, Smith V, Mera-Valera A, Bachiller-Corral J, Cabezas Rodriguez I, Brandy-Garcia AM, Maurier F, Perrin J, Gonzalez-Moreno J, Drott U, Delbruck C, Schwarting A, Arrigoni E, Sebastiani GD, Iuliano A, Nannini C, Quartuccio L, Rodriguez Cambon AB, Blázquez Cañamero MÁ, Villa Blanco I, Cagnotto G, Pesci A, Luppi F, Dei G, Romero Bueno FI, Franceschini F, Chiapparoli I, Zanframundo G, Lettieri S, De Stefano L, Cutolo M, Mathieu A, Piga M, Prieto-González S, Moraes-Fontes MF, Fonseca JE, Jovani V, Riccieri V, Santaniello A, Montfort S, Bilocca D, Erre GL, Bartoloni E, Gerli R, Monti MC, Lorenz HM, Sambataro D, Bellando Randone S, Schneider U, Valenzuela C, Lopez-Mejias R, Cifrian J, Mejia M, Gonzalez Perez MI, Wendel S, Fornaro M, De Luca G, Orsolini G, Rossini M, Dieude P, Knitza J, Castañeda S, Voll RE, Rojas-Serrano J, Valentini A, Vancheri C, **Matucci-Cerinic M**, Feist E, Codullo V, Iannone F, Distler JH, Montecucco C, Gonzalez-Gay MA; AENEAS collaborative group. *Clinical spectrum time course in non-Asian patients positive for anti-MDA5 antibodies*. Clin Exp Rheumatol. 2022 Feb. doi: 10.55563/clinexp/rheumatol/di1083
216. De Luca G, Palmisano A, Campochiaro C, Vignale D, Cavalli G, Bruno E, Sartorelli S, Ferlito A, Peretto G, Sala S, **Matucci-Cerinic M**, Dagna L, Esposito A *Cardiac magnetic resonance in systemic sclerosis myocarditis: the value of T2 mapping to detect myocardial inflammation*. Rheumatology (Oxford). 2022 Feb 21;keac098. doi: 10.1093/rheumatology/keac098
217. Manetti M, Rosa I, Fioretto BS, **Matucci-Cerinic M**, Eloisa R: *Decreased Serum Levels of SIRT1 and SIRT3 Correlate with Severity*

- of Skin and Lung Fibrosis and Peripheral Microvasculopathy in Systemic Sclerosis* J Clin Med 2022;11, 1362.
218. Ruaro B, Salton F, Baratella E, Confalonieri P, Geri P, Pozzan R, Torregiani C, Bulla R, Confalonieri M, **Matucci-Cerinic M**, Hughes M *An Overview of Different Techniques for Improving the Treatment of Pulmonary Hypertension Secondary in Systemic Sclerosis Patients* *Diagnostics* 2022; 12, 616. <https://doi.org/10.3390/diagnostics12030616>
 219. Alten R.; Burmester G.; **Matucci-Cerinic M.**; Salmon J. H.; Zaremba-Pechmann L.; Fakhouri W.; de La Torre I; Herrera M.; Holzkamper T.; Fautrel, B. *Healthcare Resource Use By European Patients Enrolled In Ra-Be-Real: A Multinational, Prospective, Observational Study Of The Effectiveness, Healthcare Resource Utilization And Costs In Patients With Rheumatoid Arthritis Receiving Baricitinib, Targeted Synthetic Or Biologic Disease Modifying Therapies.* Jan 2022 in *Value in Health*
 220. Lepri G, Bellando Randone S, **Matucci Cerinic M**, Guiducci S. *Early diagnosis of systemic sclerosis, where do we stand today?* *Expert Rev Clin Immunol.* 2022 Jan;18(1):1-3. doi: 10.1080/1744666X.2022.2015327
 221. Longo D, Branchi E, Matucci-Cerinic P, Bagni MA, **Matucci-Cerinic M**, Melchiorre D. *Shoulder impingement syndrome in water polo players: muscle shortening manoeuvre controls pain intensity, recovers function and normalizes sonographic parameters* *J Ultrasound.* 2022 Jan 20. doi: 10.1007/s40477-021-00645-0.
 222. Campochiaro C, Tomelleri A, **Matucci-Cerinic M**, Dagna L. *One year later: The case of tocilizumab in COVID-19.* *Eur J Intern Med.* Jan 2022. doi: 10.1016/j.ejim.2021.10.024
 223. Paoloni M, Agostini F, Bernasconi S, Bona G, Cisari C, Fioranelli M, Invernizzi M, Madeo A, **Matucci-Cerinic M**, Migliore A, Quirino N, Ventura C, Viganò R, *Bernetti A Information Survey on the Use of Complementary and Alternative Medicine.* *Medicina (Kaunas).* Jan. 2022 doi: 10.3390/medicina5801012
 224. El Aoufy K, Melis MR, Bellando Randone S, Blagojevic J, Bartoli F, Fiori G, Nacci F, Conforti ML, Cometi L, Bruni C, Orlandi M, Moggi-Pignone A, Rasero L, Guiducci S, **Matucci-Cerinic M** *The positive side of the coin: Sars-Cov-2 pandemic has taught us how much Telemedicine is useful as standard of care procedure in real life.* *Clin Rheumatol.* 2022 Feb. doi: 10.1007/s10067-021-05975-2
 225. Bandini G, Cometi L, Accogli E, Andrea D, Tofani L, Bruni C, Bellando-Randone S, Lepri G, Orlandi M, Guiducci S, El-Aoufy K, Ciuti G, Fabbri A, **Matucci Cerinic M**, Moggi Pignone A *Ultrasound evaluation of bowel vasculopathy in systemic sclerosis.* Study Group of Rheumatology and Internal Medicine. *Eur J Intern Med.* Jan. 2022 doi: 10.1016/j.ejim.2022.01.026.
 226. De Angelis R, Giuggioli D, Bajocchi G, Dagna L, Zanframundo G, Foti R, Cacciapaglia F, Cuomo G, Ariani A, Rosato E, Guiducci S, Girelli F, Riccieri V, Zanatta E, Bosello S, Cavazzana I, Ingegnoli F, Santis M, Murdaca G, Abignano G, Romeo N, Della Rossa A, Caminiti M, Iuliano A, Ciano G, Beretta L, Bagnato G, Lubrano E, De Andres I, Giollo A, Saracco M, Agnes C, Lumetti F, Spinella A, Magnani L, Campochiaro C, De Luca G, Codullo V, Visalli E, Masini F, Gigante A, Bellando-Randone S, Pellegrino G, Pigatto E, Dall'Ara F, Lazzaroni MG, Generali E, Mennillo G, Barsotti S, Mariano GP, Calabrese F, Furini F, Vultaggio L, Parisi S, Peroni CL, Risa AM, Rozza D, Zanetti A, Carrara G, Landolfi G, Scirè CA, Bianchi G,

- Fusaro E, Sebastiani GD, Govoni M, D'Angelo S, Cozzi F, Doria A, Iannone F, Salvarani C, **Matucci-Cerinic M**, Ferri C; Sex-related Differences in Systemic Sclerosis: A Multicenter Cross-sectional Study From the National Registry of the Italian Society for Rheumatology. *Systemic sclerosis PROgression INvestiGation group (SPRING)*. *J Rheumatol*. 2022;49:176-185
227. Landini N, Orlandi M, Bruni C, Carlesi E, Nardi C, Calistri L, Morana G, Tomassetti S, Colagrande S, **Matucci-Cerinic M** Computed Tomography Predictors of Mortality or Disease Progression in Systemic Sclerosis-Interstitial Lung Disease: A Systematic Review. *Front Med (Lausanne)*. 2022 Jan 27;8:807982
228. Orlandi M, Meliante LA, Damiani A, Tofani L, Bruni C, Guiducci S, **Matucci-Cerinic M**, Bellando-Randone S, Tomassetti S. The Role of Bronchoalveolar Lavage in Systemic Sclerosis Interstitial Lung Disease: A Systematic Literature Review. *Pharmaceuticals (Basel)*. 2022 Dec 19;15(12):1584
229. Lepri G, Catalano M, Bellando-Randone S, Pillozzi S, Giommoni E, Giorgione R, Botteri C, **Matucci-Cerinic M**, Antonuzzo L, Guiducci S. Systemic Sclerosis Association with Malignancy. *Clin Rev Allergy Immunol*. 2022 Dec;63(3):398-41

2021

230. Bellando-Randone S, Del Galdo F, Lepri G, Minier T, Huscher D, Furst DE, Allanore Y, Distler O, Czirják L, Bruni C, Guiducci S, Avouac J, Cutolo C, Smith V, **Matucci-Cerinic M** and , *Very Early Diagnosis of Systemic Sclerosis collaborators Progression of patients with Raynaud's phenomenon to systemic sclerosis: a five-year analysis of the European Scleroderma Trial and Research group multicentre, longitudinal registry study for Very Early Diagnosis of Systemic Sclerosis (VEDOSS)* *Lancet Rheumatol* 2021; 3: e834–e843
231. Bruni C.; Garaiman I. A.; Tofani L.; Jordan S.; Mihai C. M.; Dobrota R.; Elhai M.; Becker M.O.; **Matucci-Cerinic M.**; Distler O. *A Histogram-based Densitometry Index to Support the Identification and the Assessment of Severity of Interstitial Lung Disease in Systemic Sclerosis: Applicability in Conventional and Low-dose Computed Tomography*. Sep 2021 in *Swiss Medical Weekly*
232. De Luca R, Maresca M, Orlandi M, Bruni C, Solanki K, Wang Y, Lepri G, Guiducci S, Melchiorre D, Moggi-Pignone A, Rossi W, De Paulis A, Dzhush M, **Matucci-Cerinic M**, Bellando-Randone S *The emerging challenge of pain in systemic sclerosis: Similarity to the pain experience reported by Sjögren's syndrome patients* *Rheumatol Immunol Res* 2021;2:113-28
233. Orlandi M; Landini N; **Cerinic M Matucci**; Colagrande S *Pulmonary magnetic resonance imaging in systemic sclerosis: a jump in the future to unravel inflammation in interstitial lung disease* Sep 2021 in *Clinical Rheumatology*. DOI: 10.1007/S10067-021-05869-3
234. Orlandi M, Landini N, Sambataro G, Nardi C, Tofani L, Bruni C, Bellando-Randone S, Blagojevic J, Melchiorre D, Hughes M, Denton CP, Luppi F, Ruaro B, Della Casa F, Rossi FW, De Luca G, Campochiaro C, Spinicci M, Zammarchi L, Tomassetti S, Caminati A, Cavigli E, Albanesi M, Melchiorre F, Palmucci S, Vegni V, Guiducci S, Moggi-Pignone A, Allanore Y, Bartoloni A, Confalonieri M, Dagna L, De Cobelli F, De Paulis A, Harari S, Khanna D, Kuwana M, Taliani

- G, Lavorini F, Miele V, Morana G, Pesci A, Vancheri C, Colagrande S, **Matucci-Cerinic M**. *The role of chest CT in deciphering interstitial lung involvement: systemic sclerosis vs covid-19*. *Rheumatology* (Oxford). 2021 Jul 28;keab615. doi: 10.1093/rheumatology/keab615.
235. Campochiaro C, Tomelleri A, Farina N, Cavalli G, De Luca G, Palmisano A, Peretto G, Esposito A, Rizzo S, Basso C, **Matucci-Cerinic M**, Dagna L. *Myocarditis as a manifestation of Erdheim-Chester Disease: successful use of anti- IL1 and BRAF inhibitor combination therapy* *Scand J Rheumatol*. 2021 Nov 17:1-3. doi: 10.1080/03009742.2021.1992846
236. Migliore A, Gigliucci G, Alekseeva L, Bannuru RR, Blicharski T, Diracoglu D, Georgiadis A, Hamoud H, Martusevich N, **Matucci Cerinic M**, Perduk J, Szerb I, Trč T, Chevalier X. *Systematic Literature Review and Expert Opinion for the Use of Viscosupplementation with Hyaluronic Acid in Different Localizations of Osteoarthritis*. *Orthop Res Rev*. 2021;13:255-273. doi: 10.2147/ORR.S336185
237. Paderi A, E Gambale, C Botteri, R Giorgione, D Lavacchi, M Brugia, F Mazzoni, E Giommoni, S Bormioli, S Pillozzi, **M Matucci Cerinic**, L Antonuzzo *Association of systemic steroid treatment and outcome in patients treated with Immune Checkpoint Inhibitors: a real-world analysis* *Molecules* Molecules. 2021 Sep. doi: 10.3390/molecules26195789.
238. Wang Y, Lin Q, Lin J, Du G, **Matucci-Cerinic M**. *Infliximab Precipitated Urachal Remnant Infection* *J Clin Rheumatol*. Sep. 2021 doi: 10.1097/rhu.0000000000000946
239. Wang Y, Xie X, Zhang C, Su M, Gao S, Wang J, Lu C, Lin Q, Lin J, **Matucci-Cerinic M**, Furst DE, Zhang G. *Rheumatoid arthritis, systemic lupus erythematosus and primary Sjögren's syndrome shared megakaryocyte expansion in peripheral blood*. *Ann Rheum Dis*. Aug. 2021 doi: 10.1136/annrheumdis-2021-220066.
240. d'Alessandro M, Bellisai F, Bergantini L, Cameli P, D'Alessandro R, Mazzei, F Gentili MA, Conticini E, Selvi E, Frediani B, **Matucci-Cerinic M**, Bargagli E *Prognostic role of KL-6 in SSc-ILD patients with pleuroparenchymal fibroelastosis*. *Eur J Clin Invest* 2021 Aug. doi: 10.1111/eci.13543
241. Bruni C, Gentileschi S, Pacini G, Bardelli M, Tofani L, Bartoli F, Baldi C, Cometi L, Fiori G, Nacci F, Cantarini L, Guiducci S, Moggi-Pignone A, Frediani B, **Matucci-Cerinic M**. *Switching from originator adalimumab to biosimilar SB5 in a rheumatology cohort: persistence on treatment, predictors of drug interruption and safety analysis*. *Ther Adv Musculoskelet Dis*. Jul. 2021 doi: 10.1177/1759720X211033679.
242. Campochiaro C, G De Luca, N Farina D Vignale A Palmisano, **M Matucci-Cerinic**, L Dagna *Severe acute respiratory syndrome coronavirus-2-induced flare of systemic sclerosis* *Scand J Rheumatol*. 2021 Jul. doi: 10.1080/03009742.2021.1932582
243. Melchiorre D, Ceccherini MT, Romano E, Cometi L, El-Aoufy K, Bellando-Randone S, Roccotelli A, Bruni C, Moggi-Pignone A, Carboni D, Guiducci S, Lepri G, Tofani L, Pietramellara G, **Matucci-Cerinic M** *Oral Lactobacillus Species in Systemic Sclerosis*. *Microorganisms* 2021 Jun. doi: 10.3390/microorganisms9061298
244. Bellando-Randone S, E. Russo, V. Venerito, **M. Matucci Cerinic**, F. Iannone, S. Tangaro, A. Amedei *Exploring the oral-gut microbiome axis in rheumatic diseases: state of the art and future perspectives*

- through a machine learning approach. J Pers Med. 2021 Jun. doi: 10.3390/jpml1070625
245. Lescoat A, Varga J, **Matucci-Cerinic M**, Khanna K *New promising drugs for the treatment of systemic sclerosis: pathogenic considerations, enhanced classifications, and personalized medicine.* Expert Opin Investig Drugs 2021 May doi: 10.1080/13543784.2021.1923693.
 246. Orlandi M, N Landini, C Bruni, S Colagrande, **M Matucci-Cerinic**, M Kuwana *Infection or Autoimmunity? The Clinical Challenge of Interstitial Lung Disease in Systemic Sclerosis During the COVID-19 Pandemic* J Rheumatol 2021 May doi: 10.3899/jrheum.200832
 247. Ferri C; Giuggioli D; Raimondo V; L'Andolina M; Dagna L; Tavoni A; Caso F; Ursini F; Ruscitti, P; Caminiti M; Foti R; Ricciardi V; Guiducci S; Pellegrini R; Zanatta E; Varcasia G; Olivo D; Gigliotti P; Cuomo G; Murdaca G; Cecchetti R; De Angelis R; Romeo N; Ingegnoli F; Cozzi F; Codullo V; Cavazzana I; Colaci M; Abignano G; De Santis M; Lubrano E; Fusaro E; Della Rossa A; Spinella, A; Lumetti F; De Luca G; Bellando Randone S; Visalli E; Dal Bosco Y; Amato G; Giannini D; Bilia S; Masini F; Pellegrino G; Pigatto E; Generali E; Mariano GP; Pettiti G; Zanframundo G; Brittelli R; Aiello V; Caminiti R; Scorpiniti D; Ferrari T; Campochiaro C; Brusi V; Fredi M; Moschetti L; Cacciapaglia F; Gragnani L; Monti M; Lorini S; Paparo SR; Ragusa F; Mazzi V; Elia G; Ferrari SM; Di Cola I; Vadacca M; Lorusso S; Barsotti S; Aprile ML; M Tasso; Miccoli M; Bosello S; **Matucci Cerinic M**; D'Angelo S; Doria A; Franceschini F; Meliconi R; Iannone F; Giacomelli R; Zignego AL; Fallahi P; Antonelli A. *Covid-19 and Rheumatic Autoimmune Systemic Diseases: Role of Pre-Existing Lung Involvement and Ongoing Treatments* Nov 2021 in Current Pharmaceutical Design. doi: 10.2174/1381612827666210903103935
 248. Vannucchi AM, B Sordi, A Morettini, C Nozzoli, L Poggesi, F Pieralli, A Bartoloni, A Atanasio, F Miselli, C Paoli, GG Loscocco, A Fanelli, O Para, A Berni, ITassinari, L Zammarchi, L Maggio, A Mazzoni, V Scotti, G Falchetti, D Malandrino, F Luise, G Millotti, S Bencini, M Capone, MP Piccinni, F Annunziato, P Guglielmelli, RUXO-COVID Study Group *Compassionate use of JAK1/2 inhibitor ruxolitinib for severe COVID-19: a prospective observational study.* Leukemia 2021 Apr doi: 10.1038/s41375-020-01018-y.
 249. Hughes M, Bruni C, Ruaro B, Confalonieri M, **Matucci-Cerinic M**, Bellando-Randone S. *Digital Ulcers in Systemic Sclerosis* Presse Med. Apr.2021 doi: 10.1016/j.lpm.2021.104064
 250. Cox M, Sandler RD, **Matucci-Cerinic M**, Hughes M *Bone health in idiopathic inflammatory myopathies.* Apr 2021 in Autoimmunity Reviews.
 251. Hughes M, Allanore Y, Chung L, Pauling JD, Denton CP, **Matucci-Cerinic M**, *Raynaud phenomenon and digital ulcers in systemic sclerosis.* Apr 2021 Nature Reviews Rheumatology. DOI: 10.1038/S41584-021-00591-5
 252. Talarico R, Aguilera S, Alexander T, Amoura Z, Antunes AM, Arnaud L, Avcin T, Beretta L, Bombardieri S, Burmester GR, Cannizzo S, Cavagna L, Chaigne B, Cornet A, Costedoat-Chalumeau N, Doria A, Ferraris A, Fischer-Betz R, Fonseca JE, Frank C, Gaglioti A, Galetti I, Grunert J, Guimarães V, Hachulla E, Houssiau F, Iaccarino L, Krieg T, Limper M, Malfait F, Mariette X, Marinello D, Martin T, Matthews L, **Matucci-Cerinic M**, Meyer A, Montecucco C, Mouthon L, Müller-Ladner U, Rednic S, Romão VC, Schneider M, Smith V, Sulli A,

- Tamirou F, Taruscio D, Taulaigo AV, Terol E, Tincani A, Ticciati S, Turchetti G, van Hagen PM, van Laar JM, Vieira A, de Vries-Bouwstra JK, Cutolo M, Mosca *The impact of COVID-19 on rare and complex connective tissue diseases: the experience of ERN ReCONNET*. Nat Rev Rheumatol. 2021 Mar. doi: 10.1038/s41584-020-00565-z.
253. Galluccio F, D'Angela D, Polistena B, Porta F, Barskova T, Tofani L, Spandonaro F, **Matucci-Cerinic M** *Comparison of three treatment protocols with intra-articular low or intermediate molecular weight hyaluronic acid in early symptomatic knee osteoarthritis*. Ther Adv Muscul Dis. DOI: 10.1177/1759720X21994024
254. Campochiaro C.; Tomelleri A.; Farina N.; Cavalli G.; De Luca G.; Palmisano A.; Peretto G.; Esposito A.; Rizzo S.; Basso C.; **Matucci Cerinic M.**; Dagna L. *Myocarditis as a manifestation of Erdheim-Chester Disease: successful use of anti-IL1 and BRAF inhibitor combination therapy*. Nov 2021 in Scandinavian Journal of Rheumatology. doi: 10.1080/03009742.2021.1992846
255. Rosa I; Romano E; Fioretto BS; Guasti D; Ibba Manneschi L; **Matucci Cerinic M**; Manetti M. *Scleroderma-like Impairment in the Network of Telocytes/CD34(+) Stromal Cells in the Experimental Mouse Model of Bleomycin-Induced Dermal Fibrosis*. Nov 2021 in International Journal of Molecular Sciences. doi: 10.3390/ijms222212407
256. Bellando-Randone S.; Del Galdo F; Lepri G; Minier T; Huscher D; Furst D.E.; Allanore Y; Distler O; Czirjak L; Bruni C; Guiducci S; Avouac J; Cutolo M; Smith V; **Matucci Cerinic M.** *Progression of patients with Raynaud's phenomenon to systemic sclerosis: a five-year analysis of the European Scleroderma Trial and Research group multicentre, longitudinal registry study for Very Early Diagnosis of Systemic Sclerosis (VEDOSS)* Dec 2021 in The Lancet Rheumatology
257. Baimukhamedov C, Barskova T, **Matucci-Cerinic M** *Arthritis after SARS-CoV-2 infection* Lancet Rheumatol, March 2021 doi.org/10.1016/S2665-9913(21)00067-9
258. De Luca G, Cavalli G, Campochiaro C, Bruni C, Tomelleri A, Dagna L, **Matucci-Cerinic M.** *Interleukin-1 and Systemic Sclerosis: Getting to the Heart of Cardiac Involvement*. Frontiers in Immunology. Mar 2021 Doi: 10.3389/FIMMU.2021.653950
259. Lazzeri C, Bonizzoli M, Batacchi S, Socci F, **Matucci-Cerinic M**, Peris A. *Combined lung and cardiac ultrasound in COVID-related acute respiratory distress syndrome*. Internal Emerg Med. Mar 2021 DOI: 10.1007/S11739-021-02646-7
260. Ferri C, Giuggioli D., Raimondo V, Dagna L, Riccieri V, Zanatta E, Guiducci S, Tavoni A, Foti R, Cuomo G, De Angelis R, Cozzi F, Murdaca G, Cavazzana Ilaria, Romeo N, Codullo V, Ingegnoli F, Pellegrini R, Varcasia G, Della Rossa A, De Santis M, Abignano G, Colaci M, Caminiti M, L'Andolina M, Lubrano E, Spinella A, Lumetti F, De Luca G., Bellando-Randone S, Visalli E, Bilia S, Giannini D, Masini F, Pellegrino G, Pigatto E, Generali E, Dall'Ara F, Mariano GP, Barsotti S, Pettiti G, Zanframundo G, Brittelli R, Aiello V, Scorpiniti D, Ferrari T, Caminiti R, Campochiaro C, D'Angelo S, Iannone F, **Matucci-Cerinic M**, Doria A, Miccoli M, Fallahi P, Antonelli A. *COVID-19 and systemic sclerosis: clinicopathological implications from Italian nationwide survey study*. Lancet Rheumatol Mar 2021 . DOI: 10.1016/S2665-9913(21)00007-2
261. Lazzeri C, M Bonizzoli, S Batacchi, F Socci, **M Matucci-Cerinic**, A Peris *Combined lung and cardiac ultrasound in COVID-related acute respiratory distress syndrome*. Intern Emerg Med 2021 Mar doi:

- 10.1007/s11739-021-02646-7.
262. Coi A, Barsotti S, Santoro M, A Fabio, Bargagli E, Caproni M, Emmi G, Frediani B, Guiducci S, **Cerinic Matucci M**, Mosca M, Parronchi P, Prediletto R, Selvi E, Simonini G, Tavoni AG, Bianchi F, Pierini A. *Epidemiology of systemic sclerosis: a multi-database population-based study in Tuscany (Italy)*. Feb 2021 in Pharmaceuticals. DOI: 10.3390/PH14020154
 263. Ruaro B, Confalonieri M, **Matucci-Cerinic M**, Salton F, Confalonieri P, Santagiuliana M, Citton GM, Baratella E, Bruni C. *The Treatment of Lung Involvement in Systemic Sclerosis*. Feb 2021 in Pharmaceuticals. DOI: 10.3390/PH14020154
 264. Rosa I, Faussone-Pellegrini MS, Romano E, Ibba-Manneschi L, **Matucci-Cerinic M**, Manetti M. *Impairment in the telocyte/CD34 + stromal cell network in human rheumatoid arthritis synovium* J Cell Mol Med 2021 Feb. doi: 10.1111/jcmm.16225.
 265. Rosa I, Romano E, Fioretto BS, **Matucci-Cerinic M**, Manetti M. *Adipose-derived stem cells: Pathophysiologic implications vs therapeutic potential in systemic sclerosis*. Feb 2021 in Journal of Cellular and Molecular Medicine. DOI: 10.1111/JCMM.16225
 266. Blaja E, Jordan S, Mihai CM, Dobrota R, Becker MO, Maurer B, **Matucci-Cerinic M**, Distler O. *The Challenge of Very Early Systemic Sclerosis: A Combination of Mild and Early Disease?* Jan. 2021 J Rheumatol doi: 10.3899/JRHEUM.190976
 267. Hughes M, Kahaleh B, Denton CP, Mason JC, **Matucci-Cerinic M** *ANCA in systemic sclerosis, when vasculitis overlaps with vasculopathy: a devastating combination of pathologies*. Rheumatology (Oxford). 2021 Dec doi: 10.1093/rheumatology/keab278.
 268. De Luca G, Cavalli G, Campochiaro C, Bruni C, Tomelleri A, Dagna L, **Matucci-Cerinic M** *Interleukin-1 and Systemic Sclerosis: Getting to the Heart of Cardiac Involvement*. Front Immunol. 2021 Mar doi:10.3389/fimmu.2021.653950.
 269. Ruaro B, Salton F, Baratella E, Confalonieri P, Geri P, Pozzan R, Torregiani C, Bulla R, Confalonieri M, **Matucci-Cerinic M**, Hughes M. *An Overview of Different Techniques for Improving the Treatment of Pulmonary Hypertension Secondary in Systemic Sclerosis Patients*. Diagnostics (Basel). 2022 Mar 1;12(3):616. doi: 10.3390/diagnostics12030616
 270. Maraghelli D, Brandi ML, **Matucci Cerinic M**, Peired AJ, Colagrande S *Edema-like marrow signal intensity: a narrative review with a pictorial essay*. Skeletal Radiol. 2021 Apr. doi: 10.1007/s00256-020-03632-4.
 271. Tomassetti S, Colby TV, Wells AU, Poletti V, Costabel U, **Matucci-Cerinic M**. *Bronchoalveolar lavage and lung biopsy in connective tissue diseases, to do or not to do?* Ther Adv Musculoskelet Dis. 2021 Dec. doi: 10.1177/1759720X211059605.
 272. Tufan A, **Matucci-Cerinic M**. *Immune dysfunction in COVID-19 and judicious use of antirheumatic drugs for the treatment of hyperinflammation*. Med Sci. 2021 Dec. doi: 10.3906/sag-2110-17
 273. **Matucci-Cerinic M**, Hughes M, Taliani G, Kahaleh B *Similarities between COVID-19 and systemic sclerosis early vasculopathy: A "viral" challenge for future research in scleroderma*. Autoimmun Rev. 2021 Oct;20(10):102899. doi: 10.1016/j.autrev.2021.102899
 274. Andreucci E; Margheri F; Peppicelli S; Bianchini F; Ruzzolini J; Laurenzana A; Fibbi G; Bruni C; Bellando-Randone S; Guiducci S; Romano E; Manetti M; **Matucci Cerinic M**; Calorini L. *Glycolysis-*

- derived acidic microenvironment as a driver of endothelial dysfunction in systemic sclerosis.* Oct 2021 in Rheumatology. doi: 10.1093/rheumatology/keab022
275. Lescoat A, Varga J, **Matucci-Cerinic M**, Khanna D. *New promising drugs for the treatment of systemic sclerosis: pathogenic considerations, enhanced classifications, and personalized medicine* Expert Opin Investig Drugs. 2021 Jun;30(6):635-652.
 276. Bruni C, **Matucci Cerinic M** *Response to: 'Correspondence on 'Systemic sclerosis and the COVID-19 pandemic: World Scleroderma Foundation preliminary advice for patient management' by Snarskaya and Vasileva* Ann Rheum Dis 2021 Jan doi: 10.1136/annrheumdis-2020-219533.
 277. Romano E, Rosa I, Fioretto BS, **Matucci-Cerinic M**, Manetti M *New Insights into Profibrotic Myofibroblast Formation in Systemic Sclerosis: When the Vascular Wall Becomes the Enemy.* Life (Basel). 2021 Jun 24;11(7):610. doi: 10.3390/life1107061
 278. Wang Y, Chen S, Zheng S, Lin J, Hu S, Zhuang J, Lin Q, Xie X, Zheng K, Zhang W, Du G, Zhang G, Hoffmann-Vold AM, **Matucci-Cerinic M**, Furst DE *The role of lung ultrasound B-lines and serum KL-6 in the screening and follow-up of rheumatoid arthritis patients for an identification of interstitial lung disease: review of the literature, proposal for a preliminary algorithm, and clinical application to cases.* Arthritis Res Ther. 2021 Aug 14;23(1):212. doi: 10.1186/s13075-021-02586-9.
 279. Russo B, Ben Shimol J, **Matucci-Cerinic M**, Bruni C *Systemic sclerosis and COVID-19: what's new in the literature.* Clin Exp Rheumatol. 2021 Jul-Aug;39 Suppl 131(4):157-158. Epub 2021 May 3
 280. Agostini E, De Luca G, Bruni C, Bartoli F, Tofani L, Campochiaro C, Pacini G, Moggi-Pignone A, Guiducci S, Bellando-Randone S, Shoenfeld Y, Dagna L, **Matucci-Cerinic M** *Intravenous immunoglobulins reduce skin thickness in systemic sclerosis: evidence from Systematic Literature Review and from real life experience.* Autoimmun Rev. 2021 Dec;20(12):102981. doi: 10.1016/j.autrev.2021.102981. Epub 2021 Oct 28
 281. De Luca G, Tomelleri A, Dagna L, **Matucci-Cerinic M** *The target on B cells in Systemic Sclerosis: a "midsummer dream" to extinguish inflammation and prevent early disease progression to fibrosis.* Clin Rheumatol. 2021 Jul;40(7):2529-2533
 282. Umair HM, Sandler RD, Alunno A, **Matucci-Cerinic M**, Hughes M *Association between central nervous system stimulants used to treat attention deficit hyperactivity disorder (ADHD) and Raynaud's phenomenon: A scoping review.* Semin Arthritis Rheum 2021 Dec;51(6):1200-1204. doi: 10.1016/j.semarthrit.2021.09.002. Epub 2021 Sep 16.
 283. Maddali Bongi S, Passalacqua M, Landi G, Mikhaylova S, Tofani L, Del Rosso A, El Aoufy K, Baccini M, **Matucci-Cerinic M**, Melchiorre D *Rehabilitation of the face and temporomandibular joint in systemic sclerosis.* Ther Adv Musculoskelet Dis. 2021 Jun 8;13:1759720X211020171. doi: 10.1177/1759720X211020171. eCollection 2021.
 284. D Giuggioli, C Bruni, F Cacciapaglia, F Dardi, A De Cata, N Del Papa, F Iannone, C Lunardi, W Maglione, F Molinaro, M Palazzini, A Spinella, E Tinazzi, **M Matucci Cerinic** *Pulmonary arterial hypertension: guidelines and unmet clinical needs* Reumatismo 2021 Jan doi: 10.4081/reumatismo.2020.1310
 285. F. Cappelli, M. Zampieri, C. Fumagalli, G. Nardi, G. Del Monaco, **M.**

- Matucci Cerinic**, M. Allinovi, G. Taborchi, R. Martone, M. Gabriele, A. Ungar, A. Moggi Pignone, N. Marchionni, C. Di Mario, I. Olivotto, F. Peretto. *Tenosynovial complications identify TTR cardiac amyloidosis among patients with hypertrophic cardiomyopathy phenotype*. J Intern Med 2021;289(6):831-83
286. Caforio ALP, De Luca G, Baritussio A, Seguso M, Gallo N, Bison E, Cattini MG, Pontara E, Gargani L, Pepe A, Campochiaro C, Plebani M, Iliceto S, Peretto G, Esposito A, Tofani L, Moggi-Pignone A, Dagna L, Marcolongo R, **Matucci-Cerinic M**, Bruni C. *Serum Organ-Specific Anti-Heart and Anti-Intercalated Disk Autoantibodies as New Autoimmune Markers of Cardiac Involvement in Systemic Sclerosis: Frequency, Clinical and Prognostic Correlates*. Diagnostics (Basel). 2021 Nov 22;11(11):2165
287. Becker MO, Dobrota R, Garaiman A, Debelak R, Fligelstone K, Tyrrell Kennedy A, Roennow A, Allanore Y, Carreira PE, Czirájk L, Denton CP, Hesselstrand R, Sandqvist G, Kowal-Bielecka O, Bruni C, **Matucci-Cerinic M**, Mihai C, Gheorghiu AM, Mueller-Ladner U, Sexton J, Kvien TK, Heiberg T, Distler O. *Development and validation of a patient-reported outcome measure for systemic sclerosis: the EULAR Systemic Sclerosis Impact of Disease (ScleroID) questionnaire*. Ann Rheum Dis. 2021 Nov 25;annrheumdis-2021-220702. doi: 10.1136/annrheumdis-2021-220702
288. Tomassetti S, Ravaglia C, Puglisi S, Ryu JH, Colby TV, Cavazza A, Wells AU, Pavone M, Vancheri C, Lavorini F, **Matucci-Cerinic M**, Rosi E, Luzzi V, Gori L, Rossi G, Donati L, Dubini A, Picciocchi S, Poletti V. *Impact of Lung Biopsy Information on Treatment Strategy of Patients with Interstitial Lung Diseases*. Ann Am Thorac Soc. 2021 Nov 5. doi: 10.1513/AnnalsATS.202104-466OC
289. Gargani L, Romei C, Bruni C, Lepri G, El-Aoufy K, Orlandi M, D'Errico L, Bandini G, D'Angelo G, Guiducci S, Dagna L, Falaschi F, **Matucci-Cerinic M**, Moggi-Pignone A. *Lung ultrasound B-lines in systemic sclerosis: cut-off values and methodological indications for interstitial lung disease screening*. Oct 2021 in Rheumatology doi: 10.1093/rheumatology/keab801
290. Kuwana M, Allanore Y, Denton CP, Distler JHW, Steen V, Khanna D, **Matucci-Cerinic M**, Mayes MD, Volkmann ER, Miede C, Gahlemann M, Quaresma M, Alves M, Distler O. *Nintedanib in Patients With Systemic Sclerosis-Associated Interstitial Lung Disease: Subgroup Analyses by Autoantibody Status and Modified Rodnan Skin Thickness Score*. Arthritis Rheumatol. 2021 Sep 12. doi: 10.1002/art.41965
291. Spiera R, Khanna D, Kuwana M, Furst DE, Frech TM, Hummers L, Stevens W, **Matucci-Cerinic M**, Baron M, Distler O, Dgetluck N, Bloom BJ, Dinh Q, White B, Denton CP. *A randomised, double-blind, placebo-controlled phase 3 study of lenabasum in diffuse cutaneous systemic sclerosis: RESOLVE-1 design and rationale*. Clin Exp Rheumatol. 2021 Jul-Aug;39 Suppl 131(4):124-133
292. Karalilova RV, Batalov ZA, Sapundzhieva TL, **Matucci-Cerinic M**, Batalov AZ. *Tofacitinib in the treatment of skin and musculoskeletal involvement in patients with systemic sclerosis, evaluated by ultrasound*. Rheumatol Int. 2021 Oct;41(10):1743-1753.
293. Mahran SA, Galluccio F, Khedr TM, Elsonbaty A, Allam AE, Garcia Martos A, Osman DMM, **Matucci-Cerinic M**, Guiducci S, Galal MAA. *Peripheral neuropathy in systemic lupus erythematosus: what can neuromuscular ultrasonography (NMUS) tell us? A cross-sectional*

- study. *Lupus Sci Med*. 2021 Jul;8(1):e000521. doi: 10.1136/lupus-2021-000521
294. Hughes M, Heal C, Henes J, Balbir-Gurman A, Distler JHW, Airò P, Müller-Ladner U, Hunzelmann N, Kerzberg E, Rudnicka L, Truchetet ME, Stebbings S, Tanaka Y, Hoffman-Vold AM, Gabrielli A, Distler O, **Matucci-Cerinic M**; *EUSTAR Collaborators*. *Digital pitting scars are associated with a severe disease course and death in systemic sclerosis: a study from the EUSTAR cohort*. *Rheumatology (Oxford)*. 2021 Jun 19:keab510. doi: 10.1093/rheumatology/keab510
 295. Hughes M, Allanore Y, El Aoufy K, Denton CP, Khanna D, Krieg T, **Matucci-Cerinic M**. *A Practical Approach to the Management of Digital Ulcers in Patients With Systemic Sclerosis: A Narrative Review*. *JAMA Dermatol*. 2021 Jul 1;157(7):851-858. doi: 10.1001/jamadermatol.2021.1463.
 296. Tesei G, Cometi L, Nacci F, Terenzi R, Tofani L, Capassoni M, Bartoli F, Fiori G, **Matucci-Cerinic M**, Bruni C. *Baricitinib in the treatment of rheumatoid arthritis: clinical and ultrasound evaluation of a real-life single-centre experience* *Ther Adv Musculoskelet Dis*. 2021 May 10;13:1759720X211014019. doi: 10.1177/1759720X211014019
 297. De Luca G, Tomelleri A, Dagna L, **Matucci-Cerinic M**. *The target on B cells in Systemic Sclerosis: a "midsummer dream" to extinguish inflammation and prevent early disease progression to fibrosis*. *Clin Rheumatol*. 2021 Jul;40(7):2529-2533. doi: 10.1007/s10067-021-05733
 298. Nevskaya T, Pope JE, Turk MA, Shu J, Marquardt A, van den Hoogen F, Khanna D, Fransen J, **Matucci-Cerinic M**, Baron M, Denton CP, Johnson SR. *Systematic Analysis of the Literature in Search of Defining Systemic Sclerosis Subsets*. *J Rheumatol*. 2021 Nov;48(11):1698-1717. doi: 10.3899/jrheum.201594. Epub 2021 May 15
 299. Galluccio F, D'Angela D, Polistena B, Porta F, Barskova T, Tofani L, Spandonaro F, **Matucci-Cerinic M**. *Comparison of three treatment protocols with intra-articular low or intermediate molecular weight hyaluronic acid in early symptomatic knee osteoarthritis*. *Ther Adv Musculoskelet Dis*. 2021 ;13:1759720X21994024. doi: 10.1177/1759720X21994024
 300. Suliman YA, Bruni C, Hughes M, **Matucci-Cerinic M**, Furst DE. *Ultrasonographic imaging of systemic sclerosis digital ulcers: A systematic literature review and validation steps*. *Semin Arthritis Rheum*. 2021;51(2):425-429. doi: 10.1016/j.semarthrit.2021.02.008. Epub 2021 Feb 19

2020

301. Bruni C, Cigolini C, Tesei G, Cometi L, Bartoli F, Fiori G, Nacci F, Bellando-Randone S, Guiducci S, **Matucci-Cerinic M**. *Combination of denosumab and biologic DMARDs in inflammatory muscle-skeletal diseases and connective tissue diseases*. *Eur J Rheumatol*. Oct. doi: 10.5152/eurjrheum.2020.21162.
302. Hughes M, Pauling JD, Jones J, Denton CP, Domsic RT, Frech TM, Herrick AL, Khanna D, **Matucci-Cerinic M**, McKenzie L, Saketkoo LA, Gooberman-Hill R, Moore A. *Patient experiences of digital ulcer development and evolution in systemic sclerosis*. *Rheumatology (Oxford)*. 2020;59(8):2156-2158. DOI: 10.1093/Rheumatology/Keaa037
303. Hughes M, Heal C, Siegert E, Hachulla E, Airò P, Riccardi A, Distler

- O, **Matucci-Cerinic M**; EUSTAR Collaborators *Significant weight loss in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database.* Ann Rheum Dis. 2020 Aug;79(8):1123-1125. doi: 10.1136/annrheumdis-2020-217035.
304. Avouac J, Airo P, Carlier N, **Matucci-Cerinic M**, Allanore Y. *Severe COVID-19-associated pneumonia in 3 patients with systemic sclerosis treated with rituximab.* Ann Rheum Dis DOI: 10.1136/ANNRHEUMDIS-2020-217864
305. Cometi L, Bruni C, Passavanti S, Tofani L, Bartoli F, Fiori G, Nacci F, Lepri G, Orlandi M, Melchiorre D, Antonuzzo L, **Matucci-Cerinic, M**, Moggi-Pignone A *Risk of malignancy and biologic therapy in rheumatic inflammatory diseases: A single-center experience* Rheumatol Immunol Res 2020;1; 35-41
306. Chung L, Spino C, McLain R, Johnson SR, Denton CP, Molitor JA, Steen VD, Lafyatis R, Simms RW, Kafaja S, Frech TM, Hsu V, Domsic RT, Pope JE, Gordon JK, Mayes MD, Sandorfi N, Hant FN, Bernstein EJ, Chatterjee S, Castellino FV, Ajam Ali, Allanore Y, **Matucci-Cerinic M**, Whitfield ML, Distler O, Singer O, Young A, Nagaraja V, Fox DA, Furst DE, Khanna D. *Safety and efficacy of abatacept in early diffuse cutaneous systemic sclerosis (ASSET): open-label extension of a phase 2, double-blind randomised trial.* Dec. in The Lancet Rheumatology. DOI: 10.1016/S2665-9913(20)30237-X
307. El Aoufy K, Bruni C, Rasero L, **Matucci Cerinic M**, Furst DE. *Patient preferences for systemic sclerosis treatment: A descriptive study within an Italian cohort.* Journal of Scleroderma and Related Disorders Dec.2020 doi.org/10.1177/2397198320971984
308. Mavrogeni, S.; Gargani, L.; Pepe, A.; Monti, L.; Markousis-Mavrogenis, G.; Koutsogeorgopoulou, L.; Karabela, G.; Katsifis, G.; Bruni, C.; Dimitroulas, T.; Mukherjee, M.; Lima, J.; Kitas, G. D.; Sfrikakis, P. P.; **Matucci-Cerinic, M.** *The relationship between arrhythmogenicity and novel parametric cardiac magnetic resonance indices in systemic sclerosis patients.* Nov 2020 in European Heart Journal. DOI: 10.1093/EHJCI/EHAA946.0270
309. Gargani, L.; Pugliese, N. R.; Meloni, A.; Bruni, C.; Todiere, G.; Guiducci, S.; Moggi-Pignone, A.; Lombardi, M.; Mavrogeni, S.; **Matucci-Cerinic, M.**; Pepe, A. *Late Gadolinium Enhancement at cardiac magnetic resonance predicts malignant ventricular arrhythmias in systemic sclerosis.* Nov 2020 in European Heart Journal . doi: 10.1093/ehjci/ehaa946.0219
310. Bruni C, Tashkin DP, Steen V, Allanore Y, Distler O, Grotts J, **Matucci-Cerinic M**, Furst DE; EUSTAR, SLS I & SLS II centres collaborators. *Intravenous versus oral cyclophosphamide for lung and/or skin fibrosis in systemic sclerosis: an indirect comparison from EUSTAR and randomised controlled trials.* Clin Exp Rheumatol. 2020. PMID: 32865169 Clinical Trial.
311. Del Galdo F, **Matucci-Cerinic M.** *A special European Journal of Rheumatology issue on systemic sclerosis: What and why? Published: Oct 2020 in European Journal of Rheumatology. doi: 10.5152/eurjrheum.2020.090121*
312. Johnson SR, van den Hoogen F, Devakandan K, **Matucci-Cerinic M**, Pope JE. *Systemic sclerosis: To subset or not to subset, that is the question.* Oct 2020 in European Journal of Rheumatology doi: 10.5152/eurjrheum.2020.19116
313. F Marini, F Falcini, S Stagi, S Fabbri, S Ciuffi, D Rigante, **M Matucci Cerinic**, ML Brandi *Study of vitamin D status and vitamin D receptor polymorphisms in a cohort of Italian patients with juvenile idiopathic*

- arthritis. Sci Rep. 2020 Oct. doi: 10.1038/s41598-020-74861-9.
314. Landini N, Orlandi M, Fusaro M, Ciet P, Nardi C, Bertolo S, Catalanotti V, **Matucci-Cerinic M**, Colagrande S, Morana G. *The role of imaging in COVID-19 pneumonia diagnosis and management: Main positions of the experts, key imaging features and open answers.* Oct 2020 in Journal of Cardiovascular Echography. DOI: 10.4103/JCECHO.JCECHO_59_20
 315. Romano E, Rosa I, Fioretto BS, Lucattelli E, Innocenti M, Ibba-Manneschi Lidia, **Matucci-Cerinic M**, Manetti M. *A Two-Step Immunomagnetic Microbead-Based Method for the Isolation of Human Primary Skin Telocytes/CD34+Stromal Cells.* International Journal of Molecular Sciences. Aug 2020. Doi: 10.3390/Ijms21165877
 316. Y Wang, G Du, G Zhang, **M Matucci-Cerinic**, DE Furst *Similarities and differences between severe COVID-19 pneumonia and anti-MDA-5-positive dermatomyositis-associated rapidly progressive interstitial lung diseases: a challenge for the future* Ann Rheum Dis 2020 Aug doi: 10.1136/annrheumdis-2020-218594.
 317. Lepri G, Orlandi M, Lazzeri C, Bruni C, Hughes M, Bonizzoli M, Wang Y, Peris A, **Matucci-Cerinic M** *The emerging role of lung ultrasound in COVID-19 pneumonia.* doi: 10.5152/Eurjrheum.2020.2063.
 318. M Hughes, S Rogers, G Lepri, C Bruni, **M Matucci-Cerinic** *Further evidence that chilblains are a cutaneous manifestation of COVID-19 infection.* Br J Dermatol 2020 Sep doi: 10.1111/bjd.19243. Epub 2020 Jun 25.
 319. Bruni C, De Luca G, Lazzaroni MGr, Zanatta E, Lepri G, Airo P, Dagna L, Doria A, **Matucci-Cerinic M** *Screening for pulmonary arterial hypertension in systemic sclerosis: A systematic literature review.* European Journal of Internal Medicine. Aug. 2020. Doi: 10.1016/J.Ejim.2020.05.042.
 320. D Khanna, CJF Lin, DE Furst, J Goldin, G Kim, M Kuwana, Y Allanore, **M Matucci-Cerinic**, O Distler, Y Shima, JM van Laar, H Spotswood, B Wagner, J Siegel, A Jahreis, CP Denton, focuSSced investigators. *Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial.* Lancet Respir Med. 2020 Oct: doi: 10.1016/S2213-2600(20)30318-0.
 321. Gerd R Burmester, F Buttgereit, C Bernasconi, JM Álvaro-Gracia, N Castro, M Dougados, C Gabay, JM van Laar, JM Nebesky, A Pethoe-Schramm, C Salvarani, M Y Donath, M R John, SEMIRA collaborators. *Continuing versus tapering glucocorticoids after achievement of low disease activity or remission in rheumatoid arthritis (SEMIRA): a double-blind, multicentre, randomised controlled trial.* Lancet 2020 Jul. doi: 10.1016/S0140-6736(20)30636-X.
 322. L Cometi, C Bruni, S Passavanti, L Tofani, F Bartoli, G Fiori, F Nacci, G Lepri, M Orlandi, D Melchiorre, L Antonuzzo, **M Matucci-Cerinic**, A Moggi-Pignone. *Risk of malignancy and biologic therapy in rheumatic inflammatory diseases: A single-center experience.* Rheumatology Immunology Res. doi: 10.2478/rir-2020-0001
 323. Naredo E, Pascau J, Damjanov N, Lepri G, Gordaliza PM, Janta I, Gabriel Ovalles-Bonilla J, Javier Lopez-Longo, Francisco, **Matucci-Cerinic M** *Performance of ultra-high-frequency ultrasound in the evaluation of skin involvement in systemic sclerosis: a preliminary report.* Rheumatology. Jul 2020. Doi: 10.1093/Rheumatology/Kez439.
 324. Orlandi M, Lepri G, Bruni C, Wang Yukai, Bartoloni A, Zammarchi L, Cometi L, Guiducci S, **Matucci-Cerinic M**, Bellando-Randone S.

The systemic sclerosis patient in the COVID-19 era: the challenging crossroad between immunosuppression, differential diagnosis and long-term psychological distress. Clin Rheumatol Jul 2020. Doi: 10.1007/S10067-020-05193-2

325. M Orlandi, G Lepri, C Bruni, Y Wang, A Bartoloni, L Zammarch, L Cometi, S Guiducci, **M Matucci-Cerinic**, S Bellando-Randone *The systemic sclerosis patient in the COVID-19 era: the challenging crossroad between immunosuppression, differential diagnosis and long-term psychological distress* Clin Rheumatol 2020 Jul doi: 10.1007/s10067-020-05193-2.
326. Nagaraja V, **Matucci-Cerinic M**, Furst DE, Kuwana M, Allanore Y, Denton CP, Raghu G, McLaughlin V, Rao PS, Seibold JR, Pauling John D, Whitfield ML, Khanna D, *Current and Future Outlook on Disease Modification and Defining Low Disease Activity in Systemic Sclerosis.* Arthritis & Rheumatology. 2020. Doi: 10.1002/Art.41246
327. GR Burmester, F Buttgereit, C Bernasconi, JM Álvaro-Gracia, N Castro, M Dougados, C Gabay, JM van Laar, JM Nebesky, A Pethoe-Schramm, C Salvarani, Marc Y Donath, arkus R John, SEMIRA collaborators. *Continuing versus tapering glucocorticoids after achievement of low disease activity or remission in rheumatoid arthritis (SEMIRA): a double-blind, multicentre, randomised controlled trial.* Lancet 2020 Jul. doi: 10.1016/S0140-6736(20)30636-X.
328. Jaeger VK, Tikly M, Xu D, Siegert E, Hachulla E, Airo P, Valentini G, **Cerinic M Matucci**, Distler O, Cozzi F, Carreira P, Allanore Y, Muller-Ladner U, Ananieva LP, Balbir-Gurman A, Distler JHW, Czirjak L, Li M, Henes J, Jimenez SA, Smith V, Damjanov N, Denton CP, DelGaldo F, Saketkoo LA, Walker UA. *Racial differences in systemic sclerosis disease presentation: a European Scleroderma Trials and Research group study.* Rheumatology. Jul2020. Doi: 10.1093/Rheumatology/Kez486
329. Guler AA, Rossi FW, Bellando-Randone S, Prevete N, Tufan A, Manetti M, DePaulis A, **Matucci-Cerinic M**. *The Role of Endogenous Eicosapentaenoic Acid and Docosaheptaenoic Acid-Derived Resolvins in Systemic Sclerosis.* Frontiers in Immunology. Jun2020. Doi: 10.3389/Fimmu.2020.01249.
330. Bruni C, Bitti R, Nacci F, Cometi L, Tofani L, Bartoli F, Fiori G, **Matucci-Cerinic M**. *Efficacy and safety of switching from reference adalimumab to SB5 in a real-life cohort of inflammatory rheumatic joint diseases.* Clinical Rheumatology. Jun 2020. Doi: 10.1007/S10067-020-05199-W.
331. Bellando-Randone S, **Matucci Cerinic M**. *The race against time to disclose lung inflammation in interstitial lung disease in systemic sclerosis: is PET scan the winning solution?* Rheumatology. Jun 2020. Doi: 10.1093/Rheumatology/Keaa077
332. **Matucci-Cerinic M**, Bruni C, Allanore Y, Clementi M, Dagna L, Damjanov, NS, De Paulis A, Denton CP, Distler O, Fox D, Furst DE, Khanna D, Krieg, T, Kuwana M, Lee EB, Li M, Pillai S, Wang Y, Zeng X, Taliani G, *Systemic sclerosis and the COVID-19 pandemic: World Scleroderma Foundation preliminary advice for patient management.* Annals of the Rheumatic Diseases. Jun 2020. Doi: 10.1136/Annrheumdis-2020-217407
333. Hughes, M, **Matucci-Cerinic, M**. *Impact and associates of digital pitting in patients with systemic sclerosis: a pilot study. Comment on the article by Nolan et al.* Scand J Rheumatol May2020. Doi: 10.1080/03009742.2020.1735509.

- 334.Cometi L, Bruni C, Chiti, N, Tofani L, Nacci F; Bartoli F, Bellando-Randone, S, Melchiorre D, Fiori G, Guiducci S, **Matucci-Cerinic M** *Effect of Dysmetabolisms and Comorbidities on the Efficacy and Safety of Biological Therapy in Chronic Inflammatory Joint Diseases.* J Clin I Med. May 2020 Doi: 10.3390/Jcm9051310.
- 335.Hughes M, Pauling JD, Jones J, Denton CP, Domsic RT, Frech TM, Herrick, AL, Khanna D, **Matucci-Cerinic M**, McKenzie L, Saketkoo LA, Gooberman-Hill R, Moore A, *Multicenter Qualitative Study Exploring the Patient Experience of Digital Ulcers in Systemic Sclerosis.* Arthritis Care & Research. 2020 Doi: 10.1002/Acr.24127
- 336.Khanna D, Allanore Y, Denton CP, Kuwana M, **Matucci-Cerinic M**, Pope JE, Atsumi T, Becvar R, Czirjak L, Hachulla E, Ishii T, Ishikawa O, Johnson SR, De Langhe E, Stagnaro C, Riccieri V, Schiopu E, Silver RM, Smith V, Steen V, Stevens W, Szucs G, Truchetet, ME, Wosnitza M, Laapas K, Pena JO, Yao Z, Kramer F, Distler O, *Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): randomised, double-blind, placebo-controlled multicentre trial.* Ann Rheum Dis 2020. Doi: 10.1136/Annrheumdis-2019-216823.
- 337.Tufan A, Avanoğlu Güler A, **Matucci-Cerinic M** *COVID-19, immune system response, hyperinflammation and repurposing antirheumatic drugs* Turk J Med Sci. 2020;50(SI-1):620-632. Apr.2020. Doi: 10.3906/Sag-2004-168
- 338.Sandler RD, **Matucci-Cerinic M**, Hughes M. *Musculoskeletal hand involvement in systemic sclerosis.* Semin Arthritis Rheum. 2020 Apr;50(2):329-334
- 339.Lagi F, M Piccica, L Graziani, I Vellere, A Botta, M Tilli, L Ottino, B Borch, M Pozzi, F Bartalesi, J Mencarini, M Spinicci, L Zammarchi, F Pieralli, G Zagli, C Nozzoli, S Romagnoli, A Bartoloni, COCORA working group members not listed as individual author *Early experience of an infectious and tropical diseases unit during the coronavirus disease (COVID-19) pandemic, Florence, Italy, February to March 2020* Euro Surveill 2020 Apr doi: 10.2807/1560-7917.ES.2020.25.17.2000556.
- 340.Hughes M, Allanore Y, Chung L, Pauling JD, Denton, CP, **Matucci-Cerinic, M.** *Raynaud phenomenon and digital ulcers in systemic sclerosis.* Nature Rev Rheumatol. Apr 2020. Doi: 10.1038/S41584-020-0386-4
- 341.Terenzi R, Karalilova R, Lepri G, Bruni C, Bellando-Randone S; Manetti M; Romano E, Melchiorre D, Blagojevic J, Wang Y, Solanki K, Moggi-Pignone, A, Batalov Z, Guiducci S, Batalov A, **Matucci-Cerinic, M** *Enthesopathy and involvement of synovio-entheseal complex in systemic sclerosis: an ultrasound pilot study.* Rheumatology, Mar 2020 doi: 10.1093/Rheumatology/Kez322
- 342.Nagaraja V, **Matucci Cerinic M**, Furst DE, Kuwana M, Allanore Y, Denton CP, Raghu G, McLaughlin V, Rao PS, Seibold JR, Pauling JD, Whitfield ML, Khanna D *Current and future outlook on disease modification and defining low disease activity in systemic sclerosis.* Arthritis Rheumatol. 2020 Mar 5. doi:
- 343.Hughes M, Alcacer-Pitarch B, Gheorghiu AM, Praino, E, Sandler RD, Tavor Y, Bruni C, Matucci-Cerinic, M. *Digital ulcer debridement in systemic sclerosis: a systematic literature review.* Clin Rheumatol, Mar 2020 doi: 10.1007/S10067-019-04924-4
- 344.Varju C, Kumanovics G, Czirjak L, **Matucci-Cerinic M**, Minier T. *Scleroderma-like syndromes: Great imitators.* Clinics in Dermatology, Mar 2020. doi: 10.1016/J.Clindermatol.2019.10.010

345. Quartuccio L, Bond M, Isola M, Monti S, Felicetti M, Furini F, Murgia S, Berti A, Silvestri E, Pazzola G, Bozzolo E, Leccese P, Raffener B, Parisi S, Leccese I, Cianci F, Bettio S, Sainaghi P, Ianniello A, Ravagnani V, Bellando Randone S, Faggioli P, Lomater C, Stobbione P, Ferro F, Colaci M, Alfieri G, Carubbi F, Erre GL, Giollo A, Franzolini N, Ditto MC, Balduzzi S, Padoan R, Bortolotti R, Bortoluzzi A, Cariddi A, Padula A, Di Scala G, Gremese E, Conti F, D'Angelo S, **Matucci Cerinic M**, Dagna L, Emmi G, Salvarani C, Paolazzi G, Roccatello D, Govoni M, Schiavon F, Caporali R, De Vita S; Italian Study Group on Lung Involvement in Rheumatic Diseases and the Italian Vasculitis Study Group. *Alveolar haemorrhage in ANCA-associated vasculitis: Long-term outcome and mortality predictors*. J Autoimmun. 2020 Mar. doi: 10.1016/j.jaut.2019.102397. doi: 10.1016/j.jaut.2019.102397.
346. Blagojevic J, Abignano G, Avouac J, Cometi L, Frerix M, Bellando-Randone S, Guiducci S, Bruni C, Huscher D, Jaeger VK, Lóránd V, Maurer B, Nihtyanova S, Riemekasten G, Siegert E, Tarner IH, Vettori S, Walker UA, Czirják L, Denton CP, Distler O, Allanore Y, Müller-Ladner U, Moggi-Pignone A, **Matucci-Cerinic M**, Del Galdo F; EUSTAR co-workers *Use of vasoactive/vasodilating drugs for systemic sclerosis (SSc)-related digital ulcers (DUs) in expert tertiary centres: results from the analysis of the observational real-life DeSScIPHER study*. Clin Rheumatol. 2020;39(1):27-36
347. Bellando-Randone S, **Matucci-Cerinic M**. *The race against time to disclose lung inflammation in interstitial lung disease in systemic sclerosis: is PET scan the winning solution?* Rheumatology (Oxford). 2020 Mar.
348. Blaja E, Jordan S, Mihai CM, Dobrota R, Becker MO, Maurer B, **Matucci-Cerinic M**, Distler O. *The challenge of Very Early Systemic Sclerosis: a Combination of Mild and Early Disease?* J Rheumatol. 2020 Mar.
349. Castellví I, Elhai M, Bruni C, Airò P, Jordan S, Beretta L, Codullo V, Montecucco CM, Bokarewa M, Iannone F, Balbir A, Hsu VM, Distler O, **Matucci-Cerinic M**, Allanore Y; for EUSTAR network. *Safety and effectiveness of abatacept in systemic sclerosis: The EUSTAR experience*. Semin Arthritis Rheum. 2020 Feb.
350. Frantz C, Huscher D, Avouac J, Hachulla E, Balbir-Gurman A, Riemekasten G, Siegert E, Lazzaroni MG, Carreira PE, Vettori S, Zanatta E, Ullman S, Czirják L, Kowal-Bielecka O, Distler O, **Matucci-Cerinic M**, Allanore Y; EUSTAR co-authors. *Outcomes of limited cutaneous systemic sclerosis patients: Results on more than 12,000 patients from the EUSTAR database*. Autoimmun Rev. 2020 Feb
351. Sambataro G, Ferro F, Orlandi M, Sambataro D, Torrisi SE, Quartuccio L, Vancheri C, Baldini C, **Matucci Cerinic M**. *Clinical, morphological features and prognostic factors associated with interstitial lung disease in primary Sjögren's syndrome: A systematic review from the Italian Society of Rheumatology*. Autoimmun Rev. 2020 Feb.
352. Wang Y, Chen S, Chen J, Xie X, Gao S, Zhang C, Zhou S, Wang J, Mai R, Lin Q, Lin J, **Matucci-Cerinic M**, Zhang G, Furst DE. *Germline genetic patterns underlying familial rheumatoid arthritis, systemic lupus erythematosus and primary Sjögren's syndrome highlight T cell-initiated autoimmunity*. Ann Rheum Dis. 2020 Feb.
353. Favalli EG, **Matucci-Cerinic M**, Szekanecz Z. *The Giants (biologicals) against the Pigmies (small molecules), pros and cons of*

two different approaches to the disease modifying treatment in rheumatoid arthritis. *Autoimmun Rev.* 2020 Jan;19

- 354.D. Khanna, C Spino, S Johnson, L Chung, M Whitfield,CP. Denton, V Berrocal,F Jennifer,B Mehta,J Molitor,VD. Steen, R Lafyatis, R.W. Simms, A Gill, S Kafaja, T M. Frech, V Hsu, RT. Domsic, J E. Pope, J K. Gordon, M D. Mayes, E Schiopu, A Young, N Sandorfi, J Park, F N. Hant, E J. Bernstein, S Chatterjee, F V. Castelino, A Ajam, Y Wang, T Wood, Y Allanore, **M Matucci-Cerinic**, O Distler, O Singer, E Bush, D Fox, DE. Furst *Abatacept in Early Diffuse Cutaneous Systemic Sclerosis – Results of a Phase 2 Investigator-Initiated, Multicenter, DoubleBlind Randomized Placebo-Controlled Trial* Arthritis Rheumatol. 2020 Jan.
- 355.Hughes M, Allanore Y, Chung L, Pauling JD, Denton CP, **Matucci-Cerinic M**.Raynaud phenomenon and digital ulcers in systemic sclerosis. *Nat Rev Rheumatol.* 2020 Apr;16(4):208-221

2019

- 356.C Khouri, M Lepelley,S Bailly,S Blaise, AL Herrick, **M Matucci-Cerinic**,Y Allanore, L Trinquart ,JL Cracowski, M Roustit: *Comparative efficacy and safety of treatments for secondary Raynaud's phenomenon: a systematic review and network meta-analysis of randomised trials.* *The Lancet Rheumatology* 2019;1:
- 357.Bargagli E, Mazzei MA, Orlandi M, Gentili F, Bellisai F, Frediani B, Bergantini L, Carobene L, Randone SB, Guiducci S, Cameli P, Bruni C, **Matucci Cerinic M** *Pleuroparenchymal fibroelastosis in patients affected by systemic sclerosis: What should the rheumatologist do?* .*Medicine (Baltimore).* 2019 Jun;98(26):e16086.
- 358.Bruni C, Rosato E, Maestripieri V, Gigante A, Tesei G, Bellando-Randone S, Guiducci S, Chiostrì M, El Aoufy K, Blagojevic J, Moggi-Pignone A, De Paulis A, Furst DE, Boddi M, **Matucci-Cerinic M**. *The Renal Resistive Index in systemic sclerosis: Determinants, prognostic implication and proposal for specific age-adjusted cut-offs.* *Eur J Intern Med.* 2019 Dec.
- 359.Blagojevic J, Legendre P, **Matucci-Cerinic M**, Mouthon L. *Is there today a place for corticosteroids in the treatment of scleroderma?* *Autoimmun Rev.* 2019 Dec.
- 360.Hughes M, Pauling JD, Jones J, Denton CP, Domsic RT, Frech TM, Herrick AL, Khanna D, **Matucci-Cerinic M**, McKenzie L, Saketkoo LA, Gooberman-Hill R, Moore A. *A Multi-Centre Qualitative Study Exploring the Patient Experience of Digital Ulcers in Systemic Sclerosis.* *Arthritis Care Res (Hoboken).* 2019 Dec
- 361.Mihai C, Distler O, Gheorghiu AM, Constantin PI, Dobrota R, Jordan S, Smith V, Hachulla E, Henes J, Siegert E, Vettori S, Müller-Ladner U, **Matucci Cerinic M**, Allanore Y; EUSTAR *Incidence and risk factors for gangrene in patients with systemic sclerosis from the EUSTAR cohort.* *Rheumatology (Oxford).* 2019 Dec.
- 362.Wang Y, Chen S, Lin J, Xie X, Hu S, Lin Q, Zheng K, Du G, Huang X, Zhang G, Gargani L, **Matucci-Cerinic M**, Furst DE. *Lung ultrasound B-lines and serum KL-6 correlate with the severity of idiopathic inflammatory myositis-associated interstitial lung disease.* *Rheumatology (Oxford).* 2019 Dec.
- 363.Manetti M, Romano E, Rosa I, Fioretto BS, Guiducci S, Bellando-Randone S, Pigatto E, Cozzi F, Ibba-Manneschi L, **Matucci-Cerinic M**. *Systemic Sclerosis Serum Significantly Impairs the Multi-Step Lymphangiogenic Process: in Vitro Evidence.* *Int J Mol Sci.* 2019 Dec.

364. Cavagna L, Trallero-Araguás E, Meloni F, Cavazzana I, Rojas-Serrano J, Feist E, Zanframundo G, Morandi V, Meyer A, Pereira da Silva JA, Matos Costa CJ, Molberg O, Andersson H, Codullo V, Mosca M, Barsotti S, Neri R, Scirè C, Govoni M, Furini F, Lopez-Longo FJ, Martinez-Barrio J, Schneider U, Lorenz HM, Doria A, Ghirardello A, Ortego-Centeno N, Confalonieri M, Tomietto P, Pipitone N, Rodriguez Cambron AB, Blázquez Cañamero MÁ, Voll RE, Wendel S, Scarpato S, Maurier F, Limonta M, Colombelli P, Giannini M, Geny B, Arrigoni E, Bravi E, Migliorini P, Mathieu A, Piga M, Drott U, Delbrueck C, Bauhammer J, Cagnotto G, Vancheri C, Sambataro G, De Langhe E, Sainaghi PP, Monti C, Gigli Berzolari F, Romano M, Bonella F, Specker C, Schwarting A, Villa Blanco I, Selmi C, Ceribelli A, Nuno L, Mera-Varela A, Perez Gomez N, Fusaro E, Parisi S, Sinigaglia L, Del Papa N, Benucci M, Cimmino MA, Riccieri V, Conti F, Sebastiani GD, Iuliano A, Emmi G, Cammelli D, Sebastiani M, Manfredi A, Bachiller-Corral J, Sifuentes Giraldo WA, Paolazzi G, Saketkoo LA, Giorgi R, Salaffi F, Cifrian J, Caporali R, Locatelli F, Marchioni E, Pesci A, Dei G, Pozzi MR, Claudia L, Distler J, Knitz J, Schett G, Iannone F, Fornaro M, Franceschini F, Quartuccio L, Gerli R, Bartoloni E, Bellando Randone S, Zampogna G, Gonzalez Perez MI, Mejia M, Vicente E, Triantafyllis K, Lopez-Mejias R, **Matucci-Cerinic M**, Selva-O'Callaghan A, Castañeda S, Montecucco C, Gonzalez-Gay MA. *Influence of Antisynthetase Antibodies Specificities on Antisynthetase Syndrome Clinical Spectrum Time Course*. J Clin Med. 2019 Nov.
365. Mavrogeni S, Gargani L, Pepe A, Monti L, Markousis-Mavrogenis G, Santis M, Marchi D, Koutsogeorgopoulou L, Karabela G, Stavropoulos E, Katsifis G, Bratis K, Bellando-Randone S, Guiducci S, Bruni C, Moggi-Pignone A, Dimitroulas T, Kolovou G, Bournia VK, Sfrikakis PP, **Matucci-Cerinic M**. *Cardiac magnetic resonance predicts ventricular arrhythmias in scleroderma: the Scleroderma Arrhythmia Clinical Utility Study (SAnCtUS)*. Rheumatology (Oxford). 2019 Nov.
366. Jaeger VK, Tikly M, Xu D, Siegert E, Hachulla E, Airò P, Valentini G, **Matucci Cerinic M**, Distler O, Cozzi F, Carreira P, Allanore Y, Müller-Ladner U, Ananieva LP, Balbir-Gurman A, Distler JHW, Czirják L, Li M, Henes J, Jimenez SA, Smith V, Damjanov N, Denton CP, DelGaldo F, Saketkoo LA, Walker UA; EUSTAR co-authors. *Racial differences in systemic sclerosis disease presentation: a European Scleroderma Trials and Research group study*. Rheumatology (Oxford). 2019 Nov.
367. Manetti M, **Matucci-Cerinic M**. *In search for the ideal anatomical composition of vascularised human skin equivalents for systemic sclerosis translational research: should we recruit the telocytes?* Ann Rheum Dis. 2019 Oct. doi: 10.1136/annrheumdis-2019-216371
368. Varju C, Kumánovics G, Czirják L, **Matucci-Cerinic M**, Minier T. *Scleroderma-like syndromes: The great imitator*. Clinics in Dermatology. Oct. 2019
369. Naredo E, Pascau J, Damjanov N, Lepri G, Gordaliza PM, Janta I, Ovalles-Bonilla JG, López-Longo FJ, **Matucci-Cerinic M**. *Performance of ultra-high-frequency ultrasound in the evaluation of skin involvement in systemic sclerosis: a preliminary report*. Rheumatology (Oxford). 2019 Oct.
370. Bruni C, Rosato E, Maestripieri V, Gigante A, Tesei G, Bellando-Randone S, Guiducci S, Chiostri M, El Aoufy K, Blagojevic J, Moggi-Pignone A, De Paulis A, Furst DE, Boddi M, **Matucci-Cerinic M**. *The*

- Renal Resistive Index in systemic sclerosis: Determinants, prognostic implication and proposal for specific age-adjusted cut-offs.* Eur J Intern Med. 2019 Sep.
371. Blagojevic J, AlOdhaibi KA, Aly AM, Bellando-Randone S, Lepri G, Bruni C, Moggi-Pignone A, Guiducci S, Mecacci F, **Matucci-Cerinic M**, Furst DE. *Pregnancy in systemic sclerosis (SSc): results of systematic review and meta-analysis.* J Rheumatol. 2019 Sep.
 372. Becker M, Graf N, Sauter R, Allanore Y, Curram J, Denton CP, Khanna D, **Matucci-Cerinic M**, de Oliveira Pena J, Pope JE, Distler O; EUSTAR Collaborators; EUSTAR Collaborators (numerical order of centres). *Predictors of disease worsening defined by progression of organ damage in diffuse systemic sclerosis: a European Scleroderma Trials and Research (EUSTAR) analysis.* Ann Rheum Dis. 2019 Sep.
 373. Mor A, Segal Salto M, Katav A, Barashi N, Edelshtein V, Manetti M, Levi Y, George J, **Matucci-Cerinic M**. *Blockade of CCL24 with a monoclonal antibody ameliorates experimental dermal and pulmonary fibrosis.* Ann Rheum Dis. 2019 Sep.
 374. Manetti M, Romano E, Rosa I, Fioretto BS, Praino E, Guiducci S, Iannone F, Ibba-Manneschi L, **Matucci-Cerinic M**. *Systemic Sclerosis Serum Steers the Differentiation of Adipose-Derived Stem Cells Toward Profibrotic Myofibroblasts: Pathophysiologic Implications.* J Clin Med. 2019 Aug.
 375. Terenzi R, Karalilova R, Lepri G, Bruni C, Bellando-Randone S, Manetti M, Romano E, Melchiorre D, Blagojevic J, Wang Y, Solanki K, Moggi-Pignone A, Batalov Z, Guiducci S, Batalov A, **Matucci-Cerinic M**. *Enthesopathy and involvement of synovio-entheseal complex in systemic sclerosis: an ultrasound pilot study.* Rheumatology (Oxford). 2019 Aug.
 376. Bellando-Randone S, **Matucci-Cerinic M**. *Very early systemic sclerosis.* Best Pract Res Clin Rheumatol. 2019 Aug.
 377. Valentini G, Huscher D, Riccardi A, Fasano S, Irace R, Messiniti V, **Matucci-Cerinic M**, Guiducci S, Distler O, Maurer B, Avouac J, Tarner IH, Frerix M, Riemekasten G, Siegert E, Czirájk L, Lóránd V, Denton CP, Nihtyanova S, Walker UA, Jaeger VK, Del Galdo F, Abignano G, Ananieva LP, Gherghe AM, Mihai C, Henes JC, Schmeiser T, Vacca A, Moiseev S, Foeldvari I, Gabrielli K, Krummel-Lorenz B, Rednic S, Allanore Y, Müller-Ladner U. *Vasodilators and low-dose acetylsalicylic acid are associated with a lower incidence of distinct primary myocardial disease manifestations in systemic sclerosis: results of the DeSSciper inception cohort study.* Ann Rheum Dis. 2019 Aug.
 378. Khanna D, Spino C, Johnson S, Chung L, Whitfield M, Denton CP, Berrocal V, Franks J, Mehta B, Molitor J, Steen VD, Lafyatis R, Simms RW, Gill A, Kafaja S, Frech TM, Hsu V, Domsic RT, Pope JE, Gordon JK, Mayes MD, Schiopu E, Young A, Sandorfi N, Park J, Hant FN, Bernstein EJ, Chatterjee S, Castellino FV, Ajam A, Wang Y, Wood T, Allanore Y, **Matucci-Cerinic M**, Distler O, Singer O, Bush E, Fox D, Furst DE. *Abatacept in Early Diffuse Cutaneous Systemic Sclerosis - Results of a Phase 2 Investigator-Initiated, Multicenter, Double-Blind Randomized Placebo-Controlled Trial.* Arthritis Rheumatol. 2019 Jul.
 379. Manetti M, Linari S, Romano E, Rosa I, Carulli C, Innocenti M, **Matucci-Cerinic M**, Ibba-Manneschi L, Castaman G, Melchiorre D. *TNF- α /TNF-R System May Represent a Crucial Mediator of Proliferative Synovitis in Hemophilia A.* J Clin Med. 2019 Jun.
 380. Jaworski J, **Matucci-Cerinic M**, Schulze-Koops H, Buch MH,

- Kucharz EJ, Allanore Y, Kavanaugh A, Young P, Babic G. *Switch from reference etanercept to SDZ ETN, an etanercept biosimilar, does not impact efficacy, safety, and immunogenicity of etanercept in patients with moderate-to-severe rheumatoid arthritis: 48-week results from the phase III, randomized, double-blind EQUIRA study*. Arthritis Res Ther. 2019 May
381. Mor A, Segal Salto M, Katav A, Barashi N, Edelshtein V, Manetti M, Levi Y, George J, **Matucci-Cerinic M**. *Blockade of CCL24 with a monoclonal antibody ameliorates experimental dermal and pulmonary fibrosis*. Ann Rheum Dis. 2019 May.
382. de Vries-Bouwstra J, Allanore Y, **Matucci-Cerinic M**, Balbir-Gurman A. *Worldwide expert agreement on updated recommendations for the treatment of systemic sclerosis*. J Rheumatol. 2019 May
383. Romano E, Rosa I, Fioretto BS, Guiducci S, Manetti M, **Matucci-Cerinic M**. *A new avenue in the pathogenesis of systemic sclerosis: the molecular interface between the endothelial and the nervous systems*. Clin Exp Rheumatol. 2019 Apr
384. Sobanski V, Giovannelli J, Allanore Y, Riemekasten G, Airò P, Vettori S, Cozzi F, Distler O, **Matucci-Cerinic M**, Denton C, Launay D, Hachulla E; EUSTAR collaborators. *Phenotypes determined by cluster analysis and their survival in the prospective EUSTAR cohort of patients with systemic sclerosis*. Arthritis Rheum 2019 Apr.
385. Elhai M, Boubaya M, Distler O, Smith V, **Matucci-Cerinic M**, Alegre Sancho JJ, Truchetet ME, Braun-Moscovici Y, Iannone F, Novikov PI, Lescoat A, Siegert E, Castellví I, Airó P, Vettori S, De Langhe E, Hachulla E, Erler A, Ananieva L, Krusche M, López-Longo FJ, Distler JHW, Hunzelmann N, Hoffmann-Vold AM, Riccieri V, Hsu VM, Pozzi MR, Ancuta C, Rosato E, Mihai C, Kuwana M, Saketkoo LA, Chizzolini C, Hesselstrand R, Ullman S, Yavuz S, Rednic S, Caimmi C, Bloch-Queyrat C, Allanore Y; for EUSTAR network. *Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: a prospective cohort study*. Ann Rheum Dis. 2019 Apr.
386. Bruni C, Shirai Y, Kuwana M, **Matucci-Cerinic M**. *Cyclophosphamide: similarities and differences in the treatment of SSc and SLE*. Lupus. 2019 Apr
387. Wu W, Jordan S, Graf N, de Oliveira Pena J, Curram J, Allanore Y, **Matucci-Cerinic M**, Pope JE, Denton CP, Khanna D, Distler O; EUSTAR Collaborators. *Progressive skin fibrosis is associated with a decline in lung function and worse survival in patients with diffuse cutaneous systemic sclerosis in the European Scleroderma Trials and Research (EUSTAR) cohort*. Ann Rheum Dis. 2019 Mar
388. Wang Y, Chen S, Lin Z, Lin J, Xie X, Lin Q, Du G, Huang X, **Matucci-Cerinic M**, Furst DE. *Utilize lung ultrasound B-lines and KL-6 to monitor anti-MDA-5 antibody-positive clinically amyopathic dermatomyositis-associated interstitial lung disease: a case report and literature review*. Clin Rheumatol. 2019 Feb
389. Andreoli L, Gerardi MC, Fernandes M, Bortoluzzi A, Bellando-Randone S, Brucato A, Caporali R, Chighizola CB, Chimenti MS, Conigliaro P, Cutolo M, Cutro MS, D'Angelo S, Doria A, Elefante E, Fredi M, Galeazzi M, Gerosa M, Govoni M, Iuliano A, Larosa M, Lazzaroni MG, **Matucci-Cerinic M**, Meroni M, Meroni PL, Mosca M, Patané M, Pazzola G, Pendolino M, Perricone R, Ramoni V, Salvarani C, Sebastiani GD, Selmi C, Spinelli FR, Valesini G, Scirè CA, Tincani A. *Disease activity assessment of rheumatic diseases during pregnancy: a comprehensive review of indices used in clinical*

- studies. Autoimmun Rev. 2019 Feb.
390. Blagojevic J, Bellando-Randone S, Abignano G, Avouac J, Cometi L, Czirjak L, Denton CP, Distler O, Frerix M, Guiducci S, Huscher D, Jaeger VK, Lóránd V, Maurer B, Nihtyanova S, Riemekasten G, Siegert E, Turner IH, Vettori S, Walker UA, Allanore Y, Müller-Ladner U, Del Galdo F, **Matucci-Cerinic M**; EUSTAR co-workers. *Classification, categorization and essential items for digital ulcer evaluation in systemic sclerosis: a DeSScipher/European Scleroderma Trials and Research group (EUSTAR) survey*. Arthritis Res Ther. 2019 Jan
391. McMahan ZH, Frech T, Berrocal V, Lim D, Bruni C, **Matucci-Cerinic M**, Smith V, Melsens K, Proudman S, Zhang J, Mendoza F, Woods M, Khanna D. *Longitudinal Assessment of Patient-reported Outcome Measures in Systemic Sclerosis Patients with Gastroesophageal Reflux Disease - Scleroderma Clinical Trials Consortium*. J Rheumatol. 2019 Jan

2018

392. Gargani L, Todiere G, Guiducci S, Bruni C, Pingitore A, De Marchi D, Bellando Randone S, Aquaro GD, Bazzichi L, Mosca M, Lombardi M, Pepe A, **Matucci-Cerinic M**, Picano E. *Early Detection of Cardiac Involvement in Systemic Sclerosis: The Added Value of Magnetic Resonance Imaging*. JACC Cardiovasc Imaging. 2018 Dec. .
393. Wang Y, Lin Q, Lin J, Du G, **Matucci-Cerinic M**. *Infliximab Precipitated Urachal Remnant Infection*. Int J Clin Rheumatol. 2018 Dec.
394. **Matucci-Cerinic M**, Allanore Y, Kavanaugh A, Buch MH, Schulze-Koops H, Kucharz EJ, Woehling H, Babic G, Poetzl J, Davis A, Schwebig A. *Efficacy, safety and immunogenicity of GP2015, an etanercept biosimilar, compared with the reference etanercept in patients with moderate-to-severe rheumatoid arthritis: 24-week results from the comparative phase III, randomised, double-blind EQUIRA study*. RMD Open. 2018 Nov.
395. Bruni C, Ngcozana T, Braschi F, Pucci T, Piemonte G, Benelli L, Poli M, Suliman YA, Guiducci S, Bellando-Randone S, Balduzzi S, Grotts J, Denton CP, Rasero L, Montecucco C, Furst DE, **Matucci-Cerinic M**. *Preliminary Validation of the Digital Ulcer Clinical Assessment Score in Systemic Sclerosis*. J Rheumatol. 2018 Nov 15. pii: jrheum.171486. doi: 10.3899/jrheum.171486. [Epub ahead of print]
396. McMahan ZH, Frech T, Berrocal V, Lim D, Bruni C, **Matucci-Cerinic M**, Smith V, Melsens K, Proudman S, Zhang J, Mendoza F, Woods M, Khanna D. *Longitudinal Assessment of Patient-reported Outcome Measures in Systemic Sclerosis Patients with Gastroesophageal Reflux Disease - Scleroderma Clinical Trials Consortium*. J Rheumatol. 2018 Nov 15.
397. Smith V, Scirè CA, Talarico R, Airo P, Alexander T, Allanore Y, Bruni C, Codullo V, Dalm V, De Vries-Bouwstra J, Della Rossa A, Distler O, Galetti I, Launay D, Lepri G, Mathian A, Mouthon L, Ruaro B, Sulli A, Tincani A, Vandecasteele E, Vanhaecke A, Vanthuyne M, Van den Hoogen F, Van Vollenhoven R, Voskuyl AE, Zanatta E, Bombardieri S, Burmester G, Eurico FJ, Frank C, Hachulla E, Houssiau F, Mueller-Ladner U, Schneider M, van Laar JM, Vieira A, Cutolo M, Mosca M, **Matucci-Cerinic M**. *Systemic sclerosis: state of the art on clinical practice guidelines*. RMD Open. 2018;4(Suppl 1):e000782.
398. Park JW, Ahn GY, Kim JW, Park ES, Kang JH, Chang SH, Choi IA,

- Yoo SJ, Park JK, Shin K, Park YB, Jun JB, Czirják L, Allanore Y, **Matucci-Cerinic M**, Lee EB Impact of EUSTAR standardized training on accuracy of modified Rodnan skin score in patients with systemic sclerosis. *Int J Rheum Dis*. 2018 Nov 5
399. Wang Y, Chen S, Lin Z, Du G, Lin J, Lin Q, Xiufeng H, Zhang G, Furst DE, Gargani L, **Matucci-Cerinic M** *Imaging and serum biomarkers in connective tissue disease-associated interstitial lung diseases: correlation between lung ultrasound B-lines and KL-6 levels*. *Ann Rheum Dis*. 2018 Oct
400. Manetti M, Pratesi S, Romano E, Rosa I, Bruni C, Bellando-Randone S, Guiducci S, Maggi E, Ibba-Manneschi L, **Matucci-Cerinic M**. “Decreased circulating lymphatic endothelial progenitor cells in digital ulcer-complicated systemic sclerosis”. *Ann Rheum Dis*. 2018 Oct.
401. Bellando-Randone S, Tartarelli L, Cavigli E, Tofani L, Bruni C, Lepri G, Blagojevic J, Moggi-Pignone A, Mihai C, Avouac J, Passeri A, De Cristofaro MT, Distler O, Allanore Y, Guiducci S, **Matucci-Cerinic M**. 18. *F-fluorodeoxyglucose positron-emission tomography/CT and lung involvement in systemic sclerosis*. *Ann Rheum Dis*. 2018 Oct.
402. Abignano G, Blagojevic J, Bissell LA, Dumitru RB, Eng S, Allanore Y, Avouac J, Bosello S, Denton CP, Distler O, Ferraccioli G, Jordan S, **Matucci-Cerinic M**, Ong V, Messenger M, Hutchinson M, Buch MH, Emery P, Del Galdo F.: “European multicentre study validates enhanced liver fibrosis test as biomarker of fibrosis in systemic sclerosis.” *Rheumatology (Oxford)*. 2018 Sep
403. Bruni C, Frech T, Manetti M, Rossi FW, Furst DE, De Paulis A, Rivellese F, Guiducci S, **Matucci-Cerinic M**, Bellando-Randone S. : “Vascular Leaking, a Pivotal and Early Pathogenetic Event in Systemic Sclerosis: Should the Door Be Closed?”. *Front Immunol*. 2018 Sep
404. Di Paola M, Gatti D, Viapiana O, Cianferotti L, Cavalli L, Caffarelli C, Conversano F, Quarta E, Pisani P, Girasole G, Giusti A, Manfredini M, Arioli G, **Matucci-Cerinic M**, Bianchi G, Nuti R, Gonnelli S, Brandi ML, Muratore M, Rossini M.: “Radiofrequency echographic multispectrometry compared with dual X-ray absorptiometry for osteoporosis diagnosis on lumbar spine and femoral neck.” *Osteoporos Int*. 2018 Sep
405. Gargani L, Bruni C, Barskova T, Hartwig V, Marinelli M, Trivella MG, **Matucci-Cerinic M**, L'Abbate A : “Near-infrared spectroscopic imaging of the whole hand: A new tool to assess tissue perfusion and peripheral microcirculation in scleroderma.”. *Semin Arthritis Rheum*. 2018 Aug
406. Fiori G, Marzi T, Bartoli F, Bruni C, Ciceroni C, Palomba M, Zolferino M, Corsi E, Galimberti M, Moggi Pignone A, Viggiano MP, Guiducci S, Calamai M, **Matucci-Cerinic M**. “The challenge of pet therapy in systemic sclerosis: evidence for an impact on pain, anxiety, neuroticism and social interaction.” *Clin Exp Rheumatol*. 2018 Jul-Aug
407. Carreira PE, Carmona L, Joven BE, Loza E, Andreu JL, Riemekasten G, Vettori S, Balbir-Gurman A, Airò P, Walker UA, Damjanov N, **Matucci-Cerinic M**, Ananieva LP, Rednic S, Czirják L, Distler O, Farge D, Hesselstrand R, Corrado A, Caramaschi P, Tikly M, Allanore Y; and the EUSTAR co-authors: “Gender differences in early systemic sclerosis patients: a report from the EULAR scleroderma trials and research group (EUSTAR) database” .*Clin Exp Rheumatol*. 2018 Jul-Aug;
408. Bartoli F, Bae S, Cometi L, **Matucci Cerinic M**, Furst DE.:

- "Sirukumab for the treatment of rheumatoid arthritis: update on sirukumab, 2018."* Expert Rev Clin Immunol. 2018 Jul.
409. Gargani L, Voilliot D, D'Alto M, Agoston G, Moreo A, Serra W, Pieri F, Mori F, Wierzbowska-Drabik K, **Matucci-Cerinic M**, Moggi-Pignone A.: Pulmonary Circulation on the Crossroads Between the Left and Right Heart in Systemic Sclerosis: A Clinical Challenge for Cardiologists and Rheumatologists. Heart Fail Clin. 2018 Jul.
 410. Gragnani L, Cerretelli G, Lorini S, Steidl C, Giovannelli A, Monti M, Petraccia L, Sadalla S, Urraro T, Caini P, Xheka A, Simone A, Arena U, Matucci-Cerinic M, Vergani D, Laffi G, Zignego AL.: "Interferon-free therapy in hepatitis C virus mixed cryoglobulinaemia: a prospective, controlled, clinical and quality of life analysis." Aliment Pharmacol Ther. 2018 Jun.
 411. Cavagna L, Gonzalez Gay MA, Allanore Y, **Matucci-Cerinic M**.: "Interstitial pneumonia with autoimmune features: a new classification still on the move." Eur Respir Rev. 2018 Jun.
 412. Jaeger VK, Valentini G, Hachulla E, Cozzi F, Distler O, Airó P, Czirják L, Allanore Y, Siegert E, Rosato E, **Matucci-Cerinic M**, Caimmi C, Henes J, Carreira PE, Smith V, Del Galdo F, Denton CP, Ullman S, Langhe E, Riccieri V, Alegre-Sancho JJ, Rednic S, Müller-Ladner U, Walker UA; EUSTAR co-authors: "Smoking in Systemic Sclerosis: a Longitudinal European Scleroderma Trials and Research Group Study." Arthritis Rheumatol. 2018 May
 413. Wang Y, Zhao S, Du G, Ma S, Lin Q, Lin J, Zheng K, Zhang G, **Matucci-Cerinic M**. *Acute fibrinous and organizing pneumonia as initial presentation of primary Sjögren's syndrome: a case report and literature review.* Clin Rheumatol. 2018 May.
 414. Ingegnoli F, Schioppo T, Allanore Y, Caporali R, Colaci M, Distler O, Furst DE, Hunzelmann N, Iannone F, Khanna D, **Matucci-Cerinic M**.: *Practical suggestions on intravenous iloprost in Raynaud's phenomenon and digital ulcer secondary to systemic sclerosis: Systematic literature review and expert consensus.* Semin Arthritis Rheum. 2018 Apr
 415. Napolitano F, Rossi FW, Pesapane A, Varricchio S, Ilardi G, Mascolo M, Staibano S, Lavecchia A, Ragno P, Selleri C, Marone G, **Matucci-Cerinic M**, de Paulis A, Montuori N.: *N-Formyl Peptide Receptors Induce Radical Oxygen Production in Fibroblasts Derived From Systemic Sclerosis by Interacting With a Cleaved Form of Urokinase Receptor.* Front Immunol. 2018 Apr
 416. Pauling JD, Saketkoo LA, **Matucci-Cerinic M**, Ingegnoli F, Khanna D.: *The patient experience of Raynaud's phenomenon in systemic sclerosis.* Rheumatology (Oxford). 2018 Mar
 417. Jalil B, Hartwig V, Salvetti O, Potì L, Gargani L, Barskova T, **Matucci Cerinic M**, L'Abbate A.: Assessment of hand superficial oxygenation during ischemia/reperfusion in healthy subjects versus systemic sclerosis patients by 2D near infrared spectroscopic imaging. Comput Methods Programs Biomed. 2018 Mar
 418. Allanore Y, Distler O, **Matucci-Cerinic M**, Denton CP. *Review: Defining a Unified Vascular Phenotype in Systemic Sclerosis.* Arthritis Rheumatol. 2018 Feb
 419. Rotondo C, Nivuroi M, Chialà A, Praino E, **Matucci Cerinic M**, Cutolo M, Lapadula G, Iannone F. *Evidence for increase in finger blood flow, evaluated by laser Doppler flowmetry, following iloprost infusion in patients with systemic sclerosis: a week-long observational longitudinal study.* Scand J Rheumatol. 2018 Feb
 420. Distler O, Allanore Y, Denton CP, **Matucci-Cerinic M**, Pope JE,

- Hinzmann B, Davies S, de Oliveira Pena J, Khanna D. :*Factors influencing early referral, early diagnosis and management in patients with diffuse cutaneous systemic sclerosis*. Rheumatology (Oxford). 2018 Feb
- 421.Ndosi M, Alcacer-Pitarch B, Allanore Y, Del Galdo F, Frerix M, García-Díaz S, Hesselstrand R, Kendall C, **Matucci-Cerinic M**, Mueller-Ladner U, Sandqvist G, Torrente-Segarra V, Schmeiser T, Sierakowska M, Sierakowska J, Sierakowski S, Redmond A.: *Common measure of quality of life for people with systemic sclerosis across seven European countries: a cross-sectional study*. Ann Rheum Dis. 2018 Feb
- 422.Bellando-Randone S, Bruni C, Lepri G, Fiori G, Bartoli F, Conforti ML, Moggi-Pignone A, Guiducci S, Giuggioli D, Colaci M, Spinella A, Ferri C, **Matucci-Cerinic M**:*The safety of iloprost in systemic sclerosis in a real-life experience*.Clin Rheumatol. 2018 Feb
- 423.Herrick AL, Peytrignet S, Lunt M, Pan X, Hesselstrand R, Mouthon L, Silman AJ, Dinsdale G, Brown E, Czirják L, Distler JHW, Distler O, Fligelstone K, Gregory WJ, Ochiel R, Vonk MC, Ancuța C, Ong VH, Farge D, Hudson M, Matucci-Cerinic M, Balbir-Gurman A, Midtvedt Ø, Jobanputra P, Jordan AC, Stevens W, Moinzadeh P, Hall FC, Agard C, Anderson ME, Diot E, Madhok R, Akil M, Buch MH, Chung L, Damjanov NS, Gunawardena H, Lanyon P, Ahmad Y, Chakravarty K, Jacobsen S, MacGregor AJ, McHugh N, Müller-Ladner U, Riemekasten G, Becker M, Roddy J, Carreira PE, Fauchais AL, Hachulla E, Hamilton J, İnanç M, McLaren JS, van Laar JM, Pathare S, Proudman SM, Rudin A, Sahhar J, Coppere B, Serratrice C, Sheeran T, Veale DJ, Grange C, Trad GS, Denton CP: *Patterns and predictors of skin score change in early diffuse systemic sclerosis from the European Scleroderma Observational Study*. Ann Rheum Dis. 2018 Jan
- 424.Adler S, Huscher D, Siegert E, Allanore Y, Czirják L, DelGaldo F, Denton CP, Distler O, Frerix M, **Matucci-Cerinic M**, Mueller-Ladner U, Tärner IH, Valentini G, Walker UA, Villiger PM, Riemekasten G; EUSTAR co-workers on behalf of the DeSScIPHER project research group within the EUSTAR network: *Systemic sclerosis associated interstitial lung disease - individualized immunosuppressive therapy and course of lung function: results of the EUSTAR group*. Arthritis Res Ther. 2018 Jan
425. Suliman YA, Kafaja S, Fitzgerald J, Wortsman X, Grotts J, **Matucci-Cerinic M**, Ranganath VK, Furst DE. *Ultrasound characterization of cutaneous ulcers in systemic sclerosis*. Clin Rheumatol. 2018;37(6):1555-1561

2017

- 426.Pauling JD, Domsic RT, Saketkoo LA, Almeida C, Withey J, Jay H, Frech TM, Ingegnoli F, Dures E, Robson J, McHugh NJ, Herrick AL, **Matucci-Cerinic M**, Khanna D, Hewlett S.: A multi-national qualitative research study exploring the patient experience of Raynaud's phenomenon in systemic sclerosis. Arthritis Care Res (Hoboken). 2017 Nov
- 427.Bellando-Randone S, **Matucci-Cerinic M**: The Measurement of the Endothelial Glycocalyx as a New Biomarker of Endothelial Derangement in Systemic Sclerosis: A Challenge for the Future. J Rheumatol. 2017 Nov.

428. Stagi S, Lepri G, Rigante D, **Matucci Cerinic M**, Falcini F. Cross-Sectional Evaluation of Plasma Vitamin D Levels in a Large Cohort of Italian Patients with Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections. *J Child Adolesc Psychopharmacol*. 2017 Nov 7
429. Mecacci F, Simeone S, Cirami CL, Cozzolino M, Serena C, Rambaldi MP, Gallo P, Emmi L, Cammelli D, Mello G, **Matucci Cerinic M**. Preeclampsia in pregnancies complicated by systemic lupus erythematosus (SLE) nephritis: prophylactic treatment with multidisciplinary approach are important keys to prevent adverse obstetric outcomes. *J Matern Fetal Neonatal Med*. 2017 Nov 27
430. Allanore Y, Distler O, **Matucci-Cerinic M**, Denton CP. Defining a unified vascular phenotype in systemic sclerosis. *Arthritis Rheumatol*. 2017 Nov 16.
431. Galli M, Antinori S, Atzeni F, Meroni L, Riva A, Scirè C, Adorni F, Quartuccio L, Sebastiani M, Airò P, Bazzichi L, Cristini F, Del Bono V, Manfredi A, Viapiana O, De Rosa F, Favalli E, Petrelli E, Salvarani C, Govoni M, Corcione S, Scrivo R, Sarmati L, Lazzarin A, Grassi W, Mastroianni C, Gaeta GB, Ferraccioli G, Cutolo M, De Vita S, Lapadula G, **Matucci-Cerinic M**, Armignacco O, Sarzi-Puttini P. Recommendations for the management of pulmonary fungal infections in patients with rheumatoid arthritis. *Clin Exp Rheumatol*. 2017 Nov 28
432. Peytrignet S, Denton CP, Lunt M, Hesselstrand R, Mouthon L, Silman A, Pan X, Brown E, Czirják L, Distler JHW, Distler O, Fligelstone K, Gregory WJ, Ochiel R, Vonk M, Ancuta C, Ong VH, Farge D, Hudson M, **Matucci-Cerinic M**, Balbir-Gurman A, Midtvedt Ø, Jordan AC, Stevens W, Moinzadeh P, Hall FC, Agard C, Anderson ME, Diot E, Madhok R, Akil M, Buch MH, Chung L, Damjanov N, Gunawardena H, Lanyon P, Ahmad Y, Chakravarty K, Jacobsen S, MacGregor AJ, McHugh N, Müller-Ladner U, Riemekasten G, Becker M, Roddy J, Carreira PE, Fauchais AL, Hachulla E, Hamilton J, Inanç M, McLaren JS, van Laar JM, Pathare S, Proudman S, Rudin A, Sahhar J, Coppere B, Serratrice C, Sheeran T, Veale DJ, Grange C, Trad GS, Herrick AL. Disability, fatigue, pain and their associates in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study. *Rheumatology (Oxford)*. 2017 Nov 30.
433. Terenzi R, Manetti M, Rosa I, Romano E, Galluccio F, Guiducci S, Ibba-Manneschi L, **Matucci-Cerinic M**. Angiotensin II type 2 receptor (AT2R) as a novel modulator of inflammation in rheumatoid arthritis synovium. *Sci Rep*. 2017 Oct 16.
434. Johnson SR, Soowamber ML, Fransen J, Khanna D, Van Den Hoogen F, Baron M, **Matucci-Cerinic M**, Denton CP, Medsger TA Jr, Carreira PE, Riemekasten G, Distler J, Gabrielli A, Steen V, Chung L, Silver R, Varga J, Müller-Ladner U, Vonk MC, Walker UA, Wollheim FA, Herrick A, Furst DE, Czirjak L, Kowal-Bielecka O, Del Galdo F, Cutolo M, Hunzelmann N, Murray CD, Foeldvari I, Mouthon L, Damjanov N, Kahaleh B, Frech T, Assassi S, Saketkoo LA, Pope JE. There is a need for new systemic sclerosis subset criteria. A content analytic approach. *Scand J Rheumatol*. 2017 Oct
435. Wang Y, Gargani L, Barskova T, Furst DE, **Matucci Cerinic M**. Usefulness of lung ultrasound B-lines in connective tissue disease-associated interstitial lung disease: a literature review. *Arthritis Res Ther*. 2017 Sep
436. Bellando-Randone S, **Matucci-Cerinic M**. Very Early Systemic Sclerosis and Pre-systemic Sclerosis: Definition, Recognition, Clinical

- Relevance and Future Directions. *Curr Rheumatol Rep*. 2017 Sep
437. Colaci M, Lumetti F, Giuggioli D, Guiducci S, Bellando-Randone S, Fiori G, **Matucci-Cerinic M**, Ferri C. Long-term treatment of scleroderma-related digital ulcers with iloprost: a cohort study. *Clin Exp Rheumatol*. 2017 Sep
 438. Galluccio F, Müller-Ladner U, Furst DE, Khanna D, **Matucci-Cerinic M**. Points to consider in renal involvement in systemic sclerosis. *Rheumatology (Oxford)*. 2017 Sep
 439. Migliore A, Scirè CA, Carmona L, Herrero-Beaumont G, Bizzi E, Branco J, Carrara G, Chevalier X, Collaku L, Aslanidis S, Denisov L, Di Matteo L, Bianchi G, Diracoglu D, Frediani B, Maheu E, Martusevich N, Bagnato GF, Scarpellini M, Minisola G, Akkoc N, Ramonda R, Barskova T, Babic-Naglic D, Muelas JVM, Ionescu R, Rashkov R, Damjanov N, **Matucci Cerinic MM**. The challenge of the definition of early symptomatic knee osteoarthritis: a proposal of criteria and red flags from an international initiative promoted by the Italian Society for Rheumatology. *Rheumatol Int*. 2017 ;37:1227-1236
 440. Chora I, Romano E, Manetti M, Mazzotta C, Costa R, Machado V, Cortez A, Bruni C, Lepri G, Guiducci S, De Paulis A, Soares R, **Matucci-Cerinic M**. "Evidence for a Derangement of the Microvascular System in Patients with a Very Early Diagnosis of Systemic Sclerosis." *J Rheumatol*. 2017 Aug
 441. Manetti M, Pratesi S, Romano E, Bellando-Randone S, Rosa I, Guiducci S, Fioretto BS, Ibba-Manneschi L, Maggi E, **Matucci-Cerinic M**. "Angiogenic T cell expansion correlates with severity of peripheral vascular damage in systemic sclerosis." *PLoS One*. 2017 Aug
 442. Elhai M, Meune C, Boubaya M, Avouac J, Hachulla E, Balbir-Gurman A, Riemekasten G, Airò P, Joven B, Vettori S, Cozzi F, Ullman S, Czirják L, Tikly M, Müller-Ladner U, Caramaschi P, Distler O, Iannone F, Ananieva LP, Hesselstrand R, Becvar R, Gabrielli A, Damjanov N, Salvador MJ, Riccieri V, Mihai C, Szűcs G, Walker UA, Hunzelmann N, Martinovic D, Smith V, Müller CS, Montecucco CM, Opris D, Ingegnoli F, Vlachoyiannopoulos PG, Stamenkovic B, Rosato E, Heitmann S, Distler JHW, Zenone T, Seidel M, Vacca A, De Langhe E, Novak S, Cutolo M, Mouthon L, Henes J, Chizzolini C, Mühlen CAV, Solanki K, Rednic S, Stamp L, Anic B, Santamaria VO, Santis M, Yavuz S, Sifuentes-Giraldo WA, Chatelus E, Stork J, Laar JV, Loyo E, García de la Peña Lefebvre P, Eyerich K, Cosentino V, Alegre-Sancho JJ, Kowal-Bielecka O, Rey G, Matucci-Cerinic M, Allanore Y; EUSTAR group. "Mapping and predicting mortality from systemic sclerosis." *Ann Rheum Dis*. 2017 Aug 23.
 443. **Matucci-Cerinic M**, Manetti M, Bruni C, Chora I, Bellando-Randone S, Lepri G, De Paulis A, Guiducci S.: The "myth" of loss of angiogenesis in systemic sclerosis: a pivotal early pathogenetic process or just a late unavoidable event? *Arthritis Res Ther*. 2017 Jul.
 444. Carreira PE, Carmona L, Joven BE, Loza E, Andreu JL, Riemekasten G, Vettori S, Allanore Y, Balbir-Gurman A, Airò P, Walker UA, Damjanov N, Ananieva LP, Rednic S, Czirják L, Distler O, Farge D, Hesselstrand R, Corrado A, Caramaschi P, Tikly M, **Matucci-Cerinic M**; and EUSTAR co-authors. Clinical determinants of elevated systolic pulmonary artery pressure measured by transthoracic Doppler echocardiography in early systemic sclerosis. *Clin Exp Rheumatol*. 2017 Jun 20.
 445. Caforio ALP, Adler Y, Agostini C, Allanore Y, Anastasakis A, Arad M, Böhm M, Charron P, Elliott PM, Eriksson U, Felix SB, Garcia-

- Pavia P, Hachulla E, Heymans S, Imazio M, Klingel K, Marcolongo R, **Matucci Cerinic M**, Pantazis A, Plein S, Poli V, Rigopoulos A, Seferovic P, Shoenfeld Y, Zamorano JL, Linhart A. Diagnosis and management of myocardial involvement in systemic immune-mediated diseases: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Disease. *Eur Heart J*. 2017 Jun 26.
446. Chiarello F, Spitoni S, Hollander E, **Matucci Cerinic M**, Pallanti S. An expert opinion on PANDAS/PANS: highlights and controversies. *Int J Psychiatry Clin Pract*. 2017 Jun
447. Caporali R, Idolazzi L, Bombardieri S, Ferraccioli G, Gerli R, Govoni M, **Matucci Cerinic M**, Pomponio G, Salaffi F, Tirri R, Benaglio F, Bianchino L, Sarzi-Puttini P; TRUST study investigators. Tocilizumab in the treatment of patients with rheumatoid arthritis in real clinical practice: results of an Italian observational study. *Clin Exp Rheumatol*. 2017 May 8.
448. Bartalesi F, Scirè C, Requena-Méndez A, Abad MA, Buonfrate D, Caporali R, Conti F, Diaz-Gonzalez F, Fernández-Espartero C, Martínez-Fernández C, Mascarello M, Generali E, Minisola G, Morrone A, Muñoz J, Richi P, Sakellariou G, Salas Coronas J, Spinicci M, Castelli F, Bartoloni A, Bisoffi Z, Gimenez-Sanchez F, Muñoz-Fernandez S, **Matucci-Cerinic M**. Recommendations for infectious disease screening in migrants to Western Europe with inflammatory arthropathies before starting biologic agents. Results from a multidisciplinary task force of four European societies (SIR, SER, SIMET, SEMTSI) facing the lar. *Clin Exp Rheumatol*. 2017 May 8
449. Rivellese F, Nerviani A, Rossi FW, Marone G, **Matucci-Cerinic M**, de Paulis A, Pitzalis C. Mast cells in rheumatoid arthritis: friends or foes? *Autoimmun Rev*. 2017 Jun.
450. Melchiorre D, Manetti M, **Matucci-Cerinic M**. Pathophysiology of Hemophilic Arthropathy. *J Clin Med*. 2017 Jun
451. Manetti M, Romano E, Rosa I, Guiducci S, Bellando-Randone S, De Paulis A, Ibba-Manneschi L, Matucci-Cerinic M. Endothelial-to-mesenchymal transition contributes to endothelial dysfunction and dermal fibrosis in systemic sclerosis. *Ann Rheum Dis*. 2017 May.
452. Galluccio F, Bellucci E, Porta F, Tofani L, De Paulis A, Bianchedi D, Barskova T, **Matucci-Cerinic M**. The waterpolo shoulder paradigm: results of ultrasound surveillance at poolside. *BMJ Open Sport Exerc Med*. 2017 Jul.
453. Jaeger VK, Distler O, Maurer B, Czirják L, Lóránd V, Valentini G, Vettori S, Del Galdo F, Abignano G, Denton C, Nihtyanova S, Allanore Y, Avouac J, Riemekasten G, Siegert E, Huscher D, **Matucci-Cerinic M**, Guiducci S, Frerix M, Tarner IH, Garay Toth B, Fankhauser B, Umbricht J, Zakharova A, Mihai C, Cozzi F, Yavuz S, Hunzelmann N, Rednic S, Vacca A, Schmeiser T, Ricciari V, García de la Peña Lefebvre P, Gabrielli A, Krummel-Lorenz B, Martinovic D, Ancuta C, Smith V, Müller-Ladner U, Walker UA. Functional disability and its predictors in systemic sclerosis: a study from the DeSSciphir project within the EUSTAR group. *Rheumatology (Oxford)*. 2017 May.
454. Beyer C, Huscher D, Ramming A, Bergmann C, Avouac J, Guiducci S, Meier F, Vettori S, Siegert E, Jaeger VK, Maurer B, Riemekasten G, Walker U, Müller-Ladner U, Valentini G, **Matucci-Cerinic M**, Allanore Y, Distler O, Schett G, Distler JHW. Elevated serum levels of sonic hedgehog are associated with fibrotic and vascular

- manifestations in systemic sclerosis. *Ann Rheum Dis*. 2017 May 11
455. Bruni C, Guiducci S, Bellando-Randone S, **Matucci-Cerinic M**. Avascular bone necrosis: An underestimated complication of systemic sclerosis. *Semin Arthritis Rheum*. 2017 Mar.
 456. Rossi FW, Lobasso A, Selleri C, **Matucci-Cerinic M**, Rivellesse F, Shoenfeld Y, de Paulis A. Autoimmune Tautology in a Complex Case of Polyautoimmunity: Systemic Sclerosis, Autoimmune Liver Involvement, Antiphospholipid Syndrome and Hashimoto's Thyroiditis. *Isr Med Assoc J*. 2017 Mar
 457. Huffstutter JE, Kafka S, Brent LH, **Matucci-Cerinic M**, Tang KL, Chevrier M, Sprabery T, DeHoratius RJ. Clinical response to golimumab in rheumatoid arthritis patients who were receiving etanercept or adalimumab: results of a multicenter active treatment study. *Curr Med Res Opin*. 2017 Apr.
 458. Khanna D, Furst DE, Clements PJ, Allanore Y, Baron M, Czirjak L, Distler O, Foeldvari I, Kuwana M, **Matucci-Cerinic M**, Mayes M, Medsger T Jr, Merkel PA, Pope JE, Seibold JR, Steen V, Stevens W, Denton CP. "Standardization of the modified Rodnan skin score for use in clinical trials of systemic sclerosis." *J Scleroderma Relat Disord*. 2017 Jan-Apr.
 459. Mavrogeni SI, Schwitter J, Gargani L, Pepe A, Monti L, Allanore Y, **Matucci-Cerinic M**. Cardiovascular magnetic resonance in systemic sclerosis: "Pearls and pitfalls". *Semin Arthritis Rheum*. 2017 Mar.
 460. Terao C, Kawaguchi T, Dieude P, Varga J, Kuwana M, Hudson M, Kawaguchi Y, **Matucci-Cerinic M**, Ohmura K, Riemekasten G, Kawasaki A, Airo P, Horita T, Oka A, Hachulla E, Yoshifuji H, Caramaschi P, Hunzelmann N, Baron M, Atsumi T, Hassoun P, Torii T, Takahashi M, Tabara Y, Shimizu M, Tochimoto A, Ayuzawa N, Yanagida H, Furukawa H, Tohma S, Hasegawa M, Fujimoto M, Ishikawa O, Yamamoto T, Goto D, Asano Y, Jinnin M, Endo H, Takahashi H, Takehara K, Sato S, Ihn H, Raychaudhuri S, Liao K, Gregersen P, Tsuchiya N, Ricciari V, Melchers I, Valentini G, Cauvet A, Martinez M, Mimori T, Matsuda F, Allanore Y. Transethnic meta-analysis identifies GSDMA and PRDM1 as susceptibility genes to systemic sclerosis. *Ann Rheum Dis*. 2017 Mar.
 461. Kowal-Bielecka O, Chwiesko-Minarowska S, Bernatowicz PL, Allanore Y, Radstake T, **Matucci-Cerinic M**, Broen J, Hesselstrand R, Krasowska D, Riemekasten G, Vonk M, Kowalczyk O, Bielecki M, Milewski R, Chyczewski L, Niklinski J, Kowal K. The arachidonate 5-lipoxygenase activating protein gene polymorphism is associated with the risk of scleroderma-related interstitial lung disease: a multicentre European Scleroderma Trials and Research group (EUSTAR) study. *Rheumatology (Oxford)*. 2017 Feb 4.
 462. Mazzotta C, Manetti M, Rosa I, Romano E, Blagojevic J, Bellando-Randone S, Bruni C, Lepri G, Guiducci S, Ibba-Manneschi L, **Matucci-Cerinic M**.: Proangiogenic effects of soluble α -Klotho on systemic sclerosis dermal microvascular endothelial cell. *Arthritis Res Ther*. 2017 Feb.
 463. Herrick AL, Pan X, Peytrignet S, Lunt M, Hesselstrand R, Mouthon L, Silman A, Brown E, Czirjak L, Distler JH, Distler O, Fligelstone K, Gregory WJ, Ochiel R, Vonk M, Ancuța C, Ong VH, Farge D, Hudson M, **Matucci-Cerinic M**, Balbir-Gurman A, Midtvedt Ø, Jordan AC, Jobanputra P, Stevens W, Moinszadeh P, Hall FC, Agard C, Anderson ME, Diot E, Madhok R, Akil M, Buch MH, Chung L, Damjanov N, Gunawardena H, Lanyon P, Ahmad Y, Chakravarty K, Jacobsen S, MacGregor AJ, McHugh N, Müller-Ladner U, Riemekasten G, Becker

- M, Roddy J, Carreira PE, Fauchais AL, Hachulla E, Hamilton J, İnanç M, McLaren JS, van Laar JM, Pathare S, Proudman S, Rudin A, Sahhar J, Coppere B, Serratrice C, Sheeran T, Veale DJ, Grange C, Trad GS, Denton CP: Treatment outcome in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study (ESOS). *Ann Rheum Dis*. 2017 Feb.
464. Bruni C, Lages A, Patel H, Nihtyanova SI, Green B, AbuHilal M, Harvey J, Ong VH, Matucci Cerinic M, Derrett-Smith E, Denton CP.: Resolution of paraneoplastic PM/Scl-positive systemic sclerosis after curative resection of a pancreatic tumour. *Rheumatology (Oxford)*. 2017 Feb.
465. Braschi F, Bartoli F, Bruni C, Fiori G, Fantauzzo C, Paganelli L, De Paulis A, Rasero L, Matucci-Cerinic M.: Lidocaine controls pain and allows safe wound bed preparation and debridement of digital ulcers in systemic sclerosis: a retrospective study. *Clin Rheumatol*. 2017 Jan.

2016

466. Kovacs G, Avian A, Foris V, Tscherner M, Kqiku X, Douschan P, Bachmaier G, Olschewski A, **Matucci-Cerinic M**, Olschewski H: Use of ECG and Other Simple Non-Invasive Tools to Assess Pulmonary Hypertension. *PLoS One*. 2016 Dec
467. Bruni C, Praino E, Allanore Y, Distler O, Gabrielli A, Iannone F, **Matucci-Cerinic M**.: Use of biologics and other novel therapies for the treatment of systemic sclerosis. *Expert Rev Clin Immunol*. 2016 Nov
468. Bandinelli F, Scazzariello F, Pimenta da Fonseca E, Barreto Santiago M, Marcassa C, Nacci F, **Matucci Cerinic M**.: Low-dose modified-release prednisone in axial spondyloarthritis: 3-month efficacy and tolerability. *Drug Des Devel Ther*. 10:3717-3724.
469. Galluccio F, **Matucci-Cerinic M**: Efficacy of Short-term Teriparatide for Hip Osteonecrosis. *J Rheumatol*. 2016 Nov.
470. Johnson SR., Khanna D, Allanore Y, **Matucci-Cerinic M**, Furst, DEJ Systemic sclerosis trial design moving forward *J Scleroderma relat disord* 2016; 1(2): 177-180
471. Bartoli F, Bruni C, Cometi L, Blagojevic J, Fiori G, Tofani L, Galluccio F, Furst DE, **Matucci Cerinic M**.: Premedication prevents infusion reactions and improves retention rate during infliximab treatment. *Clin Rheumatol*. 2016 Nov.
472. Bellis E, Scirè CA, Carrara G, Adinolfi A, Batticciotto A, Bortoluzzi A, Cagnotto G, Caprioli M, Canzoni M, Cavatorta FP, De Lucia O, Di Sabatino V, Draghessi A, Filippou G, Farina I, Focherini MC, Gabba A, Gutierrez M, Idolazzi L, Luccioli F, Macchioni P, Massarotti MS, Mastaglio C, Menza L, Muratore M, Parisi S, Picerno V, Piga M, Ramonda R, Raffeiner B, Rossi D, Rossi S, Rossini P, Sakellariou G, Scioscia C, Venditti C, Volpe A, **Matucci-Cerinic M**, Iagnocco A.: Ultrasound-detected tenosynovitis independently associates with patient-reported flare in patients with rheumatoid arthritis in clinical remission: results from the observational study STARTER of the Italian Society for Rheumatology. *Rheumatology (Oxford)* 2016 Oct.
473. **Matucci-Cerinic M**, Krieg T, Guillemin L, Schwierin B, Rosenberg D, Cornelisse P, Denton CP: Elucidating the burden of recurrent and chronic digital ulcers in systemic sclerosis: long-term results from the DUO Registry. *Ann Rheum Dis*. 2016 Oct. 75(10):1770-6.
474. Koumakis E, Bouaziz M, Dieudé P, Cauvet A, Ruiz B, Airò P, Cusi D,

- Matucci-Cerinic M**, Salvi E, Cuomo G, Hachulla E, Diot E, Caramaschi P, Riccieri V, Avouac J, Allanore Y: A candidate gene study identifies a haplotype of CD2 as novel susceptibility factor for systemic sclerosis. *Clin Exp Rheumatol*. 2016 Sep-Oct. 34 Suppl 100(5):43-48.
475. Melchiorre D, Linari S, **Matucci-Cerinic M**, Castaman G.: A contribution to the debate about the possible different clinical severity between hemophilia A and B. *Haematologica*. 2016 Oct. 75(10):1770-6.
476. Lepri G, Avouac J, Airò P, Anguita Santos F, Bellando-Randone S, Blagojevic J, Garcia Hernández F, Gonzalez Nieto JA, Guiducci S, Jordan S, Limaye V, Maurer B, Selva-O'Callaghan A, Riccieri V, Distler O, **Matucci-Cerinic M**, Allanore Y: Effects of rituximab in connective tissue disorders related interstitial lung disease. *Clin Exp Rheumatol*. 2016 Sep-Oct. Suppl 100(5):181-185.
477. Allanore Y, Denton CP, Krieg T, Cornelisse P, Rosenberg D, Schwierin B, **Matucci-Cerinic M**; DUO Investigators: Clinical characteristics and predictors of gangrene in patients with systemic sclerosis and digital ulcers in the Digital Ulcer Outcome Registry: a prospective, observational cohort. *Ann Rheum Dis*. 2016 Sep. 75(9):1736-40.
478. Distler O, Pope J, Denton C, Allanore Y, **Matucci-Cerinic M**, de Oliveira Pena J, Khanna D: RISE-SSc: Riociguat in diffuse cutaneous systemic sclerosis. *Respir Med*. 2016 Sep. pii: S0954-6111(16)30234-7.
479. Bruni C, Bellando-Randone S, Gargani L, Picano E, Pingitore A, **Matucci-Cerinic M**, Guiducci S.: Critical finger ischemia and myocardial fibrosis development after sudden interruption of sildenafil treatment in a systemic sclerosis patient. *Reumatismo*. 2016 Sep. 9;68(2):109-11
480. Kviatkovsky MJ, Ramiro S, Landewé R, Dougados M, Tubach F, Bellamy N, Hochberg M, Ravaud P, Martin-Mola E, Awada H, Bombardier C, Felson D, Hajjaj-Hassouni N, Logeart I, **Matucci-Cerinic M**, van de Laar M, van der Heijde D: The Minimum Clinically Important Improvement and Patient-acceptable Symptom State in the BASDAI and BASFI for Patients with Ankylosing Spondylitis. *J Rheumatol*. 2016 Sep. 43(9):1680-6
481. Weisz GM, Albury WR, **Matucci-Cerinic M**, Lazzeri D.: 'Epidemic' of hand deformities in the French Renaissance paintings of Jean and François Clouet. *QJM*. 2016 Sep. 109(9):633-5
482. Bartoli F, Fiori G, Braschi F, Amanzi L, Bruni C, Blagojevic J, Bellando-Randone S, Cometi L, de Souza Mueller C, Guiducci S, Rasero L, Epifani F, Furst DE, **Matucci-Cerinic M**.: Calcinosis in systemic sclerosis: subsets, distribution and complications. *Rheumatology (Oxford)* 2016 Sep. 55(9):1610-4
483. Mavrogeni SI, Kitas GD, Dimitroulas T, Sfrikakis PP, Seo P, Gabriel S, Patel AR, Gargani L, Bombardieri S, **Matucci-Cerinic M**, Lombardi M, Pepe A, Aletras AH, Kolovou G, Miszalski T, van Riel P, Semb A, Gonzalez-Gay MA, Dessein P, Karpouzas G, Puntmann V, Nagel E, Bratis K, Karabela G, Stavropoulos E, Katsifis G, Koutsogeorgopoulou L, van Rossum A, Rademakers F, Pohost G, Lima JA.: Cardiovascular magnetic resonance in rheumatology: Current status and recommendations for use. *Int J Cardiol*. 2016 Aug. 217:135-48.
484. Frantz C, Avouac J, Distler O, Amrouche F, Godard D, Kennedy AT, Connolly K, Varga J, **Matucci-Cerinic M**, Allanore Y.: Impaired

- quality of life in systemic sclerosis and patient perception of the disease: A large international survey. *Semin Arthritis Rheum.* 2016 Aug. 46(1):115-23.
485. Melchiorre D, Pratelli E, Torricelli E, Sofi F, Abbate R, **Matucci-Cerinic M**, Gensini G, Pepe G.: A group of patients with Marfan's syndrome, who have finger and toe contractures, displays tendons' alterations upon an ultrasound examination: are these features common among classical Marfan patients? *Intern Emerg Med.* 2016 Aug. 11(5):703-11
 486. Fischer A, Denton CP, **Matucci-Cerinic M**, Gillies H, Blair C, Tislow J, Nathan SD.: Ambrisentan response in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) - A subgroup analysis of the ARIES-E clinical trial. *Respir Med.* 2016; 117:254-63.
 487. Romano E, Chora I, Manetti M, Mazzotta C, Rosa I, Bellando-Randone S, Blagojevic J, Soares R, Avouac J, Allanore Y, Ibba-Manneschi L, **Matucci-Cerinic M**, Guiducci S.: Decreased expression of neuropilin-1 as a novel key factor contributing to peripheral microvasculopathy and defective angiogenesis in systemic sclerosis. *Ann Rheum Dis.* 2016; 75(8):1541-9
 488. Allanore Y, **Matucci-Cerinic M**, Distler O.: Treatment of systemic sclerosis: is there any hope for the future? *RMD Open.* 2016 Jul. 2(2):e000260
 489. Rinaldi LA, Simoni D, Maresca M, Monaco V, **Matucci-Cerinic M**, Melchiorre D.: Gait abnormalities in early rheumatoid arthritis with temporomandibular joint involvement. *Clin Exp Rheumatol.* 2016 May-Jun. 34(3):561.
 490. Lazzeri D, Castello MF, **Matucci-Cerinic M**, Lippi D, Weisz GM.: Osteoarthritis in the hands of Michelangelo Buonarroti. *J.R.Soc.Med.* 2016. 109(5):180-3.
 491. Ramonda R, Marchesoni A, Carletto A, Bianchi G, Cutolo M, Ferraccioli G, Fusaro E, De Vita S, Galeazzi M, Gerli R, **Matucci-Cerinic M**, Minisola G, Montecucco C, Pellerito R, Salaffi F, Paolazzi G, Sarzi-Puttini P, Scarpa R, Bagnato G, Triolo G, Valesini G, Punzi L, Olivieri I; ATLANTIS study group. Patient-reported impact of spondyloarthritis on work disability and working life: the ATLANTIS survey. 2016 Apr. 1;18:78.
 492. Cantini F, Niccoli L, Nannini C, Cassarà E, Kaloudi O, Giulio Favalli E, Becciolini A, Biggioggero M, Benucci M, Li Gobbi F, Grossi V, Infantino M, Meacci F, Manfredi M, Guiducci S, Bellando-Randone S, **Matucci-Cerinic M**, Foti R, Di Gangi M, Mosca M, Tani C, Palmieri F, Goletti D; Italian board for the Tailored BIOlogic therapy (ITABIO).: Tailored first-line biologic therapy in patients with rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis. *Semin Arthritis Rheum.* 2016 Apr. 45(5):519-32
 493. Blagojevic J, Piemonte G, Benelli L, Braschi F, Fiori G, Bartoli F, Guiducci S, Bellando Randone S, Galluccio F, Cometi L, Castellani S, Boddi M, Moggi Pignone A, Rasero L, Epifani F, **Matucci-Cerinic M**.: Assessment, Definition, and Classification of Lower Limb Ulcers in Systemic Sclerosis: A Challenge for the Rheumatologist. *Rheumatol.* 2016 Mar. 43(3):592-8.
 494. Melchiorre D, Linari S, Manetti M, Romano E, Sofi F, **Matucci-Cerinic M**, Carulli C, Innocenti M, Ibba-Manneschi L, Castaman G.: Clinical, instrumental, serological and histological findings suggest that hemophilia B may be less severe than hemophilia A. *Haematologica.* 2016 ;01(2):219-25.
 495. Manetti M, Guiducci S, **Matucci-Cerinic M**.: The crowded crossroad

- to angiogenesis in systemic sclerosis: where is the key to the problem? *Arthritis Res Ther*. 2016 Feb. 5;18:36.
496. Khanna D, Berrocal VJ, Giannini EH, Seibold JR, Merkel PA, Mayes MD, Baron M, Clements PJ, Steen V, Assassi S, Schioppa E, Phillips K, Simms RW, Allanore Y, Denton CP, Distler O, Johnson SR, **Matucci-Cerinic M**, Pope JE, Proudman SM, Siegel J, Wong WK, Wells AU, Furst DE: The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic Sclerosis. *Arthritis Rheum*. 2016 Feb.
 497. Olivieri I, Cortesi PA, de Portu S, Salvarani C, Cauli A, Lubrano E, Spadaro A, Cantini F, Ciampichini R, Cutro MS, Mathieu A, **Matucci-Cerinic M**, Punzi L, Scarpa R, Mantovani LG; PACE Working Group: Long-term costs and outcomes in psoriatic arthritis patients not responding to conventional therapy treated with tumour necrosis factor inhibitors: the extension of the Psoriatic Arthritis Cost Evaluation (PACE) study. *Clin Exp Rheumatol*. 2016.34(1):68-75.
 498. Scirè CA, Carrara G, Viroli C, Cimmino MA, Taylor WJ, Manara M, Govoni M, Salaffi F, Punzi L, Montecucco C, **Matucci-Cerinic M**, Minisola G; KING Study Group: Development and first validation of a disease activity score for gout. *Arthritis Care Res (Hoboken)* 2016.68(10):1530-7
 499. Bellando-Randone S, Lepri G, Bruni C, Blagojevic J, Radicati A, Cometi L, De Paulis A, **Matucci-Cerinic M**, Guiducci S: Combination therapy with Bosentan and Sildenafil improves Raynaud's phenomenon and fosters the recovery of microvascular involvement in systemic sclerosis. *Clin Rheumatol*. 2016 Jan. 35(1):127-32

2015

500. Gargani L, Raso R, Tartarisco G, **Matucci Cerinic M**, Pioggia G, Picano E.: Reply: Objectively Measuring the Ghost in the Machine: B-Lines as Uncertain Measures on Which to Base Clinical Assessment. *JACC Cardiovasc Imaging*. 2015 Dec. 8(12):1470-1.
501. Baron M, Pope JE, VAN DEN Hoogen F, Khanna D, Fransen J, Johnson SR, **Matucci-Cerinic M**.: Specificity of Systemic Sclerosis Classification Criteria. *J Rheumatol*. 2015 Dec. 42(12):2512.
502. Ingegnoli F, Boracchi P, Gualtierotti R, Smith V, Cutolo M, Foeldvari I; EUSTAR co-authors: A comparison between nailfold capillaroscopy patterns in adulthood in juvenile and adult-onset systemic sclerosis: A EUSTAR exploratory study. *Microvasc Res*. 2015 Nov. 102:19-24.
503. Manetti M, **Matucci-Cerinic M**.: The new frontier in systemic sclerosis: from epigenetics to new treatments. *Rheumatology (Oxford)*. 2015 Oct. 4(10):1757-8.
504. Cappelli S, Bellando Randone S, Camiciottoli G, De Paulis A, Guiducci S, **Matucci-Cerinic M**. Interstitial lung disease in systemic sclerosis: where do we stand? *Eur Respir Rev*. 2015 Sep. 24(137):411-9
505. Galluccio F, Barskova T, **Cerinic MM**. Short-term effect of the combination of hyaluronic acid, chondroitin sulfate, and keratin matrix on early symptomatic knee osteoarthritis. *Eur J Rheumatol*. 2015 Sep;2(3):106-108
506. Harari S, Humbert M, Blasi F, Collard HR, **Matucci-Cerinic M**, Simonneau G, Vancheri C, Wells AU, Cottin V.: Rare pulmonary diseases and orphan drugs: where do we stand and where are we going

- to? Eur Respir Rev. 2015 Sep. 24(137):375-7
507. Mazzotta C, Romano E, Bruni C, Manetti M, Lepri G, Bellando-Randone S, Blagojevic J, Ibba-Manneschi L, Matucci-Cerinic M, Guiducci S. Plexin-D1/Semaphorin 3E pathway may contribute to dysregulation of vascular tone control and defective angiogenesis in systemic sclerosis. *Arthritis Res. Ther.* 2015 Sep. 17:221
 508. Galiè N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, Simonneau G, Peacock A, Vonk Noordegraaf A, Beghetti M, Ghofrani A, Gomez Sanchez MA, Hansmann G, Klepetko W, Lancellotti P, **Matucci Cerinic M**, McDonagh T, Pierard LA, Trindade PT, Zompatori M, Hoeper M; Authors/Task Force Members: Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS) Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). *Eur Heart J.* 2015 Aug. 7(1):67-119
 509. Romano E, Bellando-Randone S, Manetti M, Bruni C, Lepri G, **Matucci-Cerinic M**, Guiducci S.: Bosentan blocks the antiangiogenic effects of sera from systemic sclerosis patients: an in vitro study. *Clin Exp Rheumatol.* 2015 Jul-Aug. 33(4 Suppl 91):S148-52
 510. Bandinelli F, Salvadorini G, Sedie AD, Riente L, Bombardieri S, **Matucci-Cerinic M**.: Impact of gender, work, and clinical presentation on diagnostic delay in Italian patients with primary ankylosing spondylitis. *Clin Rheumatol.* 2015 Aug. 35(2):473-8
 511. Donzelli G, Carnesecchi G, Amador C, di Tommaso M, Filippi L, Caporali R, Codullo V, Ricciari V, Valesini G, Gabrielli A, Bagnati R, McGreevy KS, De Masi S, **Matucci Cerinic M**. Fetal programming and systemic sclerosis. *Am J. Obstet Gynecol.* 2015 Jul. 213(6):839.e1-8.
 512. Bruni C, Raja J, Denton CP, **Matucci-Cerinic M**. The clinical relevance of sexual dysfunction in systemic sclerosis. *Autoimmun Rev.* 2015 Jul. 14(12):1111-5
 513. Oranges CM, **Matucci-Cerinic M**.: Endocrinology and art. Hypertrichosis and dwarfism in a painting of Agostino Carracci (1598-1600). *J Endocrinol Invest.* 2015 Jul. 38(7):807
 514. Borghini A, Manetti M, Nacci F, Bellando-Randone S, Guiducci S, **Matucci-Cerinic M**, Ibba-Manneschi L, Weber E.: Systemic Sclerosis Sera Impair Angiogenic Performance of Dermal Microvascular Endothelial Cells: Therapeutic Implications of Cyclophosphamide. *PLoS One.* 2015 Jun. 10(6):e0130166.
 515. Rossi FW, Napolitano F, Pesapane A, Mascolo M, Staibano S, **Matucci-Cerinic M**, Guiducci S, Ragno P, di Spigna G, Postiglione L, Marone G, Montuori N, de Paulis A.: Upregulation of the N-formyl Peptide receptors in scleroderma fibroblasts fosters the switch to myofibroblasts. *J Immunol.* 2015 Jun. 194(11):5161-73.
 516. Oranges CM, **Matucci-Cerinic M**. Maddalena Ventura: an impressive case of hirsutism in a painting of Jusepe De Ribera (1631). *J Endocrinol Invest.* 2015 Jun. 39(1):123.
 517. Stagi S, Rigante D, Lepri G, **Matucci Cerinic M**, Falcini F.: Severe vitamin D deficiency in patients with Kawasaki disease: a potential role in the risk to develop heart vascular abnormalities? *Clin Rheumatol.* 2015 May. 35(7):1865-72

518. Dickneite G, Herwald H, Korte W, Allanore Y, Denton CP, **Matucci Cerinic M**. Coagulation factor XIII: a multifunctional transglutaminase with clinical potential in a range of conditions. *Thromb Haemost*. 2015 Apr. 113(4):686-97
519. Chora I, Guiducci S, Manetti M, Romano E, Mazzotta C, Bellando-Randone S, Ibba-Manneschi L, **Matucci-Cerinic M**, Soares R: Vascular biomarkers and correlation with peripheral vasculopathy in systemic sclerosis. *Autoimmun Rev*. 2015 Apr. 14(4):314-22.
520. Raso R, Tartarisco G, **Matucci Cerinic M**, Pioggia G, Picano E, Gargani L.: A soft computing-based B-line analysis for objective classification of severity of pulmonary edema and fibrosis. *JACC Cardiovasc Imaging*. 2015 Apr. 8(4):495-6
521. Arismendi M, Giraud M, Ruzehaji N, Dieudé P, Koumakis E, Ruiz B, Airo P, Cusi D, **Matucci-Cerinic M**, Salvi E, Cuomo G, Hachulla E, Diot E, Caramaschi P, Riccieri V, Avouac J, Kayser C, Allanore Y.: Identification of NF- κ B and PLCL2 as new susceptibility genes and highlights on a potential role of IRF8 through interferon signature modulation in systemic sclerosis. *Arthritis Res Ther*. 2015 Mar. 21, 17:71
522. Bandinelli F, Denaro V, Prignano F, Collaku L, Ciancio G, **Matucci-Cerinic M**: Ultrasonographic wrist and hand abnormalities in early psoriatic arthritis patients: correlation with clinical, dermatological, serological and genetic indices. *Clin Exp Rheumatol*. 2015 Mar. 3(3):330-5
523. Aissopou EK, Bournia VK, Protogerou AD, Panopoulos S, Papaioannou TG, Vlachoyiannopoulos PG, **Matucci-Cerinic M**., Sfikakis PP Intact Calibers of Retinal Vessels in Patients with Systemic Sclerosis. *J Rheumatol*. 2015 Feb. 42(4):608-13
524. Mihai C, Landewé R, van der Heijde D, Walker UA, Constantin PI, Gherghe AM, Ionescu R, Rednic S, Allanore Y, Avouac J, Czirják L, Hachulla E, Riemekasten G, Cozzi F, Airò P, Cutolo M, Mueller-Ladner U, **Matucci-Cerinic M**; EUSTAR co-authors. Digital ulcers predict a worse disease course in patients with systemic sclerosis. *Ann Rheum Dis*. 2015 Feb. 75(4):681-6.
525. Melchiorre D, Maresca M, Bracci R, Ravaschio A, Valiensi B, Casale R, Bandinelli F, Candelieri A, Maddali Bongi S, Porta F, Innocenti M, Carulli C, **Matucci Cerinic M**.: Muscle shortening manoeuvre reduces pain and functional impairment in shoulder impingement syndrome: clinical and ultrasonographic evidence. *Clin Exp Rheumatol* 2014 Jan-Feb. 32(1):5-10
526. Hizal M, Bruni C, Romano E, Mazzotta C, Guiducci S, Bellando-Randone S, Blagojevic J, Lepri G, Tufan A, **Matucci Cerinic M**.: Decrease of LL-37 in systemic sclerosis: a new marker for interstitial lung disease? *Clin Rheumatol*. 2015 Jan. 34(4):795-8
527. Hachulla E, Clerson P, Airò P, Cuomo G, Allanore Y, Caramaschi P, Rosato E, Carreira PE, Riccieri V, Sarraco M, Denton CP, Riemekasten G, Pozzi MR, Zeni S, Mihai CM, Ullman S, Distler O, Rednic S, Smith V, Walker UA, **Matucci-Cerinic M**, Müller-Ladner U, Launay D; on behalf of the EUSTAR co-workers: Value of systolic pulmonary arterial pressure as a prognostic factor of death in the systemic sclerosis EUSTAR population. *Rheumatology (Oxford)*. 2015 Jan. 54(7):1262-9.
528. Bellamy N, Hochberg M, Tubach F, Martin-Mola E, Awada H, Bombardier C, Hajjaj-Hassouni N, Logeart I, **Matucci-Cerinic M**, van

- de Laar M, van der Heijde D, Dougados M.:Development of multinational definitions of minimal clinically important improvement and patient acceptable symptomatic state in osteoarthritis. *Arthritis Care Res (Hoboken)*. 2015 Jan.67(7):972-80
- 529.Falcini F, Rigante D, Candelli M, Martini G, Corona F, Petaccia A, La Torre F, Raffaele CG, **Matucci Cerinic M.**:Anti-nuclear antibodies as predictor of outcome in a multi-center cohort of Italian children and adolescents with Raynaud's phenomenon. *Clin Rheumatol*. 2015 Jan. 34(1):167-9
- 530.Maddali Bongi S, Del Rosso A, Mikhaylova S, Rasero L, Amanzi L, Braschi F, Del Nero M, **Matucci Cerinic M.** District disability, fatigue and mood disorders as determinants of health related quality of life in patients with systemic sclerosis. *Joint Bone Spine*. 2015 Jan. 82(1):67-8.
- 531.Barison A, Gargani L, De Marchi D, Aquaro GD, Guiducci S, Picano E, **Matucci Cerinic M**, Pingitore A.:Early myocardial and skeletal muscle interstitial remodelling in systemic sclerosis: insights from extracellular volume quantification using cardiovascular magnetic resonance.*Eur Heart J Cardiovasc Imaging*. 2015 Jan. 16(1):74-80
- 532.Bandinelli F, Milia AF, Manetti M, Lastraioli E, D' Amico M, Tonelli P, Fazi M, Arcangeli A, **Matucci-Cerinic M**, Ibba-Manneschi L: Lymphatic endothelial progenitor cells and vascular endothelial growth factor-C in spondyloarthritis and Crohn's disease: two overlapping diseases? *Clin Exp Rheumatol*. 2015 Jan. 33(2):195-200

2014

- 533.Picano E, Semelka R, Ravenel J, **Matucci-Cerinic M.** Rheumatological diseases and cancer: the hidden variable of radiation exposure. *Ann Rheum Dis*. 2014 Dec. 73(12):2065-8.
- 534.Elhai M, Avouac J, Walker UA, **Matucci-Cerinic M**, Riemekasten G, Airo P, Hachulla E, Valentini G, Carreira PE, Cozzi F, Balbir Gurman A, Braun-Moscovici Y, Damjanov N, Ananieva LP, Scorza R, Jimenez S, Busquets J, Li M, Müller-Ladner U, Kahan A, Distler O, Allanore Y: A gender gap in primary and secondary heart dysfunctions in systemic sclerosis: a EUSTAR prospective study. *Ann Rheum Dis*. 2014 Oct.75(1):163-9.
- 535.Maddali Bongi S, Del Rosso A, Mikhaylova S, Landi G, Ferretti B, Cavigli E, Baccini M, **Matucci-Cerinic M.**: A comparison of two podiatric protocols for metatarsalgia in patients with rheumatoid arthritis and osteoarthritis.*Clin Exp Rheumatol*. 2014 Nov-Dec. 32(6):855-63
- 536.Weisz GM, Albury WR, Matucci-Cerinic M SSc and the 2013 diagnostic criteria: the case of Paul Klee's manual pathology and dysgraphia. *Clin Rheumatol*. 2014 Nov. 33(11):1671-4
- 537.Maddali Bongi S, Del Rosso A, **Matucci Cerinic M.** Rheumatologic rehabilitation: towards recommendations. *Reumatismo*. 2014 Nov. 6;66(3):197-207
- 538.Romano E, Terenzi R, Manetti M, Peruzzi F, Fiori G, Nacci F, Bellando-Randone S, **Matucci-Cerinic M**, Guiducci S.: Disease Activity Improvement in Rheumatoid Arthritis Treated with Tumor Necrosis Factor- α Inhibitors Correlates with Increased Soluble Fas Levels. *J Rheumatol*. 2014 Oct. 41(10):1961-5
- 539.Giacomelli R, Gorla R, Trotta F, Tirri R, Grassi W, Bazzichi L, Galeazzi M, **Matucci-Cerinic M**, Scarpa R, Cantini F, Gerli R,

- Lapadula G, Sinigaglia L, Ferraccioli G, Olivieri I, Ruscitti P, Sarzi-Puttini P: Quality of life and unmet needs in patients with inflammatory arthropathies: results from the multicentre, observational RAPSODIA study. *Rheumatology (Oxford)*. 2014 Oct.54(5):792-7.
540. Avouac J, Walker UA, Hachulla E, Riemekasten G, Cuomo G, Carreira PE, Caramaschi P, Ananieva LP, **Matucci-Cerinic M**, Czirjak L, Denton C, Ladner UM, Allanore Y, the EUSTAR collaborators: Joint and tendon involvement predict disease progression in systemic sclerosis: a EUSTAR prospective study. *Ann Rheum Dis*. 2014 Aug.75(1):103-9.
541. Stagi S, Rigante D, Lepri G, Bertini F, **Matucci-Cerinic M**, Falcini F. Evaluation of autoimmune phenomena in patients with pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections (PANDAS). *Autoimmun Rev*. 2014 Aug. 13(12):1236-40
542. Khanna D, Furst DE, Allanore Y, Bae S, Bodukam V, Clements PJ, Cutolo M, Czirjak L, Denton CP, Distler O, Walker UA, **Matucci-Cerinic M**, Müller-Ladner U, Seibold JR, Singh M, Tyndall A Twenty-two points to consider for clinical trials in systemic sclerosis, based on EULAR standards. *Rheumatology (Oxford)*. 2014 Aug. 54(1):144-51.
543. Agoston G, Gargani L, Miglioranza MH, Caputo M, Badano LP, Moreo A, Muraru D, Mondillo S, Moggi Pignone A, **Matucci Cerinic M**, Sicari R, Picano E, Varga A. Left atrial dysfunction detected by speckle tracking in patients with systemic sclerosis. *Cardiovasc Ultrasound*. 2014 Aug. 5;12:30.
544. Bandinelli F, Terenzi R, Giovannini L, Milla M, Genise S, Bagnoli S, Biagini S, Annese V, **Matucci Cerinic M**. Occult radiological sacroiliac abnormalities in patients with inflammatory bowel disease who do not present signs or symptoms of axial spondylitis. *Clin Exp Rheumatol*. 2014 Aug.32(6):949-52
545. Bruni C, Guiducci S, Bellando-Randone S, Lepri G, Braschi F, Fiori G, Bartoli F, Peruzzi F, Blagojevic J, **Matucci-Cerinic M**. Digital ulcers as a sentinel sign for early internal organ involvement in very early systemic sclerosis. *Rheumatology (Oxford)*. 2014 Jul. 54(1):72-6
546. George J, **Matucci-Cerinic M**, Bar I, Shimoni S Circulating autoantibodies to endothelial progenitor cells: binding characteristics and association with risk factors for atherosclerosis. *PLoS One*. 2014 Jun.9(6):e97836
547. Weisz GM, Albury WR, **Matucci-Cerinic M**, Girolomoni G, Lippi D. Skin disease in the Medici family and the illness of Contessina de' Bardi de' Medici: a dermatological puzzle. *Int J Dermatol*. 2014 Jun.53(6):786-8.
548. van Laar JM, Farge D, Sont JK, Naraghi K, Marjanovic Z, Larghero J, Schuerwegh AJ, Marijt EW, Vonk MC, Schattenberg AV, **Matucci-Cerinic M**, Voskuyl AE, van de Loosdrecht AA, Daikeler T, Kötter I, Schmalzing M, Martin T, Lioure B, Weiner SM, Kreuter A, Deligny C, Durand JM, Emery P, Machold KP, Sarrot-Reynauld F, Warnatz K, Adoue DF, Constans J, Tony HP, Del Papa N, Fassas A, Himsel A, Launay D, Lo Monaco A, Philippe P, Quéré I, Rich É, Westhovens R, Griffiths B, Saccardi R, van den Hoogen FH, Fibbe WE, Socié G, Gratwohl A, Tyndall A; EBMT/EULAR Scleroderma Study Group: Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial. *JAMA* 2014 Jun.311(24):2490-8.

549. Johnson SR, Naden RP, Fransen J, van den Hoogen F, Pope JE, Baron M, Tyndall A, **Matucci-Cerinic M**, Denton CP, Distler O, Gabrielli A, van Laar JM, Mayes M, Steen V, Seibold JR, Clements P, Medsger TA Jr, Carreira PE, Riemekasten G, Chung L, Fessler BJ, Merkel PA, Silver R, Varga J, Allanore Y, Mueller-Ladner U, Vonk MC, Walker UA, Cappelli S, Khanna D. Multicriteria decision analysis methods with 1000Minds for developing systemic sclerosis classification criteria. *J Clin Epidemiol*. 2014 Jun.67(6):706-14.
550. Falcini F, La Torre F, Vittadello F, Rigante D, Martini G, Corona F, Buoncompagni A, Alessio M, Cortis E, Insalaco A, Magni-Manzoni S, Breda L, **Matucci-Cerinic M**, Zulian F: Clinical overview and outcome in a cohort of children with polyarteritis nodosa. *Clin Exp Rheumatol*. 2014 May-Jun. 32(3 Suppl 82):S134-7
551. Maddali Bongi S, Del Rosso A, Mikhaylova S, Francini B, Branchi A, Baccini M, **Matucci-Cerinic M**.:Impact of hand face disabilities on global disability and quality of life in systemic sclerosis patients. *Clin Exp Rheumatol*. 2014 May. 32(6 Suppl 86):S-15-20
552. Galdo F, **Matucci-Cerinic M**.:The search for the perfect animal model discloses the importance of biological targets for the treatment of systemic sclerosis. *Ann Rheum Dis*. 2014 Apr.73(4):635-6.
553. Bruni C, Lepri G, Peruzzi F, Bellando-Randone S, Radicati A, **Matucci-Cerinic M**, Guiducci S.:Anti-oxidant agents help primary Raynaud's phenomenon. *Int Angiol*. 2014 Apr. 34(1):94-5
554. Stagi S, Cavalli L, Signorini C, Bertini F, **Matucci Cerinic M**, Brandi ML, Falcini F: Bone mass and quality in patients with juvenile idiopathic arthritis: longitudinal evaluation of bone-mass determinants by using dual-energy x-ray absorptiometry, peripheral quantitative computed tomography, and quantitative ultrasonography *Arthritis Res Ther* 2014 Mar. 16(2):R83.
555. Maddali-Bongi S, Del Rosso A, Galluccio F, Sigismondi F, **Matucci Cerinic M**.:Is an intervention with a custom-made splint and an educational program useful on pain in patients with trapeziometacarpal joint osteoarthritis in a daily clinical setting? *Int J Rheum Dis* 2014 Mar. 19(8):773-80.
556. Melchiorre D, Morfini M, Linari S, Zignego AL, Innocenti M, **Matucci Cerinic M**.:Anti-TNF- α therapy prevents the recurrence of joint bleeding in haemophilia and arthritis. *Rheumatology (Oxford)* 2014 Mar. 53(3):576-8
557. Manetti M, Rosa I, Messerini L, Guiducci S, **Matucci-Cerinic M**, Ibba-Manneschi L. A loss of telocytes accompanies fibrosis of multiple organs in systemic sclerosis. *J Cell Mol Med*. 2014 Feb.18(2):253-62.
558. Burmester GR, **Matucci-Cerinic M**, Mariette X, Navarro-Blasco F, Kary S, Unnebrink K, Kupper H. Safety and effectiveness of adalimumab in patients with rheumatoid arthritis over 5 years of therapy in a phase 3b and subsequent postmarketing observational study. *Arthritis Res Ther*. 2014 Feb.16(1):R24
559. Lippi D, **Matucci-Cerinic M**, Albury WR, Weisz GM. Inherited knee disorders in the Medici family. *Knee*. 2014 Feb. 21(1):2-5.
560. Fransen J, Pope J, Baron M, Johnson S, Khanna D, **Matucci-Cerinic M**, Tyndall A, van den Hoogen F. Response to 'Are autoantibodies to RNA-polymerase III to be incorporated in routine diagnostic laboratory algorithms for systemic autoimmune rheumatic diseases?' *Ann Rheum Dis*. 2014 Feb.73(5):e30.

561. Müller-Ladner U, Tyndall A, Czirjak L, Denton C, **Matucci-Cerinic M**; EUSTAR centres. Ten years EULAR Scleroderma Research and Trials (EUSTAR): what has been achieved? *Ann Rheum Dis*. 2014 Feb;73(2):324-7
562. Mavarakis E, Patel F, Kronenberg DG, Chung L, Fiorentino D, Allanore Y, Guiducci S, Hesselstrand R, Hummers LK, Duong C, Kahaleh B, Macgregor A, **Matucci-Cerinic M**, Wollheim FA, Mayes MD, Gershwin ME.: International consensus criteria for the diagnosis of Raynaud's phenomenon. *J Autoimmun*. 2014 Jan;48-49:60-5.
563. Romano E, Manetti M, Peruzzi F, Melchiorre D, Milia AF, Bellando-Randone S, Nishioka K, Innocenti M, Carulli C, Linari S, Morfini M, Ibba-Manneschi L, **Matucci-Cerinic M**, Guiducci S.: Agonistic anti-human Fas monoclonal antibody induces fibroblast-like synoviocyte apoptosis in haemophilic arthropathy: potential therapeutic implications. *Haemophilia*. 2014 Jan;20(1):e32-9.
564. Weisz GM, Albury WR, Houang MD, **Matucci-Cerinic M**: Scanogram for sagittal imbalance of the spine: low dose alternative for a safer diagnosis. *Curr Rheumatol Rev*. 2014 10(1):35-7.

2013

565. Grifoni E, Fabbri A, Ciuti G, **Matucci Cerinic M**: A. Hypokalemia-induced rhabdomyolysis. *Moggi Pignone Intern Emerg Med*. 2013;9(4):487-8.
566. Stagi S, Cavalli L, Bertini F, **Matucci Cerinic M**, Luisa Brandi M, Falcini F. Cross-sectional and longitudinal evaluation of bone mass and quality in children and young adults with juvenile onset systemic lupus erythematosus (JSLE): role of bone mass determinants analyzed by DXA, PQCT and QUS. *Lupus*. 2013;23:57-68.
567. Manetti M, Guiducci S, Romano E, Rosa I, Ceccarelli C, Mello T, Milia AF, Conforti ML, Ibba-Manneschi L, **Matucci-Cerinic M**: Differential expression of junctional adhesion molecules in different stages of systemic sclerosis. *Arthritis Rheum*. 2013; 65:247-57
568. Gargani L, Pignone A, Agoston G, Moreo A, Capati E, Badano LP, Doveri M, Bazzichi L, Costantino MF, Pavellini A, Pieri F, Musca F, Muraru D, Epis O, Bruschi E, De Chiara B, Perfetto F, Mori F, Parodi O, Sicari R, Bombardieri S, Varga A, **Matucci Cerinic M**, Bossone E, Picano E. Clinical and echocardiographic correlations of exercise-induced pulmonary hypertension in systemic sclerosis: a multicenter study. *Am Heart J* 2013;165:200-7
569. Manetti M, Guiducci S, Ruffo M, Rosa I, Faussone-Pellegrini MS, **Matucci-Cerinic M**, Ibba-Manneschi L.: Evidence for progressive reduction and loss of telocytes in the dermal cellular network of systemic sclerosis. *J Cell Mol Med*. 2013;17:482-96
570. Masi L, Franceschelli F, Leoncini G, Gozzini A, Rigante D, La Torre F, **Matucci-Cerinic M**, Brandi ML, Falcini F: Can fibroblast growth factor (FGF)-23 circulating levels suggest coronary artery abnormalities in children with Kawasaki disease? *Clin Exp Rheumatol*. 2013;31:149-53.
571. Bandinelli F, Melchiorre D, Scazzariello F, Candelieri A, Conforti D, **Matucci-Cerinic M**.: Clinical and radiological evaluation of sacroiliac joints compared with ultrasound examination in early spondyloarthritis. *Rheumatology (Oxford)* 2013; 52(7):1293-7.
572. Avouac J, Huscher D, Furst DE, Opitz CF, Distler O, Allanore Y; for the EPOSS group. Expert consensus for performing right heart

- catheterisation for suspected pulmonary arterial hypertension in systemic sclerosis: a Delphi consensus study with cluster analysis. *Ann Rheum Dis.* 2013; 73(1):191-7
573. Barskova T, Gargani L, Guiducci S, Randone SB, Bruni C, Carnesecchi G, Conforti ML, Porta F, Pignone A, Caramella D, Picano E, **Matucci Cerinic M**. Lung ultrasound for the screening of interstitial lung disease in very early systemic sclerosis. *Ann Rheum Dis.* 2013; 72:390-5
574. Weisz G, Lippi D, **Matucci Cerinic M**, Albury R: Revealing the "secrets" of the Medici Family- no proofs as yet for hip dysplasia. *Hip Int.* 2013; 23:108-109
575. Pingitore A, Guiducci S, Conforti ML, De Marchi D, Gargani L, Moggi-Pignone A, Randone SB, Lombardi M, Picano E, **Matucci-Cerinic M**.: Early detection of myocardial and pulmonary oedema with MRI in an asymptomatic systemic sclerosis patient: successful recovery with pulse steroid. *Rheumatology (Oxford).* 2013; 52(10):1920-1.
576. Bandinelli F, Bonacci E, **Matucci-Cerinic M**: Ultrasound-integrated tight control in early psoriatic arthritis during adalimumab treatment. *Clin Exp Rheumatol.* 2013;31:440-2
577. Manetti M, Guiducci S, Romano E, Bellando-Randone S, Lepri G, Bruni C, Conforti ML, Ibba-Manneschi L, **Matucci-Cerinic M**.: Increased plasma levels of the VEGF165b splice variant are associated with the severity of nailfold capillary loss in systemic sclerosis. *Ann Rheum Dis.* 2013; 72(8):1425-7.
578. Manara M, Bortoluzzi A, Favero M, Prevete I, Scirè CA, Bianchi G, Borghi C, Cimmino MA, D'Avola GM, Desideri G, Di Giacinto G, Govoni M, Grassi W, Lombardi A, Marangella M, **Matucci Cerinic M**, Medea G, Ramonda R, Spadaro A, Punzi L, Minisola G: Italian Society of Rheumatology recommendations for the management of gout. *Reumatismo.* 2013;65:4-21
579. Terenzi R, Romano E, Manetti M, Peruzzi F, Nacci F, **Matucci-Cerinic M**, Guiducci S: Neuropeptides activate TRPV1 in rheumatoid arthritis fibroblast-like synoviocytes and foster IL-6 and IL-8 production. *Ann Rheum Dis.* 2013;72:1107-9
580. Maddali Bongi S, Del Rosso A, Orlandi M, **Matucci-Cerinic M**: Gynaecological symptoms and sexual disability in women with primary Sjögren's syndrome and sicca syndrome. *Clin Exp Rheumatol.* 2013; 31(5):683-90.
581. Foris V, Kovacs G, **Matucci-Cerinic M**, Olschewski H.: PL-7 positive antisynthetase syndrome and pulmonary hypertension. *J Rheumatol.* 2013;40:1777-9.
582. Scire CA, Manara M, Cimmino MA, Govoni M, Salaffi F, Punzi L, Monti MC, Carrara G, Montecucco C, **Matucci-Cerinic M**, Minisola G; KING Study Collaborators. Gout impacts on function and health-related quality of life beyond associated risk factors and medical conditions: results from the KING observational study of the Italian Society for Rheumatology (SIR). *Arthritis Res Ther.* 2013;15:R101.
583. Camiciottoli G, Diciotti S, Bartolucci M, Orlandi I, Bigazzi F, **Matucci-Cerinic M**, Pistolesi M, Mascalchi M.: Whole-lung volume and density in spirometrically-gated inspiratory and expiratory CT in systemic sclerosis: correlation with static volumes at pulmonary function tests. *Sarcoidosis Vasc Diffuse Lung Dis.* 2013;30:17-27.
584. Cappelli S, Guiducci S, Bellando Randone S, **Matucci Cerinic M**..

- Immunosuppression for interstitial lung disease in systemic sclerosis. *Eur Respir Rev.* 2013; 22:236-43.
585. Maddali Bongi S, Del Rosso A, Mikhaylova S, Baccini M, **Matucci Cerinic M**. Sexual function in Italian women with systemic sclerosis is affected by disease-related and psychological concerns. *J Rheumatol.* 2013;40:1697-705.
586. Del Rosso A, Mikhaylova S, Baccini M, Lupi I, **Matucci Cerinic M**, Maddali Bongi S.: In systemic sclerosis, anxiety and depression assessed by hospital anxiety depression scale are independently associated with disability and psychological factors. *Biomed Res Int.* 2013; 507493.
587. **Matucci-Cerinic M**, Kahaleh B, Wigley FM.: Review: evidence that systemic sclerosis is a vascular disease. *Arthritis Rheum.* 2013;65(8):1953-62.
588. Bagnato G, Bitto A, Pizzino G, Irrera N, Sangari D, Cinquegrani M, Roberts WN, **Matucci Cerinic M**, Squadrito F, Altavilla D, Bagnato G, Saitta A.: Simvastatin attenuates the development of pulmonary and cutaneous fibrosis in a murine model of systemic sclerosis. *Rheumatology (Oxford)* 2013; 52(8):1377-86.
589. Blagojevic J, **Matucci-Cerinic M**. Imaging: Ultrasonography to detect hand and wrist involvement in SSc. *Nat Rev Rheumatol.* 2013;9:700-1.
590. Manara M, Bortoluzzi A, Favero M, Prevete I, Sciré CA, Bagnato G, Bianchi G, Ceruso M, Checchia GA, D'Avola GM, Di Giacinto G, Frediani B, Lombardi A, Mannoni A, Mascheroni G, **Matucci Cerinic M**, Punzi L, Richelmi P, Scarpellini M, Torretta F, Migliore A, Ramonda R, Minisola G.: Italian Society for Rheumatology recommendations for the management of hand osteoarthritis. *Reumatismo.* 2013; 65:167-85.
591. Cappelli S, Bellando-Randone S, Guiducci S, **Matucci-Cerinic M**. Is immunosuppressive therapy the anchor treatment to achieve remission in systemic sclerosis? *Rheumatology (Oxford).* 2013; 53(6):975-87.
592. Bellando Randone S, Guiducci S, Conforti ML, Blagojevic J, Salvadorini G, Fiori G, Bartoli F, Nacci F, Candelieri A, Bruni C, Moggi Pignone A, **Matucci Cerinic M**: Sildenafil and Raynaud phenomenon in systemic sclerosis: results from a retrospective study. *Eur J Musculoskeletal Dis* 2013;2:21-26
593. Koumakis E, Bouaziz M, Dieudé P, Ruiz B, Riemekasten G, Airo P, Müller-Nurasyid M, Cusi D, **Matucci-Cerinic M**, Melchers I, Salvi E, Strauch K, Peters A, Cuomo G, Hachulla E, Diot E, Hunzelmann N, Caramaschi P, Ricciari V, Distler JH, Turner I, Avouac J, Letenneur L, Amouyel P, Lambert JC, Chiochia G, Boileau C, Allanore Y.: Regulatory variant in CCR6 is associated with susceptibility to antitopoisomerase-positive systemic sclerosis. *Arthritis Rheum.* 2013; 65(12):3202-8.
594. Sciré CA, Caporali R, Sarzi-Puttini P, Frediani B, Di Franco M, Tincani A, Sinigaglia L, Sfriso P, Tirri R, Bellis E, Delsante G, Porru G, Salaffi F, Giuggioli D, Rossini M, Todoerti M, Bazzichi L, Govoni M, Gerli R, Raschetti R, Minisola G, Montecucco C, Todesco S: MonitorNet project. Drug survival of the first course of anti-TNF agents in patients with rheumatoid arthritis and seronegative spondyloarthritis: analysis from the MonitorNet database. *Clin Exp Rheumatol.* 2013;3:857-63.
595. Villano M, Borghini A, Manetti M, Gabbriellini E, Rossi A, Sestini P,

- Milia AF, Nacci F, Guiducci S, **Matucci-Cerinic M**, Ibba-Manneschi L, Weber E.: *Systemic sclerosis sera affect fibrillin-1 deposition by dermal blood microvascular endothelial cells: therapeutic implications of cyclophosphamide*. Arthritis Res Ther. 2013;15(4):R90
596. Bandinelli F, Saccardi R, Salvadorini G, Bosi A, Gozzini A, **Matucci Cerinic M**. *Stiff skin syndrome and myeloma successfully treated with autologous haematopoietic stem cell transplantation (HSCT)*. Clin Exp Rheumatol. 2013; 31(2 Suppl 76):181-3.
597. Guillevin L, Hunsche E, Denton CP, Krieg T, Schwierin B, Rosenberg D, **Matucci-Cerinic M**; DUO Registry Group. *Functional impairment of systemic scleroderma patients with digital ulcerations: results from the DUO Registry*. Clin Exp Rheumatol. 2013;31(2 Suppl 76):71-80.
598. Borie R, Crestani B, Dieude P, Nunes H, Allanore Y, Kannengiesser C, Airo P, **Matucci-Cerinic M**, Wallaert B, Israel-Biet D, Cadranel J, Cottin V, Gazal S, Peljto AL, Varga J, Schwartz DA, Valeyre D: Grandchamp B *The MUC5B variant is associated with idiopathic pulmonary fibrosis but not with systemic sclerosis interstitial lung disease in the European Caucasian population*. PLoS One. 2013;8(8):e70621.
599. Minier T, Guiducci S, Bellando-Randone S, Bruni C, Lepri G, Cziráj L, Distler O, Walker UA, Fransen J, Allanore Y, Denton C, Cutolo M, Tyndall A, Müller-Ladner U, **Matucci-Cerinic M**; and the EUSTAR co-workers: *Preliminary analysis of the Very Early Diagnosis of Systemic Sclerosis (VEDOSS) EUSTAR multicentre study: evidence for puffy fingers as a pivotal sign for suspicion of systemic sclerosis*. Ann Rheum Dis. 2013; 73(12):2087-93.
600. Bartalesi F, Bartoloni A, Bisoffi Z, Spinicci M, Giménez Sánchez F, Muñoz J, Richi P, Minisola G, Muñoz-Fernandez S, **Matucci-Cerinic M**: *The emerging problem of biological treatment in migrant and travelling populations: it is time to extend guidelines for the screening of infectious diseases*. Ann Rheum Dis. 2013; 73(5):794-6.
601. Manetti M, Guiducci S, Romano E, Avouac J, Rosa I, Ruiz B, Lepri G, Bellando-Randone S, Ibba-Manneschi L, Allanore Y, **Matucci-Cerinic M**: *Decreased expression of the endothelial cell-derived factor EGFL7 in systemic sclerosis: potential contribution to impaired angiogenesis and vasculogenesis*. Arthritis Res Ther. 2013;25;15:R165.
602. van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, **Matucci-Cerinic M**, Naden RP, Medsger TA Jr, Carreira PE, Riemekasten G, Clements PJ, Denton CP, Distler O, Allanore Y, Furst DE, Gabrielli A, Mayes MD, van Laar JM, Seibold JR, Czirjak L, Steen VD, Inanc M, Kowal-Bielecka O, Müller-Ladner U, Valentini G, Veale DJ, Vonk MC, Walker UA, Chung L, Collier DH, Csuka ME, Fessler BJ, Guiducci S, Herrick A, Hsu VM, Jimenez S, Kahaleh B, Merkel PA, Sierakowski S, Silver RM, Simms RW, Varga J, Pope JE.: *Classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative*. Arthritis Rheum. 2013;65:2737-47.
603. Grifoni E, Fabbri A, Ciuti G, **Matucci Cerinic M**, Moggi Pignone A.: *Hypokalemia-induced rhabdomyolysis*. Intern Emerg Med. 2013; 9(4):487-8.
604. Porta F, Damjanov N, Galluccio F, Iagnocco A, **Matucci-Cerinic M**: *Ultrasound elastography is a reproducible and feasible tool for the evaluation of the patellar tendon in healthy subjects*. Int J Rheum Dis.

2013;17(7):762-6.

605. Porta F, Kaloudi O, Garzitto A, Prignano F, Nacci F, Falcini F, **Matucci Cerinic M.**: High frequency ultrasound can detect improvement of lesions in juvenile localized scleroderma. *Modern Rheumatol.* 2013; 24(5):869-73.
606. Vacca A, Meune C, Gordon J, Chung L, Proudman S, Assassi S, Nikpour M, Rodriguez-Reyna TS, Khanna D, Lafyatis R, **Matucci-Cerinic M**, Distler O, Allanore Y; on behalf of the Scleroderma Clinical Trial Consortium (SCTC): Cardiac Subcommittee. Cardiac arrhythmias and conduction defects in systemic sclerosis. *Rheumatology (Oxford)* 2013; 53(7):1172-7.
607. Falcini F, Rigante D, Masi L, Covino M, Franceschelli F, Leoncini G, Tarantino G, **Matucci Cerinic M**, Brandi ML.: Fibroblast growth factor 23 (FGF23) gene polymorphism in children with Kawasaki syndrome (KS) and susceptibility to cardiac abnormalities. *Ital J Pediatr.* 2013;29;39:69.

2012

608. Carrai V, Miniati I, Guiducci S, Capaccioli G, Alterini R, Saccardi R, Conforti ML, Rigacci L, Rotunno G, Bosi A, **Matucci Cerinic M.**: Evidence for reduced angiogenesis in bone marrow in SSc: immunohistochemistry and multiparametric computerized imaging analysis. *Rheumatology (Oxford)* 2012;51:1042-8.
609. Bandinelli F, Fedi R, Generini S, Porta F, Candelieri A, Mannoni A, Innocenti M, **Matucci Cerinic M.**: Longitudinal osteoarthritis ultrasound and clinical follow-up of Baker's cysts injection with steroids in knee. *Clin Rheumatol.* 2012;31:727-31.
610. Johnson SR, Fransen J, Khanna D, Baron M, van den Hoogen F, Medsger TA Jr, Peschken CA, Carreira PE, Riemekasten G, Tyndall A, **Matucci-Cerinic M**, Pope JE.: Validation of potential classification criteria for systemic sclerosis. *Arthritis Care Res (Hoboken)* 2012;64:358-6.
611. Fransen J, Johnson SR, van den Hoogen F, Baron M, Allanore Y, Carreira PE, Cziráj L, Denton CP, Distler O, Furst DE, Gabrielli A, Herrick A, Inanc M, Kahaleh B, Kowal-Bielecka O, Medsger TA Jr, Mueller-Ladner U, Riemekasten G, Sierakowski S, Valentini G, Veale D, Vonk MC, Walker U, Chung L, Clements PJ, Collier DH, Csuka ME, Jimenez S, Merkel PA, Seibold JR, Silver R, Steen V, Tyndall A, **Matucci-Cerinic M**, Pope JE, Khanna D.: Items for developing revised classification criteria in systemic sclerosis: Results of a consensus exercise. *Arthritis Care Res (Hoboken)* 2012;64:351-7
612. Kivity S, Gilburd B, Agmon-Levin N, Carrasco MG, Tzafrir Y, Sofer Y, Mandel M, Buttner T, Roggenbuck D, **Matucci-Cerinic M**, Danko K, Hoyos ML, Shoenfeld Y: Novel automated indirect immunofluorescence autoantibody evaluation. *Clin Rheumatol.* 2012;31:503-9.
613. Shapira Y, Agmon-Levin N, Selmi C, Petříková J, Barzilai O, Ram M, Bizzaro N, Valentini G, **Matucci-Cerinic M**, Anaya JM, Katz BS, Shoenfeld Y: Prevalence of anti-toxoplasma antibodies in patients with autoimmune diseases. *J Autoimmun.* 2012; 39(1-2):112-6.
614. Weisz GM, **Matucci-Cerinic M**, Albury WR, Lippi D: The illnesses of Carlo di Ferdinando I de' Medici: a second opinion. *Clin Exp Rheumatol.* 2012;30:6-11
615. Manetti M, Guiducci S, Romano E, Bellando-Randone S, Conforti

- ML, Ibba-Manneschi L, **Matucci-Cerinic M**: Increased serum levels and tissue expression of matrix metalloproteinase-12 in patients with systemic sclerosis: correlation with severity of skin and pulmonary fibrosis and vascular damage. *Ann Rheum Dis*. 2012;71:1064-72.
616. Denton CP, Krieg T, Guillemin L, Schwierin B, Rosenberg D, Silkey M, Zultak M, **Matucci-Cerinic M**: Demographic, clinical and antibody characteristics of patients with digital ulcers in systemic sclerosis: data from the DUO Registry. *Ann Rheum Dis*. 2012;71:718-21.
617. Lakota K, Thallinger GG, Sodin-Semrl S, Rozman B, Ambrozic A, Tomsic M, Praprotnik S, Cucnik S, Mrak-Poljsak K, Ceribelli A, Cavazzana I, Franceschini F, Vencovsky J, Czirjak L, Varju C, Steiner G, Aringer M, Stamenkovic B, Distler O, **Matucci-Cerinic M**, Kveder T: International cohort study of 73 anti-Ku positive patients: association of p70/p80 anti-Ku antibodies with joint/bone features and differentiation of disease populations using principle component analysis. *Arthritis Res Ther*. 2012;14:R2.
618. Cappelli S, Bellando Randone S, Martinović D, Tamas MM, Pasalić K, Allanore Y, Mosca M, Talarico R, Opris D, Kiss CG, Tausche AK, Cardarelli S, Riccieri V, Koneva O, Cuomo G, Becker MO, Sulli A, Guiducci S, Radić M, Bombardieri S, Aringer M, Cozzi F, Valesini G, Ananyeva L, Valentini G, Riemekasten G, Cutolo M, Ionescu R, Czirjak L, Damjanov N, Rednic S, **Matucci Cerinic M**: "To Be or Not To Be," Ten Years After: Evidence for Mixed Connective Tissue Disease as a Distinct Entity. *Semin Arthritis Rheum*. 2012;4:589-98.
619. Manetti M, Allanore Y, Saad M, Fatini C, Cohignac V, Guiducci S, Romano E, Airó P, Caramaschi P, Tinazzi I, Riccieri V, Rossa AD, Abbate R, Caporali R, Cuomo G, Valesini G, Dieudé P, Hachulla E, Cracowski JL, Tiev K, Letenneur L, Amouyel P, Lambert JC, Chiocchia G, Martinez M, Ibba-Manneschi L, **Matucci-Cerinic M**: Evidence for caveolin-1 as a new susceptibility gene regulating tissue fibrosis in systemic sclerosis. *Ann Rheum Dis*. 2012;71:1034-41.
620. Koumakis E, Giraud M, Dieudé P, Cohignac V, Cuomo G, Airo P, Hachulla E, **Matucci Cerinic M**, Diot E, Caramaschi P, Mouthon L, Riccieri V, Cracowski JL, Tiev KP, Frances C, Amoura Z, Sibilia J, Cosnes A, Carpentier P, Valentini G, Manetti M, Guiducci S, Meyer O, Kahan A, Boileau C, Chiocchia G, Allanore Y: Candidate gene study in systemic sclerosis identifies a rare and functional variant of TNFAIP3 locus as a risk factor for individual polyautoimmunity. *Arthritis Rheum*. 2012;64:2746-52.
621. Melchiorre D, Milia AF, Linari S, Romano E, Benelli G, Manetti M, Guiducci S, Ceccarelli C, Innocenti M, Carulli C, Civinini R, Morfini M, **Matucci-Cerinic M**, Ibba-Manneschi L: RANK-RANKL-OPG in Hemophilic Arthropathy from Clinical and Imaging Diagnosis to Histopathology. *J Rheumatol*. 2012;39(8):1678-86.
622. Foeldvari I, Tyndall A, Zulian F, Müller-Ladner U, Czirjak L, Denton C, Kowal-Bielecka O, Bancel DF, **Matucci-Cerinic M**: Juvenile and young adult-onset systemic sclerosis share the same organ involvement in adulthood: data from the EUSTAR database. *Rheumatology (Oxford)*. 2012. 51(10):1832-7.
623. Tubach F, Ravaud P, Martin-Mola E, Awada H, Bellamy N, Bombardier C, Felson D, Hassouni N, Hochberg M, Logeart I, **Matucci-Cerinic M**, van de Laar M, van der Heijde D, Dougados M: Minimal clinically important improvement and patient acceptable

- symptomatic state in pain and function in rheumatoid arthritis, ankylosing spondylitis, chronic back pain, hand osteoarthritis, and hip and knee osteoarthritis: The reflect multinational study. *Arthritis Care Res (Hoboken)*. 2012;64:1699-707.
- 624.Coaccioli S, Varrassi G, Marinangeli F, Aurilio C, Finco G, Gatti A, Geppetti P, **Matucci-Cerinic M**, Polati E, Sabato: An ethics code for pain. *AF. Eur J Pain*. 2012
- 625.Salvadorini G, Bandinelli F, Delle Sedie A, Riente L, Candelieri A, Generini S, Possemato N, Bombardieri S, **Matucci-Cerinic M**. Ankylosing spondylitis: how diagnostic and therapeutic delay have changed over the last six decades. *Clin Exp Rheumatol*. 2012; 30(4):561-5.
- 626.Maddali Bongi S, **Matucci Cerinic M**: Rheumatologic rehabilitation: the great expectation for rheumatic patients. *Reumatismo*. 2012;64:1-6.
- 627.Weisz GM, Albury WR, Lippi D, Matucci-Cerinic M: Right or left hand: is this the real problem of Pontormo's Halberdier. *Rheumatol Int*. 2012; 33(8):2177-8.
- 628.Bandinelli F, Del Rosso A, Gabrielli A, Giacomelli R, Bartoli F, Guiducci S, **Matucci Cerinic M**.:CCL2, CCL3 and CCL5 chemokines in systemic sclerosis: the correlation with SSc clinical features and the effect of prostaglandin E1 treatment. *Clin Exp Rheumatol*. 2012;30(2 Suppl 71):S44-9.
- 629.Sfriso P, Cozzi F, Oliviero F, Caso F, Cardarelli S, Facco M, Fittà C, Del Rosso A, **Matucci-Cerinic M**, Punzi L, Agostini C.:CXCL11 in bronchoalveolar lavage fluid and pulmonary function decline in systemic sclerosis. *Clin Exp Rheumatol*. 2012;30(2 Suppl 71):S71-5.
- 630.Koumakis E, Wipff J, Dieudé P, Ruiz B, Bouaziz M, Revillod L, Guedj M, Distler JH, **Matucci-Cerinic M**, Humbert M, Riemekasten G, Airo P, Melchers I, Hachulla E, Cusi D, Wichmann HE, Hunzelmann N, Tiev K, Caramaschi P, Diot E, Kowal-Bielecka O, Cuomo G, Walker U, Cziráj L, Damjanov N, Lupoli S, Conti C, Müller-Nurasyid M, Müller-Ladner U, Riccieri V, Cracowski JL, Cozzi F, Bournia VK, Vlachoyiannopoulos P, Chiocchia G, Boileau C, Allanore Y.:TGFβ receptor gene variants in systemic sclerosis-related pulmonary arterial hypertension: results from a multicentre EUSTAR study of European Caucasian patients. *Ann Rheum Dis*.2012;71:1900-3.
- 631.Rubin LJ, Simonneau G, Badesch D, Galiè N, Humbert M, Keogh A, Massaro J, **Matucci Cerinic M**, Sitbon O, Kymes S.: The study of risk in pulmonary arterial hypertension. *Eur Respir Rev*. 2012;21:234-23.
- 632.Bellando-Randone S, Guiducci S, **Matucci-Cerinic M**.:Very early diagnosis of systemic sclerosis. *Pol Arch Med Wewn*. 2012;122 Suppl 1:18-23.
- 633.Porta F, Gargani L, Kaloudi O, Schmidt WA, Picano E, Damjanov N, **Matucci-Cerinic M**.: The new frontiers of ultrasound in the complex world of vasculitides and scleroderma. *Rheumatology (Oxford)* 2012;51 Suppl 7:vii26-vii30.
- 634.Bandinelli F, Prignano F, Bonciani D, Bartoli F, Collaku L, Candelieri A, Lotti T, **Matucci Cerinic M**.:Ultrasound detects occult enthesal involvement in early psoriatic arthritis independently of clinical features and psoriasis severity. *Clin Exp Rheumatol*. 2012; 31(2):219-24.
- 635.**Matucci-Cerinic M**, Bellando-Randone S, Lepri G, Bruni C, Guiducci

- S.:Very early versus early disease: the evolving definition of the 'many faces' of systemic sclerosis. *Ann Rheum Dis.* 2012; 72(3):319-21.
636. Bartalesi F, Goletti D, Spinicci M, Cavallo A, Attala L, Mencarini J, Fiori G, Li Gobbi F, Mantella A, Benucci M, Prignano F, Pimpinelli N, **Matucci Cerinic M**, Girardi E, Bartoloni A.: Serial QuantiFERON TB-Gold in-tube testing during LTBI therapy in candidates for TNFi treatment. *J Infect.* 2012; S0163-4453(12)00303-9.
637. Guiducci S, Bellando Randone S, Bruni C, Carnesecchi G, Maresta A, Iannone F, Lapadula G, **Matucci Cerinic M.**: Bosentan fosters microvascular de-remodelling in systemic sclerosis. *Clin Rheumatol.* 2012;31:1723-5.
638. Elhai M, Meunier M, **Matucci-Cerinic M**, Maurer B, Riemekasten G, Leturcq T, Pellerito R, Von Mühlen CA, Vacca A, Airo P, Bartoli F, Fiori G, Bokarewa M, Riccieri V, Becker M, Avouac J, Müller-Ladner U, Distler O, Allanore Y: on behalf of EUSTAR (EULAR Scleroderma Trials and Research group): Outcomes of patients with systemic sclerosis-associated polyarthritis and myopathy treated with tocilizumab or abatacept: a EUSTAR observational study. *Ann Rheum Dis.* 2012; 72(7):1217-20.
639. Bandinelli F, Prignano F, Bonciani D, Pallanti S, Lotti T, Salaffi F, Bartoli F, Candelieri A, Giovannini L, Maddali Bongi S, **Matucci-Cerinic M.**: Clinical and demographic factors influence on anxiety and depression in early psoriatic arthritis (ePsA). *Clin Exp Rheumatol.* 2012; 31(2):318-9.

2011

640. Felson D, Smolen J, Wells G, Zhang B, van Tuyl LHD, Funovits J, Aletaha D, Allaart R, Bathon J, Bombardieri S, Brooks P, Brown A, **Matucci Cerinic M**, Choi H, Combe B, de Wit M, Dougados M, Emery P, Furst D, Gomez-Reino J, Hawker G, Keystone E, Khanna D, Kirwan J, Kvien T, Landewé R, Listing J, Michaud K, Martin Mola E, Montie P, Pincus T, Richards P, Siegel J, Simon L, Sokka T, Strand V, Tugwell P, Tyndall A, van der Heijde D, Verstappen S, White B, Wolfe F, Zink A, Boers M: *American College of Rheumatology/European League against Rheumatism Preliminary Definition of Remission in Rheumatoid Arthritis for Clinical Trials* *Rheum* 2011;63:573-86.
641. Smolen JS, Boers M, Abadie E, Breedveld F, Emery P, Bardin, Ethgen J, Avouac BP, Dere W, Patrick Durez, **Matucci-Cerinic M**, Flamion B, Laslop A: Recommendations for an update of 2003 European regulatory requirements for registration of drugs to be used in the treatment of RA *Curr Med Res Op.* 2011;27: 315–325
642. Punzi L, **Matucci Cerinic M**, Cantini F, Bagnato G, Fiocco U, Ferri C, Bombardieri S: Treatment Patterns of Anti-TNF Agents in Italy: an observational study. *Reumatismo.* 2011;63:18-28.
643. Manetti M, Guiducci S, **Matucci-Cerinic M**: *The origin of the myofibroblast in fibroproliferative vasculopathy: Does the endothelial cell steer the pathophysiology of systemic sclerosis?* *Arthritis Rheum.* 2011; 63(8):2164-7.
644. Weisz GM, Albury WR, Lippi D, **Matucci-Cerinic M**: *Who was Pontormo's Halberdier? The evidence from pathology.* *Rheumatol Int.* 2011; 32(7):1915-20.
645. Wipff J, Coriat R, Masciocchi M, Caramaschi P, Derk CT, Hachulla E, Riccieri V, Mouthon L, Krasowska D, Ananieva LP, Kahan A,

- Matucci-Cerinic M**, Chaussade S, Allanore Y: Outcomes of Barrett's esophagus related to systemic sclerosis: a 3-year EULAR/EUSTAR prospective follow-up study. *Rheumatology* 2011; 50(8):1440-4.
646. Guiducci S, Ricci L, Romano E, Ceccarelli C, Distler JH, Miniati I, Calabri GB, Distler O, **Matucci Cerinic M**, Falcini F.: *Microparticles and Kawasaki disease: a marker of vascular damage?* *Clin Exp Rheumatol.* 2011;29(1 Suppl 64):S121-5.
647. Moots RJ, Haraoui B, **Matucci-Cerinic M**, van Riel PL, Kekow J, Schaeffer T, Davis A, Tedeschi MA, Freundlich B, Chang DJ, Singh A.: *Differences in biologic dose-escalation, non-biologic and steroid intensification among three anti-TNF agents: evidence from clinical practice.* *Clin Exp Rheumatol.* 2011;29:26-34.
648. Arnson Y, Amital H, Agmon-Levin N, Alon D, Sánchez-Castañón M, López-Hoyos M, **Matucci-Cerinic M**, Szücs G, Shapira Y, Szekanecz Z, Shoenfeld Y. *Serum 25-OH vitamin D concentrations are linked with various clinical aspects in patients with systemic sclerosis: A retrospective cohort study and review of the literature.* *Autoimmun Rev.* 2011;0(8):490-4.
649. Weisz GM, **Matucci-Cerinic M**, Lippi D, Albury WR.: *The ossification diathesis in the Medici family: DISH and other features.* *Rheumatol Int.* 2011;31(12):1649-52.
650. Dieudé P, Guedj M, Truchetet ME, Wipff J, Revillod L, Riemekasten G, **Matucci-Cerinic M**, Melchers I, Hachulla E, Airo P, Diot E, Hunzelmann N, Mouthon L, Cabane J, Cracowski JL, Riccieri V, Distler J, Amoura Z, Valentini G, Camaraschi P, Tarner I, Frances C, Carpentier P, Brembilla NC, Meyer O, Kahan A, Chizzolini C, Boileau C, Allanore Y: *Association of the CD226 Ser(307) variant with systemic sclerosis: evidence of a contribution of costimulation pathways in systemic sclerosis pathogenesis.* *Arthritis Rheum.* 2011;63:1097-105.
651. Gossec L, Paternotte S, Aanerud GJ, Balanescu A, Boumpas DT, Carmona L, de Wit M, Dijkmans BA, Dougados M, Englbrecht M, Gogus F, Heiberg T, Hernandez C, Kirwan JR, Mola EM, **Matucci Cerinic M**, Otsa K, Schett G, Scholte-Voshaar M, Sokka T, von Krause G, Wells GA, Kvien TK: *Finalisation and validation of the rheumatoid arthritis impact of disease score, a patient-derived composite measure of impact of rheumatoid arthritis: a EULAR initiative* *Ann Rheum Dis.* 2011;70:935-42.
652. Maddali Bongi S, Del Rosso A, Passalacqua M, Miccio S, **Matucci Cerinic M**: *Manual lymph drainage improves upper limb oedema and hand function in patients with systemic sclerosis in oedematous phase.* *Arthritis Care Res* 2011;63(8):1134-41.
653. Bandinelli F, Milla M, Genise S, Giovannini L, Bagnoli S, Candelieri A, Collaku L, Biagini S, **Matucci Cerinic M**: *Ultrasound discloses enthesal involvement in inactive and low active inflammatory bowel disease without clinical signs and symptoms of spondyloarthropathy* *Rheumatology (Oxford).* 2011;50:1275-9.
654. Dieudé P, Guedj M, Wipff J, Ruiz B, Riemekasten G, Airo P, Melchers I, Hachulla E, **Matucci Cerinic M**, Diot E, Hunzelmann N, Camaraschi P, Sibilia J, Tiev K, Mouthon L, Riccieri V, Cracowski JL, Carpentier PH, Distler J, Amoura Z, Tarner I, Avouac J, Meyer O, Kahan A, Boileau C, Allanore Y.: *NLRP1 influences the systemic sclerosis phenotype: a new clue for the contribution of innate immunity in systemic sclerosis-related fibrosing alveolitis*

- pathogenesis* Ann Rheum Dis. 2011;70:668-74.
655. Meune C, Avouac J, Airò P, Beretta L, Dieude P, Wahbi K, Caramaschi P, Tiev K, Cappelli S, Diot E, Vacca A, Cracowski JL, Sibilia J, Kahan A, **Matucci-Cerinic M**, Allanore Y; *Prediction of pulmonary hypertension related to systemic sclerosis by an index based on simple clinical observations*. Arthritis Rheum. 2011; 63(9):2790-6.
 656. Maddali Bongi S, Del Rosso A, Passalacqua M, Miccio S, **Matucci-Cerinic M**: *Manual Lymph drainage improve upper limb edema and hand function in patients with systemic sclerosis in oedematous phase*. Arthritis Care Res 2011;63:1134-41.
 657. Bernardo P, Conforti ML, Bellando-Randone S, Pieragnoli P, Blagojevic J, Kaloudi O, Guiducci S, Porta F, Padeletti L, Gensini GF, **Matucci-Cerinic M**: *Implantable cardioverter defibrillator may prevent malignant ventricular arrhythmias and sudden death in systemic sclerosis*. J Rheumatol 2011;38:1617.
 658. Guiducci S, Manetti M, **Matucci Cerinic M**: *Autologous Mesenchymal Stem Cells Foster Revascularization of Ischemic Limbs in Systemic Sclerosis* Ann Int Med 2011.
 659. Beyer C, Distler JH, Allanore Y, Aringer M, Avouac J, Czirják L, Cutolo M, Damjanov N, Del Galdo F, Fligelstone K, Guiducci S, Kowal-Bielecka O, van Laar JM, **Matucci-Cerinic M**, Müller-Ladner U, Riemekasten G, Tarner IH, Tyndall A, Kennedy AT, Valentini G, Vettori S, Walker UA, Denton C, Distler O; *EUSTAR Biobanking Group. EUSTAR biobanking: recommendations for the collection, storage and distribution of biospecimens in scleroderma research*. Ann Rheum Dis. 2011;155:68.
 660. Denton CP, Avouac J, Behrens F, Furst DE, Foeldvari I, Humbert M, Huscher D, Kowal-Bielecka O, **Matucci-Cerinic M**, Nash P, Opitz CF, Pittrow D, Rubin LJ, Seibold JR, Distler O: *Systemic sclerosis-associated pulmonary hypertension: why disease-specific composite endpoints are needed*. Arthritis Res Ther. 2011; 13(3):114.
 661. Allanore Y, Saad M, Dieudé P, Avouac J, Distler JH, Amouyel P, **Matucci-Cerinic M**, Riemekasten G, Airo P, Melchers I, Hachulla E, Cusi D, Wichmann HE, Wipff J, Lambert JC, Hunzelmann N, Tiev K, Caramaschi P, Diot E, Kowal-Bielecka O, Valentini G, Mouthon L, Czirják L, Damjanov N, Salvi E, Conti C, Müller M, Müller-Ladner U, Riccieri V, Ruiz B, Cracowski JL, Letenneur L, Dupuy AM, Meyer O, Kahan A, Munnich A, Boileau C, Martinez M.: *Genome-Wide Scan Identifies TNIP1, PSORS1C1, and RHOB as Novel Risk Loci for Systemic Sclerosis*. PLoS Genet. 2011;7:e1002091
 662. Manetti M, Guiducci S, Romano E, Ceccarelli C, Bellando-Randone S, Conforti ML, Ibba-Manneschi L, **Matucci-Cerinic M**: *Overexpression of VEGF165b, an Inhibitory Splice Variant of Vascular Endothelial Growth Factor, Leads to Insufficient Angiogenesis in Patients With Systemic Sclerosis*. Circ Res. 2011;109:e14-26
 663. Manetti M, Guiducci S, Ceccarelli C, Romano E, Bellando-Randone S, Conforti ML, Ibba-Manneschi L, **Matucci-Cerinic M**. *Increased circulating levels of interleukin 33 in systemic sclerosis correlate with early disease stage and microvascular involvement*. Ann Rheum Dis. 2011;70:1876-8.
 664. Weisz GM, Albury WM, Lippi D, **Matucci Cerinic M**: *The Gouty Joseph in Giulio Romano's Holy Family* Intl J Rheum Dis 2011;14: e30.

665. Fransen J, Popa-Diaconu D, Hesselstrand R, Carreira P, Valentini G, Beretta L, Airo P, Inanc M, Ullman S, Balbir-Gurman A, Sierakowski S, Allanore Y, Czirjak L, Riccieri V, Giacomelli R, Gabrielli A, Riemekasten G, **Matucci-Cerinic M**, Farge D, Hunzelmann N, Van den Hoogen FH, Vonk MC: *Clinical prediction of 5-year survival in systemic sclerosis: validation of a simple prognostic model in EUSTAR centres*. Ann Rheum Dis. 2011; 70(10):1788-92.
666. Maddali Bongi SM, Di Felice C, Del Rosso A, Landi G, Maresca M, Giambalvo Dal Ben G, **Matucci-Cerinic M**: *Efficacy of the 'body movement and perception' method in the treatment of fibromyalgia syndrome: an open pilot study*. Clin Exp Rheumatol. 2011 ;29(6 Suppl 69):S12-8.
667. Romano E, Manetti M, Guiducci S, Ceccarelli C, Allanore Y, **Matucci-Cerinic M**: *The genetics of systemic sclerosis: an update*. Clin Exp Rheumatol. 2011;29(2 Suppl 65):S75-86.
668. Distler JH, Jordan S, Airo P, Alegre-Sancho JJ, Allanore Y, Balbir Gurman A, Caporali R, Caramaschi P, Carreira PE, Chizzolini C, Cutolo M, Tuncay Duruöz M, Farge-Bancel D, Hesselstrand R, Iannone F, De Keyser F, Kucharz EJ, Launay D, García de la Peña Lefebvre P, Lukacova O, Marasini B, Martinovic D, Marques Neto JF, Radic M, Rednic S, Riemekasten G, Rovinsky J, Seidel MF, Senel S, Smith V, Sunderkötter C, Ton E, van Laar JM, **Matucci-Cerinic M**, Müller-Ladner U, Distler O; *Is there a role for TNF α antagonists in the treatment of SSc? EUSTAR expert consensus development using the Delphi technique*. Clin Exp Rheumatol. 2011;29(2 Suppl 65):S40-5.
669. Gargani L, Picano E, **Matucci Cerinic M**: *Lung Ultrasound in Systemic Sclerosis—Will Comets Guide Us in the Diagnosis and Follow-up of Pulmonary Fibrosis?* US Radiology, 2011;2011;3:44–7.
670. Kowal-Bielecka O, Avouac J, Pittrow D, Huscher D, Behrens F, Denton CP, Foeldvari I, Humber M, **Matucci-Cerinic M**, Nash P, Opitz CF, Rubin LJ, Seibold JR, Strand V, Furst DE, Distler O, for the EPOSS group: *Analysis of the validation status of the quality of life and functional disability measures in scleroderma-related pulmonary arterial hypertension Results of a systematic literature analysis by the EPOSS (Expert Panel on Outcomes Measures in PAH related to Systemic Sclerosis) group*. J Rheumatol 2011;38(11):2419-27.
671. Livi R, Guiducci S, Perfetto F, Ciuti G, Grifoni E, Conforti L, Galluccio F, Moggi Pignone A, **Matucci Cerinic M**. *Lack of activation of renal functional reserve predicts the risk of significant renal involvement in systemic sclerosis*. Ann Rheum Dis. 2011;70(11):1963-7.
672. Mariette X, **Matucci-Cerinic M**, Pavelka K, Taylor P, van Vollenhoven R, Heatley R, Walsh C, Lawson R, Reynolds A, Emery P. *Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis*. Ann Rheum Dis 2011;70:1895-904.
673. Maddali Bongi S, Del Rosso A, Miniati I, Galluccio F, Landi G, Tai G, **Matucci-Cerinic M**. *The Italian version of the Mouth Handicap in Systemic Sclerosis scale (MHISS) is valid, reliable and useful in assessing oral health-related quality of life (OHRQoL) in systemic sclerosis patients*. Rheumatol Int 2011;;32(9):2785-90.
674. Guiducci S, Manetti M, Romano E, Mazzanti B, Ceccarelli C, Dal Pozzo S, Milia AF, Bellando-Randone S, Fiori G, Conforti ML, Saccardi R, Ibba-Manneschi L, **Matucci-Cerinic M**: *Bone marrow-*

derived mesenchymal stem cells from early diffuse systemic sclerosis exhibit a paracrine machinery and stimulate angiogenesis in vitro. Ann Rheum Dis 2011;70:2011:16-21.

675. Avouac J, Fransen J, Walker UA, Riccieri V, Smith V, Muller C, Miniati I, Tarner IH, Randone SB, Cutolo M, Allanore Y, Distler O, Valentini G, Czirjak L, Müller-Ladner U, Furst DE, Tyndall A, **Matucci-Cerinic M**: *EUSTAR Group Preliminary criteria for the very early diagnosis of systemic sclerosis: results of a Delphi Consensus Study from EULAR Scleroderma Trials and Research Group.* Ann Rheum Dis;70:476-81.
676. Dieudé P, Bouaziz M, Guedj M, Riemekasten G, Airo P, Müller M, Cusi D, **Matucci Cerinic M**, Melchers I, Koenig W, Salvi E, Wichmann H, Cuomo G, Hachulla E, Diot E, Hunzelmann N, Caramaschi P, Mouthon L, Riccieri V, Distler J, Tarner I, Avouac J, Meyer O, Kahan A, Chiocchia G, Boileau C, Allanore Y: *Evidence for the contribution of the X chromosome to Systemic Sclerosis susceptibility: Association with the functional IRAK1 196Phe/532Ser haplotype.* Arthritis Rheum. 2011.63:3979-87.
677. Fransen J, Johnson SR, van den Hoogen F, Baron M, Allanore Y, Carreira PE, Czirják L, Denton CP, Distler O, Furst DE, Gabrielli A, Herrick A, Inanc M, Kahaleh B, Kowal-Bielecka O, Medsger TA Jr, Mueller-Ladner U, Riemekasten G, Sierakowski S, Valentini G, Veale D, Vonk MC, Walker U, Chung L, Clements PJ, Collier DH, Csuka ME, Jimenez S, Merkel PA, Seibold JR, Silver R, Steen V, Tyndall A, **Matucci-Cerinic M**, Pope JE, Khanna D: *Items for developing revised classification criteria in systemic sclerosis: Results of a consensus exercise with the ACR/EULAR working committee for classification criteria in systemic sclerosis.* Arthritis Care Res 2011;64(3):351-7.
678. Kowal-Bielecka O, Avouac J, Pittrow D, Huscher D, Behrens F, Denton CP, Foeldvari I, Humbert M, **Matucci-Cerinic M**, Nash P, Opitz CF, Rubin LJ, Seibold JR, Strand V, Furst DE, Distler O; for the *Expert Panel on Outcomes Measures in Pulmonary Arterial Hypertension Related to Systemic Sclerosis. Analysis of the Validation Status of Quality of Life and Functional Disability Measures in Pulmonary Arterial Hypertension Related to Systemic Sclerosis: Results of a Systematic Literature Analysis by the Expert Panel on Outcomes Measures in Pulmonary Arterial Hypertension Related to Systemic Sclerosis (EPOSS).* J Rheumatol. 2011;38:2419-2427.
679. Todoerti M, Pipitone N, **Matucci-Cerinic M**, Montecucco C, Caporali R: *Recommendations for the use of biologic therapy from the Italian Society for Rheumatology: off-label use.* Clin Exp Rheumatol. 2011;29(3 Suppl 66):S42-62.
680. Salvarani C, Pipitone N, Marchesoni A, Cantini F, Cauli A, Lubrano E, Punzi L, Scarpa R, Spadaro A, **Matucci-Cerinic M**, Olivieri I: *Recommendations for the use of biologic therapy in the treatment of psoriatic arthritis: update from the Italian Society for Rheumatology.* Clin Exp Rheumatol. 2011;29(3 Suppl 66):S28-41.
681. Favalli EG, Caporali R, Sinigaglia L, Pipitone N, Miniati I, Montecucco C, **Matucci-Cerinic M**: *Recommendations for the use of biologic therapy in rheumatoid arthritis: update from the Italian Society for Rheumatology II. Safety.* Clin Exp Rheumatol. 2011;29(3 Suppl 66):S15-27.
682. Conti F, Alivernini S, Atzeni F, Serio B, Cutolo M, Valesini G, Ferraccioli G, Sarzi-Puttini P, Salvarani C, Guiducci S, Zampogna G, Gremese E, Pipitone N, Scrivo R, Bugatti S, Montecucco C, **Matucci-**

Cerinic M:*Recommendations for the use of biologic therapy in rheumatoid arthritis: update from the Italian Society for Rheumatology I. Efficacy.*Clin Exp Rheumatol. 2011;29(3 Suppl 66):S7-14.

683. Montecucco C, Caporali R, **Matucci-Cerinic M:** *Updating the Italian Society for Rheumatology recommendations for biologic therapy in adult patients with inflammatory rheumatic diseases.* Clin Exp Rheumatol. 2011;29(3 Suppl 66):S3-6.
684. Nacci F, **Matucci-Cerinic M.:***Tuberculosis and other infections in the anti-tumour necrosis factor-alpha (anti-TNF- α) era. Best Pract Res. Clin Rheumatol.* 2011;25:375-88.
685. Taraborelli M, Ramoni V, Brucato A, Airò P, Bajocchi G, Bellisai F, Biasi D, Blagojevic J, Canti V, Caporali R, Caramaschi P, Chiarolanza I, Codullo V, Cozzi F, Cuomo G, Cutolo M, De Santis M, De Vita S, Di Poi E, Doria A, Faggioli P, Favaro M, Ferraccioli G, Ferri C, Foti R, Gerosa A, Gerosa M, Giacuzzo S, Giani L, Giuggioli D, Imazio M, Iudici M, Iuliano A, Leonardi R, Limonta M, Lojacono A, Lubatti C, **Matucci Cerinic M,** Mazzone A, Meroni M, Meroni PL, Mosca M, Motta M, Muscarà M, Nava S, Padovan M, Pagni G, Paolazzi G, Peccatori S, Ravagnani V, Riccieri V, Rosato E, Rovere-Querini P, Salsano F, Santaniello A, Scorza R, Tani C, Valentini G, Valesini G, Vanoli M, Vigone B, Zeni S, Tincani A; *on behalf of the IMPRESS investigators: Successful pregnancies but a higher risk of preterm births in systemic sclerosis: An Italian multicentric study.* Arthritis Rheum. 2011; 64(6):1970-7.
686. Maddali Bongi S, Del Rosso A, Passalacqua M, Miccio S, **Matucci Cerinic M.:** *Manual lymph drainage improving upper extremity edema and hand function in patients with systemic sclerosis in edematous phase.* Arthritis Care Res (Hoboken). 2011;63:1134-41.
687. Manetti M, Guiducci S, Ibba-Manneschi L, **Matucci-Cerinic M:** *Impaired Angiogenesis in Systemic Sclerosis: The Emerging Role of the Antiangiogenic VEGF165b Splice Variant.* Trends in Cardiovascular Medicine 2011;21:204-210
688. Bandinelli F, Milla M, Genise S, Giovannini L, Bagnoli S, Candelieri A, Collaku L, Biagini S, **Matucci Cerinic M.:***Ultrasound discloses enthesal involvement in inactive and low active inflammatory bowel disease without clinical signs and symptoms of spondyloarthropathy.*Rheumatology (Oxford). 2011;50:1275-9.
689. Manetti M, Guiducci S, Ibba-Manneschi L, **Matucci-Cerinic M.:** *Impaired Angiogenesis in Systemic Sclerosis: The Emerging Role of the Antiangiogenic VEGF(165)b Splice Variant.* Trends Cardiovasc Med.2011;21:204-10.

2010

690. Manetti M, Milia AF, Benelli G, Messerini L, **Matucci-Cerinic M,** Ibba-Manneschi L:*The gastric wall in systemic sclerosis patients: a morphological study.* Ital J Anat Embryol. 2010;115:115-21.
691. Kowal-Bielecka O, Avouac J, Pittrow D, Huscher D, Behrens F, Denton CP, Foeldvari I, Humbert M, **Matucci-Cerinic M,** Nash P, Opitz CF, Rubin LJ, Seibold JR, Strand V, Furst DE, Distler O; *EPOSS Group Echocardiography as an outcome measure in scleroderma-related pulmonary arterial hypertension: a systematic literature analysis by the EPOSS group.* J Rheumatol. 2010;37:105-15.
692. Riccieri V, Alessandri C, Germano V, Guiducci S, Rogai V, Colasanti

- T, Delunardo F, Margutti P, Ortona E, **Matucci Cerinic M**, Valesini G.: *Nedd5, a novel autoantigen in systemic sclerosis: is it a marker of more severe disease?* Ann Rheum Dis. 2010;69:314-5.
693. Allanore Y, Meune C, Vonk MC, Airo P, Hachulla E, Caramaschi P, Riemekasten G, Cozzi F, Beretta L, Derk CT, Komócsi A, Farge D, Balbir A, Riccieri V, Distler O, Chialà A, Papa ND, Simic KP, Ghio M, Stamenkovic B, Rednic S, Host N, Pellerito R, Zegers E, Kahan A, Walker UA, **Matucci-Cerinic M** &EUSTAR co-authors: *Prevalence and factors associated with left ventricular dysfunction in the EULAR Scleroderma Trial and Research group (EUSTAR) database of patients with systemic sclerosis.* Ann Rheum Dis. 2010;69:218-21.
694. Avouac J, Airò P, Dieude P, Caramaschi P, Tiev K, Diot E, Sibilia J, Cappelli S, Granel B, Vacca A, Wipff J, Meyer O, Kahan A, **Matucci-Cerinic M**, Allanore Y: *Associated autoimmune diseases in systemic sclerosis define a subset of patients with milder disease: results from 2 large cohorts of European caucasian patients.* J Rheumatol. 2010;37:608-14.
695. Lippi D, **Matucci-Cerinic M**, Villari N, Fornaciari G, Mascalchi M: *Osteochondritis dissecans of the patella in a XVII century player of the Florentine historic kickball.* Knee. 2010;17:172-3.
696. Scarpato S, Antivalle M, Favalli EG, Nacci F, Frigelli S, Bartoli F, Bazzichi L, Minisola G, **Matucci Cerinic M**; *RIVIERA co-authors.: Patient preferences in the choice of anti-TNF therapies in rheumatoid arthritis. Results from a questionnaire survey (RIVIERA study).* Rheumatology (Oxford) 2010;49:289-94.
697. Petrarca A, Rigacci L, Caini P, Colagrande S, Romagnoli P, Vizzutti F, Arena U, Giannini C, Monti M, Montalto P, **Matucci-Cerinic M**, Bosi A, Laffi G, Zignego AL: *Safety and efficacy of rituximab in patients with hepatitis C virus related mixed cryoglobulinemia and severe liver disease.* Blood. 2010; 116(3):335-42.
698. Amanzi L, Braschi F, Fiori G, Galluccio F, Miniati I, Guiducci S, Conforti ML, Kaloudi O, Nacci F, Sacu O, Candelieri A, Pignone A, Rasero L, Conforti D, **Matucci-Cerinic M**: *Digital ulcers in scleroderma: staging, characteristics and sub-setting through observation of 1614 digital lesions.* Rheumatology (Oxford). 2010; 49(7):1374-82.
699. Scarpa R, Altomare G, Marchesoni A, Balato N, **Matucci Cerinic M**, Lotti T, Olivieri I, Vena GA, Salvarani C, Valesini G, Giannetti A: *Psoriatic disease: concepts and implications.* J Eur Acad Dermatol Venereol. 2010 ;4(6):627-30.
700. Maddali-Bongi S, Landi G, Galluccio F, Del Rosso A, Miniati I, Conforti ML, Casale R, **Matucci-Cerinic M**: *The rehabilitation of facial involvement in systemic sclerosis: efficacy of the combination of connective tissue massage, Kabat's technique and kinesitherapy: a randomized controlled trial.* Rheumatol Int. 2010; 31(7):895-90.
701. Kaloudi O, Bandinelli F, Filippucci E, Letizia Conforti M, Miniati I, Guiducci S, Porta F, Candelieri A, Conforti D, Grassiri G, Grassi W, **Matucci-Cerinic M**: *High frequency ultrasound measurement of digital dermal thickness in systemic sclerosis.* Ann Rheum Dis. 2010; 69(6):1140-3.
702. Manetti M, Guiducci S, Ibba-Manneschi L, **Matucci-Cerinic M**: *Mechanisms in the loss of capillaries in systemic sclerosis: angiogenesis versus vasculogenesis.* J Cell Mol Med. 2010; 14(6A):1241-54.

703. Huscher D, Pittrow D, Distler O, Denton CP, Foeldvari I, Humbert M, **Matucci-Cerinic M**, Kowal-Bielecka O, Avouac J, Behrens F, Nash P, Opitz CF, Rubin LJ, Seibold JR, Strand V, Furst DE; EPOSS-OMERACT Group *Interactions between rheumatologists and cardio/pulmonologists in the assessment and use of outcome measures in pulmonary arterial hypertension related to systemic sclerosis*. Clin Exp Rheumatol. 2010; ;28(2 Suppl 58):S47-52.
704. Wipff J, Dieudé P, Guedj M, Ruiz B, Riemekasten G, Cracowski J, **Matucci-Cerinic M**, Melchers I, Humbert M, Hachulla E, Airo P, Diot E, Hunzelmann N, Caramaschi P, Sibilia J, Valentini G, Tiev K, Girerd B, Mouthon L, Riccieri V, Carpentier P, Distler J, Amoura Z, Tarner I, Degano B, Avouac J, Meyer O, Kahan A, Boileau C, Allanore Y: *Association of KCNA5 gene polymorphism with systemic sclerosis-associated pulmonary arterial hypertension in the European Caucasian population* Arthritis Rheum. 2010;62(10):3093-100.
705. Alizadeh BZ, Broen J, Rueda B, Hesselstrand R, Wuttge D, Simeon C, Ortego-Centeno N, Gonzalez-Gay M, Pros A, Herrick A, Worthington J, Denton C, Fonseca C, Riemekasten G, Vonk MC, van den Hoogen F, Guiducci S, **Matucci-Cerinic M**, Scorza R, Beretta L, Airó P, Coenen M, Martin J, Koeleman BP, Radstake TR: *Functional Variants of Fc Gamma Receptor (FCGR2A) and FCGR3A Are Not Associated with Susceptibility to Systemic Sclerosis in a Large European Study (EUSTAR)*. J Rheumatol. 2010; 1;37(8):1673-9.
706. Avouac J, Walker U, Tyndall A, Kahan A, **Matucci-Cerinic M**, Allanore Y et al. *Characteristics of Joint Involvement and Relationships with Systemic Inflammation in Systemic Sclerosis: Results from the EULAR Scleroderma Trial and Research Group EUSTAR) Database*. J Rheumatol. 2010;37(7):1488-501.
707. Perfetto F, Moggi-Pignone A, Livi R, Tempestini A, Bergesio F, **Matucci-Cerinic M**: *Systemic amyloidosis: a challenge for the rheumatologist*. Nat Rev Rheumatol. 2010;6(7):417-29.
708. Weisz GM, **Matucci-Cerinic M**, Albury WR, Lippi D: *The Medici syndrome: a medico-historical puzzle*. Int J Rheum Dis. 2010;13:125-31.
709. Stagi S, Masi L, Capannini S, Cimaz R, Tonini G, **Matucci-Cerinic M**, de Martino M, Falcini F: *Cross-sectional and Longitudinal Evaluation of Bone Mass in Children and Young Adults with Juvenile Idiopathic Arthritis: The Role of Bone Mass Determinants in a Large Cohort of Patients*. J Rheumatol. 2010;37(9):1935-43.
710. Dieudé P, Guedj M, Wipff J, Ruiz B, Riemekasten G, **Matucci-Cerinic M**, Melchers I, Hachulla E, Airo P, Diot E, Hunzelmann N, Cabane J, Mouthon L, Cracowski JL, Riccieri V, Distler J, Meyer O, Kahan A, Boileau C, Allanore Y: *Association of the TNFAIP3 rs5029939 variant with systemic sclerosis in the European Caucasian population*. Ann Rheum Dis. 2010;69(11):1958-64.
711. Seibold JR, Denton CP, Furst DE, Guillevin L, Rubin LJ, Wells A, **Matucci-Cerinic M**, Riemekasten G, Emery P, Chadha-Boreham H, Charef P, Roux S, Korn J, Black CM.: *Randomized, prospective, placebo-controlled trial of bosentan in interstitial lung disease secondary to systemic sclerosis*. Arthritis Rheum. 2010;62(7):2101-8.
712. Prignano F, Bonciani D, Bandinelli F, **Matucci Cerinic M**, Lotti T: *Juvenile psoriatic arthritis and comorbidities: report of a case associated with enthesitis and celiac disease*. Dermatol Ther. 2010;23 Suppl 2:S47-50.

713. Manetti M, Ibba-Manneschi L, Fatini C, Guiducci S, Cuomo G, Bonino C, Bazzichi L, Liakouli V, Giacomelli R, Abbate R, Bombardieri S, Montecucco C, Valentini G, **Matucci-Cerinic M**: *Association of a Functional Polymorphism in the Matrix Metalloproteinase-12 Promoter Region with Systemic Sclerosis in an Italian Population*. J Rheumatol 2010; 37(9):1852-7.
714. Iagnocco A, Kaloudi O, Perella C, Bandinelli F, Riccieri V, Vasile M, Porta F, Valesini G, **Matucci-Cerinic M**: *Ultrasound Elastography Assessment of Skin Involvement in Systemic Sclerosis: Lights and Shadows*. J Rheumatol. 2010; 37(8):1688-91.
715. Galluccio F, Walker UA, Nihtyanova S, Moynzadeh P, Hunzelmann S, Krieg T, Steen V, Baron M, Sampaio-Barros P, Kayser C, Nash P, Denton CP, Tyndall A, Müller-Ladner U, **Matucci-Cerinic M**: *Registries in systemic sclerosis: a worldwide experience*. Rheumatology 2010;50(1):60-8.
716. Galluccio F, **Matucci-Cerinic M**: *Registry evaluation of digital ulcers in systemic sclerosis* Intl. J Rheumatol 2010; pii: 363679
717. Pagnini I, Savelli S, **Matucci-Cerinic M**, Fonda C, Cimaz R, Simonini G.: *Early Predictors of Juvenile Sacroiliitis in Enthesitis-related Arthritis* J Rheumatol. 2010; 37(11):2395-401
718. Avouac J, Airò P, Meune C, Beretta L, Dieude P, Caramaschi P, Tiev K, Cappelli S, Diot E, Vacca A, Cracowski JL, Sibilia J, Kahan A, **Matucci-Cerinic M**, Allanore Y.: *Prevalence of Pulmonary Hypertension in Systemic Sclerosis in European Caucasians and Metaanalysis of 5 Studies*. J Rheumatol. 2010;37(11):2290-8
719. Czirjak L, **Matucci Cerinic M**: *Beyond Raynaud's phenomenon hides very early systemic sclerosis - the assessment of organ involvement is always mandatory!* Rheumatology 2010; 50 (2): 250-251.
720. Avouac J, Kowal-Bielecka O, Pittrow D, Huscher D, Behrens F, Denton CP, Foeldvari I, Humbert M, **Matucci-Cerinic M**, Nash P, Opitz CF, Rubin LJ, Seibold JR, Distler O, Furst DE; *EPOSS Group Validation of the 6 min walk test according to the OMERACT filter: a systematic literature review by the EPOSS-OMERACT group*. Ann Rheum Dis. 2010; 69(7):1360-3.
721. Picano E, **Matucci-Cerinic M**: *Unnecessary radiation exposure from medical imaging in the rheumatology patient*. Rheumatology (Oxford). 2010; 50(9):1537-9.
722. **M Matucci-Cerinic**, Denton CP, Furst D E, Mayes MD, Hsu VM, Carpentier P, Wigley FM, Black CM, Fessler BJ, Merkel P, Pope JE, Sweiss N, Doyle M, Hellmich B, Medsger TA, Morganti A, Kramer F, Korn J, Seibold JR: *Bosentan treatment of digital ulcerations related to systemic sclerosis: results of a randomised double-blind placebo-controlled trial*. Ann Rheum Dis 2010;70(1):32-8.
723. Galluccio F, **Matucci-Cerinic M**: *Two faces of the same coin: Raynaud phenomenon and digital ulcers in systemic sclerosis*. Autoimm Rev 2010;10(5):241-3.
724. Manetti M, Milia AF, Guiducci S, Romano E, **Matucci-Cerinic M**, Ibba-Manneschi L: *Progressive Loss of Lymphatic Vessels in Skin of Patients with Systemic Sclerosis*. J Rheumatol. 2010; 38(2):297-301.
725. **Matucci-Cerinic M**, Denton CP, Furst DE, Mayes MD, Hsu VM, Carpentier P, Wigley FM, Black CM, Fessler BJ, Merkel PA, Pope JE, Sweiss NJ, Doyle MK, Hellmich B, Medsger TA Jr, Morganti A, Kramer F, Korn JH, Seibold JR. *Bosentan treatment of digital ulcers*

related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2010; 70(1):32-8.

726. F Bandinelli, Kaloudi O, Miniati I, Conforti ML, Candelieri A, Melchiorre D, Casale R, **Matucci-Cerinic M**: *High-resolution 18 MHz ultrasonography detects carpal tunnel syndrome in Systemic Sclerosis patients.* Clin Exp Rheumatol 2010; 28(5 Suppl 62):S15-8.
727. Sarzi-Puttini P, Atzeni F, Gerli R, Bartoloni E, Doria A, Barskova T, **Matucci-Cerinic M**, Sitia S, Tomasoni L, Turiel M.: *Cardiac involvement in systemic rheumatic diseases: An update.* Autoimmun Rev. 2010
728. D. Melchiorre, Falcini F, Kaloudi O, Bandinelli F, Nacci F, **Matucci Cerinic M**: *Sonographic evaluation of the temporomandibular joints in juvenile idiopathic arthritis.* J Ultras 2010;9(12):849-52.
729. Guiducci S, Porta F, Saccardi R, Guidi S, Ibba-Manneschi L, Manetti M, Mazzanti B, Dal Pozzo S, Milia AF, Bellando-Randone S, Miniati I, Fiori G, Fontana R, Amanzi L, Braschi F, Bosi A, **Matucci-Cerinic M**: *Autologous mesenchymal stem cells foster revascularization of ischemic limbs in systemic sclerosis: a case report.* Ann Intern Med. 2010; 153(10):650-4.
730. Melchiorre D, Linari S, Innocenti M, Biscoglio I, Toigo M, **Matucci Cerinic M**, Morfini M.: *Ultrasound detects joint damage and bleeding in haemophilic arthropathy: a proposal of a score.* Haemophilia. 2010;17(1):112-7.
731. Riemekasten G, Philippe A, Näther M, Slowinski T, Müller DN, Heidecke H, **Matucci-Cerinic M**, Czirják L, Lukitsch I, Becker M, Kill A, van Laar JM, Catar R, Luft FC, Burmester GR, Hegner B, Dragun D.: *Involvement of functional autoantibodies against vascular receptors in systemic sclerosis.* Ann Rheum Dis. 2010;70(3):530-6.
732. Huscher D, Pittrow D, Distler O, Denton CP, Foeldvari I, Humbert M, **Matucci-Cerinic M**, Kowal-Bielecka O, Avouac J, Behrens F, Nash P, Opitz CF, Rubin LJ, Seibold JR, Strand V, Furst DE; *EPOSS-OMERACT Group*.: *Interactions between rheumatologists and cardiopulmonologists in the assessment and use of outcome measures in pulmonary arterial hypertension related to systemic sclerosis.* Clin Exp Rheumatol. 2010;28(2 Suppl 58):S47-52.
733. Ostensen M, Brucato A, Carp H, Chambers C, Radboud, Dolhain JEM, Doria A, Forger F, Gordon C, Hahn S, Khamashta M, Lockshin MD, **Matucci-Cerinic M**, Meroni PL, Nelson JL, Parke A, Petri M, Raio L, Ruiz-Irastorza G, Silva CA, Tincani A, Villiger PM, Wunder D, Cutolo M: *Pregnancy and reproduction in autoimmune rheumatic diseases.* Rheumatology 2010;10.1093
734. Conforti D, Guerriero F, Guido R, **Matucci Cerinic M**, Conforti ML: *An optimal decision making model for supporting week hospital management.* Health Care Manag Sci 2010;14(1):74-88.

2009

735. Blagojevic, **Matucci Cerinic M**: *Statins in systemic sclerosis.* Nature Clin Pract Rheumatol 2009;5:70-1.
736. CM Black, **Matucci-Cerinic M**, Guillevin L: *Progress in systemic sclerosis: a 10-year perspective.* Rheumatology (Oxford). 2009;48 Suppl 3:iii1-2.
737. I Miniati, Valentini G, **Matucci Cerinic M**: *Cyclophosphamide in systemic sclerosis. Still in search for a real life scenario.* Arthritis Res

- Ther 2009;11(1):103.
738. J Avouac, Kowal Bielecka O, Landewe R, Chwiesko S, Miniati I, Czirjak L, Clements P, Denton C, Farge D, Fligelstone K, Foldvari I, Furst DE, Muller-Ladner U, Seibold J, Silver RM, Takehara K, Garay Toth B, Tyndal A, Valentini G, van den Hoogen F, Wigley F, Zulian F, **Matucci-Cerinic M**: *EULAR Scleroderma Trial and Research group (EUSTAR) recommendations for the treatment of systemic sclerosis: Methods of elaboration and results of systematic literature research*. Ann Rheum Dis 2009; 68(5):629-34.
 739. F Mecacci, Bianchi B, Pieralli A, Mangani B, Moretti A, Cioni R, Giorgi L, Mello G, **Matucci-Cerinic M**. *Pregnancy outcome in systemic lupus erythematosus complicated by anti-phospholipid antibodies*. Rheumatology (Oxford). 2009; 48(3):246-9
 740. O Kowal-Bielecka, Landewe R, Avouac J, Chwiesko S, Miniati I, Czirjak L, Clements P, Denton C, Farge D, Fligelstone K, Foldvari I, Furst DE, Müller-Ladner U, Seibold J, Silver RM, Takehara K, Garay Toth B, Tyndall A, Valentini G, van den Hoogen F, Wigley F, Zulian F, **Matucci-Cerinic M**: *EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR)*. Ann Rheum Dis. 2009;68(5):620-8.
 741. P Emery, Van Vollenhoven R, Ostergaard M, Choy E, Combe B, Graninger W, Krueger K, **Matucci-Cerinic M**, Navarro F, van Riel P, Settas L, Steinfeld S: *Guidelines for initiation of anti-tumour necrosis factor therapy in rheumatoid arthritis: similarities and differences across Europe*. Ann Rheum Dis 2009
 742. M Manetti, Liakouli V, Fatini C, Cipriani P, Bonino C, Vettori S, Guiducci S, Montecucco C, Abbate R, Valentini G, **Matucci-Cerinic M**, Giacomelli R, Ibba-Manneschi L: *Association between a stromal cell-derived factor 1 (SDF-1/CXCL12) gene polymorphism and microvascular disease in systemic sclerosis*. Ann Rheum Dis. 2009;68:408-11.
 743. Milia AF, Ibba-Manneschi L, Manetti M, Benelli G, Messerini L, **Matucci-Cerinic M**. *HLA-B27 transgenic rat: an animal model mimicking gut and joint involvement in human spondyloarthritides*. Ann N Y Acad Sci. 2009;1173:570-4.
 744. Branco JC, Bannwarth B, Failde I, Abello Carbonell J, Blotman F, Spaeth M, Saraiva F, Nacci F, Thomas E, Caubère JP, Le Lay K, Taieb C, **Matucci-Cerinic M**: *Prevalence of Fibromyalgia: A Survey in Five European Countries*. Semin Arthritis Rheum. 2009;39(6):448-53.
 745. Falcini F, Capannini S, Martini G, La Torre F, Vitale A, Mangiantini F, Nacci F, **Matucci-Cerinic M**, Cimaz R, Zulian F: *Mycophenolate mofetil for the treatment of juvenile onset SLE: a multicenter study*. Lupus. 2009;18(2):139-43c.
 746. Bartalesi F, Vicidomini S, Goletti D, Fiorelli C, Fiori G, Melchiorre D, Tortoli E, Mantella A, Benucci M, Girardi E, **Matucci-Cerinic M**, Bartoloni A: *QuantiFERON-TB Gold and the TST are both useful for latent tuberculosis infection screening in autoimmune diseases*. Eur Respir J. 2009;33(3):586-93.
 747. Miniati I, Guiducci S, Conforti ML, Rogai V, Fiori G, Cinelli M, Saccardi R, Guidi S, Bosi A, Tyndall A, **Matucci-Cerinic M**: *Autologous stem cell transplantation improves microcirculation in systemic sclerosis*. Ann Rheum Dis. 2009;68(1):94-8.
 748. Khanna D, Distler O, Avouac J, Behrens F, Clements PJ, Denton C, Foldvari I, Giannini E, Huscher D, Kowal-Bielecka O, Lovell D, **Matucci-Cerinic M**, Mayes M, Merkel PA, Nash P, Opitz CF, Pittrow D, Rubin L, Seibold JR, Steen V, Strand CV, Tugwell PS, Varga J,

- Zink A, Furst DE; CRISS; EPOSS Measures of response in clinical trials of systemic sclerosis: the Combined Response Index for Systemic Sclerosis (CRISS) and Outcome Measures in Pulmonary Arterial Hypertension related to Systemic Sclerosis (EPOSS). *J Rheumatol*. 2009;36(10):2356-61.
749. **M Matucci Cerinic**, Czirjak L: *Immune endothelial nerve interaction: an explanation for the failure of the gastrointestinal system in systemic sclerosis?* *Ann Rheum Dis* 2009;68(5):609-10.
750. S Generini, Steiner G, Miniati I, Conforti, Guiducci S, Skriner K, Kaloudi O, Giacomelli R, J Smolen, **Matucci Cerinic M**: *Anti hnRNP and other autoantibodies in systemic sclerosis with joint involvement.* *Rheumatology* 2009;48(8):920-5.
751. Marchesoni A, Altomare G, **Matucci-Cerinic M**, Balato N, Olivieri I, Salvarani C, Lotti T, Scarpa R, Vena G, Valesini G, Giannetti A. *An Italian shared dermatological and rheumatological proposal for the use of biological agents in psoriatic disease.* *J Eur Acad Dermatol Venereol*. 2009;24(5):578-86.
752. S Maddali Bongi, Del Rosso A, Galluccio F, Sigismondi F, Miniati I, Conforti ML, Nacci F, **Matucci Cerinic M**: *Efficacy of connective tissue massage and Mc Mennell joint manipulation in the rehabilitative treatment of the hands in systemic sclerosis.* *Clin Rheumatol* 2009;28(10):1167-73.
753. N Damjanov, Ostojic P, Kaloudi O, Alari S, Cinelli M, Guiducci S, Del Rosso A, Stanflin N, Orsi S, Nestorovic B, Knezevic J, Camiciottoli G, Porta F, Meoni E, Pistolesi M, Conforti M.L, Cozzi F, Sfriso P, Moggi Pignone A, **Matucci Cerinic M**: *Induced sputum: A non-invasive tool for evaluation of lung involvement and alveolar inflammation in systemic sclerosis.* *Respiration* 2009;78:56-62.
754. **Matucci-Cerinic M**, Allanore Y, Czirjak L, Tyndall A, Müller-Ladner U, Denton C, Valentini G, Distler O, Fligelstone K, Tyrrel-Kennedy A, Farge D, Kowal-Bielecka O, van den Hoogen F, Cutolo M, Sampaio-Barros PD, Nash P, Takehara K, Furst DE. *The challenge of early systemic sclerosis for the EULAR Scleroderma Trial and Research group (EUSTAR) community. It is time to cut the Gordian knot and develop a prevention or rescue strategy.* *Ann Rheum Dis*. 2009;68:1377-80.
755. Guiducci S, **Matucci Cerinic M**: *Vasculogenesis and angiogenesis: vascular damage in systemic sclerosis.* *Reumatismo*. 2009;61:81-3.
756. Pope J, Steen V, Denton C, **Matucci Cerinic M**: *Digital ulcers: overt vascular disease in systemic sclerosis.* *Rheumatology* 2009 ;48 Suppl 3:iii19-24.
757. S Guiducci, Distler JHW, Milia AF, Miniati I, Rogai V, Manetti M, Falcini F, Ibba-Manneschi L, Gay S, Distler O, **Matucci-Cerinic M**: *Stiff Skin Syndrome: evidence for an Inflammation-independent Fibrosis ?* *Rheumatology* 2009;48:849-52.
758. V Codullo, Cavazzana I, Bonino C, Lavagna L, Cozzi F, Del Papa N, Ferri C, Franceschini F, Giacomelli R, Guiducci S, **Matucci-Cerinic M**, Morozzi G, Ruffatti A, Valentini G, Montecucco CM: *Serologic profile and mortality rates of scleroderma renal crisis in Italy.* *J Rheumatol* 2009;36:1464-9.
759. A Franca Milia, Ibba-Manneschi L, Manetti M, Benelli G, Generini S, Messerini L, **Matucci-Cerinic M**: *Evidence for the prevention of enthesitis in HLA-B27/hbeta2m transgenic rats treated with a monoclonal antibody against TNFalpha.* *Cell Mol Med* 2009;15(2):270-9.
760. G Fiori, Galluccio F, Braschi F, Amanzi L, Miniati I, Conforti ML,

- Del Rosso A, Generini S, Candelieri A, Magonio A, Goretti R, Rasero L, **Matucci Cerinic M**: *Vitamin E gel reduces stime to healing of digital ulcers in sistemic sclerosis*. Clin Exp Rheumatol 2009;27(3 Suppl 54):51-4.
761. Saavedra MJ, Ambrosio C, Malcata A, **Matucci-Cerinic M**, Da Silva JAP: *Exuberant calcinosis and acroosteolysis and acroosteolysis: a diagnostic challenge*. Clin Exp Rheumatol 2009;27(3 Suppl 54):55-8.
762. Maddali Bongi S, Del Rosso A, Galluccio F, Tai G, Sigismondi F, Passalacqua M, Landi G, Baccini M, Conforti ML, Miniati I, **Matucci-Cerinic M**: *Efficacy of a tailored rehabilitation program for systemic sclerosis*. Clin Exp Rheumatol. 2009; 27(3 Suppl 54):44-50.
763. L Ibba-Manneschi, Manetti M, Milia AF, Miniati I, Benelli G, Guiducci S, Mecacci F, Mello G, Di Lollo S, **Matucci-Cerinic M**: *Severe fibrotic changes and altered expression of angiogenic factors in maternal scleroderma: placental findings*. Ann Rheum Dis. 2009; 69(2):458-61.
764. Bombardieri S, Ferraccioli G, Ferri C, Galeazzi M, Lapadula G, **Matucci Cerinic M**, Montecucco C, Triolo G, Trotta F, Valentini G.: *Copernican revolution in the therapy of rheumatoid arthritis: the contribution of anti-TNFalpha drugs* Reumatismo. 2009
765. Tyndall A, **Matucci-Cerinic M**, Müller-Ladner U.: *Future targets in the management of systemic sclerosis*. Rheumatology (Oxford). 2009;61 Suppl 1:1-23.
766. Villari N, Fornaciari G, Lippi D, **Matucci Cerinic M**, Ginestroni A, Pellicanò G, Mascalchi M: *Scenes from the past: the Medici Project: radiographic survey*. Radiographics. 2009;18(2):139-43.

2008

767. Wipff J, Giraud M, Sibilia J, Mouthon L, Meyer O, Tiev K, Airo P, Caramaschi P, Guiducci S, Garchon HJ, Matucci-Cerinic M, Kahan A, Avouac J, Boileau C, Allanore Y: *Polymorphic Markers of the Fibrillin-1 Gene and Systemic Sclerosis in European Caucasian Patients*. J Rheumatol. 2008; 35(4):643-9.
768. M Matucci-Cerinic, Guiducci S, Miniati I, Fiori G: *La vasculopathie de la sclérodermie systémique et le rôle de l'endothéline-1*. La Presse Medicale 2008 ;37:S7-S10
769. E Jimenez-Boj, Kedersha N, Tohidast-Akrad, M, Karlhofer FM, Stummvoll G, Zimmermann C, Ulrich W, Guiducci S, Hoefler E, Aringer M, Schett G, Matucci-Cerinic M, Smolen JS, Steiner: *Autoantibodies to the Translational Suppressors T Cell Intracytoplasmic Antigen 1 and T Cell Intracytoplasmic Antigen 1-Related Protein in Patients With Rheumatic Diseases Increased Prevalence in Systemic Lupus Erythematosus and Systemic Sclerosis and Correlation With Clinical Features*. Arthritis Rheum 2008; 58(5):1226-36.
770. D Melchiorre, Bernardo P, Conforti ML, C Comunian, Nacci F, Guiducci S, Fiori G, Moggi-Pignone A, Gensini GF, Matucci-Cerinic M: *“tako-tsubo like syndrome” in Systemic Sclerosis: a sign of myocardial Raynaud’s phenomenon ?* Ann Rheum Dis 2008;67(6):898-9. d
771. S D’Angelo, Padula A, Nigro A, Cantini F, Matucci Cerinic M, Modena V, Punzi L, Salvarani C, Scarpa R, Olivieri I: *Italian evidence based recommendations for the management of ankylosing spondylitis: the 3E initiative in Rheumatology*. Clin Exp Rheumatol 2008; 26(6):1005-11.

772. Distler O, Behrens F, Pittrow D, Huscher D, Denton CP, Foeldvari I, Humbert M, Matucci-Cerinic M, Nash P, Opitz CF, Rubin LJ, Seibold JR, Furst DE; EPOSS-Omeract Group.: Defining appropriate outcome measures in pulmonary arterial hypertension related to systemic sclerosis: A Delphi consensus study with cluster analysis. *Arthritis Rheum.* 2008; 59(6):867-75.
773. Liakouli V, Manetti M, Pacini A, Tolusso B, Fatini C, Toscano A, Cipriani P, Guiducci S, Bazzichi L, Codullo V, Ruocco L, Dell'orso L, Carubbi F, Marrelli A, Abbate R, Bombardieri S, Ferraccioli G, Montecucco C, Valentini G, Matucci-Cerinic M, Ibba-Manneschi L, Giacomelli R.: The -670G>A polymorphism in the FAS gene promoter region influences the susceptibility to systemic sclerosis. *Ann Rheum Dis* 2008 ;68(4):584-90.
774. AF Milia, Manetti M, Generini S, Polidori L, Benelli G, Cinelli M, Messerini L, Ibba-Manneschi L, Matucci-Cerinic M.: TNFalpha blockade prevents the development of inflammatory bowel disease in HLA-B27 transgenic rats. *J Cell Mol Med.* 2008
775. I Miniati, Guiducci S, Matucci Cerinic M: Pregnancy in systemic sclerosis *Rheumatology* 2008; 13(1):164-76.
776. UA. Walker, Tyndall A, Czirják L, Denton CP, Farge D, Kowal-Bielecka O, Mueller-Ladner UP, Matucci-Cerinic M: Geographic variation of disease manifestations in systemic sclerosis - a report from the EULAR Scleroderma Trials And Research (EUSTAR) group data base. *Ann Rheum Dis* 2008;68:856-62.
777. S Guiducci, Distler O, Distler JHW, Matucci Cerinic M: Mechanisms of vascular damage in systemic sclerosis: implications for vascular treatment strategies. *Rheumatology* 2008; 47 Suppl 5:v18-20.
778. M Aschwanden, Daikeler T, Jaeger KA, Thalhammer C, Gratwohl A, Matucci-Cerinic M, Tyndall A.: Rapid improvement of nailfold capillaroscopy after intense immunosuppression for systemic sclerosis and mixed connective tissue disease. *Ann Rheum Dis.* 2008; 67(7):1057-9.
779. G Valentini, Matucci Cerinic M: New trends in the treatment of the patient with systemic sclerosis. *Expert Opin Emerg Drugs.* 2008;13(2):227-36
780. M Matucci Cerinic, Seibold J: Digital ulcers and outcomes assessment in scleroderma. *Rheumatology* 2008;47 Suppl 5:v46-7.
781. S Guiducci, Matucci Cerinic M.: Lack of efficacy of quinapril on vascular damage in limited cutaneous systemic sclerosis. *Nat Clin Pract Rheumatol.* 2008; 4(6):288-9.
782. S Bellando Randone, Guiducci S, Matucci Cerinic M, Musculoskeletal involvement in systemic sclerosis. *Best Pract Res Clin Rheumatol.* 2008; 22(2):339-50.
783. Distler O, Matucci-Cerinic M, Müller-Ladner U, Seibold JR.: A path to the future in scleroderma. *Rheumatology (Oxford).* 2008; 47 Suppl 5:v1.
784. D Aletaha , Landewe R, Karonitsch T, Bathon J, Boers M, Bombardier C, Bombardieri S, Choi H, Combe B, Dougados M, Emery P, Gomez-Reino J, Keystone E, Koch G, Kvien TK, Martin-Mola E, Matucci-Cerinic M, Michaud K, O'Dell J, Paulus H, Pincus T, Richards P, Simon L, Siegel J, Smolen JS, Sokka T, Strand V, Tugwell P, van der Heijde D, van Riel P, Vlad S, van Vollenhoven R, Ward M, Weinblatt M, Wells G, White B, Wolfe F, Zhang B, Zink A, Felson D; EULAR; ACR : Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations. *Arthritis Rheum.* 2008;59:1371

785. Olivieri I, de Portu S, Salvarani C, Cauli A, Lubrano E, Spadaro A, Cantini F, Cutro MS, Mathieu A, Matucci-Cerinic M, Pappone N, Punzi L, Scarpa R, Mantovani LG; PACE working group.: The psoriatic arthritis cost evaluation study: a cost-of-illness study on tumour necrosis factor inhibitors in psoriatic arthritis patients with inadequate response to conventional therapy. *Rheumatology (Oxford)*. 2008;47:1664-70.
786. T Karonitsch , Aletaha D, Boers M, Bombardieri S, Combe B, Dougados M, Emery P, Felson D, Gomez-Reino J, Keystone E, Kvien TK, Martin-Mola E, Matucci-Cerinic M, Richards P, van Riel P, Siegel J, Smolen JS, Sokka T, van der Heijde D, van Vollenhoven R, Ward M, Wells G, Zink A, Landewe R.: Methods of deriving EULAR/ACR recommendations on reporting disease activity in clinical trials of patients with rheumatoid arthritis. *Ann Rheum Dis*. 2008;67:1365-73.
787. M Manetti, Neumann E, Müller A, Schmeiser T, Saar P, Milia AF, Endlicher E, Roeb E, Messerini L, Matucci-Cerinic M, Ibbamanneschi L, Müller-Ladner U.: Endothelial/lymphocyte activation leads to prominent CD4⁺ T cell infiltration in the gastric mucosa of patients with systemic sclerosis. *Arthritis Rheum*. 2008;58:2866-2873.
788. S Guiducci , Distler JH, Jüngel A, Huscher D, Huber LC, Michel BA, Gay RE, Pisetsky DS, Gay S, Matucci-Cerinic M, Distler O.: The relationship between plasma microparticles and disease manifestations in patients with systemic sclerosis. *Arthritis Rheum*. 2008 ;58:2845-53.
789. A Tyndall, Muller Ladner U, Matucci Cerinic M: The EUSTAR: an international framework for accelerating scleroderma research. *Curr Opin Rheumatol*. 2008;20:703-6
790. V Rogai, Lories RJ, Guiducci S, Luyten FP, Matucci Cerinic M: Animal models in systemic sclerosis. *Clin Exp Rheumatol*. 2008;26:941-6.
791. S Guiducci, Distler O, Distler JH, Matucci-Cerinic M.: Mechanisms of vascular damage in SSc--implications for vascular treatment strategies. *Rheumatology (Oxford)*. 2008;47 Suppl 5:v18-20.
792. JHW Distler, Allanore A, Avouac J, Giacomelli R, Guiducci S, Moritz F, Akhmetshina A, Müller-Ladner U, Matucci-Cerinic M, Distler O: EUSTAR statement and recommendations on endothelial precursor cells in systemic sclerosis. *Ann Rheum Dis* 2008;68:163-8.
793. S Bellando Randone, Guiducci S, Matucci Cerinic M :Systemic sclerosis and infections. *Autoimmun Rev*. 2008;8:36-40.
794. L Gossec, Dougados M, Rincheval N, Balanescu A, Boumpas DT, Canadello S, Carmona L, Daurès JP, de Wit M, Dijkmans BA, Englbrecht M, Gunendi Z, Heiberg T, Kirwan J, Martin Mola E, Matucci Cerinic M, Otsa K, Schett G, Sokka T, Wells GA, Aanerud GJ, Celano A, Dudkin A, Hernandez C, Koutsogianni K, Nilgun Akca F, Petre AM, Richards P, Scholte-Voshaar M, von Krause G, Kvien TK. The elaboration of the preliminary Rheumatoid Arthritis Impact of Disease (RAID) score: a EULAR initiative. *Ann Rheum Dis*. 2008;68:1680-5
795. D' Angelo S, Padula A, Nigro A, Cantini F, Matucci-Cerinic M, Modena V, Punzi L, Salvarani C, Scarpa R, Olivieri I: Italian evidence-based recommendations for the management of ankylosing spondylitis: the 3E Initiative in Rheumatology. *Clin Exp Rheumatol*. 2008;26:1005-11.

2007

796. I Miniati, Conforti ML, Bernardo P, Tyndall A, Gensini GF, Matucci-Cerinic M :Hematopoietic Stem Cell Transplantation in Autoimmune Diseases : Algorithm for Cardiovascular Assessment. *Herz.* 2007 ;32:43-50
- 797.F Bartoli, Angotti C, Fatini C, Conforti ML, Guiducci S, Blagojevic J, Melchiorre ,Fiori G, Generini S, Damjanov N, Rednic S, Pignone A, Castellani S, Abbate R, Matucci Cerinic M:Angiotensin-converting enzyme I/D polymorphism and macrovascular disease in systemic sclerosis. *Rheumatology (Oxford).* 2007;46(5):772-5.
- 798.F Zulian , Woo P, Athreya BH, Laxer RM, Medsger TA Jr, Lehman TJ, Matucci Cerinic M, Martini G, Ravelli A, Russo R, Cuttica R, de Oliveira SK, Denton CP, Cozzi F, Foeldvari I, Ruperto N: The Pediatric Rheumatology European Society/American College of Rheumatology/European League against Rheumatism provisional classification criteria for juvenile systemic sclerosis. *Arthritis Rheum.* 2007;57:203-212.
- 799.Bertinotti L, Nacci F, Matucci Cerinic M: Rehabilitation, an old useful tool in the midst of a new therapeutic era for rheumatoid arthritis. *Rheumatology (Oxford).* 2007;46:891-2.
- 800.G Camiciottoli , Orlandi I, Bartolucci M, Meoni E, Nacci F, Diciotti S, Barcaroli C, Conforti ML, Pistolesi M, Matucci-Cerinic M, Mascalchi M: Lung CT densitometry in systemic sclerosis: correlation with lung function, exercise testing, and quality of life. *Chest.* 2007;131:672-81.
- 801.F Iannone , Trotta F, Montecucco C, Giacomelli R, Galeazzi M, Matucci-Cerinic M, Ferri C, Cutolo M, Maria Bambara L, Triolo G, Ferraccioli G, Valentini G, Lapadula G; GISEA (Gruppo Italiano per lo Studio delle Early Arthritis):Etanercept maintains the clinical benefit achieved by infliximab in patients with rheumatoid arthritis who discontinued infliximab because of side effects.*Ann Rheum Dis.* 2007;66:249-52.
- 802.I Miniati , Conforti ML, Guiducci S, Matucci Cerinic M: David against Goliath: may we target and defeat interstitial lung disease in systemic sclerosis ? *Clin Exp Rheumatol.* 2007;25:169.
- 803.M Buch, Denton CP, Furst DP, Guillevin L, Rubin LJ, Wells AW, Matucci Cerinic M, Riemekasten G, Emery P, Chadha Boreham H, Charef P, Roux S, Black CM, Seibold JR: Submaximal exercise testing in the assessment of interstitial lung disease secondary to systemic sclerosis: reproducibility and correlations of the six minute walk test. *Ann Rheum Dis.* 2007;66:169.
- 804.Y Allanore, Borderie D, Airo P,Guiducci S, Czirjak L, Nassonov EL, Riemekasten G, Caramaschi P, Majdan M, Krasowska D, Friedl E, Lemarchal H, Ananieva LP,Nevskaya T, Ekindjian OG, Matucci Cerinic M, Kahan A: Lack of association between 3 vascular endothelial growth factor gene polymorphisms and systemic sclerosis: results from a multicenter EUSTAR study of European Caucasian patients. *Ann Rheum Dis.* 2007;66:257.
- 805.UA Walker, A Tyndall, L Czirják, C Denton, D Farge-Bancel, O Kowal-Bielecka, U Müller-Ladner, C Bocelli-Tyndall, M Matucci-Cerinic and EUSTAR coauthors :Clinical risk assessment of organ manifestations in systemic sclerosis - a report from the EULAR Scleroderma Trials And Research (EUSTAR) group data base. *Ann Rheum Dis* 2007;66:754.
- 806.L Czirják, Nagy Z, Aringer M, Riemekasten G, Matucci- Cerinic M, Furst DE , on behalf of the EUSTAR; The EUSTAR model for teaching and implementing the modified Rodnan skin score in

- systemic sclerosis. *Ann Rheum Dis* 2007;66: 966.
- 807.Y T. Konttinen, Pettersson T, Matucci-Cerinic M, Dadoniene J, Poduval P: Road Map to Vasculitis. A rheumatological treasure hunt. Part I. Stop sign, red flags, triggering factors, patient history and physical examination. *Ind J Rheumatol* 2007; (10)60022-2
 - 808.J Blagojevic , Matucci Cerinic M: Macrovascular involvement in systemic sclerosis: comorbidity or accelerated atherosclerosis ? *Curr Rheumatol Rep.* 2007;9:181.
 - 809.D Furst, Khanna D, Matucci-Cerinic M, Clements P, Steen V, Pope J, Merkel P, Foeldvari I, Seibold J, Pittrow D, Polissson R, Strand V.: Systemic sclerosis - continuing progress in developing clinical measures of response. *J Rheumatol.* 2007;34:1194.
 - 810.F Bartoli , Blagojevic J, Bacci M, Fiori G, Tempestini A, Conforti ML, Guiducci S, Miniati I, Di Chicco M, Del Rosso A, Perfetto F, Castellani S, Pignone A, Matucci Cerinic M: Flow-mediated vasodilation and carotid intima-media thickness in systemic sclerosis. *Ann N Y Acad Sci.* 2007;1108:283-90.
 - 811.P Cipriani , Guiducci S, Miniati I, Cinelli M, Urbani S, Marrelli A, Dolo V, Pavan A, Saccardi R, Tyndall A, Giacomelli R, Matucci Cerinic M: Impairment of endothelial cell differentiation from bone marrow-derived mesenchymal stem cells: new insight into the pathogenesis of systemic sclerosis. *Arthritis Rheum.* 2007;56:1994
 - 812.I Miniati I, Matucci Cerinic M: Pulmonary fibrosis in systemic sclerosis: is treatment with cyclophosphamide more effective than placebo ? *Nature Clin Pract Rheumatol.* 2007;3:372.
 - 813.F Nacci, Righi A, Conforti ML, Miniati I, Fiori G, Martinovic D, Melchiorre D, Sapir T, Blank M, Shoenfeld Y, Pignone AM, Matucci Cerinic M : Intravenous immunoglobulins improve the function and ameliorate joint involvement in systemic sclerosis: a pilot study. *Ann Rheum Dis.* 2007;66:977.
 - 814.F Zulian , Woo P, Athreya BH, Laxer RM, Medsger TA, Lehman TJ, Matucci Cerinic M, Martini G, Ravelli A, Russo R, Cuttica R, de Oliveira SK, Denton CP, Cozzi F, Foeldvari I, Ruperto N: The PRES/ACR/EULAR provisional classification criteria for juvenile systemic sclerosis.*Arthritis Rheum* 2007;57:203.
 - 815.A Pignone, Del Rosso A, Brosnihan K, Perfetto F, Livi R, Fiori G, Guiducci S, Cinelli M, Rogai V, Tempestini A, Generini S, Ferrario C, Matucci-Cerinic M: Reduced circulating levels of Angiotensin(1-7) in Systemic Sclerosis: a new pathway in the dysregulation of endothelial dependent vascular tone control. *Ann Rheum Dis* 2007;66:1305-10.
 - 816.Y Sherer,Matucci Cerinic M, Bartoli F, Blagojevic J, Conforti ML, Gilburd B, Ehrenfeld M, Shoenfeld Y: Early atherosclerosis and autoantibodies to heat-shock proteins and oxidized LDL in systemic sclerosis. *Ann N Y Acad Sci.* 2007;1108:259-67.
 817. LC Huber, Dsitler JHW, Moritz F, Hemmatazad H, Hauser T, Michel BA, Gay RE, Matucci Cerinic M, Gay S, Distler O, Jungel A: Trichostatin A prevents the accumulation of extracellular matrix in a mouse model of bleomycin-induced skin fibrosis. *Arthritis Rheum* 2007;56:2755-64.
 - 818.M Matucci Cerinic, Steen V, Furst D, Seibold J: Clinical trials in systemic sclerosis: lessons learned and outcomes. *Arthritis Res Ther* 2007;9 (suppl 2):s7.
 - 819.Y T. Konttinen, Pettersson T, Matucci-Cerinic M, Dadoniene J, Poduval P: Road Map to Vasculitis. A rheumatological treasure hunt. Part III. Laboratory evaluation and imaging *Ind J Rheumatol*

- 2007;2:100-4.
- 820.S Guiducci, Giacomelli R, Matucci Cerinic M: Vascular complication of scleroderma. *Autoimmunity Rev* 2007;6:520-3.
 - 821.I Mannini, Cecchi E, Fatini C, Marcucci R, Alessandriello Liotta A, Matucci Cerinic M, Abbate R, Gensini GF: Clinical haemorheology and microcirculation. *Ann Ist Super Sanita*. 2007;43:144-55.
 - 822.A Oddo, Galeota G, Fiori G, Del Rosso A, Perfetto F, Becucci A, Livi R, Tempestini A, Benvenuti C, Gramigna L, Fedi R, Generini S, Minelli M, Cinelli M, Guiducci S, Arcangeli C, Conforti ML, Bernardo P, Matucci Cerinic M: Exercise Doppler echocardiography identifies preclinic asymptomatic pulmonary hypertension in systemic sclerosis. *Ann N Y Acad Sci*. 2007;1108:291-304.
 - 823.Y T. Kontinen, Pettersson T, Matucci-Cerinic M, Dadoniene J, Poduval P: Road Map to Vasculitis: A rheumatological treasure hunt. Part II. Classification, features of individual vasculitides and differential diagnosis against pseudovasculitis. *Ind J Rheumatol* 2007;2:55.
 - 824.Khanna D, Lovell DJ, Giannini E, Clements PJ, Merkel PA, Seibold JR, Matucci Cerinic M, Denton CP, Mayes MD, Steen VD, Varga J, Furst DE: Development of a provisional core set of response measures for clinical trials of systemic sclerosis. *Ann Rheum Dis*. 2007; 67(5):703-9.
 - 825.JHW Distler, Jüngel A, Michel BA, Gay RE, Matucci-Cerinic M, Kalden JR, Marti H, Gay S, Distler O: Dermal hypoxia increases the production of extracellular matrix proteins in systemic sclerosis. *J Cell Biol* 2007;56(12):4203-15.
 - 826.M Cutolo, Matucci Cerinic M: Nailfold capillaroscopy and classification criteria for systemic sclerosis. *Clin Exp Rheumatol*. 2007;25:663-5.
 - 827.B Rozman , Sukènik S, Sodin-Semrl S, Czirják L, Varjú C, Distler O, Huscher D, Aringer M, Steiner G, Matucci-Cerinic M, Guiducci S, Stamenkovic B, Stankovic A, Kveder T. Prevalence and clinical associations of anti-KU antibodies in patients with systemic sclerosis: a European EUSTAR - initiated multicentre case-control study. *Ann Rheum Dis*. 2007;67(9):1282-6.
 - 828.F Iannone, Riccardi MT, Guiducci S, Bizzoca R, Cinelli M, Matucci-Cerinic M, Lapadula G. Bosentan regulates the expression of adhesion molecules on circulating T cells and serum soluble adhesion molecules in systemic sclerosis-associated pulmonary arterial hypertension. *Ann Rheum Dis*. 2007;67(8):1121-6.
 - 829.DE Furst, Matucci Cerinic M: Connective tissue diseases. *Best Pract Res Clin Rheumatol*. 2007;21:69-70
 830. JH Distler , Jüngel A, Pileckyte M, Zwerina J, Michel BA, Gay RE, Kowal-Bielecka O, Matucci-Cerinic M, Schett G, Marti HH, Gay S, Distler O: Hypoxia-induced increase in the production of extracellular matrix proteins in systemic sclerosis. *Arthritis Rheum*. 2007;56:4203-15.
 - 831.G Valentini, Matucci Cerinic M: Disease-specific quality indicators, guidelines and outcome measures in scleroderma. *Clin Exp Rheumatol*. 2007;25 (suppl 47):159-62.
 832. L Mancarella, Bobbio Pallavicini F, Ciccarelli F, Falappone PC, Ferrante A, Malesci D, Massara A, Nacci F, Secchi ME, Manganelli S, Salaffi F, Bambara ME, Bombardieri S, Cutolo M, Ferri C, Galeazzi M, Gerli R, Giacomelli R, Grassi W, Lapadula G, Matucci Cerinic M, Montecucco CM, Trotta F, Triolo G, Valentini G, Valesini G, Ferraccioli GF: Good clinical response, remission and predictors of

remission in rheumatoid arthritis patients treated with TNF α blockers: the GISEA study. *J Rheumatol* 2007;34:1947.

- 833.M Manetti, Neumann E, Milia AF, Tarner IH, Bechi P, Matucci Cerinic M, Ibba Manneschi L, Muller Ladner U: Severe fibrosis and increased expression of fibrogenic cytokines in the gastric wall of systemic sclerosis. *Arthritis Rheum* 2007;56:3442-7.

2006

- 834.S Guiducci, Fatini C, Rogai V, Cinelli M, Sticchi E, Abbate R, Matucci Cerinic M: Angiotensin-converting enzyme in systemic sclerosis: from endothelial injury to a genetic polymorphism. *Ann N Y Acad Sci.* 2006;1069:10-9.
- 835.L Ibba Manneschi, Niissalo S, Milia AF, Allanore Y, Del Rosso A, Pacini A, Manetti M, Toscano AR, Cipriani P, Liakouli V, Kahan A, Giacomelli R, Kontinen Y, Matucci Cerinic M,:Variations of neural nitric oxide synthase in systemic sclerosis skin. *Arthritis Rheum* 2006;54:202.
- 836.L Bertinotti, Mortilla M, Conforti ML, Fonda C, Matucci Cerinic M, Pignone A: Proton Magnetic resonance spectroscopy discloses central nervous system involvement in systemic sclerosis. *J Rheumatol* 2006;33:546.
- 837.C.Salvarani , Olivieri I, Pipitone N, Cantini F, Marchesoni A, Punzi L, Scarpa R, Matucci-Cerinic M for the Italian Society for Rheumatology: Recommendations of the Italian Society for Rheumatology for the use of biologic (TNF-alpha blocking) agents in the treatment of psoriatic arthritis *Clin Exp Rheumatol.* 2006;24:70.
- 838.AM Pignone, Del Rosso A, Fiori G, Matucci-Cerinic M, Becucci A, Tempestini A, Livi R, Generini S, Gramigna L, Benvenuti C, Carossino AM, Conforti ML, Perfetto F: Melatonin is a safe and effective treatment for chronic pulmonary and extrapulmonary sarcoidosis.*J Pineal Res.* 2006;41:95.
- 839.B Giusti, Fibbi G, Margheri F, Serrati S, Rossi L, Poggi F, Lapini I, Magi A, Del Rosso A, Cinelli M, Guiducci G, Kahaleh B, Bazzichi L, Bombardieri S, Matucci-Cerinic M, Gensini GF, Del Rosso M, Abbate R: A Model of Anti-angiogenesis: Differential Transcriptome Profiling of Microvascular Endothelial Cells from Diffuse Systemic Sclerosis patients. *Arthritis Res Ther* 2006;8:R115.
840. J Rovensky , Raffayova H, Imrich R, Radikova Z, Penesova A, Macho L, Lukac J, Matucci-Cerinic M, Vigas M:Prolactin and growth hormone responses to hypoglycemia in patients with systemic sclerosis and psoriatic arthritis. *Ann N Y Acad Sci.* 2006;1069:145
841. L Bertinotti , Nacci F, Matucci-Cerinic M: The measurement of outcome and the rheumatoid arthritis core set to lift the prejudice of the 'thumaturgus cliché'. *Rheumatology (Oxford).* 2006;45(9):1055-7.
- 842.S Guiducci, Fatini C, Rogai V, Cinelli C, Sticchi E, Abbate R, Matucci Cerinic M: Angiotensin Converting Enzyme in Systemic Sclerosis: from endothelial injury to gene polymorphism. *Ann NY Acad Sci* 2006;1069:10-9.
- 843.C Fatini , Mannini L, Sticchi E, Rogai V, Guiducci S, Conforti ML, Cinelli M, Pignone AM, Bolli P, Abbate R, Matucci Cerinic M: Hemorheologic profile in systemic sclerosis: Role of NOS3 -786T>C and 894G>T polymorphisms in modulating both the hemorheologic parameters and the susceptibility to the disease. *Arthritis Rheum* 2006;54:2263.
- 844.F Zulian, Woo P, Athreya B, Laxer R, Medsger T, Lehman T, Matucci Cerinic M, Martini G, Ravelli A, Russo R, Cuttica R, Knupp

- Feitosa de Oliveira S, Denton C, Cozzi F, Foeldvari I, Ruperto N for the Pediatric Rheumatology European Society (PRES): Preliminary EULAR/PRES/ACR classification criteria for juvenile systemic sclerosis. *Arthritis Rheum* 2006; 19(6):592-597.
845. M. Cinelli, S. Guiducci, Del Rosso A, Pignone A, Del Rosso M, Fibbi G, Serrati S, Gabrielli A, Giacomelli R, Piccardi N, Matucci Cerinic M: Piascledine modulates angiogenic factors VEGF, TIMP-1, TIMP-2 and reduces invasiveness of rheumatoid arthritis synoviocytes. *Scand J Rheumatol* 2006;44:1255.
846. PM Seferovic, Ristic AD, Maksimovic R, Simeunovic DS, Ristic GG, Radovanovic G, Seferovic D, Maisch B, Matucci-Cerinic M: Cardiac arrhythmias and conduction disturbances in autoimmune rheumatic diseases. *Rheumatology (Oxford)*. 2006;45 Suppl 4:iv39-iv42.
847. S Serrati, Cinelli M, Margheri F, Guiducci S, Del Rosso A, Pucci M, Fibbi G, Bazzichi L, Bombardieri S, Matucci-Cerinic M, Del Rosso M. Systemic sclerosis fibroblasts inhibit in vitro angiogenesis by MMP-12-dependent cleavage of the endothelial cell urokinase receptor. *J Pathol*. 2006;210:240-8.
848. R Maksimovic, Seferovic PM, Ristic AD, Vujisic-Tesic B, Simeunovic DS, Radovanovic G, Matucci-Cerinic M, Maisch B. Cardiac imaging in rheumatic diseases. *Rheumatology (Oxford)*. 2006;45 Suppl 4:iv26-31.
849. M Matucci-Cerinic, Seferovic PM: Heart involvement in autoimmune rheumatic diseases: the "phantom of the opera". *Rheumatology (Oxford)*. 2006;45 Suppl 4:iv1-iv3.
850. S Guiducci, Fatini C, Georgountzos A, Sticchi E, Cinelli M, Kaloudi O, Rogai V, Melchiorre D, Pignone A, Vlachoyannopoulos P, Abbate R, Matucci Cerinic M: Etrurians vs Greeks: May ACE I/D polymorphism still be considered as a marker of susceptibility to SSc? *Clin Exp Rheumatol*. 2006;24:432-4.
851. I Orlandi, Camiciottoli G, Diciotti S, Bartolucci M, Cavigli E, Nacci F, Matucci-Cerinic M, Villari N, Mascalchi M: Thin-section and low-dose volumetric computed tomographic densitometry of the lung in systemic sclerosis. *J Comput Assist Tomogr*. 2006;30:823-7.
852. P Cipriani, Franca Milia A, Liakouli V, Pacini A, Manetti M, Marrelli A, Toscano A, Pingiotti E, Fulminis A, Guiducci S, Perricone R, Kahaleh B, Matucci-Cerinic M, Ibba-Manneschi L, Giacomelli R: Differential expression of stromal cell-derived factor 1 and its receptor CXCR4 in the skin and endothelial cells of systemic sclerosis patients: Pathogenetic implications. *Arthritis Rheum*. 2006;31;54:3022-3033.
853. P Cipriani P, Fulminis A, Pingiotti E, Marrelli A, Liakouli V, Perricone R, Pignone A, Matucci-Cerinic M, Giacomelli R.: Resistance to Apoptosis in Circulating and T Lymphocytes from Patients with Systemic Sclerosis. *J Rheumatol*. 2006 ;33:2003-14.
854. O Distler, Behrens F, Huscher D, Foeldvari I, Zink A, Nash P, Denton CP, Humbert M, Matucci-Cerinic M, Seibold J, Rubin L, Furst DE: Need for improved outcome measures in pulmonary arterial hypertension related to systemic sclerosis. *Rheumatology (Oxford)*. 2006;45:1455.
855. S Guiducci, Cutolo M, Matucci Cerinic M: Pathogenetic mechanisms in scleroderma. *Helv Rev Rheumatol* 2006;1069:10-9.
856. A Del Rosso, Matucci Cerinic M, Rotella C, Seghieri G: Rheumatological manifestations in Diabetes Mellitus. *Curr Diabetes Rev* 2006;2:455-67.

2005

857. F Perfetto, Tarquini R, Simonini G, Bindi G, Mancuso F, Guiducci S, Matucci-Cerinic M, Falcini F: Circulating leptin levels in juvenile idiopathic arthritis: a marker of nutritional status? *Ann Rheum Dis*. 2005; 64:149
858. JP.A. Ioannidis, Vlachoyiannopoulos PA, Haidich A, Medsger TA, Jr., Lucas M, Clement M, Kuwana M, Yasuoka H, van den Hoogen F, te Boome L, M. van Laar J, Verbeet NL, Matucci Cerinic M, Georgountzos A, Moutsopoulos HM: Mortality in systemic sclerosis: an international meta-analysis of individual patient data. *Am J Med* 2005;118:2
859. S Generini, Seibold J, Matucci Cerinic M: Estrogens and Neuropeptides in Raynaud's phenomenon. *Rheum Dis Clin N Am* 2005 ;31:177
860. A Del Rosso , Distler O, Franca Milia AF, Emanuelli E, Ibba Manneschi L, Guiducci S, Conforti ML, Pignone A, Generini S, Gay S, Madeddu P, Matucci Cerinic M: Increased circulating levels of tissue kallikrein in systemic sclerosis correlate with microvascular involvement. *Ann Rheum Dis* 2005;64:382
861. T Schaible, del Rosso A, Matucci Cerinic M: Neurogenic aspects of inflammation. *Rheum Dis Clin N Am* 2005;31:77
862. J Distler, Hirth A, Jungel A, Kowal Bielecka O, Beat M, Gay RE, Sprott H, Matucci Cerinic M, Meike C, Reich K, Kalden JR, Muller Ladner U, Lorenz HM, Gay S, Distler O: Expression of IL-21 receptor in the epidermis from patients with systemic sclerosis. *Arthritis Rheum* 2005 ;52:856
863. AF Milia, Del Rosso A, Pacini A, Manetti M, Marrelli A, Nosi D, Giacomelli R, Matucci-Cerinic M, Ibba-Manneschi L: Differential expression of tissue kallikrein in the skin of systemic sclerosis. *Histol Histopathol*. 2005 ;20:415
864. L. Ibba Manneschi, Del Rosso A, Milia AF, Tani A, Nosi D, Pignone A, Generini S, Giacomelli R, Matucci Cerinic M: Damage of cutaneous peripheral nervous system evolves differently according to the disease phase and subset of systemic sclerosis. *Rheumatology (Oxford)*. 2005 ;44:607
865. G Valentini, Matucci Cerinic M, Bombardieri S on behalf of the participants to the consensus conference: The Assessment of the patient with systemic sclerosis in clinical investigation. *Scleroderma Care & Research* 2005:2:3
866. S Guiducci, Cinelli M, Del Rosso A, Margheri F, D'Alessio S, Fibbi G, Matucci Cerinic M, Del Rosso M: Rheumatoid synovial fibroblasts constitutively express the fibrinolytic pattern of invasive tumor like cells. *Clin Exp Rheumatol* 2005;23:364
867. L Robertson, Pignone A, Kowal Bielecka O, Fiori G, Denton CP, Matucci Cerinic M: Pulmonary arterial hypertension in systemic sclerosis: diagnostic pathway and therapeutic approach. *Ann Rheum Dis* 2005;64:804
868. G Simonini, Azzari C, Gelli AM, Giani T, Calabri GB, Leoncini G, Del Rosso A, Generini S, Cimaz R, Matucci Cerinic M, Falcini F.: Neprilysin levels in plasma and synovial fluid of juvenile idiopathic arthritis patients. *Rheumatol Int* .2005 ;25:336
869. A Tyndall , Mueller-Ladner U, Matucci-Cerinic M: Systemic sclerosis in Europe: first report from the EULAR Scleroderma Trials And Research (EUSTAR) group database. *Ann Rheum Dis*. 2005;64:1107
870. A. Del Rosso, M. Cinelli, S. Guiducci, A. Pignone, G. Fibbi, F. Margheri, M. Del Rosso, A. Gabrielli, R. Giacomelli, A. Coppini, M.

- Matucci Cerinic: Deflazacort modulates the fibrinolytic pattern and reduces uPA-dependent chemoinvasion and proliferation in rheumatoid arthritis synoviocytes. *Rheumatology* 2005; 44:1255
871. F Bandinelli, Bartoli F, Perfetto F, Del Rosso A, Moggi Pignone A, Guiducci S, Cinelli M, Fatini C, Generini S, Gabrielli A, Giacomelli R, Maddali Bongi S, Abbate R, Del Rosso M, Matucci Cerinic M: The fibrinolytic system components are increased in systemic sclerosis and modulated by Alprostadil. *Clin Exp Rheumatol* 2005;23:671
872. M Benucci, Del Rosso A, Gobbi FL, Manfredi M, Matucci Cerinic M, Salvarani C: Systemic Lupus Erythematosus (SLE) in Italy: an Italian prevalence study based on a two-step strategy in an area of Florence (Scandicci-Le Signe). *Med Sci Monit.* 2005 ;11:CR420
873. S Guiducci, A Del Rosso, M Cinelli, F Perfetto, R Livi, A Rossi, A Gabrielli, R Giacomelli, N Iori, G Fibbi, M Del Rosso, M Matucci Cerinic: Raloxifene reduces urokinase-type plasminogen activator-dependent proliferation of synoviocytes from patients with rheumatoid arthritis. *Arthritis Res Ther* 2005; 7:R1244
874. B Giusti, Serrati S, Margheri F, Papucci L, Rossi L, Poggi F, Magi A, Del Rosso A, Cinelli M, Guiducci S, Kahaleh B, Matucci-Cerinic M, Abbate R, Fibbi G, Del Rosso M. The antiangiogenic tissue kallikrein pattern of endothelial cells in systemic sclerosis. *Arthritis Rheum* 2005;52:3618-28
875. F Perfetto, Cantini F, Di Natale M, Livi R, Tempestini A, Matucci-Cerinic M: Seasonal pattern in the onset of polymyalgia rheumatica. *Ann Rheum Dis.* 2005 ;64:1662-3 2005
876. F Iannone, Matucci Cerinic M, Falappone PC, Guiducci S, Cinelli M, Distler O, Lapadula G: Distinct expression of adhesion molecules on skin fibroblasts from patients with diffuse and limited systemic sclerosis. A pilot study. *J Rheumatol.* 2005 ;32:1893-8.
877. Y Shoenfeld, Gerli R, Doria A, Matsumura E, Matucci Cerinic M, Ronda N, Jara LJ, Abu-Shakra M, Meroni PL, Sherer Y: Accelerated atherosclerosis in autoimmune rheumatic disease. *Circulation* 2005 22;112:3337s
878. I Miniati, Saccardi R, Pagliai F, Guiducci S, Bosi A, Guidi S, Urbani S, Tyndall A, Matucci Cerinic M: Trattamento della forma diffusa di sclerosi sistemica con trapianto autologo di cellule staminali emopoietiche: esperienza su due casi. *Reumatismo* 2005;57:277

2004

879. L Bertinotti, Bracci S, Nacci F, Colangelo N, Del Rosso A, Casale R, Pignone A, Matucci Cerinic M: The autonomic nervous system in systemic sclerosis. A review *Clin Rheumatol* 2004;23;1
880. Distler J, Hagen C, Hirth A, Muller-Ladner U, Lorenz HM, Del Rosso A, Michel BA, Gay RE, Nanagara R, Nishioka K, Matucci Cerinic M, Kalden JR, Gay S, Distler O: Bucillamine and its metabolites induce the synthesis of VEGF dose dependently in systemic sclerosis fibroblasts via NF- κ B and SP-1 pathways. *Mol Pharmacol* 2004;65:389
881. Y Levy, Amital H, Langevitz P, Nacci F, Righi A, Conforti ML, Generini S, Matucci Cerinic M, Shoenfeld Y: Intravenous immunoglobulin modulate cutaneous involvement and reduce skin fibrosis in systemic sclerosis – An open study. *Arthritis Rheum* 2004;50:1005
882. C Fatini, Guiducci S, Abbate R, Matucci-Cerinic M: Vascular injury in systemic sclerosis Angiotensin Converting Enzyme I/D polymorphism. *Curr Rheumatol Rep* 2004;6:149

- 883.N Colangelo, Bertinotti L, Nacci F, Conforti ML, Beneforti E, Pignone A, Matucci Cerinic M, Zoppi M: Dimensions of psychological dysfunction in patients with fibromyalgia: development of an Italian questionnaire. Clin Rheumatol 2004;23:102
- 884.A Del Rosso, Boldrini M, D'Agostino D, Plinio G, Placidi A, Scarpato A, Pignone A, Generini S, Kontinen Y, Zoppi M, Vlak T, Placidi, GF, Matucci Cerinic M : Health related quality of life in systemic sclerosis as measured by SF36: relationship with clinical and biological markers. Arthritis Care Res (Arthritis Rheum) 2004; 51,475
- 885.Casale R, Frazzitta G, Fundaro C, Balbi P, Rosso AD, Bertinotti L, Matucci-Cerinic M: Blink reflex discloses CNS dysfunction in neurologically asymptomatic patients with systemic sclerosis. Clin Neurophysiol 2004; 15:1917
- 886.R Giacomelli, Cipriani P, Fulminis A, Nelson L, Matucci Cerinic M: $\square$ T cells in placenta and skin: their different functions may support the paradigm of microchimerism in systemic sclerosis Clin Exp Rheumatol 2004;22 (suppl 33):s28
887. O Distler, Distler J, Scheid A, Acker T, Hirth A, Rethage J, Michel BA, Gay RE, Muller Ladner U, Matucci Cerinic M, Plate KH, Gassman M, Gay S: VEGF and its receptors in systemic sclerosis-regulation by hypoxia and hypoxia inducible factor 1alfa. Circulation Res 2004;95:109
- 888.A Falchetti, Di Stefano M, Marini F, Del Monte F, Mavilia C, Strigoli D, Cioppi F, Ghinoi V, De Feo ML, Isaia G, Masi L, Amedei A, Maddali Bongi S, Di Fede G, Sferazza C, Rini B, Melchiorre D, Matucci Cerinic M, Brandi ML: Two novel mutations at exon 8 of Sequestosome 1 gene (SQSTM1) in an italian series of patients affected by Paget's disease of bone. J Bone Min Res . 2004 ;19:1013
- 889.P Milner, Bodin P, del Rosso A, Guiducci S, Kahaleh B, Matucci Cerinic M, Burnstock G: Regulation of substance P mRNA expression in human dermal microvascular endothelial cells in systemic sclerosis. Clin Exp Rheumatol 2004;22 (suppl 33):s24
- 890.R Casale, Generini S, Luppi F, Pignone A, Matucci Cerinic M: Pulse cyclophosphamide decreases sympathetic postganglionic activity, controls alveolitis, and normalizes vascular tone dysfunction (Raynaud's phenomenon) in a case of early systemic Arthritis Care Res (Arthritis Rheum) 2004; 51: :665sclerosis
- 891.D'Alessio, Fibbi G, Cinelli M , Guiducci S, Del Rosso A, Margheri F , Pucci M, Calzolari A, Kahaleh BM, Fan P, Annunziato F, Cosmi L, Liotta F, Matucci-Cerinic M, Del Rosso M: Angiogenesis in Systemic Sclerosis: Cleavage of Urokinase Receptor (CD87) Endothelial Cell Results in Impaired Angiogenesis in Vitro Arthritis Rheum 2004;50:3275
- 892.M Dougados, Betteridge N, Burmester GR, Euller-Ziegler L, Guillemin F, Hirvonen J, Lloyd J, Özen S, Pereira da Silva AP, Emery P, Kalden J, Kvien TK, Matucci-Cerinic M, Smolen JS: EULAR Standardized Operating Procedures for the Elaboration, Evaluation, Dissemination and Implementation of Recommendations endorsed by EULAR Standing Committee Ann Rheum Dis 2004;63:1172
- 893.A del Rosso, Ibba Manneschi L, Tani A, Nosi D, Milia AF, Generini S, Guiducci, S, Melchiorre D, Pignone A, Matucci Cerinic M: Il sistema nervoso periferico nella sclerosi sistemica limitata. Reumatismo 2004;56:245
- 894.R Wu , Shoenfeld Y, Matucci Cerinic M, Gerli R, Perfetto F, Gilburd G, Shen G, Lehrhoff L, R Morris R; Leptin, Anti-HSP60, Anti-HSP65

- and AntioxLDL in Autoimmune Rheumatic Diseases. Immunology 2004, Medimond Editor, pp 315
895. S Generini, Giacomelli R, Fedi R, Fulminis A, Pignone A, Frieri G, Del Rosso A, Viscido A, Galletti B, Fazzi M, Tonelli F, Matucci Cerinic M. Infliximab in spondyloarthritis associated with Crohn's disease: an open study on the efficacy in inducing and maintaining remission of musculoskeletal and gut manifestation. Ann Rheum Dis. 2004 ;63:1664
 896. R Saccardi, Tyndall A, Coghlan J, Denton C, Edan G, Emdin M, Farge D, Fassas A, Finke MJ, Lassus M, Mancardi GL, Miniati I, Mini F, Pagliai F, Passweg J, Pignone A, van Laar JM, Tyndall A, Matucci Cerinic M: Consensus statement concerning cardiotoxicity occurring during hematopoietic stem cell transplantation of autoimmune disease, with special reference to systemic sclerosis and multiple sclerosis. Bone Marrow Transplantation 2004;34:877
 897. S Generini S, Tuveri MA, Matucci Cerinic M, Mastinu F, Manni L, Aloe L: Topical application of nerve growth factor in human diabetic foot ulcers. A study of three cases. Exp Clin Endocrinol Diabetes. 2004;112:542
 898. JT Studynkova, Kuchen S, Jeisy E, Schedel J, Charvat F, Jarosova K, Sprott H, Matucci-Cerinic M, Gay RE, Michel BA, Pavelka K, Vencovsky J, Gay S: The expression of cyclooxygenase-1, cyclooxygenase-2 and 5-lipoxygenase in inflammatory muscle tissue of patients with polymyositis and dermatomyositis. Clin Exp Rheumatol. 2004;22:395
 899. Korn JH, Mayes M, Matucci Cerinic M, Rainisio M, Pope J, Hachulla E, Rich E, Carpentier P, Molitor J, Seibold JR, Hsu V, Guillevin L, Chatterjee S, Peter HH, Coppock J, Herrick A, Merkel PA, Simms R, Denton CP, Furst D, Nguyen N, Gaitonde M, Black C :Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum. 2004;50:3985
 900. G Fiori, Amanzi L, Moggi Pignone A, Braschi F, Matucci-Cerinic M :The treatment of skin ulcers in patients with systemic sclerosis. Reumatismo. 2004;56:225

2003

901. M Matucci Cerinic, Valentini G, Sorano G, D'Angelo S, Cuomo G, Fenu L, Generini S, Cinotti S, Morfini M, Pignone A, Guiducci S, Kalfin R, Das D, Marongiu F: Blood coagulation , fibrinolysis and markers of endothelial dysfunction in systemic sclerosis. Semin Arthritis Rheum 2003 ;32,:285
902. A Del Rosso, Bertinotti L, Pietrini U, Messori A, Sicuteri R, Casale R, Generini S, Matucci Cerinic M: Pupillo-cytotoxic activity of substance P in systemic sclerosis (scleroderma). J Rheumatol 2003 ;30, 1231
903. S Generini, Del Rosso A, Pignone A, Matucci Cerinic M: Current treatment options in Raynaud's phenomenon. Curr Treat Option Cardio Med 2003, 5:147
904. M Matucci Cerinic, D'Angelo S, Denton C, Vlachoyannopoulos P, Silver R: Assessment of lung involvement. Clin Exp Rheumatol 2003;21 (suppl 29),s19
905. C Salvarani, Olivieri I, Cantini F, Matucci Cerinic M, Punzi L: Esperienze cliniche con Infliximab nella spondilite anchilosante. Reumatismo 2003;55 (suppl 7): 9
906. A Tyndall, Matucci Cerinic M: Hematopoietic stem cell transplantation for the treatment of systemic sclerosis. Expert Opinions in Biological Therapy 2003;3:1041

- 907.M Cutolo, Grassi W, Matucci Cerinic M: Capillaroscopy and Raynaud's phenomenon. *Arthritis Rheum* 2003;46: 3023
- 908.R Giacomelli, Matucci Cerinic S, Bombardieri S: The paradigm of microchimerism in Sjogren syndrome and other autoimmune diseases. *Ann Rheum Dis* 2003; 61,1039
- 909.G Simonini, Nacci F, Falcini F, Pignone AM, Desideri E, Pellegrini P, Matucci Cerinic M: Esperienza maturata in un ambulatorio pilota di reumatologia per i giovani adulti. *Toscana Medica* 2003;10:15
- 910.R Giacomelli, Valentini G, Salsano F, Fulminis A, Bombardieri S, Gabrielli A, Matucci Cerinic M: Cyclophosphamide pulse regimen in the treatment of alveolitis in Systemic Sclerosis- Reply. *J Rheumatol* 2003;30 :1122
- 911.I Olivieri, Salvarani C, Cantini F, Punzi L, Matucci Cerinic M: Raccomandazioni per l'inizio della terapia con anti tnf alfa in pazienti con spondilite anchilosante. *Reumatismo* 2003;55:220

2002

- 912.A Righi, Schiavon P, Jablonska S, Rondinone, Doria A, Todesco S, Matucci Cerinic M: Treatment of Scleromyxedema with intravenous immunoglobulins. *Ann Rheum Dis* 2002;61:59
- 913.S Guiducci, Del Rosso A, Pignone A, Generini S, Matucci Cerinic M: Il fenomeno di Raynaud nella terza età. *Giornale Italiano di Gerontologia. Geriatria* 2002;49:285
- 914.R Giacomelli, G Valentini, F Salsano, Cipriani P, Sambo P, Conforti ML, Fulminis A, De Luca A, Farina G, Candela M, Generini S, De Francisci A, Tirri E, Proietti M, Bombardieri S, Gabrielli A, Matucci Cerinic M: Cyclophosphamide pulse regimen for the treatment of alveolitis in systemic sclerosis. *J Rheumatol* 2002;29:731
- 915.S Gabbrielli, Pignone A, Matucci Cerinic M: Is bronchoalveolar lavage also an interstitial lavage? *Clin Exp Rheumatol* 2002;20:441
- 916.L Ibba Manneschi, Del Rosso A, Pacini S, Bechi P, Matucci Cerinic M: The ultrastructure of the muscle coat of the gastric wall in a case of systemic sclerosis. *Ann Rheum Dis* 2002;61:754
- 917.L Bertinotti, Pietrini U, Del Rosso A, Casale R, Colangelo N, Zoppi M, Matucci Cerinic M: The use of pupillometry in joint and connective tissue diseases. *Ann NY Acad Sci* 2002;966:446
- 918.C Fatini, Gensini F, Sticchi E, Battaglini B, Angotti C, Conforti ML, Generini S, Pignone A, Abbate R, Matucci Cerinic M: High prevalence of ACE I/D and endothelial nitric oxide synthase glu298—Asp, but not of T-786—C polymorphism in systemic sclerosis. *Am J Med* 2002;112:540
- 919.R Livi, Teghini L, Pignone A, Generini S, Matucci Cerinic M, Cagnoni M: Renal functional reserve is impaired in patients with systemic sclerosis without clinical signs of kidney involvement. *Ann Rheum Dis* 2002;61:682
- 920.R Giacomelli, Cipriani P, Matucci Cerinic M, Fulminis A, Barattelli G, Pingiotti E, Di Franco M, Trotta A, Perticone R, Zazzeroni F, Alesse E, Toniatti G: Combination therapy with cyclosporine and methotrexate in patients with early rheumatoid arthritis soon inhibits TNFalfa production without decreasing TNFalfa mRNA levels. An in vivo and in vitro study. *Clin Exp Rheumatol* 2002;20:365
- 921.O Distler, del Rosso A, Giacomelli R, Cipriani P, Conforti ML, Guiducci S, Gay R, Michel BA, Brühlmann P, Müller-Ladner U, Gay S, Matucci-Cerinic M: Angiogenic and angiostatic factors in systemic sclerosis: Increased levels of vascular endothelial growth factor (VEGF) are a feature of earliest disease stages and are

- associated with the absence of fingertip ulcers. *Arthritis Res Ther* 2002;4:r11
- 922.M Matucci Cerinic, Kahaleh BM: Beauty and the beast. The nitric oxide paradox in systemic sclerosis. *Rheumatology* 2002; 41:843.
- 923.L Bertinotti, Miniati I, Matucci Cerinic M: Angioedema and systemic sclerosis. A review of the literature. *Scand J Rheumatol* 2002;31,178
- 924.S Generini, Fiori G, Matucci Cerinic M: Therapy of spondyloarthropathy in inflammatory bowel disease. *Clin Exp Rheumatol* 2002;20 (suppl 28):s88
- 925.G Fiori, Pignone A, Matucci Cerinic M: Overlap Syndromes. *Reumatizam* 2002.;9,12
- 926.A Righi, Matucci Cerinic M: The therapy of systemic sclerosis: the rheumatologic perspective. *J Eur Acad Dermatol* 2002; 16,431
- 927.Kalfin R, Righi A, Del Rosso A, Bagchi D, Das DK, Generini S, Guiducci S, Matucci Cerinic M: Activin, a grape seed derived proanthocyanidin extract, reduces oxidative stress and adhesion molecules (ICAM-1, VCAM-1 and E-selectin) plasma levels in systemic sclerosis. *Free Radical Res* 2002; 36:819
- 928.P Failli, D'Alfonso C, Giovannelli L, Generini S, Del Rosso A, Pignone A, Stanflin N, Orsi M, Zilletti L, Matucci Cerinic M: N-acetyl cysteine reduces superoxide anion and peroxynitrite production of lung alveolar macrophages in systemic sclerosis. *Nitric Oxide* 2002; 7:277
- 929.A Pignone, Fiori G, Del Rosso A, Generini S, Matucci Cerinic M: The pathogenesis of inflammatory muscle diseases: on the cutting edge among th environment, the genetic background, the immune response and the dysregulation of apoptosis. *Autoimmunity Rev* 2002; 1: 226

2001

- 930.G Simonini, Matucci Cerinic M, Cimaz R, Anichini A, Cesaretti S, Zoppi M, Falcini F: Evidence for immune activation against oxidised lipoproteins in inactive phase of juvenile chronic arthritis *J Rheumatol* 2001;28:198
- 931.Herrick A, Matucci Cerinic M: The emerging problem of oxidative stress and the role of antioxidants in systemic sclerosis *Clin Exp Rheumatol* 2001;19:1
- 932.R Livi, Teghini L, Generini S, Matucci Cerinic M: The loss of endothelial dependent control in systemic sclerosis. *Chest* 2001;119:672
- 933.M Matucci Cerinic, Giacomelli R, Pignone , Cagnoni ML, Generini S, Casale R, Cipriani P, Del Rosso A, Tirassa P, Konttinen Y, Kahaleh MB, Pan-Sheng F, Paoletti M, Marchesi C, Cagnoni M, Aloe L: Nerve growth factor and neuropeptides circulating levels in systemic sclerosis *Ann Rheum Dis* 2001;60:487
- 934.K Djouadi, Nedelec B, Tamouza R, Genin E, Ramasawmy R, Charron D, Delpech M, Laoussadi S, and the contributing EUROAS (Matucci Cerinic M): Interleukin 1 genes cluster polymorphisms in multiplex families with spondylarthropathies. *Cytokines* 2001;13:98
- 935.G Valentini, Della Rossa A, Bombardieri S, Bencivelli W, Matucci Cerinic M and the European Scleroderma Study Group: Disease activity in systemic sclerosis. II. Identification of disease activity variables and development of preliminary criteria indexes. *Ann Rheum Dis* 2001;60:592
- 936.S Generini, Matucci Cerinic M, Partsch G, Stancikova M, Pignone A, Konttinen YT, Rovensky J, Baker DJ, Schumacher HR jr: Evidence for hyaluronan production in the air pouch model in rats. *Clin Exp*

- Rheumatol 2001;19:271
937. A Della Rossa, Valentini G, Bombardieri S, Bencivelli W, Matucci Cerinic M and the European Scleroderma Study Group: European multicentre study for defining the disease activity criteria of systemic sclerosis. I. A descriptive analysis of 318 european scleroderma patients. *Ann Rheum Dis* 2001;60:585
 938. A Del Rosso, Pignone A, Giacomelli R, Matucci Cerinic M: Familial scleroderma: Do environmental factors, genes and microchimerism share the same relevance? *J Eur Acad Dermatol* 2001;15:11
 939. A Pignone, Generini S, Matucci Cerinic M: PGE1 restores the levels of vWF and ACE in chronic critical limb ischemia in systemic sclerosis. *Clin Exp Rheumatol* 2001;19:358
 940. O Kowal-Bielecka, Distler O, Neidhart M, Künzler P, Rethage J, Nawrath M, Carossino A, Pap T, Muller-Ladner U, Michel BA, Sierakowski S, Matucci-Cerinic M, Gay R, Gay S: Evidence for 5-lipoxygenase overexpression in the skin of patients with systemic sclerosis. A new pathway to skin inflammation. *Arthritis Rheum* 2001;44:1865
 941. R Giacomelli, Cipriani P, Fulminis A, Barattelli G, Matucci Cerinic M, D'Alò S, Cifone G, Tonietti G: Circulating T lymphocytes of systemic sclerosis patients display a T helper Th1 polarization. *Clin Exp Immunol* 2001;125:310
 942. P Sambo, Amico D, Giacomelli R, Matucci Cerinic M, Salsano F, Valentini G, Gabrielli A: Intravenous N-acetylcysteine for the treatment of Raynaud's phenomenon secondary to systemic sclerosis: A pilot study *J Rheumatol* 2001;28:2257
 943. O Distler, Pap T, Kowal-Bielecka O, Meyringer R, Guiducci S, Landthaler M, Scholmerich J, Michel B, Gay R, Matucci Cerinic M, Gay S, Muller-Ladner U: Overexpression of MCP-1 in systemic sclerosis: role of PDGF and effects of monocyte chemotaxis and collagen synthesis. *Arthritis Rheum* 2001;44:2665
 944. M Matucci Cerinic: I coxib: una nuova via terapeutica. *Celecoxib. Annali Italiani di Medicina Interna*. 2001;16 (suppl 3):104s-110s
 945. A Pignone, Matucci Cerinic M: Le patologie artrosiche. *Pathos* 2001;8 (suppl),4
 946. ML Brandi, Gennari L, Matucci Cerinic M, Becherini L, Falchetti A, Gennari C, Reginster JY: Genetic markers of osteoarticular disorders: facts and hopes. *Arthritis Res* 2001;3:270

2000

947. M Matucci Cerinic, Pignone A, Generini S, Korn J: May fibroblasts determine the late different fate of systemic sclerosis and primary hypertrophic osteoarthropathy? *Clin Exp Rheumatol* 2000;18:1
948. G Simonini G, Generini S, Pignone A, Falcini F, Matucci Cerinic M: Diene conjugates and antibodies against oxidised low density lipoproteins in systemic sclerosis. *Eur J Int Med* 2000;11:289
949. M Tuveri, Generini S, Matucci Cerinic M, Aloe L: Nerve growth factor a useful tool in the treatment of chronic vasculitic ulcers in rheumatoid arthritis. *Lancet* 2000;356:1739
950. F Falcini, Calzolari A, Pignone A, Ermini ME, Scaletti C, Zulian F, Generini S, Simonini G, Matucci Cerinic M: Bcl-2, p53 and c-myc expression in juvenile dermatomyositis. *Clin Exp Rheumatol* 2000;18:643
951. A Del Rosso, Righi A, Casale R, Generini S, Pignone A, Busciglio J, Pelsman A, Rothfield N, Conforti ML, Cagnoni M, Matucci Cerinic M; Anticorpi antineurone nella sclerosi sistemica. *Reumatismo*

2000;52:210

952. Simonini S, Pignone A, Generini S, Falcini F, Matucci Cerinic M: Emerging potentials for an antioxidant therapy as a new approach to the treatment of systemic sclerosis. *Toxicology* 2000;155:1
953. M Matucci Cerinic, Fiori G, Pignone A: La disabilità da patologia muscoloscheletrica nell'anziano: trials clinici. *G Ital Geriatria e Gerontologia* 2000;48:572

1984-2000

954. M Matucci Cerinic, Iannone F, Carossino AM, Pignone A, Leoncini G, Generini S, Lapadula G, Cagnoni M: Dyscrepant expression of neprilysin on fibroblasts in diffuse systemic sclerosis. *J Rheumatol* 1999;26:347
955. F Falcini, Lombardi A, Generini S, Pignone A, Cimaz R, Partsch G, Ermini M, M Matucci Cerinic: Are angiotensin converting enzyme and von Willebrand factor circulating levels useful surrogate parameters to monitor disease activity in Kawasaki disease? *Endothelium* 1999;6:209
956. R Cimaz, Matucci Cerinic M, Zulian F, Falcini F: Reflex sympathetic dystrophy in children. *J Child Neurol* 1999;14: 363
957. G Simonini, Matucci Cerinic M, Generini S, Zoppi M, Anichini M, Cesaretti A, Pignone A, Falcini F; Lotti T, Cagnoni M. Oxidative stress in systemic sclerosis. *Mol Cell Biochem* 1999;196:185
958. M Del Rosso, Fibbi G, Matucci Cerinic M: The urokinase-type plasminogen activator system and inflammatory joint diseases. *Clin Exp Rheumatol* 1999;17:485
959. S Knupp-Oliveira, Matucci Cerinic M: Polyneuropathy as initial manifestation of systemic sclerosis. *Scand J Rheumatol* 1999;28:260
960. F Falcini, Azzari C, Gelli MG, Ermini M, Luchetti M, Gabrielli A, Calzolari A, Pignone A, Generini S, Matucci Cerinic M: Reduction of bcl-2 in T cells during immunosuppressive therapy in patients with severe juvenile onset systemic lupus erythematosus. *Clin Immunol* 1999;93:59
961. M Matucci Cerinic, G Fiori, S Generini, Systemic sclerosis: a clinical overview. *Adv Exp Med Biol* 1999;73,455
962. A Del Rosso, Generini S, Pignone A, Matucci Cerinic M: Vasculitides in internal medicine. *Clinics Dermatol* 1999;171:533
963. Sergio Generini, Marco Matucci Cerinic: Raynaud's phenomenon and vascular disease in systemic sclerosis. *Adv Exp Med Biol* 1999;93,455
964. A Del Rosso, Generini S, Casale R, Zoppi M, Matucci Cerinic M: Neurogenic inflammation and joint diseases. *On line Rheumatology Archives* 1999
965. E Witort Serraglini, Del Rosso M, Lotti T, Matucci Cerinic M: Endothelial injury in vasculitides. *Clinics Dermatol* 1999;171;587
966. R Giacomelli, Matucci-Cerinic M, Cipriani P, Ghersetich I, Lattanzio R, Pavan A, Pignone A, Cagnoni ML, Lotti T, Toniatti G: Circulating Vd1+ T cells are activated and migrate in the skin of systemic sclerosis patients. *Arthritis Rheum.* 1998;41:327
967. G Fibbi, Pucci M, Serni U, Matucci Cerinic M, Del Rosso M: Antisense targeting of the urokinase receptor blocks urokinase-dependent proliferation, chemoinvasion, and chemotaxis of human synovial cells and chondrocytes in vitro. *Proc Assoc Am Phys* 1998;110:340
968. S Generini, Fiori G, Pignone A, Matucci Cerinic M: L'interessamento vascolare nella sclerosi sistemica: dalla patogenesi alle metodiche

- diagnostiche. *Cenesthesia* 1998;IV:4
969. M Matucci Cerinic, Partsch G, Generini S, Pignone A, Dini G, Konttinen Y, Del Rosso M. Synoviocytes from osteoarthritis and rheumatoid arthritis produce plasminogen activators and plasminogen activator inhibitor-1 and display u-PA receptor on their surface *Life Sci* 1998;63:441
 970. M Matucci Cerinic, Cutolo M, Generini S, Konttinen Y: Neuropeptides and hormones in arthritis. *Curr Op Rheumatol* 1998;10:220
 971. M Del Rosso, Fibbi G, Pucci M, Matucci Cerinic M: Antisense oligonucleotides against the urokinase receptor. A common therapeutic strategy for the control of cell invasion in rheumatoid arthritis and cancer. *Clin Exp Rheumatol* 1998;16:245
 972. J Lassus, Salo J, Jiranek WA, Santavirta S, Nevalainen J, Matucci Cerinic M, Horak P, Konttinen Y: Macrophage activation results in bone resorption. *Clin Orthoped* 1998;7:352
 973. A Pignone, Scaletti C, Matucci Cerinic M, Vazquez-Abad D, Del Papa N, Meroni PL, Generini S, Calzolari A, Rothfield N, Cagnoni M: Antiendothelial cell antibodies in systemic sclerosis: correlation with vascular involvement *Clin Exp Rheumatol* 1998;16:572
 974. JW Xu, Konttinen YT, Li TF, Waris V, Lassus J, Matucci Cerinic M, Sorsa T, Santavirta S: Production of PDGF in aseptic loosening of total hip replacement. *Rheumatol Int* 1998;17:215
 975. F Falcini, De Simone L, Donzelli L, Matucci Cerinic M: Congenital conduction defects in children born to asymptomatic mothers with anti-SSA/SSB antibodies: report of two cases. *Ann Ital Med Int* 1998;13:169
 976. A Ceponis, Konttinen YT, Takagi M, Xu JW, Sorsa T, Matucci Cerinic M, Santavirta S, Bankl HC, Valent P: Expression of stem cell factor and SCF receptor (c-kit) in synovial membrane in arthritis: correlation with synovial mast cell hyperplasia and inflammation. *J Rheumatol* 1998;25:2304
 977. M Matucci Cerinic, Generini S, Pignone A, Cagnoni M: From Raynaud's phenomenon to systemic sclerosis: lack or exhaustion of adaptation? *Adv Org Biol* 1998;6:241
 978. Matucci Cerinic M, Casale R, Del Rosso A, Generini S, Pignone A, Cagnoni M: Le complicanze neurologiche in corso di sclerosi sistemica. *Ital J Neurosci* 1998;19:s235
 979. F Falcini, Taccetti G, Ermini M, Trapani S, Calzolari A, Franchi A, Matucci Cerinic M. Methotrexate provokes the appearance and rapid progression of rheumatoid nodules in systemic onset juvenile rheumatoid arthritis. *Arthritis Rheum* 1997; 40, 175
 980. A Lombardi, Matucci Cerinic M, Leoncini G, Pignone A, Generini S, Carossino AM, Scaletti C, Partsch G, Del Rosso M, Cagnoni M: Urokinase-type plasminogen activator is the main plasminogen activator produced by synoviocytes of osteoarthritis and rheumatoid arthritis. *Ann Ital Med Int* 1997;12, 132
 981. N Santavirta, Konttinen YT, Tornwall J, Segerberg M, Santavirta S, Matucci Cerinic M, Bjorvell H: Neuropeptides of the autonomic nervous system in Sjogren System. *Ann Rheum Dis* 1997, 56,737
 982. F Falcini, Generini S, Ermini M, Trapani S, Matucci Cerinic M: Clinical and laboratory features and disease outcome of Kawasaki disease The analysis of our experience and literature review. *J Clin Rheumatol* 1997;3,241
 983. R Casale, Buonocore M, Matucci Cerinic M: Rehabilitation for systemic sclerosis. *Arch Phys Med Rehabil* 1997, 78,767

- 984.M Matucci Cerinic, Generini S, Pignone A: New approaches to Raynaud's phenomenon. *Curr Op Rheumatol* 1997;9,544
- 985.F Falcini, Taccetti G, Ermini ML, Trapani S, Matucci Cerinic M: Catastrophic antiphospholipid syndrome in pediatric systemic lupus erythematosus. *J Rheumatol* 1997;24,398
- 986.ML Cagnoni, Lombardi A, Dedola G, Matucci Cerinic M, Pignone A: Melatonin a new potential tool in the treatment of chronic refractory sarcoidosis. *Lancet* 1995;346:1229
- 987.A Lombardi, Matucci Cerinic M, Pignone A, Generini S, Scaletti C, Cagnoni M: The endothelium in the pathogenesis of systemic sclerosis. *Life Chem Rep* 1996;14,137
- 988.S Generini, Kahaleh B, Matucci Cerinic M, Pignone A, Lombardi A, Otsuka T. Raynaud's phenomenon and systemic sclerosis. *Ann Ital Med Int* 1996;11,125
- 989.R Casale, Buonocore M, Teofoli P, Matucci Cerinic M, Elam M: Lack of sympathetic involvement in dermatitis confined to medial nerve territory. A case report. *Acta Dermatov Scand* 1996;52;76
- 990.A Carossino, Lombardi A, Pignone A, Matucci Cerinic M, Cagnoni M: Melatonin reduces the proliferation of scleroderma fibroblasts in vitro. *Clin Exp Rheumatol* 1996;14,493
- 991.F Falcini, Matucci Cerinic M, Lombardi A, Pignone A, Ermini M, Tirassa P, Lepore L, Generini S, Partsch G, Aloe L: Circulating NGF is directly correlated with disease activity in Juvenile Chronic Arthritis. *Ann Rheum Dis* 1996;55,745
992. F Falcini, Matucci Cerinic M, Ermini M, Lombardi A, Pignone A, Leoncini G, Generini S, Tirassa P, Aloe L: Nerve growth factor circulating levels are increased in Kawasaki disease. Correlation with disease activity and reduced angiotensin converting enzyme levels. *J Rheumatol* 1996;23,1798
- 993.M Matucci Cerinic, Generini S, Pignone A, Casale R: The nervous system in systemic sclerosis: clinical and pathogenetical features. *Rheum Dis Clin N Am* 1996;22,789
994. D Fabiani, Casale R, Partsch G, Matucci Cerinic M: Spas and rheumatic diseases. *Clin Dermatol* 1996;14,571
- 995.S Lori, Matucci Cerinic M, Casale R, Generini S, Lombardi A, Pignone A, Cagnoni M: Peripheral neuropathy in systemic sclerosis. The median nerve as a target structure. *Clin Exp Rheumatol* 1996;14,601
- 996.M Matucci Cerinic, Lotti T, Valentini G, Pace J, Mallia C: Rheumatology and dermatology, sister specialties in Italy and Malta. *Br J Rheumatol* 1996;35,131
- 997.Li TF, Konttinen YT, Xu JW, Imai S, Li TF, Konttinen YT, Xu JW, Imai S, Matucci Cerinic M, Ceponis A, Santavirta S, Virtanen I: Tenascin expression in some normal and pathologic conditions of the musculoskeletal system. *Biomedical Reviews* 1996;6, 83
- 998.BM Kahaleh, Matucci Cerinic M: Raynaud's phenomenon and scleroderma: dysregulated neuroendothelial control of vascular tone. *Arthritis Rheum* 1995;38,1
- 999.G Partsch, Matucci Cerinic M: Auranofin and its combination with LTB4 influences ATP level and migration of human polymorphonuclear cells in vitro. *Inflammation* 1995;19,277
1000. M Matucci Cerinic, McCarthy G, Lombardi A, Pignone A, Partsch G: Neurogenic influences in arthritis: potential modification by capsaicin. *J Rheumatol* 1995, 22,1447
1001. M Matucci Cerinic, Generini S, Partsch G, Pignone A, Lombardi A, Stanisiz A: Sensory control of local immunity in inflamed joint.

- Regional Immunol 1995, 18,410
1002. M Matucci Cerinic, Borrelli F, Generini S, Cantelmo A, Marcucci F, Martelli F, Conz A, Marinelli P, Romagnoli P, Bacci S, Marabini S: Somatostatin-induced modulation of inflammation in experimental arthritis. *Arthritis Rheum* 1995; 38,1686
 1003. G Partsch , Petera P, Meretey K, Koo E, Dunky G, Broll D, Zamani E, Fertschak P, Matucci Cerinic M, Smolen J: High free and latent collagenase activity in psoriatic arthritis. *Br J Rheumatol* 33,702,1994
 1004. A Pignone, Matucci Cerinic M, Becucci A, De Leonardis V, Lombardi A, Fabiani D, Bernardo P, Scaletti C, Carossino AM, Cagnoni M: I potenziali ventricolari tardivi nella sclerosi sistemica: metodica non invasiva per lo studio del coinvolgimento cardiaco. *Ann Ital Med Int* 9,141,1994
 1005. M Matucci Cerinic, Pignone A, Biagini M, Lotti T. The clinical markers of systemic sclerosis. *Clin Dermatol* 12,291,1994
 1006. T Lotti , Campanile G, Matucci Cerinic M: Cutaneous and plasma fibrinolytic activity is not deficient in patients with systemic sclerosis. *J Am Acad Dermatol* 54,813,1994
 1007. S Padula, Broketa G, Sampieri A, Arakawa M, Matucci Cerinic M, Downie E, Korn J. Increased collagen synthesis in skin fibroblasts from patients with primary hypertrophic osteoarthropathy. *Arthritis Rheum* 37,1386,1994
 1008. A Pignone, Matucci Cerinic M, Lombardi A, Lotti T, Cagnoni M: Chronobiology, Fibrinolysis, and systemic sclerosis. *J Am Acad Dermatol* 31,297,1994
 1009. A Pignone, Calzolari A, Matucci Cerinic M, Scaletti C, Messerini L, Lombardi A, Generini S, Giannelli E, Carossino A, Cagnoni M: Espressione della p53 nella cute di sclerosi sistemica: studio immunoistochimico di otto casi. *Pathologica* 86,56,1994
 1010. A Lombardi , Falcini F, Trapani S, Pignone A, Leoncini G, Kahaleh BM, Matucci Cerinic M: Angiotensin converting enzyme: a new tool for the follow up of endothelial injury in paediatric vasculitides. *Br J Rheumatol* 33,1197,1994
 1011. A Pignone, Papi C, Scaletti C, Leoncini G, Livi R, Lombardi A, Lotti T, Matucci Cerinic M: Valutazione circadiana dell'attività fibrinolitica circolante nella sclerosi sistemica. *Reumatismo* 47,3,1994
 1012. A Lombardi A, Matucci Cerinic M, Pignone A, Biagini M, Kahaleh B: The central role of the endothelium in the pathogenesis of vasculitides. *Int Angiol* 14,175,1994
 1013. M Matucci Cerinic, Lombardi A, Leoncini G, Pignone A, Sacerdoti L, Spillantini G, Partsch. Neutral endopeptidase in plasma and synovial fluid of patients with rheumatoid arthritis. A marker of disease activity or a regulator of pain and inflammation? *Rheumatol Int* 13,1,1993
 1014. A Lombardi, Pignone A, Perfetto F, Tarquini R, Matucci Cerinic M. I meccanismi enzimatici coinvolti nella patogenesi dell'artrite reumatoide e dell'artrosi. Ruolo delle metalloproteasi e delle serinoproteasi nel deterioramento della cartilagine articolare. *Rec Progr Med* 84,1,1993
 1015. M Martinez Lavin, Matucci Cerinic M, Jajic I, Pineda C: Hypertrophic osteoarthropathy: Consensus on its definition, classification, assessment and diagnostic criteria. *J Rheumatol* 20, 1386, 1993
 1016. G Partsch, Matucci Cerinic M: Capsaicin stimulates the migration of human polymorphonuclear cells in vitro. *Life Sci* 53,309,1993

1017. S Generini, Matucci Cerinic M: Ileopsosas bursitis in rheumatoid arthritis. Clin Exp Rheumatol 11,549,1993
1018. M Matucci Cerinic: Sensory neuropeptides and rheumatic diseases. Rheum Dis Clinics N Am 19,975,1993
1019. T Lotti, Celasco G, Tsampau D, Teofoli P, Benci M, Dahm M, Comacchi C, Ghersetich I, Matucci Cerinic M: Mesoglycan treatment restores defective fibrinolytic potential in cutaneous necrotizing vasculitis. Int J Dermatol 32,368,1993
1020. A Pignone, Matucci Cerinic M. Il coinvolgimento polmonare nella sclerosi sistemica Il Reumatologo 1,7, 1992.
1021. M Matucci Cerinic, Lotti T, Calvieri S, Ghersetic I, Sacerdoti L, Teofoli P, Jajic I, Cagnoni M. The spectrum of dermatological symptoms of pachydermoperiostosis (primary hypertrophic osteoarthropathy): a genetic, cytogenetic and ultrastructural study. Clin Exp Rheumatol 10 (suppl 7) , 45,1992
1022. M Matucci Cerinic, Martinez Lavin M, Rojo F, Fonseca C, Kahaleh B. von Willebrand Factor levels in hypertrophic osteoarthropathy. J Rheumatol 19, 465,1992
1023. M Matucci Cerinic, Sacerdoti L, Perrone C, Carossino A, Cagnoni M, Jajic I, Lotti T. Pachydermoperiostosis (primary hypertrophic osteoarthropathy): in vitro evidence for abnormal fibroblast proliferation. Clin Exp Rheumatol 10 (suppl 7), 57,1992.
1024. F Falcini, Pignone A, Matucci Cerinic M, Camiciottoli G, Taccetti G, Trapani S, Zammarchi E, Lombardi A, Bartolozzi G, Cagnoni M. Clinical utility of noninvasive methods in the study of scleroderma lung in the paediatric age. Scand J Rheumatol 21,82,1992
1025. M Matucci Cerinic, Jajic I, M Ceruso, A Pignone, Lotti T. The treatment of pachydermoperiostosis (primary hypertrophic osteoarthropathy): a double blind study with colchicine and placebo and a surgical reduction of finger clubbing. Clin Exp Rheumatol. 10 (suppl 7), 67,1992
1026. M Matucci Cerinic, Pignone A, Lotti T, Partsch G, Livi R, Cagnoni M. Gold salts and somatostatin: a new combined analgesic treatment for psoriatic arthritis. Further evidence of a normal growth hormone circadian rhythm that is not modified by somatostatin. Drugs Exp Clin Res 18,53, 1992
1027. B. Kahaleh, Matucci Cerinic M. Endothelial injury and its implication. In: G. Neri Serneri, GF Gensini, R Abbate, D Prisco, eds. Thrombosis: an update. Ed. Scientific Press , Firenze, pp 649-658, 1992.
1028. M Matucci Cerinic, Partsch G. The contribution of the peripheral nervous system and the neuropeptide network to the development of synovial inflammation. Clin Exp Rheumatol 10,211,1992
1029. I. Ghersetic, Matucci Cerinic M, Lotti T. Systemic sclerosis: therapeutic guidelines. in: E Panconesi editor, The dermatology in Europe. Ed. Blackwell, Oxford, pp 905-907, 1992.
1030. A. Pignone, Matucci Cerinic M, Morfini M, Lombardi A, Rossi Ferrini PI, Cagnoni M. A combined treatment with concentrate porcine factor VIII, cyclophosphamide and corticosteroids in a case of rheumatoid arthritis with acquired factor VIII:c inhibitor. J Int Med 617, 231, 1992
1031. P Teofoli, Matucci Cerinic M, Sacerdoti L, Lorusso B, Benci M, Pignone A, Lotti T. Studio in vitro della cinetica di crescita di fibroblasti dermici di pazienti affetti da pachidermoperiostosi. G Ital Dermatol Venereol 127,215,1992
1032. M Matucci Cerinic, Jaffa A, Kahaleh B. Angiotensin converting

- enzyme. An in vivo and in vitro marker of endothelial injury. *J Lab Clin Med* 128, 428, 1992
1033. A Pignone, Matucci Cerinic M, Fargnoli R, Lombardi A, De Dominicis R, Cagnoni M. High resolution computed tomography in systemic sclerosis. Real diagnostic utilities and comparison to other modalities of lung investigation. *Clin Rheumatol* 11,1,1992
 1034. M Matucci Cerinic. Intervista sull'osteoartrite ipertrofica. *Il Reumatologo* 44,169,1992
 1035. A Pignone, Benci M, Matucci Cerinic M, Lotti T. Dermatologic Paraneoplastic syndromes. *Skin Cancer* 7,231,1992
 1036. M Matucci Cerinic. L'osteoartrite ipertrofica: una antica sindrome, un nuovo approccio patogenetico. *Reumatismo* 44,169,1992
 1037. G. Partsch, Matucci Cerinic M. Effect of substance P and somatostatin on migration of polymorphonuclear cells in vitro. *Inflammation* 16, 539, 1992
 1038. M Matucci Cerinic, Lotti T, Jajic I, Pignone A, Bussani C, Cagnoni M. The clinical spectrum of Pachydermoperiostosis. *Medicine* 70, 280, 1991
 1039. G.Partsch, Matucci Cerinic M, Marabini S, Jantsch S, Neumuller J, Pignone A, Cagnoni M. Collagenase synthesis of rheumatoid arthritis synoviocytes: dose dependent stimulation by somatostatin, capsaicin and substance P. *Scand J Rheumatol.* 20, 98, 1991
 1040. M Matucci Cerinic, Pignone A, Gabrielli S, Cagnoni M. Is finger clubbing a growth disorder? *Lancet* i, 434, 1991
 1041. M Matucci Cerinic, Partsch G, Marabini S, Cagnoni M. High levels of substance P in rheumatoid arthritis synovial fluid and evidence that synoviocytes are not the major source of Substance P. *Clin Exp Rheumatol* 9,1,1991
 1042. F Falcini, Taccetti G, Matucci Cerinic M. Primary antiphospholipid syndrome: a report of two cases in pediatric age. *J Rheumatol* 18,1085, 1991
 1043. A Fioravanti, Marabini S, Matucci Cerinic M, Montemerani P, Moscato P, Cagnoni M, Marcolongo R. Efficacia della somatostatina somministrata per via intr articolare nel ginocchio di pazienti con artrite reumatoide. Studio in doppio cieco controllato verso placebo. *G Ital Ric Clin Ter* 12,65,1991
 1044. A Pignone, Lombardi A, Matucci Cerinic M. Utilità delle tecniche di indagine non invasive nello studio del polmone sclerodermico. *Reumatismo* 1991;43:161-172.
 1045. A Pignone, M Matucci Cerinic, Lotti T, Lombardi A, Dahm M, Fabbri P. High resolution computed tomography in the detection of lung cancer in systemic sclerosis. *Skin Cancer* 6125,6,1991.
 1046. S Marabini, Matucci Cerinic M, Geppetti P, Del Bianco E, Marchesoni A, Tosi S, Cagnoni M, Partsch G. Substance P and somatostatin levels in rheumatoid arthritis, osteoarthritis and psoriatic arthritis synovial fluid. *Ann NY Acad Sci* 632,435,1991
 1047. M Matucci Cerinic, Marabini S, Jantsch S, Cagnoni M, Partsch G. Effect of capsaicin on the metabolism of rheumatoid arthritis synoviocytes in vitro. *Ann Rheum Dis* 49,598, 1990
 1048. M Matucci Cerinic, Partsch G. Evidence that substance P is not released by capsaicin from osteoarthritis and rheumatoid arthritis synoviocytes in vitro. *Ann Rheum Dis* 49,653, 1990
 1049. M Matucci Cerinic, Pignone A, Lotti T, Spillantini G, Curradi C, Leoncini G, Iannone F, Falcini F, Cagnoni M. Reduced angiotensin converting enzyme plasmatic activity in scleroderma. A marker of endothelial injury? *J Rheumatol* 17,328, 1990

1050. M Matucci Cerinic, Pignone A, Marabini S, Lotti T, Partsch G, Cagnoni M. Somatostatin and gold salts: a powerful association in the treatment of psoriatic arthritis. *Ann NY Acad Sci* 590,472,1990
1051. M Matucci Cerinic, Lombardi A, Pignone A, Lotti T, Senesi C, Buzzi R, Aglietti P, Partsch G, Cagnoni M. Fibrinolytic activity of synovial membrane in osteoarthritis. *Br J Rheumatol* 29, 249, 1990
1052. A Passaleva, Massai G, Matucci Cerinic M, Domeneghetti MP, Sharifian J, Cagnoni M, Ricci M. Immunological abnormalities in a group of patients with limited cutaneous systemic sclerosis and prominent vascular disease. *Autoimmunity* 6, 283, 1990
1053. M Matucci Cerinic, Pignone A, Iannone F, Lotti T, Pesciullesi E, Spillantini G, Falcini F, Cagnoni M. Clinical correlations of plasma angiotensin converting enzyme activity in systemic sclerosis. A longitudinal study of plasma ACE levels, endothelial injury and lung involvement. *Resp Med* 84,283, 1990
1054. M Matucci Cerinic, Lotti T, Pignone A, Lombardi A, Iannone F, Beneforti E, Cinotti S, Morfini M, Cagnoni M. Cutaneous and plasmatic fibrinolytic activity in systemic sclerosis: evidence of normal plasminogen activation. *Int J Dermatol* 29,644, 1990
1055. I Ghersetic, Matucci Cerinic M, Lotti T. A pathogenetic approach to the management of systemic sclerosis. *Int J Dermatol* 29,616,1990
1056. M Matucci Cerinic, Pietrini U, Marabini S. Local venomotor response to intravenous infusion of substance P and glyceryl trinitrate in systemic sclerosis. *Clin Exp Rheumatol.* 8,561,1990
1057. M Matucci Cerinic, Cinti S, Morroni M, Lotti T, Nuzzaci G, Lucente E, di Lollo S, Ceruso M, Cagnoni M. Pachydermoperiostosis: report of a case with evidence of endothelial and connective involvement. *Ann Rheum Dis* 48, 240,1989
1058. T Lotti, Matucci Cerinic M. Fibrinolytic activity is tPA dependent in Behcet syndrome. *Br J Dermatol* 121,713,1989
1059. M Matucci Cerinic, Lombardi A, Lopes Pegna A, Menicucci A, Lotti T. HLA et sclerodermie familiale. *Rev Rhumat Mal Osteoart* 55,77,1988
1060. F.Falcini F, Bartolozzi G, Tafi L, Volpi M, Pratesi G, Montanelli F, Sassoli L, Matucci Cerinic M, Valentini G. La malattia di Behçet: segnalazione di un caso in età pediatrica trattato con colchicina. *Reumatismo* 40,223,1988
1061. M Matucci Cerinic. Le sindromi paraneoplastiche reumatologiche. *Il Reumatologo* 16,192, 1988
1062. T Lotti, Matucci Cerinic M, Fattorini L, Fabbri P. Immunosuppressive effects of antimalarial drugs in discoid lupus erythematosus. *It Gen Rev Dermatol* 25,257, 1988
1063. M Matucci Cerinic, Lombardi A, Ceruso M, Calandriello B, Grecu L, Fattorini L. Pachidermoperiostosi ed acroosteolisi. Descrizione di un caso. *Giorn It Ortop Traumatol* 14, 109,1988
1064. N Giordano, Sancasciani S, Frati E, Serni U, Semmola MV, Matucci Cerinic M, Bacarelli MR, Innocenti A, Marcolongo R. Fattore VIII von Willebrand e sclerosi sistemica progressiva. *Reumatismo* 40,175,1988
1065. M Ceruso, Lauri G, Bufalini C, Bartolozzi G, Bernardini S, Cinti S, Morroni M, Matucci Cerinic M. Diabetic hand syndrome: *J Hand Surg* 13a,765,1988
1066. M Matucci Cerinic, Lotti T, Cappugi P, Boddi V, Fattorini L, Panconesi E. Somatostatin treatment of psoriatic arthritis *Int J Dermatol* 27,56,1988.
1067. M Matucci Cerinic , Marabini S. Somatostatin treatment for pain

- in rheumatoid arthritis: a double blind vs placebo study in knee involvement. Med Sci Res 16,223,1988
1068. M Matucci Cerinic, Casini A. Ketoprofen vs etofenamate in a controlled double blind study: evidence of topical effectiveness in soft tissue rheumatic pain. Int J Clin Pharm Res 8,157,1988
 1069. M Matucci Cerinic, Fattorini L, Gerini G, Lombardi A, Pignone A, Petrini N, Lotti T. Colchicine treatment in a case of pachydermoperiostosis with acroosteolysis. Rheumatol Int 8,185,1988
 1070. Matucci Cerinic, M; Massai, G; Passaleva, A. *Anticardiolipin Antibodies In Rest Variant Of Systemic-Scleriosis*. Clinical and Experimental Rheumatology 1988
 1071. M Matucci Cerinic. Takayasu arteritis and hypertrophic osteoarthropathy. Clin Exp Rheumatol 6,610,1988
 1072. M Matucci Cerinic, Sorice V, Pieri A, Lotti T. Circadian-RhythmGrowth hormone and psoriatic arthritis: a temporal evaluation. Z Rheumatol 46,339,1987
 1073. M Matucci Cerinic,Borsotti M, Barbieri R, Lombardi A, Lotti T, Morfini M, Spillantini G, Pirolo F. Angiotensin converting enzyme in scleroderma. Clin Rheumatol 6,300, 1987
 1074. L Tafi, Matucci Cerinic M, Falcini F, Valentini G, Bartolozzi G. Colchicine treatment of Behçet disease in children. Arthritis Rheum 30,1435, 1987
 1075. M Matucci Cerinic, Lotti T, Jajic I,di Lollo S,Brunetti L, Orlic D. Cutaneous fibrinolytic activity in primary hypertrophic osteoarthropathy. Scand J Rheumatol 16,205, 1987
 1076. Matucci Cerinic, M; Sorice, V; Pieri, A; Lotti, T. *Circadian-Rhythm Of Growth-Hormone In Psoriatic-Arthritis - A Temporal Evaluation*. Zeitschrift fur Rheumatologie 1987
 1077. In collaborazione. Lineamenti di Reumatologia edito nel 1987 dal Gruppo Interdisciplinare per la Lotta alle Malattie Reumatiche con la collaborazione della Regione Toscana.
 1078. M Matucci Cerinic, Fioravanti A, Lotti T, Boddi V, Giordano N, Marcolongo R. Somatostatin: clinical efficacy in a controlled study versus placebo in psoriatic arthritis. in: Progress in Rheumatology. Ed I Machtey, Petah-Tiqva, 1986
 1079. M Matucci Cerinic. La cartilagine articolare un ammortizzatore naturale. Rivista del giovane medico 7,4, 1986
 1080. M Matucci Cerinic, Sorice V, Lombardi A, Cappugi P,Lotti T. Studio cronobiologico dell'ormone dell'accrescimento nella psoriasi. Reumatismo 38,287, 1986
 1081. M Matucci Cerinic, Lopes A, Bussani C, Lotti T,Menicucci M, Lombardi A. Sclerosi sistemica in due sorelle. Reumatismo 38,235, 1986
 1082. M Matucci Cerinic. Ferritin and prostaglandins in hypertrophic osteoarthropathy. J Rheumatol 13,834, 1986
 1083. G Bartolozzi, Falcini F, Pierattelli M, Volpi M,Matucci Cerinic M. Manifestations articulaires de 11 cas de syndrome de Kawasaki observes en Toscane. Rev Rhum Malad Osteoart 52,157,1985
 1084. F Falcini, Pierattelli M, Perri I, Volpi M,Bartolozzi G, Matucci Cerinic M, Giani I. Un caso di dermatomiosite infantile con grave vasculite generalizzata Riv It Ped 11,104,1985
 1085. Cerinic, Mm, Falcini, F. *Gold Polyneuropathy In Juvenile Rheumatoid-Arthritis*. British Medical Journal (Clinical Research Edition). 1985
 1086. T Lotti, Matucci Cerinic M, Marmugi D, Fabbri P. Cutaneous fibrinolytic activity in scleroderma. Clin Exp Rheumatol 3, 248,1985

1087. M Matucci Cerinic, Falcini F, Bartolozzi G, Volpi M. Nifedipine treatment of Raynaud's phenomenon in a paediatric age. *Int J Clin Pharmacol Res* 5,67,1985
1088. M Matucci Cerinic, di Lollo F. Le principali sindromi paraneoplastiche reumatologiche nel cancro del polmone. *Clin Ter* 115, 381, 1985
1089. F di Lollo, Matucci Cerinic M. Le principali sindromi paraneoplastiche endocrine nel cancro polmonare. *Clin Ter* 115,283,1985
1090. M Matucci Cerinic. Il trattamento medico dell'artrite reumatoide. in: *Il ginocchio*, edito da Bianchi, Napoli 1985
1091. M Matucci Cerinic. Osteoarthropathie hypertrophiantes avec gynecomastie et taux elevee d'hormone de croissance au cours d'un cancer du poumon. *Rev Rhum Mal Osteart* 51,431,1984
1092. M Matucci Cerinic, Ippocratisimo digitale in corso di neoplasia polmonare: valutazione dell'angolo subungueale. *Florence J Surg* 2,85, 1984 (suppl)
1093. M Matucci Cerinic, Bartolozzi G, Falcini F, Pierattelli M, Volpi M. Terapia con nifedipina in un bambino con sclerosi sistemica complicata da ulcere digitali gravi. *Riv It Ped* 10, 787,1984
1094. F Falcini, Bartolozzi G, Volpi M, Matucci Cerinic M. Polineuropatia periferica grave in un bambino con ARI trattato con sali oro. *Riv It Ped* 10, 804,1984
1095. F Falcini, Volpi M, Pierattelli M, Taccetti G, Pratesi G, Matucci Cerinic M. Un caso di sclerosi sistemica in età pediatrica complicato da gravi ulcere digitali. *Ped Med Chir* 6,703,1984
1096. M Matucci Cerinic, Bianucci G, Lotti T. Kaposi's Sarcoma associated with rheumatoid arthritis treated with long term corticosteroid therapy. *It Gen Rev Dermatol* 21,61, 1984.
1097. M Matucci Cerinic Response of hypertrophic osteoarthropathy to drugs inhibiting growth hormone. *J Rheumatol* 11,865, 1984
1098. M Matucci Cerinic Hypertrophic Osteoarthropathy With Gynecomastia And Raised Growth-Hormone Levels Associated With Lung-Cancer - Report Of A Case Treated By Inhibitors Of Growth-Hormone Secretion. *Revue du Rhumatisme (English Ed.)*, 1984
1099. .Matucci Cerinic. Sindromi paraneoplastiche di interesse reumatologico nel carcinoma polmonare. *Reumatismo* 34,343,1982
1100. S Gabbrielli, Melli G, Righi R, Matucci Cerinic M. Cisti Timica ectopica del mediastino. *Archivio de Vecchi* 65,251,1982

BOOKS, CHAPTERS, SUPPLEMENTS

1. De Luca G, Moroni L, Tomelleri A, Marcolongo R, Dagna L, Caforio A **Matucci Cerinic M**: Heart Failure in immune mediated diseases The European Society of Cardiology Textbook, 843-48, Oxford University Press, 2024
2. Tracy Frech, Janet ,Poole, Maureen Murtaugh, **Marco Matucci Cerinic**: Expanding the treatment team, what is the role for occupational therapy, physical therapy wound care and nutritional support in systemic sclerosis. In *scleroderma the best approaches to patient care* published in *Rheum Dis Clinics* May 2023, 379-387 eds MH Weisman and TM Frech Elsevier,
3. *Unireuma-Reumatologia IV* edizione eds C Montecucco **M Matucci Cerinic** et al Idelson Gnocchi 2022
4. *Practical Management of Systemic Sclerosis in clinical practice*, eds **M Matucci Cerinic** & C Denton, Springer 2021
5. Ariane L.Herrick, Fredrick M. Wigley, **M Matucci-Cerinic**: *Raynaud's Phenomenon, Digital Ulcers and Nailfold*

- Capillaroscopy*(297-316pg) Scleroderma - From Pathogenesis to Comprehensive Management _Springer 2020
6. **M Matucci Cerinic** & Chris Denton: Atlas of Ulcers in systemic sclerosis, Springer 2018
 7. L Gargani, **M Matucci Cerinic** et al Pulmonary circulation on the crossroad between the left and right heart in systemic sclerosis: a clinical challenge for cardiologists and rheumatologists, in The right heart-pulmonary circulation Unit, eds E Bossone & L Gargani, Elsevier 2018
 8. Unireuma-Reumatologia III edizione eds G Valesini, **M Matucci Cerinic** et al Idelson Gnocchi 2018
 9. S Generini, **Matucci Cerinic M**: *Spondiloartriti, Unireuma*, Idelson Gnocchi, 2007,2011,2017
 10. C.Bruni, E.Praiano, **M Matucci Cerinic**: *Sclerosi sistemica: diagnosi e classificazione. Chapter in book: Giornate Italiano di Reumatologia Clinica*, Auxiliatrix 2016
 11. S Bellando Randone, S Guiducci, S Cappelli, C Bruni ,**M Matucci Cerinic** Esclerosis sistémica in Enfermadades Inflammatorias Reumatológicas Eds R Alba Feriz, R Munoz Louis, Espinoza LR, M Khamashta, **M Matucci Cerinic**, R Sanmarti. Primera Edicion 2016
 12. Enfermadades Inflammatorias Reumatológicas Eds R Alba Feriz, R Munoz Louis, Espinoza LR, M Khamashta, **M Matucci Cerinic**, R Sanmarti. Primera Edicion 2016
 13. S Guiducci, **M Matucci Cerinic**: *Definition, nomenclature and diagnostic criteria*. Chapter in book: in Raynaud's phenomenon a guide to pathogenesis and treatment ed: Wigley FM, Herrick AL, Flavahan NA; 2015:pp 13-21
 14. Lepri G., **M Matucci Cerinic** , Bellando Randone S., Distler JH:*Connective Tissue Diseases: concept and overlap syndromes* Eular Text book on Rheumatic Diseases second edition 509-530 BMJ Editors Bijlsma JWJ, Hachulla E. www.eular-onlinecourse.org 2015
 15. A Del Rosso, S Maddali Bongi, **M Matucci Cerinic**: *Hand function in scleroderma*. In: Hand function, a practical guide to assessment, Ed: MT Duruoz 2014;pp 63
 16. Bellando Randone, S. Guiducci, **M Matucci Cerinic**: *Diagnóstico y clasificación de la esclerosis sistémica (esclerodermia)*, Manual SER Editor Jefe , Capítulo 31: pag 191-195, 2014
 17. Unireuma-Reumatologia II edizione eds G Valesini, **M Matucci Cerinic** et al Idelson Gnocchi 2014
 18. Unireuma-Reumatologia I edizione eds G Valesini, G Valentini, CM Montecucco, **M Matucci Cerinic**, GF Ferraccioli, M Cutolo, S Bombardieri et al, Idelson Gnocchi 2014
 19. **M Matucci Cerinic**, DE Furst, D Fiorentino Skin Manifestations in Rheumatic diseases, Springer 2014
 20. William R. Albury, **Marco Matucci-Cerinic**, G. M. Weisz : Carlo di Ferdinando I. de' Medici (1596–1666) Ein Fall von extremer Langlebigkeit trotz lebenslanger Krankheit Medici catalogue, Mannheim, 2013: pp 367-3
 21. Bellando Randone S., Little Jayne, Herrick A., **M.Matucci Cerinic**: Microvascular and macrovascular disease in systemic sclerosis, with reference to the digits. Eular Text book on Systemic Sclerosis 2013:139-148 BMJ Eiditor: Hachulla E. www.eular-onlinecourse.org
 22. Bellando Randone S., Furst DE., **M Matucci Cerinic**: Very early and early systemic sclerosis. Eular Textbook on Systemic Sclerosis 2013:357-363 BMJ Eiditor Hachulla E. www.eular-onlinecourse.org
 23. S Bellando Randonee, S Cappelli, S Guiducci, **M Matucci Cerinic**,

- Sclerosi sistemica: terapia , in Malattie Autoimmuni Sistemiche ed R Perricone, SEU 2013
24. Y.Allanore, J.Avouac, C.Denton, **M Matucci Cerinic**: *Systemic Sclerosis*. Chapter in book: Eular Text book on Rheumatic Diseases, BMJ Group, 2012
 25. P Maddison, **Matucci Cerinic**: *Systemic vascular disease*, In Scleroderma, Eds J Varga, CP Denton, FM Wigley, Springer, 2012
F.Porta, **M Matucci Cerinic**: *A limited cutaneous SSc patient who develops severe calcinosis with acro-osteolysis*. In Case Studies in Systemic Sclerosis, Eds R Silver, CM Denton, Springer, 2011,259-272
 26. F Nacci, **M. Matucci Cerinic** Tuberculosis and other infections in the antiTNFalfa era, in Clinical Rheumatology- Musculoskeletal Science eds H Locht & FA Wollheim, Elsevier 2011
 27. S Bellando Randone, S Guiducci, **M Matucci Cerinic**: The microcirculation and rheumatic diseases. In Atlas of capillaroscopy in rheumatic diseases, Elsevier 2010, 7-14
 28. P.J. Clements, **M Matucci-Cerinic**, J.R. Seibold: *Scleroderma Care and Research*. Clin Exp Rheumatol 2009,2010, 2011, 2012,2013 suppl.
 29. Guiducci S, **M Matucci Cerinic**: *Epigenetics and Systemic Sclerosis*. Chapter in book: The Epigenetics of Autoimmune Diseases, Wiley-Blackwell 2009
 30. S. Guiducci, S. Bellando Randone, **M Matucci Cerinic**: *Autoantibodies in systemis sclerosis*. Chapter in book: Autoimmunity by Y Shoenfeld and N Rose 2009
 31. C Black,L Guillevin, **M Matucci Cerinic**: *Ten years of partnership: translating ideas into progress in systemic sclerosis*, Rheumatology 2009;48: supplement 3
 32. **M Matucci Cerinic**, I.Miniati, C.Denton: *Systemic Sclerosis*. Chapter in book: EULAR Compendium on Rheumatic Diseases, BMJ Group, 2009
 33. S Guiducci, **M Matucci Cerinic**: Epigenetics in systemic sclerosis In The epigenetics of autoimmune diseases, editor M Zouali, Wiley Blackwell, 209
 34. O. Distler, **M. Matucci-Cerinic**, U. Muller-Ladner, J. R. Seibold: *A path to the future in scleroderma..* Rheumatology 2008;47: suppl 5
 35. S. Bellando Randone, S. Guiducci, **M. Matucci Cerinic** Musculoskeletal involvement in systemic sclerosis in Clinical Rheumatology- Musculoskeletal Science eds T Pap & AD Woolf, Elsevier 2008
 36. **M Matucci Cerinic**: Le défi de la sclerodermie systémique débutante. Chapter of book : Sclérodermies by Med-Line Editions 2007
 37. S. Bellando Randone, S. Guiducci, **M. Matucci Cerinic**. *Topoisomerase-I (Scl-70) autoantibodies*. Chapter 31 (231-8) of Book: Autoantibodies eds Y Shoenfeld, PL Meroni & N Rosen 2007
 38. **M Matucci Cerinic** & DE Furst Clinical Rheumatology- Connective Tissue Disease, Elsevier 2007
 39. M Cutolo, Pizzorni C, Secchi ME, Calvia A, Sulli A, **Matucci Cerinic M**: **Capillaroscopy: which is its role in the diagnosis of connective tissue diseases ?** in Handbook of systemic autoimmune diseases, volume 5, The skin in systemic autoimmune diseases,2006: 221
 40. **M Matucci Cerinic** & Miniati I: *Systemic sclerosis*, in Voices of Scleroderma, vol 3, Eds J Thompson Devlin, SL Ensz, 2006, 7-19, ISN 2006
 41. Irene Miniati, **Marco Matucci Cerinic**: *Sclerosi Sistemica*, in

- Riabilitazione in Reumatologia, ed S Maddali Bongi, EDRA 2006
42. **M Matucci Cerinic** & P Seferovic: *Heart involvement in autoimmune rheumatic diseases*. Rheumatology 2006;45; Suppl 4
 43. G Fiori, Amanzi L, Pignone A, **Matucci Cerinic M**: *Le ulcere cutanee nella sclerosi sistemica*. Dall'approccio metodologico alla terapia. UTET 2005, 175
 44. S. Guiducci, Giacomelli R, Tyndall A, **Matucci Cerinic M** : *Infection and Systemic Sclerosis*. In Autoimmunity 2004, eds; Y Shoenfeld & N Rosen
 45. A Pignone, Del Rosso A, **Matucci Cerinic M**: *Connective Tissue Diseases; Dermatomyositis, Scleroderma*. In: International Dermatology and Human Mobile Population, eds Morrone A, Hercogova J, Lotti TM 2004
 46. Bombardieri S, Cutolo M, **Matucci Cerinic M**: *La reumatologia in tasca*. Clinical Experimental Rheumatology-Arthritis Foundation, 2004
 47. S. Guiducci, Giacomelli R, Tyndall A, **Matucci Cerinic M**: *Infection and Systemic Sclerosis*. In Autoimmunity 2004, eds; Y Shoenfeld & N Rosen
 48. A Pignone, Del Rosso A, **Matucci Cerinic M**: *Connective Tissue Diseases; Dermatomyositis, Scleroderma*. In: International Dermatology and Human Mobile Population, eds Morrone A, Hercogova J, Lotti TM 2004
 49. Bombardieri S, Cutolo M, **Matucci Cerinic M**: *La reumatologia in tasca*. Clinical Experimental Rheumatology-Arthritis Foundation, 2004
 50. **Matucci Cerinic M**, G Fiori, Grenbaum E, Shoenfeld Y: *Macrovascular disease in systemic sclerosis*. In: Systemic sclerosis, eds: D Furst e P Clements, 2003:241
 51. **M Matucci Cerinic e coll**: *Le Malattie Reumatiche, in Medicina Interna*, ed Idelson-Gnocchi 2003
 52. Guiducci S, Pignone A, **Matucci Cerinic M**: *Raynaud's phenomenon*. In: *Systemic sclerosis*, eds: D Furst e P Clements 2003;221
 53. R Casale, Frazzitta G, Maini M, Carapelli S, **Matucci Cerinic M**: *La riabilitazione nei pazienti sclerodermici*. In *La riabilitazione in Reumatologia*, ed G Arioli, Mattioli 1885, 2001, pp 72
 54. **M Matucci Cerinic**, Generini S, Kahaleh BM: *Vascular tone control and Raynaud's phenomenon*. In: *The vascular manifestations of autoimmune connective tissue diseases*, ed R Asherson , R Cervera, p 81, CRC press, 2001
 55. **M Matucci Cerinic**, Generini S, Seibold J: *The treatment of Raynaud's phenomenon*. In: *The vascular manifestations of autoimmune connective tissue diseases*, ed R Asherson, R Cervera, p 571, CRC press, 2001
 56. **M Matucci Cerinic**, Pignone A, Giacomelli R: *Microchimerismo e sclerosi sistemica*. In *Atti del Convegno sulle malattie autoimmuni sistemiche*, Firenze, editore SEE-Firenze, pp 41-43
 57. A Pignone, **Matucci Cerinic M**: *La patogenesi della Polimiosite/Dermatomiosite*. In *Atti del Convegno sulle malattie autoimmuni sistemiche*, editore SEE-Firenze, 2001, pp 45-49
 58. **M Matucci Cerinic**: *I COXIB una nuova via terapeutica: Celecoxib*. Atti del Congresso di Medicina Interna, 2001
 59. **M Matucci Cerinic**, Pignone A, Lombardi A, Cagnoni ML, DePità O, G Ferranti: *Rheumatic autoimmune diseases*. in Lotti T, Parish L, Roy Rogers S, *Color Atlas of Oral Diseases*, Springer Verlag, 1999

60. S Generini, **M Matucci Cerinic**: L'artropatia psoriasica, in: *La psoriasi: verso il terzo millennio- Generalità e nuove acquisizioni*. Ed: T Lotti, 1999 UTET
61. S Generini, **Matucci Cerinic M**, Pignone A, Cagnoni M: *Il fenomeno di Raynaud e la sclerosi sistemica. In La valutazione e la programmazione terapeutica nei pazienti con sclerodermia*. Editore Flavio Fantini, Edizioni C.E.L.I., Faenza Editrice, Milano 1997
62. F Falcini., Ermini M. Trapani S, Taccetti G, Bartolozzi G, De Simone L, Manetti A, Turchini S. Farsi A, Lombardi A, **Matucci Cerinic M**, Keser G, Khamashta M, Direskeneli H, Hughes G: *Kawasaki syndrome: the Florentine experience*. in; *The Vasculitides*. ed: Ansell B, Bacon PA, Lie JT, Yazici H, Chapman & Hall, London, 1996
63. **M Matucci Cerinic**, Kahaleh BM, LeRoy EC: *The vascular involvement in systemic sclerosis*. In Systemic sclerosis. ed. Daniel Furst e Phil Clements, Lea and Febiger, 1995
64. M Cagnoni, **Matucci Cerinic M**, Pignone A, Lombardi A, Carossino A: *La sclerosi sistemica*. Atti del 95° Congresso della Società Italiana di Medicina Interna, volume I, Ed L. Pozzi, Roma, 1994, pp 115-245
65. **M Matucci Cerinic**, Biagini M. *The pathogenesis of systemic sclerosis*. In a volume dedicated to the 60th anniversary of Prof. Jajic, edited by G. Ivanisevic, Zagreb (Croatia), 1992
66. F di Lollo, **M Matucci Cerinic**. *Manifestazioni reumatologiche e neoplasie. Correlazioni, inquadramento clinico e revisione della classificazione*. Atti della XXXVI Settimana Medica degli Ospedali, p 286,1991

**CONGRESS
LECTURES**

1. **M Matucci Cerinic:** La gestione dell'ILD e della ipertensione polmonare: la terapia di combinazione nella sclerosi sistemica. Congresso Italiano di Medicina Interna, Rimini, 10.10.2025
2. **M Matucci Cerinic:** Rumunian Congress of Rheumatology, 29.9.2025
3. **M Matucci Cerinic:** Medicina personalizzata nella sclerosi sistemica , Joints & Venture, Pavia 11.9.2025
4. **M Matucci Cerinic:** L'interessamento polmonare nella sclerosi sistemica II Congresso di Immunologia Clinica, Chieti, 28-29.6.2025
5. **Matucci Cerinic:** The management of vasculopathy in systemic sclerosis, EULAR, Barcelona 10-13.6.2025
6. **M Matucci Cerinic:** Nuovi approcci terapeutici nella sclerosi sistemica, Biological Therapies in Medicine, Ischia 22-24.5.2025
7. **M Matucci Cerinic:** Sclerosi Sistemica, pasato presenet e futuro, Congresso ASIAM Nazionale, 16-18.5.2025
8. **M Matucci Cerinic:** Emerging biological therapies for CTD ILD, Pneumotrieste, Trieste 13.5.2025
9. **M Matucci Cerinic:** Unveiling fibrosis in systemic sclerosis, European Workshop Rheumatology Research, Budapest 9.5.2025
10. **M Matucci Cerinic:** Early opportunity in systemic sclerosis, PANLAR congress, Mexico city 25.4.2025
11. **M Matucci Cerinic:** ILD prevalence, progression and risk factors PANLAR congress Mexico city 25.4.2025
12. **M Matucci Cerinic:** The experience of EUSTAR: what have we learned and how can we integrate with the ERN registry.New opportunities. ERN congress, Prague 10.4.2025
13. **M Matucci Cerinic:** Tailored approach to chronic joint pain: rheumatologist view, Joint challenge 2025, Baveno, 21.3.2025
14. **M Matucci Cerinic:** Should we use immunosuppressants in the treatment of limites systemic sclerosis, CORA 2025, Venezia 8.3.2025
15. **M Matucci Cerinic:** Screening, trattamento e follow-up del paziente con PAH nella sclerodermia - dall'emersione del sommerso all'ottimizzazione dell'early follow-up, Fibroreuma, Bologna, 3.3.2025
16. **M Matucci Cerinic:** New insights in The pathogenesis of Systemic Sclerosis. Highlights in Rheumatology, Napoli, 21.2.2025
17. **M Matucci Cerinic:** Il ruolo della biopsia cutaneo-fasciale nella diagnosi e nel trattamento della sclerodermia e delle malattie fibrosanti– Parere del reumatologo. La refertazione anatomo patologica di biopsie ghiandolari salivari, e cutanee, Firenze 22.2.2025
18. **M Matucci Cerinic:** State of the art on the treatment of systemic sclerosis, Immunology and cellular therapies in autoimmune diseases, 11.10.2024 Milano
19. **M Matucci Cerinic:** Th epoint of view of the rheumatologist in myocardial involvement in systemic sclerosis and myositis, Cardio Rheumatology Course, 7.10.2'24 Athens, Greece
20. **M Matucci Cerinic:** Very early diagnosis of systemic sclerosis, Algoritmi decisionali in allergologia, dalla diagnsotica molecolare all'immunoterapia allergene specifica, 29.9.2024, Nusco
21. **M Matucci Cerinic:** Sclerosi Sistemica una malattia complessa, Giornate Reumatologiche del Galeazzi 14.9.2024, Milano
22. **M Matucci Cerinic** The progression and treatment of ILD in

- Systemic Sclerosis, Summer Course 2024, 6.7.2024 Florence, Italy
23. **M Matucci Cerinic** How to diagnose and treat ILD in Rheumatoid Arthritis , Summer Course 2024, 6.7.2024 Florence, Italy
 24. **Matucci Cerinic** Il data base EUSTAR WSF, in Florheuma 2024, 28.6.2024 Firenze
 25. **M Matucci Cerinic** MRI Imaging in ILD in Rheumatic Diseases, in EULAR congress, 13.6.2024 Vienna, Austria
 26. **M Matucci Cerinic:** Nuovi Approcci terapeutici nella sclerosi sistemica, Biological Therapies in Medicine, 23-25.5.2024 Ischia
 27. **M Matucci Cerinic:** Polmone e sclerosi sistemica: presente e futuro della terapia della malattia interstiziale e della ipertensione polmonare. Nel La reumatologia del III Millennio 3.5.24 Milano
 28. **M Matucci Cerinic** La sclerosi sistemica, Congresso di Immunologia Clinica SIAAIC, 24-25.2.24 Mestre
 29. **M Matucci Cerinic:** Diagnostic and prognostic dilemmas in the management of fibrotic interstitial lung disease in systemic sclerosis, Fibrosis across organ systems 27.1.2024 Athens
 30. **M Matucci Cerinic:** Aspetti fisiopatologici delle ILD Interstiziopatia polmonare nelle malattie reumatologiche autoimmuni 14-15.12.2023 Bologna
 31. **M Matucci Cerinic:** Quadri clinici reumatologici, PF-ILD expert sharing, experience in Tuscany, 18.11.23 Firenze
 32. **M Matucci Cerinic** Le strategie terapeutiche nella gestione del paziente affetto da Sclerosi Sistemica L'approccio diagnostico e terapeutico nelle malattie reumatologiche sistemiche 1.7.2023 Cagliari
 33. **M Matucci Cerinic.** Approcci terapeutici alla interstiziopatia polmonare : aspetti peculiari in corso di malattie autoimmuni Congresso CREI, 23-24.6.2023 Roma
 34. **M Matucci Cerinic:** il polmone nelle malattie autoimmuni Biological Therapies in Medicine 26-27.5.23 Ischia
 35. **M Matucci Cerinic:** The diagnosis and classification of SSc ILD, ERN Reconnet Webinar, 17.5.2023, online
 36. **M Matucci Cerinic:** Microvascular connection with organ involvement and utility of nailfold capillaroscopy The 2nd Ain Shams congress, 16.5.2023, Cairo
 37. **M Matucci Cerinic:** "SSc e le sue complicanze nuovi scenari terapeutici", X Convegno Di Reumatologia Penisola Sorrentina-Monti Lattari, 05.05.2023
 38. **M Matucci Cerinic:** "Is Cyclophosphamide still the gold standard in early severe rapidly progressive SSc?" 7th International Congress on Controversies in Rheumatology and Autoimmunity (CORA 2023) , 16.03.2023, Torino
 39. **M Matucci Cerinic:** "Nuovi approcci diagnostici per le malattie rare in
 40. Toscana: la ricerca e il PNRR" - La Giornata mondiale delle malattie rare in Toscana, 27.02.2023, AOU-Careggi Firenze
 41. **M Matucci Cerinic:** " Round table discussion and remarks" - 3rd ILD in RD 17-19.02.2023 online
 42. **M Matucci Cerinic:** "Real life dell'utilizzo di nintedanib nei pazienti SSc-ILD" 59° Congresso Nazionale SIR 25-26.11.2023, Rimini
 43. **M Matucci Cerinic:** "PAH e CTD, tra presente e future" – Webinar la gestione multidisciplinare dell'Iipertensione Polmonare

- nelle malattie autoimmuni reumatiche nelle Ctd, 15.11.2022 online
44. **M Matucci Cerinic:** “Biosimilars : From Concept To Reality”- Kuwait Arthritis Day – Sandoz Scientific Symposium, 05.11.2022 online
 45. **M Matucci Cerinic:** “Approccio Multidisciplinare All'ipertensione Polmonare nelle malattie autoimmuni reumatiche” – Webinar BI- 04.11.2022, Milano
 46. **M Matucci Cerinic:** “Le fibrosi polmonari progressive (FFP) in reumatologia” ,Congresso SIR Toscana Update in Reumatologia, 28.10.2022, Siena
 47. **M Matucci Cerinic:** “ The opinion of the Rheumatologist” Webinar su PF-ILD University of Padova – 25.10.2022 online
 48. **M Matucci Cerinic:** “SSc: early diagnosis and treatment” Annual meeting of the Lebanese Society of Rheumatology – 14-15.10.2022 online
 49. **M Matucci Cerinic:** “Lessons from pre-scleroderma:Translational studies from VEDOSS, 17th International Workshop in Scleroderma Research, 03.08.2022 , Boston USA
 50. **M Matucci Cerinic:** “Assessing vascular involvement in pre-SS” , 17th International Workshop in Scleroderma Research, 01.08.2022 , Boston USA
 51. **M Matucci Cerinic:** “Early symptomatic knee OA (ESKOA): what we do know and what we must improve”, ISIAT Webinar, 17.07.2022
 52. **M Matucci Cerinic:** “ Heart involvement in SSc” Romanian Society of Rheumatology, Summer School 4.07.2022 online
 53. **M Matucci Cerinic:** “IMiD and Biosimilars: Access Driven Approach”, UAE Medical event on Virtual basis that focus on Biosimilars in IMiD, 30.06.2022, online
 54. **M Matucci Cerinic:** “Medicina Interna e Reumatologia: nuove interrelazioni dalla fisiopatologia alla clinica”, Emilia Romagna e Marche della SIMI, 18.06.2022, Rimini
 55. **M Matucci Cerinic:** “Artrite Reumatoide: identikit del paziente a rischio di malattia interstiziale del polmone e conseguenti scelte terapeutiche” Evento Prof. Cantarini, 17.06.2022, Prato, Italy
 56. **M Matucci Cerinic:** “La fibrosi secondaria alle collagenopatie: il punto di vista del reumatologo“ La Fibrosi Polmonare idiopatica o polmonare, 07.06.2022, Firenze, Italy
 57. **M Matucci Cerinic:** “ Interessamento interstiziale polmonare nelle malattie autoimmuni” Biological Therapies in Medicine, 28.05.2022, Ischia, Italy
 58. **M Matucci Cerinic:** “Clinica e terapia dell'interstiziopatia polmonare Sclerodermica”Convegno di Reumatologia penisola Ssorrentina-Monti Lattari, 27.05.2022
 59. **M Matucci Cerinic:** “Hyrimoz form trials to clinical practice” DHA online Webinar UAE, 24.05.2022
 60. **M Matucci Cerinic:** “ Myocardial Involvement in Systemic Sclerosis” VI Eurasian Congress of Rheumatologists, 13.05.2022 online
 61. **M Matucci Cerinic:** “The vasculopathy journey in SSc, from the digits to internal organs” Internal medicine Grand Round, University of Illinois College of Medicine 10.05.2022 online
 62. **M Matucci Cerinic:** “ La Sclerosi Sistemica nel 2022” Giornate Reumatologiche Cagliaritanee, 07.05.2022, Sardegna, Italy

63. **M Matucci Cerinic:** “Il management delle malattie reumatiche: monoterapia, terapia di combinazione ed adesso anche terapia di supporto?” Medicina dei Sistemi: Modelli di integrazione nella prassi clinica e nuove soluzioni terapeutiche – 05.05.2022, Milano, Italy
64. **M Matucci Cerinic:** “ La ricerca a che punto è?” Convegno Nazionale approccio al paziente con Sclerosi Sistemica GILS – 30.04.2022 Milano, Italy
65. **M Matucci Cerinic:** “Gli stimolatori di sGC e l’effetto protettivo nell’endotelio: una sfida per il futuro” Le nuove frontiere degli stimolatori di sGC: dall’ipertensione polmonare allo scompenso cardiaco, 21.04.2022, Roma, Italy
66. **M Matucci Cerinic:** “ SSc, one or several disease entities” EUSTAR/WSF SSc school 1.4.2022 Riccione, Italy
67. **M Matucci Cerinic:** “EBM: diagnosi differenziale e similitudini radiologiche e cliniche tra polmonite interstiziale da connettivite e da COVID19” Meeting in Reumatologia Università Padova 30.03.2022
68. **M Matucci Cerinic:** “Hyrimoz, a Value-based Biologic in IMRDs” Sandoz Symposium at AROM Congress 17.03.2022
69. **M Matucci Cerinic:** “ The early Predictors of Mortality /Disease Progression in Systemic Sclerosis” The 16th Arab Rheumatology congress 16.3.2022
70. **M Matucci Cerinic:** “The antifibrotic therapeutic approach in immune-mediated diseases” 25^o Meeting on Immunopathology and Rare Diseases 27-29.1.2022
71. **M Matucci Cerinic:** “RA in ILD: screening, diagnosis and therapy” 6th Annual Ain Shams International Rheumatology & Rehabilitation Conference 14.1.2022
72. **M Matucci Cerinic:** “L’ipertensione arteriosa polmonare: screening, diagnosi precoce e terapia” Aggiornamenti in reumatologia, immunologia clinica e allergologia 20.12.2021
73. **M Matucci Cerinic:** “Risk factors, lung images, treatment and COVID” Argentina SSc-ILD Group for SSc – Annual Meeting 2021 8.12.2021
74. **M Matucci Cerinic:** “Rheumatoid Arthritis Associated Interstitial Lung Disease: Early Screening and Therapy “ 3rd Shantou International Conference of Rheumatic Disease 4.12.2021
75. **M Matucci Cerinic:** “Pulmonary Arterial Hypertension in Systemic Sclerosis- Screening and detection of PAH” UAE 23.11.2021
76. **M Matucci Cerinic:** “RWE About Biosimilars” Hyrimoz event Rheumatology medical Egypt 29.10.2021
77. **M Matucci Cerinic:** “Unmet needs in viscosupplementation: towards the ideal product for intra-articular treatment”
78. **M Matucci Cerinic:** “Is it possible to determine which patients benefit most from nintedanib and which from immunosuppressants in SSc-ILD? CORA Congress 8.10.2021
79. **M Matucci Cerinic:** “Interstiziopatia da Covid-19 o da SSc?” Biological Therapies in Medicine 1-3.10.2021
80. **M Matucci Cerinic:** “ Terapie innovative nelle malattie reumatiche” Congresso ASIAM 1.10.2021
81. **M Matucci Cerinic:** “Ulcers in SSc” 4th Chinese scleroderma congress 1-2.10.2021
82. **M Matucci Cerinic:** “L’ipertensione polmonare: diagnosi e

- terapia” Giornate Reumatologiche Del Sacco (3° Edizione) 24-25.09.2021
85. **M Matucci Cerinic:** “ Lung involvement in SSc and other CTD” Congresso PneumoTrieste 21.09.2021
 86. **M Matucci Cerinic:** “ Actualizacion Terapeutica En Sclerosis Sistemica Y Sclerodermia Difusa” Reunión de los Reumatologos Monetvideo (Uruguay). 11.09.2021
 87. **M Matucci Cerinic:** “*La terapia antalgica nei reumatismi infiammatori*”, La terapia personalizzata in reumatologia alla luce delle nuove possibilità terapeutiche, Camera di Commercio di Prato 2-3.07.2021
 88. **M Matucci Cerinic:** “ *Evaluation and management of digital ulcers in SSc*”, APLAR e-Congress, 26.06.2021
 89. **M Matucci Cerinic:** “*Nuove opportunità nel management del paziente affetto da Artrite Reumatoide Fase 3: la gestione dei vari scenari clinici*”, videoconferenza, 18.06.2021
 90. **M Matucci Cerinic:** “ *Il ruolo del reumatologo – Adalimumab nella cura della malattia psoriasica*” Dermup – update in dermatology 17.06.2021
 91. **M Matucci Cerinic:** “*SSc what is new?*” Kazakhstan medical Academy e-congress 11.06.2021
 92. **M Matucci Cerinic:** “*Il polmone nell’artrite reumatoide*”, IPF e Pneumopatie interstiziali fibrosanti progressive: l’importanza della multidisciplinarietà e-congress , 7.06.2021
 93. **M Matucci Cerinic:** “ *How to assess heart function in Rheumatic diseases?*”, EULAR e-Congress, 3.06.2021
 94. **M Matucci Cerinic:** “ *Progresses and future of lung imaging in SSc-ILD*”, WSF Brazilian e-Masterclass 22.05.2021
 95. **M Matucci Cerinic:** “*Risultati incoraggianti da un nuovo farmaco sulla fibrosi polmonare*”, Convegno GILS, 15.05.2021
 96. **M Matucci Cerinic:** “*Sclerodermia e PAH update*”, Approccio
 97. Multidisciplinare alla Ipertensione Polmonare e Sclerosi Sistemica, 28.04.2021
 98. **M Matucci Cerinic:** “*Covid 19 Ssc-Ild*”, EUSTAR covid congress, 16.04.2021
 99. **M Matucci Cerinic:** “ *The Hrct Challenge, Covid Vs Ssc In Practice*” , Shoenfeld Fridays' Mosaic of Autoimmunity e-Meetings, 9.04.2021
 100. **M Matucci Cerinic:** “*Heart involvement in SSc, a new challenge in the disease scenario*”, CSTAR(Chinese SLE Treatment and Research Group) Annual Meeting, 26.03.2021
 101. **M Matucci Cerinic:** “ *Systemic Sclerosis*”, WSF 1ST International Symposium on Interstitial Lung Disease in Rheumatic Diseases, 19-20.02.2021
 102. **M Matucci Cerinic:** “ *La Reumatologia toscana oggi: l’Artrite Reumatoide tra Medicina di Precisione e Telemedicina*” , 19.02.2021
 103. **M Matucci Cerinic:** “*Advances in diagnosis and management of SSc patients*”, Kuwait Association of Rheumatology (KAR), 19.12.2020
 104. **M Matucci Cerinic:** “*La terapia della fibromyalgia” Sindrome fibromialgica nella visione integrata*”, Webinare Ordine dei Medici di Firenze, 18.12.2020
 105. **M Matucci Cerinic:** “*Diagnosing and monitoring of SSc-ILD*”, WSF-German e-Masterclass on SSc in ILD, 18.12.2020
 106. **M Matucci Cerinic:** “*Nintedanib (Ofev) nel*

107. *trattamento delle malattie interstiziali polmonari (ILD) fibrosanti croniche e della malattia*” interview, 14.12.2020
108. **M Matucci Cerinic:** “*Polmoniti interstiziali infettive ed autoimmuni nell’era del Covid19*”, Giornate Mediche Fiorentine e-Congress ASIAM, 13.12.2020
109. **M Matucci Cerinic:** “*Update sulla sclerodermia e approccio terapeutico*”, REUWEBINAR La Formazione Reumatologica In Web, 3.12.2020
110. **M Matucci Cerinic:** “*Biosimilari degli anti-TNF (tumor necrosis factor) nelle artriti*”, REUWEBINAR La Formazione Reumatologica In Web, 3.12.2020
111. **M Matucci Cerinic:** “*Diagnosi precoce delle IMID con focus sull’uso dei Farmaci Biologici ed inquadramento clinico delle forme miste reuma-derma-gastro*”, Anti-Tnf Alfa E Biosimilari Nel Trattamento Delle Malattie Infiammatorie Immuno-Mediate In Toscana, 1.12.2020
112. **M Matucci Cerinic:** “*Systemic Sclerosis Related Interstitial Lung Disease*”, Chinese Systemic sclerosis & correlated problems-meet the SSc expert online, 22.11.2020
113. **M Matucci Cerinic:** “*Pathogenesis, clinical features and treatment of Rheumatology*”, ILD Web Academy- Japan, 17.11.2020
114. **M Matucci Cerinic:** “*Impact of Early Immunosuppressive Treatment on Incidence of PH during CTD*”, Lebanese Multidisciplinary PAH Congress, 13.11.2020
115. **M Matucci Cerinic:** “*How to diagnose and follow up lung involvement: current practice. The future of lung assessment in SSc-ILD: biomarkers, US & MRI, capillaroscopy*”, WSF-Japanese e-Masterclass on SSc in ILD 13.11.2020
116. **M Matucci Cerinic:** “*Updates on systemic sclerosis diagnosis*”, Best of WCSSc 2020 directed to rheumatology department in Hammad Medical Corporation, 1.11.2020
117. **M Matucci Cerinic:** “*Treatment of PAH in CTDs*”, Emirates Rheumatology Acdademy meeting on Systemic Sclerosis, 30.10.2020
118. **M Matucci Cerinic:** “*Exploring the burden of ILD in CTDs*”, ILD in focus: Time to prioritize the lung in CTDs - Symposium during APLAR congress online, 24.10.2020
119. **M Matucci Cerinic:** “*PAH CTD management*”, Libian Medical Education Webinar for Rheumatologists about PAH-CTD online, 23.10.2020
120. **M Matucci Cerinic:** “*Trattare I percorsi di diagnosi e cura dei pazienti e la necessità di predisporli in maniera chiara per favorire la continuità terapeutica durante l’emergenza.*”, Le Malattie Fibrosanti Del Polmone Dalla Fibrosi Polmonare Idiopatica Alla Sclerosi Sistemica Polmonare: Gestire I Pazienti A Rischio Durante La Pandemia Causata Dal Covid – 19 Ed Oltre, 7.10.2020
121. **M Matucci Cerinic:** “*La Dermatomiosite*”, X Congresso Nazionale Asiam, Roma 26.9.2020
122. **M Matucci Cerinic:** “*Therapeutically advancements in SSc: from the stat of the art to the unmet needs*”, CSTAR Annual Meeting, 26.9.2020
123. **M Matucci Cerinic:** “*Differenziazione cellulare: quando l’endotelio diventa il nemico*”, hyper-pool le nuove frontiere degli stimolatori di sgc: dall’ipertensione polmonare allo scompenso

- cardiaco, 22.9.2020
124. **M Matucci Cerinic:** *“La terapia biologica nella artriti immuno-mediate: fra linee guida e real life”*, web symposia aggiornamenti su patologie autoimmuni, 18.9.2020
 125. **M Matucci Cerinic:** *“ Implicazioni Cliniche”* RATE _Rheumatoid Arthritis Tuscany Experience, 15.9.2020
 126. **M Matucci Cerinic:** *“ Patogenesi dell’AR, meccanismi di persistenza dell’infiammazione sinoviale”* RATE _Rheumatoid Arthritis Tuscany Experience, 15.9.2020
 127. **M Matucci Cerinic:** *“Interstitial lung diseases in systemic sclerosis. Features and differences of lung damage in Covid-19 and differences of lung damage in Covid-19.”* Qazaq College of Rheumatology, 11.9.2020
 128. **M Matucci Cerinic:** *“ Systemic Sclerosis, an overview”* rehearsal Meet the Expert, 25-26.8.2020
 129. **M Matucci Cerinic:** *“Rheumatic Diseases Management in the Covid-19 Era – The Italian Experience”* Meet the expert webinar, 2.8.2020
 130. **M Matucci Cerinic:** *“Intravenous immunoglobulin in SSc”* Csl Behring satellite symposium, 6th Systemic Sclerosis World Congress, 12-14.7.2020
 131. **M Matucci Cerinic:** *“Early diagnosis and treatment initiation: Modern Patient Management In SSc-PAH”* Janssen/Actelion satellite symposium, 6th Systemic Sclerosis World Congress, 12-14.7.2020
 132. **M Matucci Cerinic:** *“ Updates on connective tissue disease associated PAH”* Msd/Bayer satellite symposium, 6th Systemic Sclerosis World Congress, 12-14.7.2020
 133. **M Matucci Cerinic:** *“Updated Algorythm in managing DU including combination therapy”* vascular session, 6th Systemic Sclerosis World Congress, 12-14.7.2020
 134. **M Matucci Cerinic:** *“Moderated discussion: improving outcomes in patients with ILDs associated with ARDs”* Boehringer Ingelheim-Supported Satellite Symposium, EULAR 2020, June 2020
 135. **M Matucci Cerinic:** *“Moderated discussion: current understanding of the pathophysiology of SSc-ILD”* Boehringer Ingelheim-Supported Satellite Symposium, EULAR 2020, June 2020
 136. **M Matucci Cerinic:** *“Osteoarthritis Overview in light of COVID 19 Outbreak”* 14th Annual Rheumatology Orthopedic Meeting(AROM), 8.5.2020
 137. **M Matucci Cerinic:** *“Discuss current information regarding the COVID-19 pandemic and its implications for the monitoring and treatment of rheumatology patients”*, RECONNCET online meet-up 9.4.2020
 138. **M Matucci Cerinic:** *“CTD - PAH – expert guidelines”* Guideline Pulmonary arterial hypertension in scleroderma: care gaps in screening_ Duabi, UAE 21.02.2020
 139. **M Matucci Cerinic:** *“ Up to date sul trattamento ILD in corso di Sclerodermia”* ILDs Highlights advisory board, Milan, Italy _ 29.01.2020
 140. **M Matucci Cerinic:** *“Highlits della giornata”*, PsAR playtogether congress_ Florence, Italy 24-25.01.2020
 141. **M Matucci Cerinic:** *“Concept of pharmacological management of CTD-PAH in view of available evidence driven from*

- SERAPHIN and SRIPHON studies”* , medical education in Salamanayah medical complex _ Bahrain, Kingdom of Bahrain 9.12.2019
- 142.M Matucci Cerinic:** *“Pearls and pitfalls of the diagnosis of CTD-PAH”*, medical education directed to rheumatologists in Dubai Health Authorities and Dubai MOH_ Dubai, UAE 8.12.2019
- 143.M Matucci Cerinic:** *“Importance of early screening for PAH among CTD patients. How can we make patient’s screening made easy?”*, medical education directed to rheumatologists in UAE (private sector)_ Dubai, UAE 7.12.2019
- 144.M Matucci Cerinic:** *“ Il coinvolgimento cardiac nella sclerosi sistemica”* , 56° Congresso Nazionale della Società Italiana di Reumatologia_ Rimini, Italia 27-30.11.2019
- 145.M Matucci Cerinic:** *“ Intercative case: SLE associated PAH”*, 10th MENA PH forum_ Dubai, UAE 25-26.10.2019
- 146.M Matucci Cerinic:** *“Intercative case: PH in Saudi patients with SSc”* 10th MENA PH forum_ Dubai, UAE 25-26.10.2019
- 147.M Matucci Cerinic:** *“ Screening and diagnostic modalities od CTD-PAH”*, 10th MENA PH forum_ Dubai, UAE 25-26.10.2019
- 148.M Matucci Cerinic:** *“Advances om the management of CTD-PAH”*, 10th MENA PH forum_ Dubai, UAE 25-26.10.2019
- 149.M Matucci Cerinic:** *“Importance of screening and early diagnosis of CTD-PAH ; what should rheumatologist do”*, ADARRC 2019 - 9th Advanced Academic Rheumatology Review Course_ Abu Dhabi. UAE 13.09.2019
- 150.M Matucci Cerinic:** *“Correlation between early detection and improving prognosis in CTD-PAH patients”*, Early detection improves prognosis in connective tissue diseases associated symposium_ Abu Dhabi, UAE 13.10.2019
- 151.M Matucci Cerinic:** *“ Epidemiologia, dati dei registry, dati di spesa: la situazione regionale”*, Focus artrite reumatoide _ Firenze, Italia 30.9.2019
- 152.M Matucci Cerinic:** *“ Treatment options for lung disease in rheumatic diseases”*, Annual Congress of Rheumatology Association_ Belgrade, Serbia 21.9.2019
- 153.M Matucci Cerinic:** *“How to assess patients with very early Systemic Sclerosis?”*, South-East European Rheumatology Course_ Nis, Serbia 19.9.2019
- 154.M Matucci Cerinic:** *“ What does this mean for scleroderma?”*, 16th International Workshop om Scleroderma Research_ Cambridge, UK 21-31.7.2019
- 155.M Matucci Cerinic:** *“ Interstitial pneumonitis with autoimmune features”*, Summerschool 2019_ Santiago de Compostela, Spain, 4-6.7.2019
- 156.M Matucci Cerinic:** *“Building a stepwise approach to the use of CMRI in SSc: cardiologist vs rheumatologist”*, World Scleroderma Day- The heart involvement in scleroderma meeting_ Rome, Italy 28.06.2019
- 157.M Matucci Cerinic:** *“Immunosuppression in SSc - one fits all vs. individualized selection?”*, Annual European Congress of Rheumatology EULAR Congress_ Madrid, Spain 12-15.6.2019
- 158.M Matucci Cerinic:** *“How to screen in search for PAH in SSc”* , Biological Therapies in Medicine_ Ischia, Naples 29-31.5.2019
- 159.M Matucci Cerinic:** *“Pathophysiological Rationale”*, Connective Tissue and Pulmonary Arterial Hypertension_ MSD

Webcast. Frankfurt, 10.04.2019

160. **M Matucci Cerinic:** “*Management of skin problems in SSc (scleroderma, digital ulcer, calcification)*”. 39th Korean Collage of Rheumatology Annual Scientific Meeting, Seoul, Korea 16-18.05.2019
161. **M Matucci Cerinic:** “*I farmaci sintetici-molecolari*” IX Congresso Nazionale ASIAM. Napoli, 10-12.05.2019
162. **M Matucci Cerinic:** “*L’impegno polmonare nella sclerosi sistemica e terapia*”. VI congresso di reumatologia _malattie reumatiche infiammatorie croniche. Sorrento, Italy 10-11.05.2019
163. **M Matucci Cerinic:** Skin score course 2019 held in Guangzhou, China 18-21.04.2019
164. **M Matucci Cerinic:** “*Early detection of SSc & Role immunologic tests*” ; “ *Optimal Management of PAH*” ; “ *DU: diagnosis & management*”. Beirut, Lebanon 13.04.2019
165. **M Matucci Cerinic:** “*Optimal management of pulmonary artery hypertension*”, Presentorship – A Holistic Approach to SS, Beirut, Lebanon 12.04.2019
166. **M Matucci Cerinic:** “*Intrest of early detection of SS patients & role of immunology tests to predict early and late complications*”, Presentorship – A Holistic Approach to SS, Beirut, Lebanon 12.04.2019
167. **M Matucci Cerinic:** “*Sclerosi Sistemica ed intrattenimento cardiaco – un killer silenzioso*”. Napoli, Italy 28-30.03.2019
168. **M Matucci Cerinic:** “*Is there a place for corticosteroids in the treatment of Scleroderma?* “ 5th CORA congress, Florence, Italy. 13-14.03.2019
169. **M Matucci Cerinic:** “*When does the disease start?*“ EUSTAR course 2019. Nijmegen, 21-24.2.2019
170. **M Matucci Cerinic:** “*Current approaches to the treatment of SSc – PAH “What is the role of ERAs in the treatment paradigm? - SSc – PAH the key scientific questions.* Cairo, Egypt 21.12.2108
171. **M Matucci Cerinic:**“ *Evidence based detection of PAH in systemic sclerosis (DETECT STUDY) “how DETECT algorithm be applied in clinical practice?” – SSc – PAH the key scientific questions.* Cairo, Egypt 21.12.2108
172. **M Matucci Cerinic:**“ *Il punto di vista del reumatologo*” – Iperensione arteriosa polmonare: modello gestionale multidisciplinare in rete. Arezzo, 15.12.2018
173. **M Matucci Cerinic:**“*Tratamiento de las ucleras digitales, neumonia intersticial e hipertension pulmonar*”- Simposio Mixto de Capilaroscopia, Ecografia y Esclerosi Sistemica. Santo Domingo, 6-8.12.2018
174. **M Matucci Cerinic:**“ *Vias de activacion del colageno, factores de modulacion e inmunopatogenia de la esclerosi sistemica*”- Simposio Mixto de Capilaroscopia, Ecografia y Esclerosi Sistemica. Santo Domingo, 6-8.12.2018
175. **M Matucci Cerinic:**“ *Evaluacion de la ecografia en la evaluacion de la esclerosi sistemica*”- Simposio Mixto de Capilaroscopia, Ecografia y Esclerosi Sistemica. Santo Domingo, 6-8.12.2018
176. **M Matucci Cerinic:**“ *La terapia della sclerodermia*” – Le nuove frontiere della terapia della malattie reumatiche. Palermo, 30-1.12.2018
177. **M Matucci Cerinic:**“ *Patologie autoimmunitarie nell’anziano*” – Congresso Nazionale SIGG. Roma, 28-29.11.2018

- 178.M **Matucci Cerinic:** “ *Similarity throughout: dagli esercizi comparativi ai dati di real life*” - Simposio Biogen, Congresso Nazionale Società Italiana di Reumatologia. Rimini, 21-24.11.2018
- 179.M **Matucci Cerinic:** “ *Il punto di vista del Presidente del Comitato Etico AOUC*” - evento SIF “ Il ruolo del farmaco nel sistema sanitario nazionale”. Roma, 20-21.11.2018
- 180.M **Matucci Cerinic:** “ *Dolore e Gotta*” - Giornate Mediche Fiorentine. Firenze, Italia 16-18.11.2018
- 181.M **Matucci Cerinic:** “*SSc pharma treatment*” EBMT Cogress (European Society for Blood and Marrow Transplantation). Florence, Italy 15-17.11.2018
- 182.M **Matucci Cerinic:** “*Summary of the Session: Future Directions in the Diagnosis and Management of Myocardial Dysfunction in Systemic Sclerosis*” 15th Annual Conference of the ESC working group in Myocardial & Pericardial Diseases. Belgrade, Serbia 5-7.10.2018
- 183.M **Matucci Cerinic:** “*Myocardial Involvement in Systemic Autoimmune Diseases: The Rheumatologist’s Perspective*”. 15th Annual Conference of the ESC working group in Myocardial & Pericardial Diseases. Belgrade, Serbia 5-7.10.2018
- 184.M **Matucci Cerinic:** “*Heart Involvement in SSc: the challenge of early diagnosis*”. Hungarian Congress Association. Budapest, 4-6.10.2018
- 185.M **Matucci Cerinic:** “ *SSc: early diagnosis and management*”. 19th EULAR Postgraduate course. Budapest 1-3.10.2018
- 186.M **Matucci Cerinic:** “*Pregnancy in Systemic Sclerosis (SSc): Results of Systemic Review and Meta-analysis*”. 10th International Conference on Reproduction, Pregnancy and Rheumatic diseases”. Bern, Switzerland 27-29.09.2018
- 187.M **Matucci Cerinic:** “*Opening Keynote: global and international research*”. 18th Bi-annual national scleroderma conference 2018. Calgary, Alberta, 21-22.09.2018
- 188.M **Matucci Cerinic:** “*Opening Remarks CME*”. 18th Bi-annual national scleroderma conference 2018. Calgary, Alberta, 21-22.09.2018
- 189.M **Matucci Cerinic:** “ *L’interessamento cardiaco nella Sclerosi Sistemica, un nemico silenzioso*” *SSc: la ricerca una speranza per il future*. Roma, 27.06.2018
- 190.M **Matucci Cerinic:** “From registries to trials – do we have sufficient data and the appropriate design? “. *Annual European Congress of Rheumatology – EULAR 2018*. Amsterdam 13-16.06.2018
- 191.M **Matucci Cerinic:** “Caso clinico interattivo su iPad”. *GOUT: Diasgnosis and therapeutic management*. Napoli, 4-5.05.2018
- 192.M **Matucci Cerinic:** “La diagnosi di gotta: alla ricerca di un mondo sommerso” *GOUT: Diasgnosis and therapeutic management*. Napoli, 4-5.05.2018
- 193.M **Matucci Cerinic:** “Optimal management of Digital Ulcers in SSc”. *Janssen Rheumatology Forum Wave II*. Amman, Jordan 27-28.04.2018
- 194.M **Matucci Cerinic:** “Detection and management of PAH accosted with Systemic sclerosis (DETECT)”. *Janssen Rheumatology Forum Wave II*. Amman, Jordan 27-28.04.2018
- 195.M **Matucci Cerinic:** “Diagnosis and management of Myocardial involvement in systemic immune-mediated diseases”. *Working*

- Group Webinar. Nice, France, 24.04.2018*
196. **M Matucci Cerinic:** “Heart involvement seen by a rheumatologist in SSc: signs, symptoms and the additive value of cardiovascular magnetic resonance (cmr) “ – Expert meeting on SSc “ Cardiac tissue characterization and pulmonary hypertension in systemic sclerosis: how can we improve diagnostic and therapeutics”. Athens, Greece, 20-21.04.2018
 197. **M Matucci Cerinic:** “ The early disease: clinical features and diagnostic tools “ – XVII Mediterranean Congress of Rheumatology, Genoa, Italy, 12-14.04.2018
 198. **M Matucci Cerinic:** “ Management: from guidelines up to the last treatment issues” – XVII Mediterranean Congress of Rheumatology, Genoa, Italy, 12-14.04.2018
 199. **M Matucci Cerinic:** “Ultrasound in Scleroderma, from skin to lung” – *Fluid aspiration, injections, biopsies and loco-regional anesthesia of peripheral nerves, Plovdiv, Bulgaria, 29-30.03.2018*
 200. **M Matucci Cerinic:** “Sclerosi sistemica: nuovi approcci terapeutici” – Primo congresso di reumatologia della Campania. Napoli, Italy, 15-17.03.2018
 201. **M Matucci Cerinic:** Capillaroscopy Workshop – *Kuwait & Qatar, 4-6.03.2018*
 202. **M Matucci Cerinic:** “When do we need to make macro/micro vascular assessment when you see a DU? - 5th Systemic Sclerosis World Congress, Bordeaux, France, 15-18.02.2018
 203. **M Matucci Cerinic:** “The classification and the therapeutic strategy of DU in SSc” - 5th Systemic Sclerosis World Congress, Bordeaux, France, 15-18.02.2018
 204. **M Matucci Cerinic:** “Current EULAR Recommendations”; - 5th Systemic Sclerosis World Congress, Bordeaux, France, 15-18.02.2018
 205. **M Matucci Cerinic:**” Biomarkers development in psoriatic arthritis” – *La farmacodipendenza in Calabria dalla formazione, Catanzaro, 6-7.12.2017*
 206. **M Matucci Cerinic:**” Pulmonary arterial hypertension in connective tissue diseases; Scleroderma mimickers workshop” – *Annual Bahrain Rheumatology Conference, Manama, Bahrain, 1-2.12.2017*
 207. **M Matucci Cerinic:**” Cetrolizumab Pegol: For which RA patient?; Optimal Management of SpA is more than spine and joints; What’s new in scleroderma? – *Cizma scientific meeting, Qatar 24-25.11.2017*
 208. **M Matucci Cerinic:** “ Novità nella valutazione clinica del paziente con sclerosi sistemica, dai markers solubili all’imaging” - 54° Congresso Nazionale della Società Italiana di Reumatologia, Rimini, 22-25.11.2017
 209. **M Matucci Cerinic:** “Farmaci biologici, un nome soave per risultati forti” – *Giornate Mediche Fiorentine, Firenze 17-19.11.2017*
 210. **M Matucci Cerinic:** “ L’importanza della continuità terapeutica” – *Gestione Clinica & Organizzativa delle malattie reumatiche, Firenze 11.11.2017*
 211. **M Matucci Cerinic:** SSc: Early diagnosis and management - 18th EULAR postgraduate course, Belgrade 22-25.10.2017
 212. **M Matucci Cerinic:** How to treat ischemic digital ulcers refractory to conventional therapies; Assessment of pulmonary hypertension in rheumatic diseases - *ADARRC 7th Abu Dhabi*

- advances rheumatology review course, Abu Dhabi 20-21.10.2017*
213. **M Matucci Cerinic:** Termalismo e la sclerosi sistemica, in *Asma e BCPO: aspetti di immunopatogenesi e nuove strategie terapeutiche*, Ischia 13-15.10.2017
 214. **M Matucci Cerinic:** Ultrasound in systemic sclerosis; *4th EULAR Musculoskeletal Sonography Course for Rheumatologists*, Zagreb 28-30.09.2017
 215. **M Matucci Cerinic:** Systemic Sclerosis: new developments in the pathogenesis and therapeutic options in systemic sclerosis; *Amsterdam Rheumatology & Immunology Centre*, Amsterdam 13.09.2017
 216. **M Matucci Cerinic:** Indicazioni di appropriatezza prescrittiva regionale; *Appropriatezza prescrittiva delle terapie biologiche in reumatologia*, Firenze 7.9.2017
 217. **M Matucci Cerinic:** Too early - too late? Interstitial lung disease in connective tissue diseases; *3rd European Summerschool in Rheumatology*, Leipzig 6-7.7.2017
 218. **M Matucci Cerinic:** Digital Ulcers in Systemic Sclerosis: A challenge for the rheumatologists - from medical aspects to practical patients needs; *Actelion Expert's meeting*, Athen, Greece, 3-4.7.2017
 219. **M Matucci Cerinic:** Pathogenesis and management of digital ulceration in systemic sclerosis update; Updates and advances in PAH-CTD, *SNUH Rheumatology Symposium 201*, Seoul, Korea 21-24.06.2017
 220. **M Matucci Cerinic:** Ultrasound in connective tissue diseases: anything else that joints?, *EULAR 24th Sonography Course Basic – Intermediate and Advanced Musculoskeletal Ultrasound (MSUS) in Rheumatology*, Madrid, 11 -14.06.2017
 221. **M Matucci Cerinic:** Systemic Sclerosis, *Biological Therapies in Medicine*, Ischia, Italy 25.05.2017
 222. **M Matucci Cerinic:** State of art in Scleroderma, *Portuguese Society of Rheumatology Congress*, Algarve 11-12.05.2017
 223. **M Matucci Cerinic:** Dalla definizione alla classificazione delle ulcere digitali, *2° Scleroderma Day*, Milano, Italy 5-6.05.2017
 224. **M Matucci Cerinic:** Il ruolo del reumatologo, *Clinical Experiences in Idiopathic Pulmonary Fibrosis*, Firenze, Italy 7-8.04.2017
 225. **M Matucci Cerinic:** A practical approach: what are the therapeutic measures in digital ulcer disease, *X Systemic Sclerosis Forum*, Berlin, Germany 23.03.2017
 226. **M Matucci Cerinic:** Le linee guida e l'esperienza della regione Toscana, *Terapia biologica e off label in reumatologia pediatrica – linee guida di appropriatezza per l'utilizzo dei farmaci*, Milano, Italy 17.03.2017
 227. **M Matucci Cerinic:** Sclerosi sistemica Patogenesi- Diagnosi e classificazione – Gestione delle ulcere. *II Master in Reumatologia*, Trieste, Italy 13-17.03.2017
 228. **M Matucci Cerinic:** Biosimilar vs Innovator: are they identical? *4th International Congress on Controversies in Rheumatology and Autoimmunity*, Bologna, Italy, 9-10.03.2017
 229. **M. Matucci Cerinic:** Revised classification, when does the disease start? *European Scleroderma Trials and Research group (EUSTAR) Course: Split, Croatia*, 23 – 26.02.2017
 230. **M. Matucci Cerinic:** Early diagnosis of knee osteoarthritis: a challenge for the future? *Arab Health, 13th Middle East*

- Orthopaedic Conference*; Dubai, UAE, 30.01.2017 – 2.02.2017
231. **M. Matucci Cerinic**: Ultrasonography in Systemic Sclerosis: from the skin to the lung. *Musculoskeletal ultrasound courses*, Sofia, Bulgaria, 13-15.1.2017
 232. **M. Matucci Cerinic**: Novetats Diagnostico: Terapeutiques a la Esclerosi Sistèmica. *III Curs de malalties autoimmunitaries sistèmiques de la societat catalana de reumatologia*, Barcelona, Espana, 2-3.12.2016
 233. **M. Matucci Cerinic**: Esperienza e confronto del primo anticorpo monoclonale biosimilare in Italia - Ruolo della transizione endotelio-mesenchimale nella patogenesi della fibrosi dermica nella sclerosi sistemica – Controversie nel trattamento della sclerosi sistemica – Ruolo delle janus chinasi nell'artrite reumatoide, *53° Congresso Nazionale SIR*, Rimini, Italia, 23-26.11.2016
 234. **M. Matucci Cerinic**: Systemic Sclerosis a Multi- Organ Disease: How should we monitor and treat the patient, *7th Middle East & North Africa Pulmonary Hypertension Forum*, Dubai, UAE, 7-8.10.2016
 235. **M. Matucci Cerinic**: Understanding the vascular pathogenesis of systemic sclerosis: a challenge for the future, *18th Asia Pacific League Association for Rheumatology Congress*, Shanghai, China 26-29.09.2016
 236. **M. Matucci Cerinic**: A practical approach – What are the therapeutic measures in digital ulcer disease & do we act on the microvascular level?. *Systemic Sclerosis Symposium*, Berlin, 19-20.9.2016
 237. **M. Matucci Cerinic**: Managing patients with DU – Implementing guidelines in practice and monitoring the impact of therapy, *International SSc Symposium: Update and Practice in Systemic Sclerosis*, Amsterdam, Netherlands 16-17.09.2016
 238. **M. Matucci Cerinic**: The vascular involvement in systemic sclerosis – Healing and preventing DU in SSc, *EUSTAR Digital Ulcer Masterclass*, Tel Aviv, Israel 25-28.08.2016
 239. **M. Matucci Cerinic**: Criterios ACR/EULAR – Ulceras digitales – Enfermedad pulmonar intersticial, *IX Curso de Actualización en Reumatología*, Monteria, Colombia, 4-6.08.2016
 240. **M. Matucci Cerinic**: Raynauds & Digital Ulcers – Type and Management; Calcinosis in scleroderma, *International Symposium on Scleroderma*, Bangalore, India 16-17.07.2016
 241. **M. Matucci Cerinic**: Dal fenomeno di Raynaud alla sclerosi sistemica: l'importanza della diagnosi precoce, *Congresso di Reumatologia SIR*, Sicilia, Italia 17-18.06.2016
 242. **M. Matucci Cerinic**: Ipertensione polmonare: il punto di vista del reumatologo, *Biological Therapies in Medicine*, Ischia, Italy 26-29.05.2016
 243. **M. Matucci Cerinic**: Ulceres: classification et traitements des UD, *Congres medical dea patients de sclerodermie*, Aix – les – Bains, France 13-14.05.2016
 244. **M. Matucci Cerinic**: Algoritmi terapeutici, Focus su ulcere. *Le malattie in reumatologia congresso SIR*, Pisa, Italia 4-6.05.2016
 245. Khanna D, Denton CP, Merkel PA, Krieg T, Le Brun FO, Marr A, Papadakis K, Pope J, **Matucci-Cerinic M**, Furst DE; DUAL-1 Investigators; DUAL-2 Investigators. *Effect of Macitentan on the Development of New Ischemic Digital Ulcers in Patients With Systemic Sclerosis: DUAL-1 and DUAL-2 Randomized Clinical*

- Trials*. JAMA. 2016 May 10;315(18):1975-88.
246. **M. Matucci Cerinic:** Understanding biomarkers for the diagnosis, prognosis, and monitoring of autoimmune diseases, *Real exchange speaker training invitation*, Barcelona, Spain 11-12.03.2016
 247. **M. Matucci Cerinic:** Aggiornamento in tema di terapie biologiche: come, quando, perché?. Giornate Mediche Fiorentine, Firenze, Italy 20-22.11.2015
 248. **M. Matucci Cerinic:** The etiopathogenesis and treatment of scleroderma. *9th Course SIMID from the dermatological viewpoint and beyond*, Erice, 22.10.2015
 249. **M. Matucci Cerinic:** The challenge of early psoriatic arthritis: can we accomplish the mission, *2nd Palermo International Forum on Spondyloarthritis*, Palermo, Italy 24.10.2015
 250. **M. Matucci Cerinic:** How to publish in rheumatological journals, *Brazilian Congress of Rheumatology*, Curitiba, Brasil 8-9.10.2015
 251. **Matucci Cerinic:** Identificazione precoce e trattamento tempestivo della Sclerosi Sistemica e delle sue complicanze, *XX Reumameeting*, Roma, Italy 19.9.2015
 252. **M. Matucci Cerinic:** The global approach to the local treatment of digital ulcers, *WSF masterclass*, Split, Croatia 25-26-9-2015
 253. **M. Matucci Cerinic:** La nefropatia sclerodermica, *Giornate Nefrologiche di Lucca e della Versilia*, Lucca, Italy 24-25.9.2015
 254. **M. Matucci Cerinic:** From Art to Science, *German Congress of Rheumatology*, Bremen, Germany 1-3.9.2015
 255. **M. Matucci Cerinic:** Healing and preventing digital ulcers in Systemic Sclerosis, a challenge for the rheumatologist. *WSF masterclass*, Bucharest, 10-11.7.2015
 256. **M. Matucci Cerinic:** Challenges in treatment of PAH and DDis; Systemic Sclerosis & Myositis what's new in 2014-2015. *EULAR congress*, Roma, Italy 10-13.6.2015
 257. **M. Matucci Cerinic:** Farmaci biologici, farmaci biosimilari e piccole molecole nel trattamento; Cosa deve sapere il MMG della Artrite Reumatoide. VI Congresso Annuale ASIAM, Rimini, Italy 15-17.5.2015
 258. **M. Matucci Cerinic:** Connective Tissue Disease: Interstitial Lung Disease and Pulmonary Arterial Hypertension Management. *GSK Global Webinar*, Tokyo, Japan 22.3.2015
 259. **M. Matucci Cerinic:** The scleroderma lung: where do we stand?. *International Meeting on Pulmonary Rare Diseases and Orphan Drugs*, Milano, Italy 27-28.2.2015
 260. **M. Matucci Cerinic:** Nuovi criteri classificativi della sclerosi sistemica, *Humanitas Hospital*, Milano, Italy 14.1.2015
 261. **M. Matucci Cerinic,** Aggressive and complicated extraarticular rheumatoid arthritis, *III International course on Rheumatoid Arthritis*, Firenze, 4-6.12.2014
 262. **M. Matucci Cerinic:** Systemic Sclerosis management of Pulmonary Arterial Hypertension; Systemic Sclerosis: Digital Ulcers management in practice *XV Turkish Congress of Rheumatology*, Antalya, Turkey 1-2.11. 2014
 263. **M. Matucci Cerinic:** L'ipertensione polmonare nella Sclerosi Sistemica: ruolo della diagnosi differenziale tra PAH e ILD, *1° Scleroderma Day*, Milano, Italy 3.10. 2014
 264. **M. Matucci Cerinic:** treatment guidelines in digital ulcers in systemic sclerosis, *Update and Practice in Systemic Sclerosis: The*

- Management of Digital Ulcers*, Paris, France, 19-20.9.2014
265. **M Matucci Cerinic:** Stato dell'arte e hot points nelle spondiloartriti sieronegative, spondiloartrite pre-radiografica, *Casi Difficili in Reumatologia*, Pisa, 27.9.2015
 266. **M Matucci Cerinic:** Systemic Sclerosis: New Diagnostic Criteria ; Treating Beyond Joints in Spondyloarthritis, *Serbian Congress of Rheumatology*, Arandelovac, Serbia, 26-28.9.2014
 267. **M Matucci Cerinic:** Trapianto di cellule staminali nella sclerosi sistemica: un salto nel futuro. *Immunodeficienze e malattie immunomediate*, Nusco, Italy 10-12.7.2014
 268. **M Matucci Cerinic:** How to assess patients with very early systemic sclerosis, *2°South east european course in adult & pediatric rheumatology*, Belgrade, Serbia, 16 -18.9.2014
 269. **M Matucci Cerinic:** Drug survival on biologic therapy- Taking control of long term outcomes; Early and mild SSc in clinical practice: report from the VEDOSS database, *EULAR 2014*, Paris, France, 10-13.6.2014
 270. **M Matucci Cerinic:** L'artrite reumatoide, *Percorsi diagnostici e terapeutici in Toscana*, Firenze, Italy 9.5.2014
 271. **M Matucci Cerinic:** Advances in the clinical studies of Systemic Sclerosis, *Second Eurasian Congress of Rheumatology*, Moskva, Russia, 20.5. 2014
 272. **M Matucci Cerinic:** How to choose an NSAID for our patient? ; Treatment of OA patients- International experience, *Lecture at the University of Minsk*, Minsk Belarus, 22.5.2014
 273. **M Matucci Cerinic:** DART study and dose escalation, *Turbocharger Symposium*, Belgrade, Serbia, 27.5.2014
 274. **M Matucci Cerinic:** Treatment of PAH associated to CTD patients ; What can we learn from registries and post marketing surveillance, studies in PAH – CTD?; Idiopathic Pulmonary Fibrosis vs Interstitial Lung Disease-SSc, *National Japanese meeting on PAH*, Tokyo, Japan, 6-7.4.2014
 275. **M Matucci Cerinic:** La strategia Treat-to-Target nell'artrite reumatoide: cosa possiamo imparare per il Lupus, *Controversie nel lupus eritematoso*, Firenze, Italy 12.4.2014
 276. **M Matucci Cerinic:** The very early diagnosis of systemic sclerosis is possible today; Rapid Response, A Predictable Future in RA , *7th AROM congress*, Alexandria, Egypt, 23-25.4.2014
 277. **M Matucci Cerinic:** The impact of PAH on connective tissue diseases, *International Course on PAH*, Bologna, Italy 27-30.2.2014
 278. **M Matucci Cerinic:** The challenge of the very early and early diagnosis of systemic sclerosis, *PANLAR congress*, Punta de l'Este, Uruguay, 17-20.3.2014
 279. **M Matucci Cerinic:** The economic impact of dose escalation in RA and implications for clinical practice, *EHAP congress*, Paris, France 23-25.3.2014
 280. **M Matucci Cerinic:** The diagnosis of early PAH: on the cutting edge, *9th congress of autoimmunity*, Nice, France, 27-20.3.2014
 281. **M Matucci Cerinic:** The Clinical Overview, on the cutting edge; Focusing on early detection of SSc and addressing initial manifestations, *3rd World Congress on Systemic Sclerosis*, Rome, Italy, 6-9.2.2014
 282. **M Matucci Cerinic:** Treating early rheumatoid arthritis for optimal outcome; Treat To Target: Role of Abatacept in Achieving The Target, *Pan Arab Congress*, Dubai , United Arab

- Emirates, 12-14.1.2014
283. **M Matucci Cerinic:** The modification of angiogenesis, *Università Federico II, Centro Interdipartimentale di Scienze Immunologiche di Base e Cliniche*, Napoli, Italy 26.11.2013
 284. **M Matucci Cerinic:** The challenge of very early and early diagnosis of systemic sclerosis; The treatment of Raynaud phenomenon and digital ulcers in systemic sclerosis, *Ten Topics in Rheumatology*, Beirut, Lebanon, 11-12-10.2013
 285. **M Matucci Cerinic:** Jak Stat pathways, a new therapeutic target in rheumatoid arthritis, *Osteorheumatology 2013*, Genova, 14.10.2013
 286. **M. Matucci Cerinic:** Reumatologia del PANDAS, *IX Florence Summer Course Quality in Clinical Psichiatry*, Firenze, 19-21.10.2013
 287. **M Matucci Cerinic:** Current management of digital ulcers, *5th International SSc Forum Shifting the paradigm, managing manifestations of systemic sclerosis*, Prague, Czech Republic, 18-20.10-2013
 288. **M Matucci Cerinic:** Updated management of Systemic Sclerosis; The new insight in the pathogenesis of Systemic Sclerosis, *APLAR Workshop*, Bali, Indonesia, 2.9.2013
 289. **M Matucci Cerinic:** Adalimumab in SPA, tips and Tricks. *Serbian Congress of Rheumatology*, Kopaonik, Serbia. 6.9.2013
 290. **M Matucci Cerinic:** update in pulmonary arterial hypertension, *Middle East PAH Forum*, Dubai, Emirates, 26.9.2013
 291. **M Matucci Cerinic:** Prediction, Approach and Treatment of Digital Ulcers, *German Congress of Rheumatology 2013*, Mannheim, Germany, 18-21.9.2013
 292. **M Matucci Cerinic:** Keynote lecture- Alterations in angiogenesis in systemic sclerosis, *13th International Workshop on Scleroderma Research*. Boston University, USA, 3-7.8.2013
 293. **M Matucci Cerinic:** Terapie convenzionali e nuovi farmaci nella sclerosi sistemica, VI Congresso Internazionale Multidisciplinare. approccio clinico e riabilitativo in reumatologia. Percorsi diagnostici terapeutici: le nuove frontiere, Mantova, 5-7.6.2013
 294. **M Matucci Cerinic:** Digital ulcers in connective tissue diseases a matter of early detection and classification, *EULAR congress*, Madrid, Spain, 12-16.6.2013
 295. **M Matucci Cerinic:** Management of scleroderma – what can we achieve? *13. Symposium Rheumatologie im Ruhrgebiet*“, Herne, Germany, 29.6.2013
 296. **M Matucci Cerinic:** From Raynaud to gangrene-spectrum of scleroderma vascular involvement, *Croatian Workshop on Connective Tissue Diseases*, Opatija, Croatia, 11.5. 2013
 297. **M Matucci Cerinic:** Treatment of OA patients; Vascular disturbances in systemic scleroderma, *International experience Russian Congress of Rheumatology*, Moskva, Russia, 13-16.5.2013
 298. **M Matucci Cerinic:** Il fenomeno di Raynaud e la diagnosi precoce delle malattie del connettivo, *Congresso ASIAM*, Riccione, 17-19.5.2013
 299. **M Matucci Cerinic:** The new classification of SSc and the development of specific therapeutic recommendations ,*Spanish Congress of Rheumatology*, Tenerife, Spain, 22-25.5.2013
 300. **M Matucci Cerinic:** The scleroderma management, *Gulf PAH Meeting*, Dubai, Emirates, 24.5.2013

301. **M Matucci Cerinic:** L'attuale situazione dell'assistenza reumatologica in Italia tra bisogni e riduzione delle risorse: collaborazioni, *1° Forum Nazionale delle associazioni che si occupa no di Malattie Reumatiche, La persona al centro*, Abano, 31.5.2013
302. **M Matucci Cerinic:** State of the art of immusuppressive treatment in systemic sclerosis, *CORA meeting*, Budapest, Hungary, 4-6.04.2013
303. **M Matucci Cerinic:** The lung involvement in antisynthetase syndrome, *ERS course on diffuse parenchymal diseases*, Trieste, Italy, 8-10.4.2013
304. **M Matucci Cerinic:** Systemic Sclerosis- review, *ELAR congress*, Alexadria, Egypt, 23-26.4.2013
305. **M Matucci Cerinic:** Update on Rheumatod Arthritis criteria & therapeutic perspectives; State of the art of lung involvement in systemic sclerosis, from diagnosis to treatment, *II Congress of the International Hospital of Bahrain*, Bahrain, 23.3.2013
306. **M Matucci Cerinic:** Nuove prospettive terapeutiche per il paziente con artrite reumatoide, *Nuove frontiere terapeutiche in ematologia ed immunologia*, Ancona, 8.3.2013
307. **M Matucci Cerinic:** 10 years of TNFi in AS –how did they affect everyday life of a patients; Present and future of registry in Rheumatology, *MSD Regional Immunology Forum*, Rovinj, Croatia, 8-10.3.2013
308. **M Matucci Cerinic:** Clinical value of TNFa inhibitors in rheumatic disease , *EAHP 2013 Symposium*, Paris, France 14.3.2013
309. **M Matucci Cerinic:** What a practitioner should know about systemic sclerosis, *XIX Symposio de inflamacion y des enfermedad reumaticas*, Valladolid, Spain, 15-16.3.2013
310. **M Matucci Cerinic:** Artrite psoriasica: il punto di vista del reumatologo, *Reumatologia & Dermatologia insieme*, Verona, 22-23.3.2013
311. **M Matucci Cerinic:** Immunesuppression in systemic sclerosis, to be or not to be, *V International congress on rare pulmonary diseases and orphan drugs*, Milano, 8-9.2.2013
312. **M Matucci Cerinic:** Clinical features of Very Early and Early Systemic Sclerosis, *The Egyptian Society for Joint Diseases and Arthritis*, Sharm, Egypt, 18-22.2.2013
313. **M Matucci Cerinic:** The treatment of Digital Ulcers in systemic sclerosis; Raynaud phenomenon in systemic sclerosis, *5th EUSTAR course on systemic sclerosis*, Cluj, Rumunia, 24-27.1.2013
314. **M Matucci Cerinic:** Reumatologia del PANDAS, *IX Florence Summer Course*, Firenze, 19-21.10.2012
315. **M Matucci Cerinic:** The very early diagnosis of systemic sclerosis, *South East EULAR Course on pediatric and adult rheumatic disease*, Bucharest, Rumunia, 23-25.10.2012
316. **M Matucci Cerinic:** The 2 W in the treatment of ankylosing spondylitis, *Rumunian Congress of Rheumatology*, Bucharest, Rumunia, 25-27.10.2012
317. **M Matucci Cerinic:** Ipertensione polmonare e sclerosi sistemica: le occasioni perdute & la speranza della T2T, *Ipertensione polmonare ed uclere digitali nella sclerosi sistemica*, Firenze, 8.9.2012
318. **M Matucci Cerinic:** Nondifferentiated spondyloarthropathy –

- clinical approach , Serbian Congress of Rheumatology, Subotica, Serbia, 19 - 22.09.2012
319. **M Matucci Cerinic:** Integrated Approach to Pain Management in Patients with Osteoarthritis, NII Congress, Moskva, Russia, 25-26.9.2012
 320. **M Matucci Cerinic:** Il sospetto clinico e la diagnosi precoce di PAH-CTD, *LIVE 2012 Italian PAH Event Workshop*, Verona,
 321. **M Matucci Cerinic:** Vasculopathy in systemic sclerosis and management of Raynaud's Phenomenon and digital ulcers, *International Symposium on pathogenesis and management of systemic sclerosis*, University of Michigan Ann Arbor, USA, 26.4.2012
 322. **M Matucci Cerinic:** La nuova frontiera della terapia cortisonica: dalla terapia tradizionale alla Cronoterapia, *Congresso Nazionale ASIAM*, Riccione 12-13.5.2012
 323. **M Matucci Cerinic:** Uveiti In corso di spondilo-artrite sieronegative, *Corso di formazione di immunopatologia oculare*, Firenze, 18.5.2012
 324. **M Matucci Cerinic:** The growth of the community devoted to systemic sclerosis; The problem of PAH in systemic sclerosis, *Russian Congress of Rheumatology*, Vladimir, 22-24.5.2012
 325. **M Matucci Cerinic:** Infliximab efficacy in EA manifestations in AS- *Clinical update, MSD Advisory Board*, Bucuresti, Romania, 30.5.2012
 326. **M Matucci Cerinic:** Early diagnosis of PAH and connective tissue M. Matucci-Cerinic disease: What is the evidence? *European PAH Forum: From Early Diagnosis to Long-Term Efficacy*, Madrid, Spain, 14-15.6.2012
 327. **M Matucci Cerinic:** Il ruolo del reumatologo nella medicina sportiva, *Lo sport come mezzo di prevenzione*, Firenze, 9.6. 2012
 328. **M Matucci Cerinic:** The burden of co-morbidity on the choice of biologic therapy in Spondyloarthritis, *The first Clinical challenge: Eminence versus Evidence in Spondyloarthritis*, Pisa, 22.6.2012
 329. **M Matucci Cerinic:** La gestione del paziente con spondilite anchilosante e artrite reumatoide nell'ambulatorio del MMG, *La gestione del dolore nell'ambulatorio del MMG*, Monteriggioni, 23.6.2012
 330. **M Matucci Cerinic:** La terapia della gotta, *La gotta il nemico dimenticato*, Firenze, 29.6.2012
 331. **M Matucci Cerinic:** Terapie innovative nella sclerodermia, *Terapie innovative in reumatologia*, Palermo, 30.6.2012
 332. **M Matucci Cerinic:** Autoimmunity in Systemic Sclerosis, epiphenomenon?; New Therapeutic options in Systemic Sclerosis, *PANLAR 2012*, Dominican Republic, 19-22.4.2012
 333. **M Matucci Cerinic:** Red Flags; Interessamento polmonare nella sclerosi sistemica, *Pneumotrieste*, Trieste, 27-29.3.2012
 334. **M Matucci Cerinic:** Coinvolgimento polmonare nella sclerosi sistemica e lo studio Secure, *Centro Nazionale delle Ricerche*, Pisa, 29.3.2012
 335. **M Matucci Cerinic:** Early Scleroderma, *Patologia Immune & Malattie Orfane*, Torino, 19-20.1.2012
 336. **M Matucci Cerinic:** New approach to haemophilic arthropathy by targeting the Fas pathway, evidence from the bench, *Bio-Rheumatology International Congress (BRIC) & The 8th GARN Meeting*, Tokyo, Japan, 14-16.11. 2011
 337. **M Matucci Cerinic:** Il liquido sinoviale, XX^a Edizione Corso

- CEFAR- *Le Proteine: dal laboratorio alla clinica*, Firenze, 19-21.10.2011
338. **M Matucci Cerinic:** Innovative approaches to the therapy of fibrosis, *Congresso Società Italiana di Immunologia, Immunologia Clinica ed Allergologia*, Riccione, 28-30.10.2011
339. **M Matucci Cerinic:** Prospettive terapeutiche nella sclerosi sistemica, VII Corso Siculo Calabro di Reumatologia, Messina, 1-2.10.2011
340. **M Matucci Cerinic:** Iskustva u primjeni biološke terapije, *Hrvatski Kongres Reumatologije*, Dubrovnik, Croatia, 19-21.10.2011
341. **M Matucci Cerinic:** Focus on cardio respiratory complications of CTD: ILD vs. PAH; Importance of making the correct diagnosis, *2st Alpe Adria meeting on PAH*, Trieste, Italy, 22.10, 2011
342. **M Matucci Cerinic:** Benefiti TNF Inhibitora potvrđeni u kliničkoj praksi, *Serbian Congress of Rheumatology*, Novi Sad, Serbia, 6-7.9.2011
343. **M Matucci Cerinic:** Overlap syndromes, Overlap syndromes in rheumatology, *University of Osijek*, Croatia, 9.9.2011
344. **M Matucci Cerinic:** MCTD a roundabout to CTDs; Systemic sclerosis, the very early diagnosis is today possible, *Bahrein congress of Rheumatology*, Bahrein, 17.9.2011
345. **M Matucci Cerinic:** Systemic sclerosis: myths, truths and challenges; Early screening, diagnosis and management of Pulmonary Hypertension in Systemic Sclerosis; Managing comorbidities in Rheumatoid Arthritis, *Colombian Congress of Rheumatology*, Barranquilla, Colombia, 11-13.8.2011
346. **M Matucci:** Pathophysiology of hemophilic arthropathy, *Ultrasound in Hemophilia- from theory to practice*, Firenze, 30-1.6.2011
347. **M Matucci Cerinic:** Current thinking in the management of Digital Ulcers; Drug-drug interaction in pulmonary arterial hypertension; The hidden contribution of macroangiopathy to cold hands and feet, *EULAR congress*, London, England 25-28.5.2011
348. **M Matucci Cerinic:** Strategie di intervento per il dolore reumatologico, *congresso AISD*, Riccione, 29-30.5.2011
349. **M Matucci Cerinic:** Piccole Molecole, *Horizon Scanning 2011 in Reumatologia: il Reumatologo di fronte a nuovi strumenti diagnostici, nuovi farmaci e nuove tecnologie*, Roma, 5-6.5.2011
350. **M Matucci Cerinic:** Il dolore come sintomo guida per la diagnosi precoce nelle malattie reumatiche, *Congresso ASIAM*, Riccione, 13-15.2011
351. **M Matucci Cerinic:** Artrite Reumatoide- la diagnosi precoce, nuovi criteri classificativi e valutazione della risposta nella pratica clinica, *Congresso AIMEF*, Chia, 19-21.5.2011
352. **M Matucci Cerinic:** Ultrasound in systemic sclerosis, *EULAR ultrasound course 2011*, Leeds, England, 22-24.5.2011
353. **M Matucci Cerinic:** Sfide in Reumatologia- la diagnosi precoce, *I grandi maestri della Medicina*, Loreto, 5.4.2011
354. **M Matucci Cerinic:** Il coinvolgimento cardiovascolare nella sclerodermia, *Secondo Congresso Cardio IFC*, Pisa, 8-9.4.2011
355. **M Matucci Cerinic:** Defining value in anti-TNF therapy with Etanercept—achieving and sustaining treatment success in RA, *Russian Congress of Rheumatology*, Yaroslavl, Russia, 27-29.4.2011
356. **M Matucci Cerinic:** Immunosuppressants in systemic sclerosis:

- which, when and why, *Controversies in Rheumatology*, Florence, Italy, 10-12.3.2011
357. **M Matucci Cerinic:** Farmaci biologici nelle malattie reumatologiche, *congresso SLAIC*, Firenze, 25.3.2011
358. **M Matucci Cerinic:** Optimising diagnosis and management pathways in RA- Safety, a challenge for the rheumatologist, *Progress and Promise 2011*, Istanbul, Turkey, 27-28.3.2011
359. **M Matucci Cerinic:** therapeutic options for lung involvement in systemic sclerosis, *4th International Meeting on pulmonary rare diseases and orphan drugs*, Milano, Italy, 25-26.2.2011
360. **M Matucci Cerinic:** PAH and Systemic Sclerosis: Subpopulations – burden of disease, unmet need and goals of therapy , *2nd Annual European Forum on PAH* Madrid, Spain, 20–22.1.2011
361. **M Matucci Cerinic:** How to assess and manage Digital Ulcers in systemic sclerosis, *4th EUSTAR course*, Belgrade , Serbia, 23-26.1.2011
362. **M Matucci Cerinic:** Les complications sévères de la sclérodermie systémique, *Journées d'actualités physiopathologique de Strasbourg*, Strasbourg, France, 3.12.2010
363. **M Matucci Cerinic:** Ulcerations at fingertips in systemic sclerosis, Kolloquium, *Rheumatologie von A bis Z*, University of Zurich, 9.12.2010
364. **M Matucci Cerinic:** Sclerosi Sistemica: diagnosi precoce e terapia, *Seminari Scuola Specializzazione, Università di Bologna*, 4.11.2010
365. **M Matucci Cerinic:** Ipertensione polmonare nella sclerosi sistemica: terapie orali a lungo termine; Overlap sindrome: overview. *Congresso SIR 2010*, Rimini 24-27.11.2010
366. **M Matucci Cerinic:** The management of digital ulcers in systemic sclerosis, *Systemic Sclerosis Meeting, University of Liverpool*, Liverpool, UK, 4.10.2010
367. **M Matucci Cerinic:** Il rischio fratturativo nelle connettiviti, *Focus sull'osteoporosi severa*, Firenze, 28-30.10.2010
368. **M Matucci Cerinic:** The management of digital ulcers in systemic sclerosis, *Systemic Sclerosis Meeting, University of Liverpool*, Liverpool, UK, 4.10.2010
369. **M Matucci Cerinic:** Dal fenomeno di Raynaud alla sclerosi sistemica, *111 Congresso della Società Italiana di Medicina Interna*, Roma, 16-20.10.2010
370. **M Matucci Cerinic:** The very early diagnosis of Systemic Sclerosis; EULAR/EUSTAR organizational experience, how does it work and how can the interested physicians join and enter patient's data, *8th Syrian Congress of Rheumatology*, Damascus, Syria 20-22.10.2010
371. **M Matucci Cerinic:** Il rischio fratturativo nelle connettiviti, *Focus sull'osteoporosi severa*, Firenze, 28-30.10.2010
372. **M Matucci Cerinic:** Interessamento polmonare nelle connettiviti, *Master sulle Malattie Polmonari*, Firenze, 7.6.2010
373. **M Matucci Cerinic:** Ultrasound in scleroderma, *17th EULAR sonography course*, Rome, Italy, 13-16.6.2010
374. **M Matucci Cerinic:** Recurrent digital ulcers in systemic sclerosis, *EULAR congress*, Rome, Italy, 16-19.6.2010
375. **M Matucci Cerinic:** Difficult differential diagnosis in PAH in systemic sclerosis, *Focus On Pulmonary Hypertension*, Bologna 24-25.6.2010

376. **M Matucci Cerinic:** Cardiovascular involvement in Systemic Sclerosis, *Ipertensione arteriosa ed aterosclerosi: dalla disfunzione endoteliale al danno d'organo*, Milano, 25-26.6.2010
377. **M Matucci Cerinic:** Early diffuse scleroderma, vascular aspects functional vasculopathy, abnormal angiogenesis, critical ischemia; From abnormal microvasculature bed to worldwide network, *Israeli Society Meeting*, Tel Aviv, 23.4.2010
378. **M Matucci Cerinic:** Practical aspect of caring patients with severe digital ulcers in systemic sclerosis, *Rambam Grand Round*, Israel, 24.4.2010
379. **M. Matucci Cerinic:** Nuove prospettive terapeutiche: cellule staminali e trapianti, *Meet the expert-Reumatologia*, Milano, 20.3.2010
380. **M Matucci Cerinic:** How to assess and manage Digital Ulcers in systemic sclerosis; Demographics and Previous Complications/ Interventions of Patients with Digital Ulcers in Different Subsets of Scleroderma, Preliminary Findings from the DUO Registry, *World Congress on Systemic Sclerosis*, Florence, Italy, 7.2.2010
381. **M Matucci Cerinic:** Pratica clinica quotidiana e biologici: quali razionali dietro le nostre scelte? *Optimising treatment of Rheumatoid arthritis*, Barcelona, Spagna, 29-30.1.2010
382. **M Matucci Cerinic:** Early diagnosis of chronic arthritis project, *Basic sonographic course for rheumatologists*, Belgrade, Serbia, 4-5.12.2009
383. **M Matucci Cerinic:** Challenge from systemic sclerosis, learn from EUSTAR, *National Congress of The Chinese Society of Rheumatology*, Beijing, China, 13-15.11.2009
384. **M Matucci Cerinic:** I Farmaci Biologici nel trattamento del paziente anziano con artrite reumatoide, Congresso Nazionale di Geriatria, Firenze 3.12.2009
385. **M Matucci Cerinic:** Diagnostic procedures in an outpatient setting, *EFIC school for Clinical and instrumental diagnostic processes in Pain Medicine*, Montescano, Italy, 26-30.10.2009
386. **M Matucci Cerinic:** Dolore muscolo-scheletrico: la fisiopatologia del dolore infiammatorio e del dolore meccanico, *Il dolore muscolo scheletrico*, Firenze, 28.10.2009
387. **M Matucci Cerinic:** *Decorso delle spondiliti*, Taormina, 2- 3.10. 2009
388. **M Matucci Cerinic:** Placenta pathology in SSc, VI Conference on Gonadal Hormones, *Pregnancy and the Rheumatic Diseases 2009*. Lausanne, Switzerland, 10 – 12.9. 2009
389. **M Matucci Cerinic:** Efficacy of anti-TNF alpha treatment in Spondylitis, *Annual Congress of Rheumatology of Serbia*, Subotica, Serbia, 16-18.9.2009
390. **M Matucci Cerinic:** Very early diagnosis of scleroderma - VEDOSS project, *Annual Congress of Rheumatology of Serbia*, Subotica, Serbia, 16-18.9.2009
391. **M Matucci Cerinic:** Immune tolerance: Lessons from other disease areas, *First Mucopolysaccharidosis Summit*, Amsterdam, Netherlands, 25-26.9.2009
392. **M Matucci Cerinic:** Epidemiología y Clasificación. Importancia de la esclerosis sistémica tempran; Modified Rodnan skin score, a tool to assess skin involvement in systemic sclerosis, *Congreso Nacional de Reumatología Colombia*, Bogotá, 16-17.8.2009
393. **M Matucci Cerinic:** Early diagnosis of sistemic sclerosis: is this possible?; The role of phosphodiesterase-5 inhibition in an

- effective therapeutic strategy for PAH-CTD; Skin and digital vasculopathy – Assessment and treatment options, *EULAR*, Copenhagen, Denmark, 10-13.6.2009
394. **M Matucci Cerinic:** Vasculopathy, Raynaud's Phenomenon and digital ulcers in systemic sclerosis; Early diagnosis of systemic sclerosis: when to suspect? *Chilean congress of Rheumatology*, Santiago, Chile, 15-16.5.2009
395. **M Matucci Cerinic:** The Management of Digital Ulcers, *Summer Academy of Angiology*, Castiglione della Pescaia, Italy, 20-24.5.2009
396. **M Matucci Cerinic:** Recenti acquisizioni nella artrite reumatoide, *Congresso AIMEF*, Punta Ala, 22-23.5.2009
397. **M Matucci Cerinic:** Meccanismi classici d'azione e reazioni avverse dei FANS, *Congresso Nazionale AISD*, Silvi Marina, 28-30.5.2009
398. **M Matucci Cerinic:** Dolore muscolo scheletrico e dolore infiammatorio e meccanico, *Il dolore nell'ambulatorio del medico di medicina generale*, Montecatini, 4.4.2009
399. **M Matucci Cerinic:** L'artrite reumatoide precoce, *Problemi pratici nel trattamento dell'artrite reumatoide con farmaci biologici*, Artimino, 17.4.2009
400. **M Matucci Cerinic:** Artrite reumatoide, stato dell'arte, *Il dolore in reumatologia*, Firenze, 18.4.2009
401. **M Matucci Cerinic:** The early diagnosis of systemic sclerosis. *International workshop- 6th RCRD*, Bucarest, Romania, 27-29.4.2009
402. **M Matucci Cerinic:** Is the current Spondyloarthritis treatment sufficiently effective? *Advanced Treatment with Biologics in Rheumatology and Dermatology*, Opatija, Croatia, 14.3.2009
403. **M Matucci Cerinic:** Costimulation and rheumatoid arthritis; Systemic sclerosis: an overview on the state of art, *Grand Rounds, Division of Rheumatology, University of Umea*, Sweden, 16.3.2009
404. **M Matucci Cerinic:** Pulmonary Hypertension in Systemic Sclerosis
From diagnosis to treatment, *Russian Rheumatology Congress, Mosvka, Russia*, 25.3.2009
405. **M Matucci Cerinic:** The management of Digital Ulcers in systemic sclerosis; Digital Ulcers in systemic sclerosis, *International Scleroderma Forum*, Basel, Switzerland, 28.2-1.3.2009
406. **M Matucci Cerinic:** Digital ulcers: natural history, patients at risk, how to treat, *EUSTAR course*, Paris, France, 21-23.1.2009
407. **M Matucci Cerinic:** Treatment of digital ulcers in systemic sclerosis.
What is the evidence?, *7th International Medinterna*, Porto, Portugal, 29-31.1.2009
408. **M Matucci Cerinic:** Costimulation modulation in rheumatoid arthritis, *Department of Rheumatology*, Kuwait City, 5.11.2008
409. **M Matucci Cerinic:** Costimulation modulation in rheumatoid arthritis: a novel mechanism of action of abatacept. *Dubai, UAE*, 14.11.2008
410. **Matucci Cerinic:** Il trattamento della osteoporosi da glucocorticoidi. *Congresso SIOMMS*, Perugia, 19-22.11.2008
411. **M Matucci Cerinic:** Diagnosi precoce in artrite reumatoide per il raggiungimento della remissione clinica e radiografica. I risultati dello studio COMET. *25° Congresso SIMG*, Firenze, 20-

- 23.11.2008
412. **M Matucci Cerinic:** Governo Clinico ed Appropriatezza sulla strada della Standardizzazione della Spesa per Patologia, *Congresso sul Risk Management*, Arezzo, 26.11.2008
 413. **M Matucci Cerinic:** Systemic Sclerosis; an update, *EULAR postgraduate course*, Krefeld, Germany, 1-5.10. 2008
 414. **M Matucci Cerinic:** Efficacy of Abatacept, *Orencia in Rheumatoid Arthritis*, Aarhus, Denmark, 6.10. 2008
 415. **M Matucci Cerinic:** : Classificazione e trattamento delle ulcere digitali; Lo studio DART. Congresso della Società Italiana di Reumatologia, Venezia, 15-18.10.2008
 416. **M Matucci Cerinic:** The treatment of vasculopathy in systemic sclerosis; The diagnosis of PAH, *Grand Rounds, Department of Pneumology*, Calgary, 22.10.2008
 417. **M Matucci Cerinic:** The treatment of PAH in systemic sclerosis, *Grand Rounds, Department of Rheumatology*, Vancouver, 23.10.2008
 418. **M Matucci Cerinic:** The treatment of ulcers and PAH in systemic sclerosis, *American College of Rheumatology*, San Francisco, 24.10.2008
 419. **M Matucci Cerinic:** Raynaud's phenomenon and Digital Ulcers; The gut and scleroderma; From dreams to reality: The EUSTAR experience, *Annual Congress of the New Zealand Rheumatology Associations*, Hamilton, New Zealand, 4-6.9. 2008
 420. **M Matucci Cerinic:** Clinical correlates of capillaroscopy in connective tissue diseases; Endothelin and digital ulcers, *EULAR Course on capillaroscopy*, Genova, 14-16.9. 2008
 421. **M Matucci Cerinic:** Rheumatoid Arthritis and Mixed Connective Tissue disease. *International Workshop on Rheumatoid Arthritis, Bridging the gap from evidence to experience*, Bologna, 20-21.9. 2008
 422. **M Matucci Cerinic:** EUSTAR network-a challenge for the future, *APLAR congress*, Yokohama, Japan, 23-25.9. 2008
 423. **M Matucci Cerinic:** The classification and treatment options of digital ulcers in systemic sclerosis. *EULAR congress*, Paris, France, 10-14.6. 2008
 424. **M Matucci Cerinic:** Digital ulcers in systemic sclerosis: applying the evidence. *EULAR congress*, Paris, France, 10-14.6. 2008
 425. **M Matucci Cerinic:** Vi è l'esigenza di una early psoriatic arthritis clinic ? *Early Rheumatoid Arthritis*, Pavia, 20-21.6. 2008
 426. **M Matucci Cerinic:** Development of early scleroderma clinics, The VEDOSS-EUSTAR approach. *European Workshop on controversies in systemic sclerosis*. Zurich, Switzerland, 22.6. 2008
 427. **M Matucci Cerinic:** T cell modulator: latest data on efficacy and safety. *What's next in rheumatoid arthritis management*. Paris, France, 25.6. 2008
 428. **M Matucci Cerinic:** ERAs in PAH and systemic sclerosis , *Pulmonary and renal vasculopathy: role of ET-1*, *Royal Society of Medicine*, London, UK, 12.5. 2008
 429. **M Matucci Cerinic:** EUSTAR un modello di rete europea per la scleroderma esportabile al LES. *Convegno Nazionale- attualità sul LES*, Genova 17.5. 2008
 430. **M Matucci Cerinic:** Scleroderma-overview. *Nascholing Reumatologie*, Amersfoort, The Netherlands, 19.5. 2008
 431. **M Matucci Cerinic,** Robert Moots: Recenti acquisizioni dallo

- studio DART, *La remissione: un obiettivo oggi raggiungibile*, Roma, Italy, 29-30.5.2008
432. **M Matucci Cerinic:** The world of scleroderma. *EUSTAR-PANLAR course on systemic sclerosis-teach the teachers*, Campinas, Brasil, 7-10. 2008
433. **M Matucci Cerinic:** Vascular and ulcers. *EUSTAR-PANLAR course on systemic sclerosis-teach the teachers*, Campinas, Brasil, 7-10. 2008
434. **M Matucci Cerinic:** Terapia del danno polmonare nella scleroderma. *Il danno polmonare nelle malattie reumatiche*. Modena, Italy, 18.4.2008
435. **M Matucci Cerinic:** Endothelin receptor antagonism in the treatment of systemic sclerosis. *Pulmonary ad vascular disease update- The future is now*, Amsterdam, Netherlands, 25.4. 2008
436. **M Matucci Cerinic:** Ulcers in Raynaud's and Scleroderma: a challenge for the future. *Irish Raynaud's and scleroderma Society*, Dublin, Ireland, 26.4. 2008
437. **M Matucci Cerinic:** Infections and systemic sclerosis. *Infections, rheumatism and autoimmunity*, Milan, Italy, 6-8.3.2008
438. **M Matucci Cerinic:** Evidence Based treatment of systemic sclerosis: Recommendations from EULAR/EUSTAR. *2nd International Forum on Systemic Sclerosis*, Paris, France, 7-9.3.2008
439. **M Matucci Cerinic:** Defining TNF failure. *Progress and Promise in rheumatoid arthritis*, Madrid, Spain, 14-15.3.2008
440. **M Matucci Cerinic:** Farmaci biologici: Efficacia Clinica, Roma, Italy, 29.3.2008
441. **M Matucci Cerinic:** La vasculopathie de la sclerodermie systemique et le role de ET1. *Symposium sur la sclerodermie*, Lausanne, Switzerland, 21.2.2008
442. **M Matucci Cerinic:** Gli antagonisti recettoriali dell'endotelina 1 nella trattamento della sclerosi sistemica, *La nuova generazione degli antagonisti recettoriali dell'endotelina1 nell'ipertensione polmonare*, Milano, 12.1.2008
443. **M Matucci Cerinic:** EULAR/EUSTAR recommendations for the treatment of systemic sclerosis, *Grand Round Department of Dermatology*, University of Kanazawa, Japan, 17.1.2008
444. **M Matucci Cerinic:** Endothelial damage in systemic sclerosis: from bone marrow to tissue. *Japanese association for systemic sclerosis*, Tokyo, Japan, 18.1.2008
445. **M Matucci Cerinic:** A novel approach to the treatment of systemic sclerosis: the EULAR/EUSTAR recommendations, *Umehara Memorial Lecture*, Tokyo, Japan, 19.1.2008
446. **M Matucci Cerinic:** Skin ulcers in systemic sclerosis, *International Workshop on Outcomes in Rheumatology*, Bucharest, Romania, 8.12.2007
447. **M Matucci Cerinic:** Terapie Biologiche nelle malattie reumatiche, *Consensus Conference sulle Terapie Biologiche*, Firenze, 14.12.2007
448. **M Matucci Cerinic:** Complicanze cardiopolmonari della sclerosi sistemica, *Corso su Ipertensione Polmonare*, Bologna, 24.11.2007
449. **M Matucci Cerinic:** Abatacept efficacy in inadequate responders to anti tnf alfa therapy, *Educational Course on Biologic Therapy*. Paris, 30.11.2007
450. **M Matucci Cerinic:** Trattamento delle ulcere digitali: EMEA approva la prima terapia preventiva, *Congresso Italiano di*

- Reumatologia*, Venezia, 16-18.2007
451. **M Matucci Cerinic:** EULAR/EUSTAR recommendations for the treatment of systemic sclerosis, *Scleroderma Clinical Trials Consortium meeting*, Washington, USA, 7.1.07
 452. **M Matucci Cerinic:** Scleroderma overview. *5th International Symposium- Pain Management an integrated approach*, Rhodes, Greece, 6.10.2007
 453. **M Matucci Cerinic:** Scleroderma vasculopathy- is our approach rational? *Coonective Tissue Diseases Workshop*, Firenze, 7.10.2007
 454. **M Matucci Cerinic:** Ulcers and EUSTAR, *25th AGM*, London, UK, 26.7.2007
 455. **M Matucci Cerinic:** Pathogenesis of systemic sclerosis and its clinical implications; EUSTAR, news and achievements. *Turkish congress of Rheumatology*, Fethya, Turkey, 3.9.2007
 456. **M Matucci Cerinic:** Rituximab- problemi di Safety, Rituximab e Malattie Autoimmuni, 22.9.2007 Firenze,
 457. **M Matucci Cerinic:** La vasculopathie dela sclerodermie et le role de ET1. *2eme Journees Francaise de la Sclerodermie Systemique*, Paris, France, 27.9.2007
 458. **M Matucci Cerinic :** Terme e malattie reumatiche, *4° Giornate di Aggiornamento sulle Cure Termali*, Montecatini, 28.9.2007
 459. **M Matucci Cerinic:** on Behalf of recommendations committee: Recommendations for the treatment of systemic sclerosis; Rare and forgotten diseases; The complexity of managing systemic sclerosis; Scleroderma explained: pathogenesis and clinical features 13-*EULAR congress*, Barcelona, Spain, 13-16.6.lectures
 460. **M Matucci Cerinic:** Clinical Methodology & Rheumatology, *Master Course Update on Rheumatology*, Moskva, Russian Federation, 11-12.5.2007
 461. **M Matucci Cerinic:** Safety issues in antiTNFa treatment. *Advances in Rheumatology*, Lisbon, Portugal, 27-29.4.2007
 462. **M Matucci Cerinic:** Sclerosi sistemica: clinica & laboratorio. *II Corso sulle Malattie Rare*, 14-19.3.2007Pisa
 463. **Matucci Cerinic:** The complexity of managing systemic sclerosis. *First International Systemic Sclerosis Forum*, Athens. Greece, 9-11.2.2007
 464. **M Matucci Cerinic:** Percorsi diagnostici nella sclerosi sistemica. *A joint rhuematology meeting 2006*, Villa Mondragone-Università Tor Vergata, Roma
 465. **M Matucci Cerinic:** Systemic sclerosis: diagnosis, clinical activity and treatment. *Slovak Congress of Rheumatology*, Piestany, Slovakia, 8.12.2007
 466. **M Matucci Cerinic:** Severe Disease Manifestations in systemic sclerosis. *Université Catholique de Louvain*, Bruxelles, Belgium, 9.12.2007
 467. **M Matucci Cerinic:** *New therapeutic targets in Pulmonary arterial hypertension in systemic sclerosis*, Autoimmunity Congress, Sorrento, 1-2.12.06
 468. **M Matucci Cerinic:** L'artrite psoriasica, Programma di educazione ed innovazione Continua in Dermatologia, 5.12.2006, Firenze
 469. **M Matucci Cerinic:** Il dolore in reumatologia, *Convegno Nazionale SIAARTI*, 6.12.2006, Firenze
 470. **M Matucci Cerinic:** Vascular Injury in Systemic Sclerosis, the pathway to dysregulation of angiogenesis, *American College of*

- Rheumatology*, Washington, USA, 11-14.11.2006
471. **M Matucci Cerinic:** Safety and prevention for anti-TNFalfa blockade ; Systemic sclerosis, internal organ involvement. *Lithuanian congress of Rheumatology*, Vilnius, Lithuania, 23.11.2006
472. **M Matucci Cerinic:** NSAIDs: per aspera ad astra. Indications, clinical use and adverse events. *European Conference on myocardial, pericardial disease and left ventricular dysfunction*, Belgrade, Serbia, 6-8.10.2006
473. **M Matucci Cerinic:** Sclerosi Sistemica: registro EUSTAR; Gestione globale del paziente sclerodermico. *Congresso della Società Italiana di Reumatologia*, Palermo, 11-14.10.2006
474. **M Matucci Cerinic:** Sclerosi sistemica: diagnosi precoce e terapia. *Scuola di Specializzazione in Reumatologia*, Università di Bologna, Bologna, 20.10.2006
475. **M Matucci Cerinic:** Early Rheumatoid arthritis: is there a rationale to using DMARDs in monotherapy?; Patients who fail to respond to monotherapy: can biologics add efficacy to DMARDs?, *Rheumatoid arthritis, bridging the gap from evidence to experience*. Capri, 21-23.10.2006
476. **M Matucci Cerinic:** Systemic sclerosis, *EULAR postgraduate course*, Warsaw, Poland, 23-29.10.2006
477. **M Matucci Cerinic:** The management of steroid induced osteoporosis; Systemic Sclerosis. *Master Course Update in Rheumatology*, University of Helsinki, Finland, 16-17.7.06 & 27-28.9.2006
478. **M Matucci Cerinic:** The diagnosis and management of lung involvement in systemic sclerosis; Systemic sclerosis, a treatable disease, *Braslian Congress of Rheumatology*, Campinas, Brasil, 6-9.9.2006
479. **M Matucci Cerinic:** EULAR in Europe ; Microvessels in rheumatic diseases; The role of endothelin in digital ulcers ;Correlations between capillaroscopy and clinical findings, *EULAR Course on capillaroscopy*, Genova, 22-25.9.2006
480. **M Matucci Cerinic:** Psoriatic arthritis, *Meeting integrato sulle terapie biologiche*, Firenze, 29-30.9.2006
481. **M Matucci Cerinic:** Aspetti clinico patologici della artrite psoriasica. L'approccio del reumatologo. *81° Congresso Nazionale di Dermatologia*, Torino, 31.5-3.6.2006
482. **M Matucci Cerinic:** Il trattamento del dolore enelle patologie osteoarticolari e nella lombosciatalgia, tra evidenze scientifiche e linee guida. *Il dolore nelle patologie osteoarticolari e nella lombosciatalgia*, Firenze, 13.6.2006
483. **M Matucci Cerinic:** Macrovascular involvement in systemic sclerosis ; Improving care in systemic sclerosis. Solving the case, *EULAR congress*, Amsterdam, Netherlands, 21-24.6.2006
484. **M Matucci Cerinic:** Fibrinolisi e trombofilia nella sclerodermia, *Università Cattolica del S Cuore*, Roma, 3.5.2006
485. **M Matucci Cerinic:** Classificazione e clinica della sclerodermia. *Dal Raynaud alla sclerodermia*, Università di Messina, 6.5.2006
486. **M Matucci Cerinic:** Quadro clinico laboratoristico della sclerosi sistemica, *Corso teorico pratico sulle malattie rare*, S Miniato, 9.5.2006
487. **M Matucci Cerinic:** Kidney involvement: outcome measures. *OMERACT 8th*, Malta, 10-14.5.2006
488. **M Matucci Cerinic:** Anti TNF alfa blockade (Biologic Agents)

- in Psoriatic Arthritis, *International Congress on Photobiology*, Montecatini, 11-12.5.2006
489. **M Matucci Cerinic:** Approccio integrato ai giovani adulti affetti da malattie reumatiche croniche. *Congresso Nazionale del Gruppo di Studio di Reumatologia Pediatrica della SIP*, Firenze, 18-20.5.2006
490. **M Matucci Cerinic:** Eziopatogenesi dell'artrite reumatoide. Recenti acquisizioni e riflessi sulla diagnostica di laboratorio, Empoli, 18.5.2006
491. **M Matucci Cerinic:** Early Arthritis: strategie a comune per la qualità della vita, *L'Ambulatorio di reumatologia nella early arthritis*, Pistoia, 20.5.2006
492. **M Matucci Cerinic:** Interpretation of outcomes in early and established systemic sclerosis, *2nd Turkish National Rheumatic Diseases Congress*, Antalya, Turkey, 26-30.4.2006
493. **M Matucci Cerinic:** Safety procedures and adverse reactions in antiTNFalfa blockade. *Persepective of antiTNF treatment in IMiDs-conect 2006*, Bucharest, Romania, 24-25.3.2006
494. **M Matucci Cerinic:** L'impegno extrarticolare delle entesoartriti. *La early arthritis*, Bari, 21.1.2006
495. **M Matucci Cerinic:** L'experience d'EUSTAR en Europe. *Association des rhumatologues parisien*, Firenze, 7.10.2005
496. **M Matucci Cerinic:** Manifestazioni cliniche e valutazione del polmone sclerodermico, *Corso di aggiornamento di patologia respiratoria-2005i*, AOUC Firenze, 11.10.2005
497. **M Matucci Cerinic:** Macroangiopathy in systemic sclerosis. *Annual Congress of Rheumatology Serbia and Montenegro*, Belgrade, Serbia, 25-27.10.2005
498. **M Matucci Cerinic:** Uso di Teriparatide in reumatologia. *Orthoreuma 2005*, Milano, 29-30.9.2005
499. **M Matucci Cerinic:** The lung in rheumatic disease. *EULAR annual congress*, Vienna, Austria, 10-14.6.2005
500. **M Matucci Cerinic:** Ruolo degli analgesici ad azione centrale. *Reumatologia e Sport, II° Congresso Nazionale*, Cagliari, 26-28.5.2005
501. **M Matucci Cerinic:** The heart in systemic sclerosis; Angiogenesis in systemic sclerosis. *Scleroderma day, Ankara Rheumatological Association*, Ankara, Turkey, 26.4.2005
502. **M Matucci Cerinic:** Il polmone nelle Vasculiti. *Convegno sulle Malattie Rare- Le vasculiti*, Buti, 5.3.2005
503. **M Matucci Cerinic:** Ulcers in systemic sclerosis: making sense of the process. *1st EULAR/EUSTAR corse on the assessment of the patient with systemic sclerosis*, Budapest, Hungary, 13-16.1.2005
504. **M Matucci Cerinic:** The management of systemic sclerosis; Endothelium & inflammation. *EULAR postgraduate course 2004*, Praga, Czech Republic, 29.11-3.12.2004
505. **M Matucci Cerinic:** La terapia tradizionale dell'artrite psoriasica. *Nuove evidenze nel trattamento dell'artropatia psoriasica. Approccio diagnostico e terapeutico* Padova, 10.12.04
506. **M Matucci Cerinic:** The role of fibrinolytic system in the loss of angiogenesis in systemic sclerosis. *4th International Congress on Autoimmunity*, Budapest, Hungary, 3-7.11.2004
507. **M Matucci Cerinic:** La valutazione clinica e la terapia del paziente sclerodermico. *Corso educativo sulle problematiche complesse in reumatologia*. Bari, 13.11.2004

508. **M Matucci Cerinic:** The management of Immune-mediated Inflammatory Disorders. Past, Present, and Future. *Congress of European Academy of Dermatology & Venereology*, Firenze, 18.11.2004
509. **M Matucci Cerinic:** Loss of angiogenesis and pulmonary hypertension in systemic sclerosis. Lessons from the periphery. *International meeting on lung involvement and PAH in systemic sclerosis*, Bialoweza, Poland, 9-10.10.2004
510. **M Matucci Cerinic:** Microvessels in rheumatic diseases; Correlation between capillaroscopic and clinical findings, *EULAR capillaroscopy course*, Genova, 10-12.9.2004
511. **M Matucci Cerinic:** Artrite reattiva. *Le spondiloartriti*, Palermo, 18.9.2004
512. **M Matucci Cerinic:** Terapia del fenomeno di Raynaud, *Congresso Italiano di Reumatologia*, Stresa, 23-25.9.2004
513. **M Matucci Cerinic:** EUSTAR & SCTC, *International Scleroderma Workshop*, Cambridge, UK, 1-4.8.2004
514. **M Matucci Cerinic:** Infliximab in the management of active ankylosing spondylitis; The evolving role of Infliximab in the treatment of rheumatic diseases; Managing extrarticular manifestations of ankylosing spondylitis. *International Rheumatology Forum*, Cabo S Lucas, Mexico, 20-21.8.2004
515. **M Matucci Cerinic:** Il danno endoteliale: la sclerosi sistemica come modello. *Giornate Reumatologiche Aquilane*, L'Aquila, 3.7.2004
516. **M Matucci Cerinic:** Systemic Sclerosis: Treatment related morbidities; Managing Gut & Eye Involvement Related to Spondyloarthropathies: When is Intensive Treatment Warranted ?; EUSTAR: annual report. *EULAR annual congress*, Berlin, Germany, 9-12.6.2004
517. **M Matucci Cerinic:** The multifaceted approach to ulcers in systemic sclerosis, *The ERA of improved outcomes- making a difference in Pulmonary Arterial Hypertension*. Montecarlo, 9.5.2004
518. **M Matucci Cerinic:** Le malattie Reumatiche: quadro epidemiologico e classificazioni. *La riabilitazione nelle malattie reumatiche*, Firenze, 19.5.2004
519. **M Matucci Cerinic:** Adalimumab: il primo anticorpo monoclonale completamente umano. *Il paziente con artrite reumatoide: quali terapie, quale assistenza*, Firenze, 24.4.2004
520. **M Matucci Cerinic:** Impegno extrarticolare nell'artrite reumatoide. *Focus 2004 sull'artrite reumatoide*, Lucca, 20.3.2004
521. **M Matucci Cerinic:** Infliximab in the long term management of active ankylosing spondylitis and associated spondyloarthropaties. *32nd Mexican Congress Rheumatology Meeting*, Guadalajara, Mexico 14.2.2004
522. **M Matucci Cerinic:** Clinica delle forme extrarticolari della spondilite anchilosante. *Spondilite anchilosante; dalla diagnosi alla terapia biologica*, Venezia 31.1.2004
523. **M Matucci Cerinic:** Funzione endoteliale e sclerodermia. *Convegno Nazionale Interdisciplinare di patologia vascolare*, Firenze, 23.1.2004
524. **M Matucci Cerinic:** Inquadramento e subset di malattia con interessamento cutaneo della sclerosi sistemica, *Accademia Nazionale di Medicina- Diagnosi e trattamento della*

- sclerodermia*, Padova, 6.12.2003 e Firenze, 13.12.2003
525. **M Matucci Cerinic:** Interessamento cutaneo della sclerosi sistemica, *Accademia Nazionale di Medicina- Diagnosi e trattamento della sclerodermia*, Napoli, 29.11.2003
526. **M Matucci Cerinic:** Le linee guida per l'uso dei farmaci biologici nell'artrite reumatoide. *FiReuma 2003*, Firenze, 8.11.2003
527. **M Matucci Cerinic:** Le manifestazioni Cliniche della sclerosi sistemica, *Congresso SIR*, Udine, 21.11.2003
528. **M Matucci Cerinic:** The pathogenesis of systemic sclerosis: from endothelial injury to loss of angiogenesis, *Lecture au Senat Francais dans les journées pour la sclérodemie*, Paris, France, 24.11.2003
529. **M Matucci Cerinic:** Lung involvement in systemic sclerosis (Pluca u Sistemska Sklerosu). *Congress of Rheumatology of Serbia and Montenegro*, Novi Sad, Serbia i Montenegro 3-5.10.2003
530. **M Matucci Cerinic:** Fibromialgia: la terapia come network integrato. *Reumatologia e fisiatria a confronto nella gestione del paziente fibromialgico*, Pozzolatico, 9.10.2003
531. **M Matucci Cerinic:** Recent Advances in DMARDs and Biologic treatment in rheumatoid arthritis. *WHO-Austrian Rheumatage*, Vienna, Austria, 11.10.2003
532. **M Matucci Cerinic:** Le manifestazioni extrarticolari dell'artrite reumatoide. *Corso di aggiornamento Siculo Calabro*, Taormina, 18.10.2003
533. **M Matucci Cerinic:** Systemic sclerosis: differential diagnosis and therapy (Diferencijalna diagnoza Systemske Sklerose). *Dani Reumatologije*, Vela Luka, Croatia, 19.7.2003
534. **M Matucci Cerinic:** L'impegno parenchimale polmonare nella sclerosi sistemica. *Accademia Nazionale di Medicina- Problematiche difficili in reumatologia clinica*, Ferrara, 26-27.9.2003
535. **M Matucci Cerinic:** Ankylosing spondylitis and other comorbidities. *Entering a new era in the management of ankylosing spondylitis: the role of infliximab*. Barcelona, Spain, 24.5.2003
536. **M Matucci Cerinic:** Coxibs in arthritis: efficacy and safety data on osteoarthritis and rheumatoid arthritis. *Breaking the cycle of pain*, Roma, 28.2-1.3.2003
537. **M Matucci Cerinic:** La patogenesi della sclerosi sistemica. *Corso di aggiornamento in reumatologia*, Palermo, 29.3.2003
538. **M Matucci Cerinic:** Aspetti molecolari e clinici del ruolo dell'infiammazione cartilaginea nell'osteoartrite. *Seminari di Aggiornamento in Medicina Interna- Osteoartrite: patogenesi e strategie terapeutiche a confronto*. Assisi, 24-25.1.2003
539. **M Matucci Cerinic:** The peripheral nervous system in systemic sclerosis. *Piestany Research Meetings*, Piestany, Slovacchia, 21.11.2002
540. **M Matucci Cerinic:** Approccio terapeutico al paziente sclerodermico. *Incontri Catanesi di Medicina Interna*, Catania, 29.11.2002
541. **M Matucci Cerinic:** Overlap Syndromes, *Croatian Congress of Rheumatology*, Brijuni, Croatia, 18-19.10.2002
542. **M Matucci Cerinic:** From muscle to heart: the silent progression of systemic sclerosis. *Grand Round, Harvard School of Medicine*,

- Brigham and Woman Hospital, Bosoton, USA, 22.10.2002*
543. **M Matucci Cerinic:** The muscle involvement in systemic sclerosis (Misticne promijene u Sistensku Sklerosu), *Yugoslavian Congress of Rheumatology*, Vrdnik, Serbia i Montenegro, 12.9.2002
544. **M Matucci Cerinic:** The heart involvement in systemic sclerosis, *Department of Rheumatology, University of Basel*, Basel, Switzerland, 29.8.2002
545. **M Matucci Cerinic:** La patogenesi della sclerosi sistemica. *Ten Topics in Rheumatology*, Roma, 16-18.5. 2002
546. **M Matucci Cerinic:** La visione globale del paziente artrosico: dall'iter diagnostico alla costruzione di una strategia terapeutica. *Osteoartrosi una malattia vera?* Firenze, 20.4. 2002
547. **M Matucci Cerinic:** Genetica e malattie reumatiche: passato, presente e futuro. *Giornate Mediche Toscane*, Firenze, 1-2.2.2002
548. **M Matucci Cerinic:** Osteoarthritis a multifactorial disease. *Genetics of osteoarticular disorders*, Firenze, 21-23.2. 2002
549. **M Matucci Cerinic:** New insights in the treatment of osteoarthritis- clinical data on the efficacy profile of rofecoxib two years after the launch in Italy. *International congress on Successful Aging*, Catania, 4-6.12.2001
550. **M Matucci Cerinic:** La patogenesi della sclerosi sistemica. *Congresso della Società Italiana di Reumatologia*, Padova, 20-24.11.2001
551. **M Matucci Cerinic:** I COXIB una nuova via terapeutica: Celecoxib. *102° Congresso della Società Italiana di Medicina Interna*, Roma, 23-27.10. 2001
552. **M Matucci Cerinic:** Neurotrasmettitori e fenomeno di Raynaud. *Dipartimento di Medicina Interna, Scuola di Specializzazione in Reumatologia*, Università di Ferrara, 4.4.2000
553. **M Matucci Cerinic:** The loss of endothelial dependent vasodilation in systemic sclerosis. *Central European Congress of Rheumatology*, Bratislava, Slovakia, 11-15.5.2000
554. **M Matucci Cerinic:** Neuropeptides, from vascular tone control to inflammation. *Rheumaklinik und Institut fur Physikalische Medizin, UniversitatSpital*, Zurich, Switzerland, 4.6.2000
555. **M Matucci Cerinic:** Neuromodulation of connective tissue. *EULAR congress*, Nice, France, 21-25.6.2000
556. **M Matucci Cerinic:** Uso dei cortisonici nell'anziano 6° *Congresso della SIR*, Milano, Italy, 14-18.11.2000
557. **M Matucci Cerinic:** La disabilità osteoarticolare nel paziente anziano. *Trials Clinici. Congresso SIGG*, Firenze, 19-22.11.2000
558. **M Matucci Cerinic:** Neuropeptidi e meccanismi patogentici delle malattie reumatiche. *XXXVI Congresso della SIR*, Cagliari, 28.9-3.10.1999
559. **M Matucci Cerinic, R Casale:** Rehabilitation in scleroderma: Neuropeptidergic system and endothelial cells in systemic sclerosis. *17th Annual Conference of the Raynaud's and Scleroderma Association*, Alsager, England, 2.10.1999
560. **M Matucci Cerinic:** Scleroderma: Approccio clinico per una diagnosi precoce. *Dipartimento di Medicina Clinica e Sperimentale, Sezione di Medicina Interna e Scienze Oncologiche*, Università di Perugia, 18.6.1999
561. **M Matucci Cerinic:** L'infiammazione neurogena. *Meeting della Scuola di Specializzazione in Reumatologia dell'Università di Padova*, Padova, 4.4.1999

562. **M Matucci Cerinic:** Le tappe patogenetiche quali bersagli terapeutici nella sclerosi sistemica. *Seconda Università di Napoli*, Napoli, 20.4.1999
563. **M Matucci Cerinic:** Complicanze neurologiche della sclerosi sistemica. *Corso di Aggiornamento della Società Italiana di Neurologia*, Pisa, 13.11.1998
564. **M Matucci Cerinic:** Le ulcerazioni degli arti inferiori in condizioni di interesse reumatologico. *L'ipertensione venosa cronica degli arti inferiori oggi*, *Simposio Interdisciplinare*, Firenze, 21.11.1998
565. **M Matucci Cerinic:** Neuropeptides in Rheumatic Diseases. *Rheumaklinik und Institut für Physikalische Medizin, Universitätsspital*, Zurich, Switzerland, 22.10.1998
566. **M Matucci Cerinic:** Immunomodulation during pregnancy in connective tissue diseases. *EULAR Workshop*, Geneva, Switzerland, 4-8.9.1998
567. **M Matucci Cerinic:** Oxidative stress in systemic sclerosis. *Stress, adaptation, prophylaxis and treatment*, Calcutta, India, 10-12.1.1998
568. **M Matucci Cerinic:** The nervous system in systemic sclerosis. *International Conference on systemic sclerosis: pathogenesis, clinical features and treatment*. Montecatini, 22-26.3.1998
569. **M Matucci Cerinic:** La vasculopatia sclerodermica. *Dipartimento di Medicina Interna*, Università di Genova, 30.5.1998
570. **M Matucci Cerinic:** Clinical evidence of familial history in osteoarthritis. *Meeting of IFSSD on Potential role of genetic markers in osteoarticular disorders*. Florence, 21.6.1998
571. **M Matucci Cerinic:** La physiopathologie de l'atteinte vasculaire de la sclerodermie. *Université René Descartes-Paris V, Diplôme d'Immuno Rheumatologie*, Paris, France, 28.3.1997
572. **M Matucci Cerinic:** Raynaud's phenomenon, ischemia and gene expression: is there a perspective for a new approach to the treatment of reperfusion injury? *7th Interscience World Conference on Inflammation, Antirheumatics, Analgesics, Immunomodulators*, Geneva, Switzerland, 19-21.5.1997
573. **M Matucci Cerinic:** The multistep pathogenesis of systemic sclerosis. *Institute of Rheumatology*, Piestany, Slovacchia, 11.6.1997
574. **M Matucci Cerinic:** Gene expression in cutaneous microvascular endothelial cells derived from systemic sclerosis. *International Conference on Stress-Stress and adaptation from molecules to man*. Budapest, Hungary, 1-4.7.1997
575. **M Matucci Cerinic, Generini S, Biagini M, Pignone A:** Terapia della sclerosi sistemica: possibili bersagli precoci di intervento terapeutico. *34° Congresso della Società Italiana di Reumatologia*, Sorrento, 25-28.9.1997
576. **M Matucci Cerinic:** Endothelial injury, vascular tone control and peripheral nervous system involvement in systemic sclerosis. *Department of Rheumatology*, University of Helsinki, Finland, 13 March 1996
577. **M Matucci Cerinic:** Osteoporosi in Reumatologia. *I° Giornata Fiorentina sull'Osteoporosi*, Firenze, 1.6.1996
578. **M Matucci Cerinic:** Fenomeno di Raynaud: Diagnosi e meccanismi patogenetici. La valutazione e la programmazione terapeutica del paziente con sclerodermia. *Università di Milano, Istituto di Reumatologia*, Milano, 20.9.1996

579. **M Matucci Cerinic:** Infection of the host and rheumatic diseases. *International Summer School on Pathogenesis of Infectious diseases*, Crkivenica, Croatia. 20-25.9.1996
580. **M Matucci Cerinic:** The role of endothelial injury and peripheral nervous system involvement in the dysfunction of vascular tone control in systemic sclerosis. *Mini symposium on fibroblast dysfunction and pathogenesis of systemic sclerosis*, Division d'immunologie et d'allergologie, G n ve, Switzerland, 5.12.1996
581. **M Matucci Cerinic, BM Kahaleh:** The endothelial involvement in systemic sclerosis: the dysregulation of vascular tone and the markers of endothelial injury. *Scleroderma 95*, Warsaw, Poland, 21-25.1995
582. **M Matucci Cerinic, Generini S, Lombardi A, Pignone A, Cagnoni M:** The pathogenesis of hypertrophic osteoarthropathy: the role of endothelial cells and fibroblasts. *XIII European Congress of Rheumatology*, Amsterdam, The Netherlands, 18-23.6.1995
583. **M Matucci Cerinic:** Endothelial injury and the dysfunction of vascular tone in systemic sclerosis. *Grand Round, Dept. of Surgery and Div. of Cardiology, University of Connecticut Health Center*, Farmington, USA, 15.11.1995
584. **M Matucci Cerinic:** The treatment of ulcers in systemic sclerosis. *II International symposium on wound healing*. Civitavecchia, 15.12.1995
585. **M Matucci Cerinic:** The influence of peripheral nervous system on the local immunity in joints. *International Conference on Regional Immunology*, Opatija, Croatia, 30.9.1994
586. **M Matucci Cerinic:** The endothelial cells in the pathogenesis of systemic sclerosis. *Malta Derm94'*, Malta, 11.11.1994
587. **M Matucci Cerinic:** The endothelial injury in systemic sclerosis, *Grand Round, Division of Rheumatology, University of Pittsburgh*, Pittsburgh, USA, 10.3.1993
588. **M Matucci Cerinic:** Neuropeptides, somatostatin and rheumatic diseases: its role in the pathogenesis and treatment of rheumatic diseases. *Grand Round, Intestinal Disease Research Unit, McMaster University*, March 1993, , Hamilton, Canada
589. **M Matucci Cerinic:** Diagnosis, pathogenesis and treatment of hypertrophic osteoarthropathy. *Grand Round, Division of Rheumatology, University of Alabama at Birmingham*, Birmingham, USA, 13.4.1993
590. **M Matucci Cerinic:** Neuropeptides and neuropeptidases in scleroderma. *II International Workshop on scleroderma*, Chicago, USA, 20-22.9.1992
591. **M Matucci Cerinic:** Hypertrophic osteoarthropathy. *Special Conference, Medical College of Ohio*, Toledo, USA, 22.8.1991
592. **M Matucci Cerinic:** Primary and secondary hypertrophic osteoarthropathy. *Grand rounds, Division of Rheumatology, Medical University of South Carolina*, Charleston, USA, 14.4.1990
593. **M Matucci Cerinic:** Pachydermoperiostosis. *Division of Rheumatology, Instituto Nacional de Cardiologia Ignacio Chavez*, Mexico City, Mexico, 28.8.1990

I authorize the treatment of my personal data in reference to the D.Lgs. 196/2003

Milano, 10.4.2025

594.Prof. Marco Matucci-Cerinic

